[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjw1nSrC-OFZf4q5ZePt6JM4uH_IpFseIDa2T8afPc6M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":86,"rows":93},"Novo Nordisk A\u002FS",[4],1363,false,116,352,4677595,57,117,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Diabetes",635,{"name":18,"count":19},"Diabetes Mellitus, Type 2",592,{"name":21,"count":22},"Diabetes Mellitus, Type 1",223,{"name":24,"count":25},"Obesity",166,{"name":27,"count":28},"Healthy",127,{"name":30,"count":31},"Congenital Bleeding Disorder",87,{"name":33,"count":34},"Overweight",68,{"name":36,"count":37},"Haemophilia A",62,[39,44,49,53,58,62,66,71,76,81],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03878446","A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day","2021-05-05","Somapacitan",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04083781","Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","2021-12-27","Concizumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":48},"NCT04082429","Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors","2022-07-12",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04775082","SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity","2023-08-01","Liraglutide",{"nctId":59,"briefTitle":60,"date":61,"intervention":43},"NCT05723835","A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9","2024-06-07",{"nctId":63,"briefTitle":64,"date":65,"intervention":43},"NCT05330325","A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow","2024-08-05",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05567796","A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight","2024-10-30","Cagrilintide",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05726227","A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight","2025-10-15","Semaglutide",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04682145","Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol","2026-02-01","Turoctocog alfa pegol",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06574984","Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients","2026-02-27","Turoctocog alfa",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,1828,2103,2121,2341,2510,2681,2763,2955,3039,3124,3364,3394,3436,4373,4984,5065,5100,5131,5165,5187,5212,5230,5248,5266,6240,6291,6322,6410,6433,6472,6504,6531,6616,6648,6678,6709,6736,6758,6781,6799,6821,6844,6869,6892,6917,6935,6958,6982,7006,7024,7047,7155,7237,7381,7407,7429,7455,7542,7571,7597,7629,7662,7692,7714,7736,7758,7781,7805,7823,7841,7859,7877,7895,7913,7931,7949,7972,7995,8019,8037,8055,8073,8091,8109,8184,8218,8257,8319,8363,8406,8448,8480,8508,8534,8563,8607,8647,8688,8714,8749,8771,8793,8815,8837,8864,8890,8908,8926,8944,8962,8980,8998,9016,9039,9064,9082,9105,9128,9146,9164,9182,9200,9259,9307,9347,9387,9438,9470,9504,9537,9575,9601,9637,9663,9691,9713,9742,9760,9784,9807,9825,9843,9861,9879,9897,9915,9933,9957,9975,9993,10011,10029,10047,10065,10092,10110,10128,10146,10164,10182,10200,10221,10239,10257,10296,10326,10356,10386,10428,10470,10500,10526,10554,10580,10614,10657,10685,10712,10742,10770,10792,10824,10848,10879,10901,10927,10949,10993,11021,11052,11083,11105,11127,11168,11190,11212,11240,11262,11293,11315,11339,11363,11381,11402,11420,11445,11463,11481,11499,11517,11535,11559,11577,11595,11613,11631,11654,11672,11690,11708,11726,11749,11767,11785,11807,11825,11848,11871,11889,11907,11925,11943,11961,11979,11997,12015,12033,12051,12069,12087,12108,12131,12154,12172,12190,12214,12232,12250,12268,12293,12311,12333,12356,12374,12392,12410,12428,12446,12464,12482,12503,12521,12539,12562,12580,12598,12616,12634,12652,12670,12688,12706,12724,12745,12763,12781,12799,12820,12844,12865,12887,12905,12923,12941,12962,12984,13002,13020,13038,13062,13080,13098,13116,13134,13158,13176,13194,13212,13230,13254,13272,13290,13313,13331,13349,13367,13385,13403,13421,13439,13457,13475,13498,13521,13544,13562,13580,13603,13621,13650,13668,13686,13704,13722,13740,13758,13776,13802,13820,13838,13861,13879,13897,13915,13933,13951,13974,13998,14681,15174,15614,16010,16248,16419,16645,16846,17077,17204,17322,17439,17559,17635,17701,17803,17879,17936,17983,18027,18072,18124,18172,18210,18248,18295,18334,18363,18398,18423,18447,18478,18500,18529,18560,18583,18601,18619,18637,18655,18673,18695,18719,18743,18761,18779,18797,18815,18837,18860,18887,18905,18923,18947,18965],{"intervention":75,"totalTrials":95,"cells":96},178,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":714,"PHASE3":865,"PHASE4":1547,"NA":1607},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":713,"soonestReadout":382},[102,113,124,133,146,155,167,176,186,197,206,217,228,237,246,259,270,279,291,300,310,319,329,338,346,357,367,377,389,398,407,416,425,436,445,454,464,473,484,492,501,512,521,531,540,548,558,565,573,581,590,598,608,617,629,639,647,657,667,676,684,694,702],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT03144271","Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects","COMPLETED",[88],"2007-10-08","2007-06-11",58,[15,18,27],[112],"semaglutide",{"nctId":114,"briefTitle":115,"status":105,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":121},"NCT03789578","A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together",[88],"2019-10-10","2019-01-17",30,[18],[122,75,123],"NNC0148-0287sema","NNC0148-0287",{"nctId":125,"briefTitle":126,"status":105,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT00851773","Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects",[88],"2009-10","2009-02",84,[15,27],[112,112,112,112,112],{"nctId":134,"briefTitle":135,"status":105,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT05429593","A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet",[88],"2023-03-10","2023-04-13","2022-06-22",152,[142],"Healthy Volunteers",[75,144,145],"Dapagliflozin","Semaglutide\u002Fdapagliflozin",{"nctId":147,"briefTitle":148,"status":105,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT01686945","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes",[88],"2013-04-08","2012-09-19",107,[15,18,27],[112,112,112],{"nctId":156,"briefTitle":157,"status":105,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT04940078","A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity",[88],"2022-01-19","2022-02-16","2021-07-07",40,[164],"Obesity & Overweight",[70,112,166],"Cagrilintide and semaglutide",{"nctId":168,"briefTitle":169,"status":105,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"NCT02231684","Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg\u002FmL, 3 mg\u002FmL, and 10 mg\u002FmL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide",[88],"2015-01","2014-09",42,[15,27],[112,112],{"nctId":177,"briefTitle":178,"status":105,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},"NCT02210871","Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",[88],"2015-06-03","2014-08-07",44,[15,18,184],"Hepatic Impaired",[112],{"nctId":187,"briefTitle":188,"status":105,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT02845219","A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females",[88],"2016-12","2016-07",25,[15,18],[112,195,196],"SNAC","Microgynon®",{"nctId":198,"briefTitle":199,"status":105,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":119,"conditions":203,"interventions":205},"NCT02079870","Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo",[88],"2015-01-07","2014-03-06",[15,204,24],"Metabolism and Nutrition Disorder",[112],{"nctId":207,"briefTitle":208,"status":105,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":216},"NCT03357380","A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver",[88],"2020-03-20","2017-11-28",67,[214,215],"Hepatobiliary Disorders","Non-alcoholic Fatty Liver Disease",[75],{"nctId":218,"briefTitle":219,"status":105,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT02249910","Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects",[88],"2015-03-06","2014-09-18",32,[15,27],[112,226,227],"metformin","digoxin",{"nctId":229,"briefTitle":230,"status":105,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT01272973","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects",[88],"2011-07","2011-01",96,[15,18,27],[112,112],{"nctId":238,"briefTitle":239,"status":105,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":37,"conditions":244,"interventions":245},"NCT06207877","A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight",[88],"2024-10-16","2024-11-22","2024-02-23",[24],[70,75],{"nctId":247,"briefTitle":248,"status":105,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT05766709","A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations",[88],"2024-01-05","2024-02-09","2023-03-02",53,[255],"Non-alcoholic Steatohepatitis",[257,75,258,258],"NNC0194-0499","NNC0194-0499\u002FSemaglutide A",{"nctId":260,"briefTitle":261,"status":105,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT02920385","A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.",[88],"2017-04-26","2017-06-16","2016-10-10",45,[15,27],[75,195,269],"Levothyroxine",{"nctId":271,"briefTitle":272,"status":105,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT01866748","Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects",[88],"2014-04","2013-05",170,[15,18,27],[112,112],{"nctId":280,"briefTitle":281,"status":105,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":289},"NCT03574584","A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese",[88],"2019-07-27","2018-06-18",37,[287,288],"Metabolism and Nutrition Disorders","Overweight or Obesity",[290,75],"NNC0165-1562",{"nctId":292,"briefTitle":293,"status":105,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":299},"NCT02557620","Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly",[88],"2016-04","2015-09",113,[15,27],[112],{"nctId":301,"briefTitle":302,"status":105,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT02022254","Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects",[88],"2014-08-28","2013-12-17",24,[15,18,27],[112,226,309],"warfarin",{"nctId":311,"briefTitle":312,"status":105,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":37,"conditions":316,"interventions":318},"NCT00833716","Effect of Renal Impairment on the Pharmacokinetics of NN9535",[88],"2010-07-26","2009-02-02",[15,18,317],"Renal Impairment",[112],{"nctId":320,"briefTitle":321,"status":105,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT02249871","Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects",[88],"2015-04-01","2014-09-24",54,[15,27],[112,328],"Omeprazole",{"nctId":330,"briefTitle":331,"status":105,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":337},"NCT01619345","Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects",[88],"2012-08","2012-06",27,[15,27],[112],{"nctId":339,"briefTitle":340,"status":105,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":34,"conditions":344,"interventions":345},"NCT04152915","A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens",[88],"2020-05-25","2019-11-25",[142,18],[75],{"nctId":347,"briefTitle":348,"status":349,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":356},"NCT04012255","A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity","TERMINATED",[88],"2019-08-30","2019-10-22","2019-07-15",29,[33,24],[75,75],{"nctId":358,"briefTitle":359,"status":105,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT02070510","A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects",[88],"2014-08-20","2014-02-27",52,[15,27],[112,366,309],"lisinopril",{"nctId":368,"briefTitle":369,"status":105,"phases":370,"primaryCompletion":371,"completion":371,"start":139,"enrollment":372,"conditions":373,"interventions":374},"NCT05435677","A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together",[88],"2023-04-25",20,[18],[375,376,112],"IcoSema","insulin icodec",{"nctId":378,"briefTitle":379,"status":380,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":387},"NCT07225816","Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","RECRUITING",[88],"2026-06-19","2026-07-17","2025-11-07",75,[24],[57,388,75],"Oral Semaglutide",{"nctId":390,"briefTitle":391,"status":105,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":306,"conditions":395,"interventions":396},"NCT05498610","A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men",[88],"2022-10-12","2022-08-11",[18],[397,75],"NNC0480 0389",{"nctId":399,"briefTitle":400,"status":105,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":406},"NCT02172313","Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects",[88],"2014-10","2014-06",78,[15,27],[112],{"nctId":408,"briefTitle":409,"status":105,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT04228354","A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide",[88],"2020-06-01","2020-01-29",28,[142,33,24],[75],{"nctId":417,"briefTitle":418,"status":105,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT02060266","Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects",[88],"2014-04-28","2014-02-04",7,[15,27],[112],{"nctId":426,"briefTitle":427,"status":105,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT03707990","A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese",[88],"2019-08-13","2018-10-15",88,[433],"Obesity and Overweight",[435,75],"NNC0165-1875",{"nctId":437,"briefTitle":438,"status":105,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":444},"NCT01572753","Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects",[88],"2012-09-08","2012-04-12",161,[15,18,27],[112,112,112,112,112,112,112,112],{"nctId":446,"briefTitle":447,"status":380,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT07010432","The Role of the Amylin Analogue Cagrilintide in Bone Metabolism",[88],"2028-05-03","2025-06-12",144,[24],[70,75],{"nctId":455,"briefTitle":456,"status":457,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":234,"conditions":462,"interventions":463},"NCT07087795","A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes","ACTIVE_NOT_RECRUITING",[88],"2026-09-12","2026-09-25","2025-07-01",[21],[257,75],{"nctId":465,"briefTitle":466,"status":105,"phases":467,"primaryCompletion":468,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":472},"NCT04238962","A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens",[88],"2020-10-20","2020-02-03",111,[33,24],[75,75],{"nctId":474,"briefTitle":475,"status":105,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT06097390","A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III",[88],"2024-02-22","2024-03-27","2023-09-28",121,[482],"Healthy Participants",[75],{"nctId":485,"briefTitle":486,"status":105,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":182,"conditions":490,"interventions":491},"NCT00813020","A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects",[88],"2009-04","2009-01",[15,18],[112,112,112],{"nctId":493,"briefTitle":494,"status":105,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT02014259","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function",[88],"2014-10-24","2013-12-11",71,[15,18,27],[112],{"nctId":502,"briefTitle":503,"status":105,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT03466567","A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects",[88],"2018-07-10","2018-03-15",21,[15,18],[75,510,511],"Probenecid","Ciclosporin",{"nctId":513,"briefTitle":514,"status":105,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":520},"NCT02773381","A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes",[88],"2018-10-19","2016-06-02",15,[15,18],[112],{"nctId":522,"briefTitle":523,"status":380,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":530},"NCT07527195","Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)",[88],"2028-04-28","2028-06-09","2026-04-10",100,[24],[70,75],{"nctId":532,"briefTitle":533,"status":105,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":234,"conditions":537,"interventions":538},"NCT03600480","A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese",[88],"2020-06-12","2018-07-25",[24,33],[539,75],"NNC0174-0833",{"nctId":541,"briefTitle":542,"status":105,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":182,"conditions":546,"interventions":547},"NCT02146079","A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects",[88],"2014-10-20","2014-05-21",[15,18,27],[112],{"nctId":549,"briefTitle":550,"status":105,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT02243098","Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects",[88],"2015-04-07","2014-09-16",31,[15,27],[112,227,557],"atorvastatin",{"nctId":559,"briefTitle":560,"status":105,"phases":561,"primaryCompletion":275,"completion":275,"start":562,"enrollment":413,"conditions":563,"interventions":564},"NCT01766245","A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes",[88],"2012-12",[15,27],[112],{"nctId":566,"briefTitle":567,"status":105,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":480,"conditions":571,"interventions":572},"NCT05996874","A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants",[88],"2024-04-18","2023-08-12",[482],[75],{"nctId":574,"briefTitle":575,"status":105,"phases":576,"primaryCompletion":577,"completion":577,"start":545,"enrollment":578,"conditions":579,"interventions":580},"NCT02147431","A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes",[88],"2015-05-20",38,[15,18],[112],{"nctId":582,"briefTitle":583,"status":105,"phases":584,"primaryCompletion":585,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":589},"NCT03842202","A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity",[88],"2019-11-04","2019-02-15",72,[33,24],[75],{"nctId":591,"briefTitle":592,"status":105,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":34,"conditions":596,"interventions":597},"NCT04187300","A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity",[88],"2020-09-23","2019-12-16",[33,24],[75],{"nctId":599,"briefTitle":600,"status":105,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":606},"NCT02064348","A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects",[88],"2015-04-23","2014-02-26",168,[15,27],[112,607],"moxifloxacin",{"nctId":609,"briefTitle":610,"status":105,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":616},"NCT02877355","Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.",[88],"2017-11-24","2016-08-22",55,[15,18],[112],{"nctId":618,"briefTitle":619,"status":105,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT03010475","A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects",[88],"2017-06-04","2017-08-09","2017-01-05",41,[15,27],[627,628,195,75],"Furosemide","Rosuvastatin",{"nctId":630,"briefTitle":631,"status":105,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":638},"NCT06403761","Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes",[88],"2025-12-28","2026-02-02","2024-05-06",158,[18],[75,70],{"nctId":640,"briefTitle":641,"status":105,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":31,"conditions":645,"interventions":646},"NCT02212067","A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes",[88],"2015-05-11","2014-08-11",[15,18],[112],{"nctId":648,"briefTitle":649,"status":105,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":655},"NCT01324505","Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes",[88],"2012-01","2011-03",43,[15,18],[112,656],"Microgyn®",{"nctId":658,"briefTitle":659,"status":105,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":306,"conditions":663,"interventions":665},"NCT04878406","A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men",[88],"2021-07-20","2021-05-18",[664],"Healthy Volunteers Type 2 Diabetes",[666,75],"NNC0480-0389",{"nctId":668,"briefTitle":669,"status":105,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":675},"NCT02016911","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment",[88],"2015-01-12","2013-12-12",56,[15,18,27],[112],{"nctId":677,"briefTitle":678,"status":105,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":140,"conditions":682,"interventions":683},"NCT04259801","First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes",[88],"2022-03-16","2020-02-17",[142,33,24,18],[666,75],{"nctId":685,"briefTitle":686,"status":105,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":693},"NCT04032197","A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and\u002For Blood Vessels and Type 2 Diabetes",[88],"2022-12-16","2023-06-06","2019-08-12",101,[18],[75],{"nctId":695,"briefTitle":696,"status":105,"phases":697,"primaryCompletion":698,"completion":698,"start":403,"enrollment":699,"conditions":700,"interventions":701},"NCT02161588","A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects",[88],"2014-11",48,[15,18,27],[112],{"nctId":703,"briefTitle":704,"status":105,"phases":705,"primaryCompletion":241,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT06289504","A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight",[88],"2024-11-15","2024-02-27",34,[24],[70,75,711,712],"Atorvastatin","Warfarin",4,{"trials":715,"activeCount":864,"soonestReadout":835},[716,727,737,747,759,769,779,788,798,812,821,831,843,853],{"nctId":717,"briefTitle":718,"status":380,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT07415954","A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes",[89],"2027-09-03","2027-10-01","2026-04-17",270,[18],[726,75],"NNC0662-0419",{"nctId":728,"briefTitle":729,"status":105,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":736},"NCT05486065","A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight",[89],"2023-10-12","2023-12-13","2022-08-08",245,[18],[75],{"nctId":738,"briefTitle":739,"status":105,"phases":740,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":746},"NCT02970942","Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.",[89],"2020-02-13","2020-03-19","2016-11-30",320,[214,255],[75],{"nctId":748,"briefTitle":749,"status":105,"phases":750,"primaryCompletion":751,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":758},"NCT04143945","A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",[89],"2020-01-04","2019-10-28",104,[755,756,757],"Healthy Volunteers Diabetes Mellitus, Type 2","Healthy Volunteers Overweight","Healthy Volunteers Obesity",[75,75],{"nctId":760,"briefTitle":761,"status":105,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT02461589","Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes",[89],"2016-10-13","2015-09-21",706,[15,18],[112,768],"liraglutide",{"nctId":770,"briefTitle":771,"status":105,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":778},"NCT04007107","A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",[89],"2019-07-28","2019-09-04","2019-06-27",103,[755,756,757],[75,75],{"nctId":780,"briefTitle":781,"status":105,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":498,"conditions":786,"interventions":787},"NCT03987451","A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage",[89],"2021-04-22","2021-06-10","2019-06-18",[255],[75],{"nctId":789,"briefTitle":790,"status":105,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT05144984","A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes",[89],"2023-02-13","2023-03-23","2021-11-29",500,[18],[666,75],{"nctId":799,"briefTitle":800,"status":105,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":805,"interventions":807},"NCT06409130","Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease",[89],"2025-11-21","2026-01-12","2024-05-20",[806],"Alcohol-related Liver Disease",[257,75,808,809,810,70,811,809],"NNC0194-0499 placebo","Semaglutide placebo","Cagrilintide + semaglutide","Cagrilintide placebo",{"nctId":813,"briefTitle":814,"status":105,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":820},"NCT00696657","A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide",[89],"2009-02-05","2008-06-03",415,[15,18],[112,112,112,112,112,112,768,768],{"nctId":822,"briefTitle":823,"status":105,"phases":824,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":828,"interventions":829},"NCT01923181","Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes",[89],"2014-12-11","2013-12-02",632,[15,18],[112,112,830],"oral placebo",{"nctId":832,"briefTitle":833,"status":380,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":841},"NCT06717698","A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease",[89],"2026-09-01","2026-09-17","2024-12-02",465,[840],"Chronic Kidney Disease",[842,75],"NNC0519-0130",{"nctId":844,"briefTitle":845,"status":105,"phases":846,"primaryCompletion":847,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":852},"NCT02453711","Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus",[89],"2017-03-30","2017-04-12","2015-10-01",957,[204,24],[112,768],{"nctId":854,"briefTitle":855,"status":105,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT06131372","A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo",[89],"2025-09-24","2025-11-06","2024-04-01",626,[840,862,24],"Type 2 Diabetes",[70,75],2,{"trials":866,"activeCount":1546,"soonestReadout":69},[867,877,886,897,906,917,927,937,946,956,965,975,985,996,1006,1016,1024,1035,1045,1056,1065,1074,1083,1094,1104,1114,1123,1132,1142,1151,1161,1171,1181,1191,1201,1209,1219,1229,1238,1248,1255,1265,1274,1283,1293,1302,1313,1323,1333,1343,1355,1365,1374,1384,1394,1403,1412,1421,1431,1440,1450,1458,1469,1479,1489,1498,1508,1519,1526,1536],{"nctId":868,"briefTitle":869,"status":105,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":875},"NCT02128932","Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes",[90],"2015-09-03","2014-08-04",1089,[15,18],[112,876],"insulin glargine",{"nctId":878,"briefTitle":879,"status":105,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":885},"NCT02054897","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes",[90],"2015-05-08","2014-02-03",388,[15,18],[112],{"nctId":887,"briefTitle":888,"status":457,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":896},"NCT05669755","REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels",[90],"2027-09-01","2027-10-13","2023-03-01",7101,[895],"Cardiovascular Disease",[70,75],{"nctId":898,"briefTitle":899,"status":457,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":905},"NCT03811561","A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes",[90],"2027-11-07","2019-05-08",1500,[18],[75],{"nctId":907,"briefTitle":908,"status":105,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":916},"NCT04560998","A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes",[90],"2024-06-05","2024-07-12","2020-10-01",792,[18,915],"Peripheral Arterial Disease",[75],{"nctId":918,"briefTitle":919,"status":105,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT02906930","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only",[90],"2017-10-30","2017-12-08","2016-09-20",703,[15,18],[112],{"nctId":928,"briefTitle":929,"status":105,"phases":930,"primaryCompletion":931,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":936},"NCT03548935","STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity",[90],"2020-03-30","2021-03-05","2018-06-04",1961,[204,288],[75],{"nctId":938,"briefTitle":939,"status":105,"phases":940,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":945},"NCT06388187","A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight",[90],"2026-04-22","2024-06-24",300,[24],[70,75],{"nctId":947,"briefTitle":948,"status":105,"phases":949,"primaryCompletion":950,"completion":951,"start":952,"enrollment":953,"conditions":954,"interventions":955},"NCT03018028","Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes",[90],"2018-01-09","2018-08-15","2017-01-10",243,[15,18],[75,57],{"nctId":957,"briefTitle":958,"status":105,"phases":959,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":963,"interventions":964},"NCT01720446","Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes",[90],"2016-03-15","2013-02-21",3297,[15,18],[112,112],{"nctId":966,"briefTitle":967,"status":105,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":974},"NCT03191396","Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes",[90],"2018-07-09","2018-08-13","2017-06-27",577,[15,18],[75,57],{"nctId":976,"briefTitle":977,"status":105,"phases":978,"primaryCompletion":979,"completion":980,"start":923,"enrollment":981,"conditions":982,"interventions":983},"NCT02849080","Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.",[90],"2018-02-28","2019-03-27",504,[15,18],[112,984],"sitagliptin",{"nctId":986,"briefTitle":987,"status":105,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":995},"NCT05891496","A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease",[90],"2024-08-19","2025-09-08","2023-06-20",23,[994],"Alzheimers Disease",[75],{"nctId":997,"briefTitle":998,"status":105,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1005},"NCT03989232","A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes",[90],"2020-09-18","2020-11-09","2019-06-19",961,[18],[75],{"nctId":1007,"briefTitle":1008,"status":105,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT02863419","Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus",[90],"2017-08-19","2018-03-30","2016-08-10",711,[15,18],[112,768],{"nctId":1017,"briefTitle":1018,"status":105,"phases":1019,"primaryCompletion":1020,"completion":210,"start":933,"enrollment":1021,"conditions":1022,"interventions":1023},"NCT03548987","Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity",[90],"2020-02-22",902,[204,24],[75],{"nctId":1025,"briefTitle":1026,"status":105,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT06131437","A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight",[90],"2025-12-08","2026-01-09","2023-11-27",809,[24],[70,75,1034],"Tirzepatide",{"nctId":1036,"briefTitle":1037,"status":105,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1044},"NCT04102189","A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity",[90],"2022-03-25","2022-03-28","2019-10-07",201,[33,24],[75],{"nctId":1046,"briefTitle":1047,"status":105,"phases":1048,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1054},"NCT05514535","A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)",[90],"2025-03-05","2025-04-09","2022-08-29",573,[18,24],[75,1055,1055],"Insuline glargine U100",{"nctId":1057,"briefTitle":1058,"status":105,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":952,"enrollment":1061,"conditions":1062,"interventions":1063},"NCT03015220","Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes",[90],"2018-07-12",458,[15,18],[75,1064],"Dulaglutide",{"nctId":1066,"briefTitle":1067,"status":105,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT02254291","A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes",[90],"2015-11-11","2014-10-02",308,[15,18],[112,112,984],{"nctId":1075,"briefTitle":1076,"status":105,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1082},"NCT03914326","A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes",[90],"2024-08-23","2019-06-17",9651,[18],[75],{"nctId":1084,"briefTitle":1085,"status":380,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT07564414","A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight",[90],"2028-02-23","2028-04-19","2026-05-21",2500,[24,862],[1093,75],"Cagrisema",{"nctId":1095,"briefTitle":1096,"status":105,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":1012,"enrollment":1100,"conditions":1101,"interventions":1102},"NCT02863328","Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus",[90],"2017-08-01","2018-03-08",822,[15,18],[112,1103],"empagliflozin",{"nctId":1105,"briefTitle":1106,"status":105,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT05890976","Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)",[90],"2025-01-16","2023-05-30",200,[33,24],[75,1113],"Semaglutide Placebo",{"nctId":1115,"briefTitle":1116,"status":105,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1122},"NCT04251156","Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.",[90],"2022-08-23","2020-12-08",375,[33,24,18],[75],{"nctId":1124,"briefTitle":1125,"status":105,"phases":1126,"primaryCompletion":1127,"completion":1127,"start":826,"enrollment":1128,"conditions":1129,"interventions":1130},"NCT01885208","Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes",[90],"2015-07-13",813,[15,18],[112,1131],"exenatide",{"nctId":1133,"briefTitle":1134,"status":1135,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":99,"conditions":1140,"interventions":1141},"NCT04287179","SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","WITHDRAWN",[90],"2020-11-16","2021-01-25","2020-03-09",[18],[75],{"nctId":1143,"briefTitle":1144,"status":105,"phases":1145,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1150},"NCT04788511","Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity",[90],"2023-04-18","2021-03-16",529,[24],[75],{"nctId":1152,"briefTitle":1153,"status":105,"phases":1154,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT04074161","Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity",[90],"2021-03-27","2021-05-11","2019-09-11",338,[33,24],[75,57],{"nctId":1162,"briefTitle":1163,"status":105,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1170},"NCT06323174","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise",[90],"2025-10-01","2025-12-22","2024-03-19",189,[862],[70,75],{"nctId":1172,"briefTitle":1173,"status":105,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1180},"NCT06323161","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin",[90],"2025-09-09","2025-10-23","2024-03-26",274,[862],[70,75],{"nctId":1182,"briefTitle":1183,"status":105,"phases":1184,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1190},"NCT06041217","A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range",[90],"2025-04-02","2025-05-07","2023-09-15",242,[33,24],[75],{"nctId":1192,"briefTitle":1193,"status":380,"phases":1194,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":1198,"conditions":1199,"interventions":1200},"NCT07253285","A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight",[90],"2030-03-20","2033-09-20","2026-01-08",460,[33,24],[70,75],{"nctId":1202,"briefTitle":1203,"status":105,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1079,"enrollment":1206,"conditions":1207,"interventions":1208},"NCT03819153","A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease",[90],"2024-01-09",3533,[18],[75],{"nctId":1210,"briefTitle":1211,"status":1135,"phases":1212,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":99,"conditions":1216,"interventions":1217},"NCT05444153","Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity",[90],"2024-10-02","2025-08-29","2022-10-06",[18],[75,1218],"Empagliflozin",{"nctId":1220,"briefTitle":1221,"status":105,"phases":1222,"primaryCompletion":1223,"completion":1224,"start":1225,"enrollment":1226,"conditions":1227,"interventions":1228},"NCT03574597","Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity",[90],"2023-06-21","2023-06-29","2018-10-24",17604,[33,24],[75],{"nctId":1230,"briefTitle":1231,"status":105,"phases":1232,"primaryCompletion":569,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1237},"NCT05564117","Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range",[90],"2024-05-07","2022-10-11",307,[33,24],[75],{"nctId":1239,"briefTitle":1240,"status":105,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1247},"NCT03611582","Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program",[90],"2020-03-18","2020-04-28","2018-08-01",611,[33,24],[75],{"nctId":72,"briefTitle":73,"status":457,"phases":1249,"primaryCompletion":74,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1254},[90],"2026-12-07","2023-07-07",210,[24],[75],{"nctId":1256,"briefTitle":1257,"status":105,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1264},"NCT06221969","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor",[90],"2026-03-04","2026-04-06","2024-01-16",1024,[862],[70,75,1034],{"nctId":1266,"briefTitle":1267,"status":105,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1273},"NCT04865770","A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)",[90],"2024-11-21","2021-04-28",106,[18,840],[75],{"nctId":1275,"briefTitle":1276,"status":105,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":872,"enrollment":1279,"conditions":1280,"interventions":1281},"NCT02207374","A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes",[90],"2016-02-27",601,[15,18],[112,1282],"DPP-4 inhibitor",{"nctId":1284,"briefTitle":1285,"status":105,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":943,"conditions":1290,"interventions":1292},"NCT05996848","A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight",[90],"2025-01-06","2025-02-22","2023-08-15",[1291],"Obesity or Overweight",[70,75],{"nctId":1294,"briefTitle":1295,"status":105,"phases":1296,"primaryCompletion":69,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1301},"NCT05646706","A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)",[90],"2024-11-26","2023-01-04",1407,[24],[75,75],{"nctId":1303,"briefTitle":1304,"status":105,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT03689374","A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes",[90],"2021-02-22","2018-10-01",2274,[18],[75,1311,1312],"Insulin aspart","Insulin glargine U100",{"nctId":1314,"briefTitle":1315,"status":105,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1322},"NCT02648204","Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.",[90],"2017-04-10","2017-05-19","2016-01-06",1201,[15,18],[112,1064],{"nctId":1324,"briefTitle":1325,"status":105,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":662,"enrollment":1329,"conditions":1330,"interventions":1332},"NCT04777409","A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)",[90],"2025-09-15","2026-01-30",1840,[1331],"Early Alzheimer´s Disease",[75],{"nctId":1334,"briefTitle":1335,"status":105,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT03021187","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin",[90],"2018-01-18","2018-08-22","2017-02-02",731,[15,18],[112,112,112],{"nctId":1344,"briefTitle":1345,"status":1346,"phases":1347,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT07400107","AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","NOT_YET_RECRUITING",[90],"2028-12-12","2029-01-26","2026-05-20",1000,[24,33,18],[1354,75],"NNC0487-0111",{"nctId":1356,"briefTitle":1357,"status":105,"phases":1358,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1364},"NCT02607865","Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes",[90],"2017-02-14","2018-03-28","2016-02-15",1864,[15,18],[112,984],{"nctId":1366,"briefTitle":1367,"status":105,"phases":1368,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1373},"NCT02692716","A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes",[90],"2018-09-25","2017-01-17",3183,[15,18],[112],{"nctId":1375,"briefTitle":1376,"status":457,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1383},"NCT06780449","A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity",[90],"2028-08-28","2028-10-31","2025-02-10",400,[24],[70,75],{"nctId":1385,"briefTitle":1386,"status":105,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1393},"NCT04916470","Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes",[90],"2023-10-11","2021-06-15",617,[1392],"Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2",[75],{"nctId":1395,"briefTitle":1396,"status":105,"phases":1397,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1402},"NCT02305381","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes",[90],"2015-11-21","2014-12-01",397,[15,18],[112],{"nctId":1404,"briefTitle":1405,"status":105,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1298,"enrollment":1409,"conditions":1410,"interventions":1411},"NCT05649137","A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight",[90],"2024-10-28","2024-12-13",512,[24,18],[75,75],{"nctId":1413,"briefTitle":1414,"status":105,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1420},"NCT03811574","STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity",[90],"2020-11-20","2019-01-21",401,[33,24],[75],{"nctId":1422,"briefTitle":1423,"status":105,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1430},"NCT05813925","A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight",[90],"2025-01-17","2025-03-07","2023-04-03",331,[1291],[70,75],{"nctId":1432,"briefTitle":1433,"status":457,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1439},"NCT04822181","Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)",[90],"2029-04-25","2021-04-01",1205,[255],[75],{"nctId":1441,"briefTitle":1442,"status":105,"phases":1443,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT03086330","Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus",[90],"2018-07-04","2018-08-06","2017-03-15",302,[15,18],[75],{"nctId":1451,"briefTitle":1452,"status":105,"phases":1453,"primaryCompletion":1454,"completion":1454,"start":826,"enrollment":1455,"conditions":1456,"interventions":1457},"NCT01930188","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and\u002For TZD in Subjects With Type 2 Diabetes",[90],"2015-10-12",1231,[15,18],[112,984],{"nctId":1459,"briefTitle":1460,"status":105,"phases":1461,"primaryCompletion":1462,"completion":1463,"start":1464,"enrollment":1465,"conditions":1466,"interventions":1468},"NCT06065540","A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor",[90],"2025-11-19","2026-01-06","2023-09-27",2734,[1467],"Type 2 Diabetes Mellitus",[70,75],{"nctId":1470,"briefTitle":1471,"status":1135,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":99,"conditions":1476,"interventions":1477},"NCT06083675","Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes",[90],"2025-01-24","2027-05-28","2024-01-26",[18],[75,1218,1478],"Metformin",{"nctId":1480,"briefTitle":1481,"status":105,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":1446,"enrollment":1485,"conditions":1486,"interventions":1487},"NCT03136484","Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes",[90],"2018-10-16","2018-11-16",788,[15,18],[75,1488],"Canagliflozin",{"nctId":1490,"briefTitle":1491,"status":105,"phases":1492,"primaryCompletion":1493,"completion":1494,"start":923,"enrollment":1495,"conditions":1496,"interventions":1497},"NCT02827708","Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment",[90],"2018-04-10","2018-05-15",324,[15,18],[112],{"nctId":1499,"briefTitle":1500,"status":457,"phases":1501,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1507},"NCT06534411","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both",[90],"2026-06-02","2026-07-14","2024-11-05",1023,[18],[70,75,1034],{"nctId":1509,"briefTitle":1510,"status":105,"phases":1511,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":1516,"interventions":1517},"NCT05813912","A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes",[90],"2025-04-14","2025-05-16","2023-09-22",148,[18],[1518,75],"Insulin Icodec",{"nctId":67,"briefTitle":68,"status":457,"phases":1520,"primaryCompletion":69,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1525},[90],"2026-10-19","2022-11-01",3400,[24],[70,75],{"nctId":1527,"briefTitle":1528,"status":105,"phases":1529,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1535},"NCT05394519","A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight",[90],"2025-01-28","2025-02-03","2023-02-01",1200,[33,24,1467],[70,75],{"nctId":1537,"briefTitle":1538,"status":105,"phases":1539,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1545},"NCT03693430","Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity",[90],"2021-01-29","2021-03-23","2018-10-05",304,[33,24],[75],10,{"trials":1548,"activeCount":1606,"soonestReadout":1569},[1549,1557,1565,1574,1584,1595],{"nctId":1550,"briefTitle":1551,"status":105,"phases":1552,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":753,"conditions":1555,"interventions":1556},"NCT05533632","Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes",[91],"2024-01-18","2022-04-25",[18],[75],{"nctId":1558,"briefTitle":1559,"status":105,"phases":1560,"primaryCompletion":412,"completion":1561,"start":1562,"enrollment":753,"conditions":1563,"interventions":1564},"NCT04189848","Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc",[91],"2020-02-27","2019-12-03",[142,18,33,24],[75,1064],{"nctId":1566,"briefTitle":1567,"status":457,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":795,"conditions":1572,"interventions":1573},"NCT06571383","STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss",[91],"2028-11-15","2031-11-15","2024-09-17",[24],[75],{"nctId":1575,"briefTitle":1576,"status":105,"phases":1577,"primaryCompletion":1578,"completion":1578,"start":1579,"enrollment":1580,"conditions":1581,"interventions":1582},"NCT05035082","A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)",[91],"2025-06-18","2021-09-01",1020,[18],[112,1583],"oral glucose-lowering medications",{"nctId":1585,"briefTitle":1586,"status":105,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":795,"conditions":1590,"interventions":1591},"NCT05579249","A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America",[91],"2024-11-27","2023-01-19",[24],[75,1592,1593,1594,57],"Orlistat","Phentermine\u002FTopiramate","Naltrexone\u002FBupropion",{"nctId":1596,"briefTitle":1597,"status":105,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT03596450","Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial",[91],"2022-06-09","2023-06-09","2018-07-13",1278,[18],[75,1605],"Standard of care",1,{"trials":1608,"activeCount":1827,"soonestReadout":1657},[1609,1618,1627,1635,1644,1653,1662,1671,1680,1688,1697,1707,1715,1724,1732,1741,1749,1757,1766,1775,1784,1793,1801,1809,1818],{"nctId":1610,"briefTitle":1611,"status":105,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1617},"NCT06351748","Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)",[],"2024-03-29","2024-01-02",34238,[18],[75],{"nctId":1619,"briefTitle":1620,"status":105,"phases":1621,"primaryCompletion":1622,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1626},"NCT05443191","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice",[],"2023-04-27","2022-10-20",50,[18],[75],{"nctId":1628,"briefTitle":1629,"status":105,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":838,"conditions":1633,"interventions":1634},"NCT05443334","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice",[],"2024-07-04","2022-07-28",[18],[75],{"nctId":1636,"briefTitle":1637,"status":105,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1643},"NCT06507475","Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes",[],"2024-12-20","2024-09-07",209,[18],[75],{"nctId":1645,"briefTitle":1646,"status":105,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1652},"NCT03876015","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)",[],"2020-08-12","2019-05-01",215,[18],[75],{"nctId":1654,"briefTitle":1655,"status":1346,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":1659,"conditions":1660,"interventions":1661},"NCT05714683","Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",[],"2026-10-30","2025-12-31",600,[18],[75],{"nctId":1663,"briefTitle":1664,"status":105,"phases":1665,"primaryCompletion":1666,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1670},"NCT05316662","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice",[],"2024-04-06","2022-04-06",187,[18],[75],{"nctId":1672,"briefTitle":1673,"status":105,"phases":1674,"primaryCompletion":1675,"completion":1675,"start":1676,"enrollment":1677,"conditions":1678,"interventions":1679},"NCT05755360","DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy",[],"2024-10-21","2023-02-21",291,[18],[75],{"nctId":1681,"briefTitle":1682,"status":105,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":752,"enrollment":1685,"conditions":1686,"interventions":1687},"NCT04094415","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",[],"2021-07-28",581,[18],[75],{"nctId":1689,"briefTitle":1690,"status":105,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1696},"NCT05468632","A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)",[],"2022-07-31","2022-07-05",314,[18],[75],{"nctId":1698,"briefTitle":1699,"status":1700,"phases":1701,"primaryCompletion":1702,"completion":1702,"start":1703,"enrollment":1704,"conditions":1705,"interventions":1706},"NCT07055607","A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice","ENROLLING_BY_INVITATION",[],"2028-08-15","2025-05-01",1250,[24],[75],{"nctId":1708,"briefTitle":1709,"status":105,"phases":1710,"primaryCompletion":1711,"completion":1711,"start":741,"enrollment":1712,"conditions":1713,"interventions":1714},"NCT04261933","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)",[],"2021-05-25",789,[18],[112],{"nctId":1716,"briefTitle":1717,"status":105,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT04469855","Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®",[],"2025-05-12","2020-07-27",3217,[18],[112],{"nctId":1725,"briefTitle":1726,"status":105,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":1650,"conditions":1730,"interventions":1731},"NCT03631186","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)",[],"2019-12-18","2018-09-12",[18],[75],{"nctId":1733,"briefTitle":1734,"status":105,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1740},"NCT03929679","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)",[],"2020-11-24","2019-05-28",218,[18],[112],{"nctId":1742,"briefTitle":1743,"status":349,"phases":1744,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":528,"conditions":1747,"interventions":1748},"NCT07081178","A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).",[],"2025-12-18","2025-08-08",[24],[75],{"nctId":1750,"briefTitle":1751,"status":105,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1543,"conditions":1755,"interventions":1756},"NCT06478550","A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment",[],"2025-04-23","2024-06-26",[18],[75],{"nctId":1758,"briefTitle":1759,"status":105,"phases":1760,"primaryCompletion":1761,"completion":1761,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1765},"NCT05716724","O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait",[],"2023-07-09","2023-01-25",288,[18],[75],{"nctId":1767,"briefTitle":1768,"status":105,"phases":1769,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1774},"NCT03648281","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK\u002FSWEDEN)",[],"2020-01-10","2018-08-24",333,[18],[75],{"nctId":1776,"briefTitle":1777,"status":457,"phases":1778,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1781,"conditions":1782,"interventions":1783},"NCT06283667","Special Use - Results Surveillance on Long-term Use With Wegovy®",[],"2028-01-31","2024-06-11",1071,[24],[75],{"nctId":1785,"briefTitle":1786,"status":105,"phases":1787,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1792},"NCT04067999","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice",[],"2021-07-19","2019-08-05",230,[18],[75],{"nctId":1794,"briefTitle":1795,"status":1700,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":634,"enrollment":1659,"conditions":1799,"interventions":1800},"NCT05689372","Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",[],"2026-11-30","2027-05-31",[18],[75],{"nctId":1802,"briefTitle":1803,"status":1700,"phases":1804,"primaryCompletion":1805,"completion":1805,"start":1806,"enrollment":795,"conditions":1807,"interventions":1808},"NCT07280221","WEgovy Real World Assessment of Weight Loss in Korea",[],"2027-10-31","2025-11-10",[24],[75],{"nctId":1810,"briefTitle":1811,"status":105,"phases":1812,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1817},"NCT04083820","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)",[],"2021-09-27","2019-09-16",521,[18],[112],{"nctId":1819,"briefTitle":1820,"status":105,"phases":1821,"primaryCompletion":1822,"completion":1822,"start":1823,"enrollment":1824,"conditions":1825,"interventions":1826},"NCT03457012","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice",[],"2019-12-19","2018-03-29",462,[18],[75],5,{"intervention":1829,"totalTrials":119,"cells":1830},"Insulin icodec",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1937,"PHASE3":1966,"PHASE4":2071,"NA":2084},{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[1835,1841,1849,1857,1861,1871,1879,1888,1897,1903,1911,1920,1929],{"nctId":1836,"briefTitle":1837,"status":105,"phases":1838,"primaryCompletion":1667,"completion":1667,"start":1270,"enrollment":306,"conditions":1839,"interventions":1840},"NCT04857398","A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes",[88],[18],[376],{"nctId":1842,"briefTitle":1843,"status":105,"phases":1844,"primaryCompletion":1845,"completion":1845,"start":371,"enrollment":1846,"conditions":1847,"interventions":1848},"NCT05790681","A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers",[88],"2024-02-08",18,[18],[1829],{"nctId":1850,"briefTitle":1851,"status":105,"phases":1852,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":109,"conditions":1855,"interventions":1856},"NCT03723785","A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems",[88],"2019-09-06","2018-11-09",[18],[1829],{"nctId":368,"briefTitle":369,"status":105,"phases":1858,"primaryCompletion":371,"completion":371,"start":139,"enrollment":372,"conditions":1859,"interventions":1860},[88],[18],[375,376,112],{"nctId":1862,"briefTitle":1863,"status":105,"phases":1864,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":1867,"conditions":1868,"interventions":1869},"NCT03723772","A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week",[88],"2020-06-26","2018-11-29",66,[21],[1829,1870],"IGlar U100",{"nctId":1872,"briefTitle":1873,"status":105,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":192,"conditions":1877,"interventions":1878},"NCT04597697","A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease",[88],"2022-03-24","2020-12-22",[18],[1829],{"nctId":1880,"briefTitle":1881,"status":105,"phases":1882,"primaryCompletion":1883,"completion":1512,"start":1884,"enrollment":119,"conditions":1885,"interventions":1886},"NCT06288412","A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting",[88],"2025-03-10","2024-02-26",[18],[1829,1887],"Insulin degludec",{"nctId":1889,"briefTitle":1890,"status":105,"phases":1891,"primaryCompletion":1892,"completion":1892,"start":1893,"enrollment":1894,"conditions":1895,"interventions":1896},"NCT04582435","A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes",[88],"2022-04-22","2020-10-16",46,[18],[1518],{"nctId":1898,"briefTitle":1899,"status":105,"phases":1900,"primaryCompletion":1813,"completion":1813,"start":912,"enrollment":192,"conditions":1901,"interventions":1902},"NCT04582448","A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes",[88],[18],[1829],{"nctId":1904,"briefTitle":1905,"status":105,"phases":1906,"primaryCompletion":1813,"completion":1813,"start":1907,"enrollment":653,"conditions":1908,"interventions":1909},"NCT03945656","A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes",[88],"2019-05-07",[18],[376,1910],"Insulin glargine",{"nctId":1912,"briefTitle":1913,"status":105,"phases":1914,"primaryCompletion":1915,"completion":1915,"start":1916,"enrollment":1624,"conditions":1917,"interventions":1918},"NCT02964104","A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes",[88],"2017-12-12","2016-11-15",[15,18],[1829,1919],"insulin degludec",{"nctId":1921,"briefTitle":1922,"status":105,"phases":1923,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT02148861","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes",[88],"2015-06-01","2014-05-26",49,[15,1467],[1829,1919],{"nctId":1930,"briefTitle":1931,"status":105,"phases":1932,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":306,"conditions":1935,"interventions":1936},"NCT03766854","A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week",[88],"2019-12-09","2018-12-07",[21],[376,1312],{"trials":1938,"activeCount":99},[1939,1948,1958],{"nctId":1940,"briefTitle":1941,"status":105,"phases":1942,"primaryCompletion":1822,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1947},"NCT03922750","A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine",[89],"2020-01-27","2019-05-09",154,[18],[1829,1312],{"nctId":1949,"briefTitle":1950,"status":105,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1944,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT03951805","A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before",[89],"2019-12-12","2020-01-17",205,[18],[1829,1957],"Insulin Glargine",{"nctId":1959,"briefTitle":1960,"status":105,"phases":1961,"primaryCompletion":595,"completion":1953,"start":1866,"enrollment":1962,"conditions":1963,"interventions":1964},"NCT03751657","A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units\u002FmL) Once a Day in People With Type 2 Diabetes.",[89],247,[18],[1829,1478,1965,1910],"Dipeptidyl peptidase-4 inhibitors",{"trials":1967,"activeCount":1606,"soonestReadout":2032},[1968,1979,1989,2001,2011,2020,2028,2038,2047,2056,2067],{"nctId":1969,"briefTitle":1970,"status":105,"phases":1971,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":1975,"conditions":1976,"interventions":1977},"NCT04848480","A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)",[90],"2022-04-28","2022-12-02","2021-04-30",582,[21],[376,1919,1978],"insulin aspart",{"nctId":1980,"briefTitle":1981,"status":105,"phases":1982,"primaryCompletion":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1988},"NCT05823948","A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)",[90],"2024-03-06","2024-04-11","2023-04-11",51,[18],[1518],{"nctId":1990,"briefTitle":1991,"status":105,"phases":1992,"primaryCompletion":1993,"completion":1051,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1997},"NCT04760626","A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before",[90],"2022-08-12","2021-03-01",1085,[18],[1829,1998,1999,2000],"Insulin Glargine 100U\u002FmL","Insulin Degludec","Insulin Glargine 300U\u002FmL",{"nctId":2002,"briefTitle":2003,"status":105,"phases":2004,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2010},"NCT04460885","A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before",[90],"2022-05-29","2022-12-01","2020-11-25",984,[18],[1829,1910],{"nctId":2012,"briefTitle":2013,"status":105,"phases":2014,"primaryCompletion":1167,"completion":2015,"start":2016,"enrollment":2017,"conditions":2018,"interventions":2019},"NCT05352815","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec",[90],"2024-04-23","2022-06-01",1291,[18],[375,1829],{"nctId":2021,"briefTitle":2022,"status":105,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":1975,"conditions":2026,"interventions":2027},"NCT04880850","A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)",[90],"2022-06-16","2021-05-14",[18],[1829,1910,1311],{"nctId":2029,"briefTitle":2030,"status":380,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2037},"NCT07076199","A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes",[90],"2027-01-25","2027-03-01","2025-08-11",877,[21],[1829,1910,1311],{"nctId":2039,"briefTitle":2040,"status":105,"phases":2041,"primaryCompletion":2042,"completion":2043,"start":932,"enrollment":2044,"conditions":2045,"interventions":2046},"NCT04770532","A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin",[90],"2022-01-27","2022-03-01",526,[18],[1887,1518],{"nctId":2048,"briefTitle":2049,"status":105,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":2053,"conditions":2054,"interventions":2055},"NCT04795531","A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)",[90],"2022-06-23","2021-03-24",588,[18],[1829,1887],{"nctId":2057,"briefTitle":2058,"status":105,"phases":2059,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2066},"NCT06340854","A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes",[90],"2025-05-08","2025-06-13","2024-04-19",429,[2065],"Diabetes, Type 2",[1829,1910],{"nctId":1509,"briefTitle":1510,"status":105,"phases":2068,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":2069,"interventions":2070},[90],[18],[1518,75],{"trials":2072,"activeCount":1606,"soonestReadout":2077},[2073],{"nctId":2074,"briefTitle":2075,"status":380,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2082},"NCT07112339","A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes",[91],"2026-08-04","2028-08-31","2025-08-15",586,[18],[1829,2083],"Basal insulin analogues",{"trials":2085,"activeCount":864,"soonestReadout":2090},[2086,2094],{"nctId":2087,"briefTitle":2088,"status":380,"phases":2089,"primaryCompletion":2090,"completion":2090,"start":2091,"enrollment":734,"conditions":2092,"interventions":2093},"NCT07160816","A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar",[],"2027-01-20","2025-08-28",[21],[1829],{"nctId":2095,"briefTitle":2096,"status":380,"phases":2097,"primaryCompletion":2098,"completion":1779,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2102},"NCT06807190","General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus",[],"2027-07-31","2025-05-30",630,[21],[1518],{"intervention":2083,"totalTrials":1606,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2119},{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[],{"trials":2110,"activeCount":99},[],{"trials":2112,"activeCount":99},[],{"trials":2114,"activeCount":1606,"soonestReadout":2077},[2115],{"nctId":2074,"briefTitle":2075,"status":380,"phases":2116,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2117,"interventions":2118},[91],[18],[1829,2083],{"trials":2120,"activeCount":99},[],{"intervention":2122,"totalTrials":992,"cells":2123},"eptacog alfa",{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2176,"PHASE3":2218,"PHASE4":2244,"NA":2264},{"trials":2125,"activeCount":99},[],{"trials":2127,"activeCount":99},[2128,2140,2149,2158,2167],{"nctId":2129,"briefTitle":2130,"status":105,"phases":2131,"primaryCompletion":2132,"completion":2132,"start":2133,"enrollment":2134,"conditions":2135,"interventions":2139},"NCT01949792","A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors",[88],"2013-11","2013-09",6,[30,36,2136,2137,2138],"Haemophilia A With Inhibitors","Haemophilia B","Haemophilia B With Inhibitors",[2122,2122],{"nctId":2141,"briefTitle":2142,"status":105,"phases":2143,"primaryCompletion":2144,"completion":2144,"start":2145,"enrollment":2146,"conditions":2147,"interventions":2148},"NCT01561924","Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography",[88],"2006-05","2005-11",17,[30,2136,2138],[2122],{"nctId":2150,"briefTitle":2151,"status":1135,"phases":2152,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":99,"conditions":2155,"interventions":2156},"NCT02084810","Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects",[88],"2014-07","2014-03",[30,36,2136,2137,2138,27],[2157,2122],"activated recombinant human factor VII",{"nctId":2159,"briefTitle":2160,"status":105,"phases":2161,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":28,"conditions":2164,"interventions":2166},"NCT01561937","Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment",[88],"2008-07","2007-01",[2165,27],"Haemostasis",[309,2122],{"nctId":2168,"briefTitle":2169,"status":349,"phases":2170,"primaryCompletion":489,"completion":489,"start":2171,"enrollment":2172,"conditions":2173,"interventions":2174},"NCT01561950","Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding",[88],"2008-05",91,[2165,27],[2122,2175],"clopidogrel",{"trials":2177,"activeCount":99},[2178,2189,2200,2209],{"nctId":2179,"briefTitle":2180,"status":105,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2187},"NCT03196284","A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors",[89],"2018-09-19","2020-01-31","2017-08-10",26,[30,2136,2138],[48,2188],"Eptacog alfa",{"nctId":2190,"briefTitle":2191,"status":105,"phases":2192,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2199},"NCT00266006","Factor VIIa in Acute Intracerebral Haemorrhage",[89],"2007-04","2006-01",90,[2197,2198],"Acquired Bleeding Disorder","Intracerebral Haemorrhage",[2122],{"nctId":2201,"briefTitle":2202,"status":105,"phases":2203,"primaryCompletion":2204,"completion":2204,"start":2205,"enrollment":1986,"conditions":2206,"interventions":2207},"NCT00486278","Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds",[89],"2010-06","2007-06",[30,36,2137],[2122,2208,2208,2208,2208,2208],"vatreptacog alfa",{"nctId":2210,"briefTitle":2211,"status":105,"phases":2212,"primaryCompletion":2213,"completion":2213,"start":2214,"enrollment":1624,"conditions":2215,"interventions":2217},"NCT00102037","Use of Activated Recombinant FVII in Spinal Surgery",[89],"2006-02","2004-07",[2197,2216],"Spinal Fusion",[2122],{"trials":2219,"activeCount":99},[2220,2230,2238],{"nctId":2221,"briefTitle":2222,"status":349,"phases":2223,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":2227,"interventions":2229},"NCT00184548","Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding",[90],"2008-09","2005-10",554,[2197,2228],"Trauma",[2122],{"nctId":2231,"briefTitle":2232,"status":105,"phases":2233,"primaryCompletion":2163,"completion":2163,"start":2234,"enrollment":2235,"conditions":2236,"interventions":2237},"NCT00127283","Recombinant Factor VIIa in Acute Intracerebral Haemorrhage",[90],"2005-05",829,[2197,2198],[2122],{"nctId":2239,"briefTitle":2240,"status":105,"phases":2241,"primaryCompletion":333,"completion":333,"start":232,"enrollment":587,"conditions":2242,"interventions":2243},"NCT01392547","Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors",[90],[30,2136,2138],[2208,2122],{"trials":2245,"activeCount":1606,"soonestReadout":2250},[2246,2256],{"nctId":2247,"briefTitle":2248,"status":380,"phases":2249,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2255},"NCT07157423","A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India",[91],"2027-03-26","2025-08-26",64,[2254],"Severe Postpartum Haemorrhage",[2188],{"nctId":2257,"briefTitle":2258,"status":105,"phases":2259,"primaryCompletion":2213,"completion":2213,"start":2260,"enrollment":173,"conditions":2261,"interventions":2262},"NCT00108797","Trial of NovoSeven® in Haemophilia - Joint Bleeds",[91],"2001-09",[30,2136,2138],[2122,2263],"Feiba VH",{"trials":2265,"activeCount":99},[2266,2274,2283,2292,2301,2312,2319,2327,2334],{"nctId":2267,"briefTitle":2268,"status":105,"phases":2269,"primaryCompletion":2270,"completion":2270,"start":2271,"enrollment":518,"conditions":2272,"interventions":2273},"NCT01830712","A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors",[],"2011-08","2011-04",[30,2136,2138],[2122],{"nctId":2275,"briefTitle":2276,"status":105,"phases":2277,"primaryCompletion":2278,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT00703911","Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors",[],"2010-07","2008-03",102,[30,2136,2138],[2122],{"nctId":2284,"briefTitle":2285,"status":105,"phases":2286,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":2290,"interventions":2291},"NCT04444856","Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern",[],"2021-01-13","2020-06-29",225,[2254],[2188],{"nctId":2293,"briefTitle":2294,"status":105,"phases":2295,"primaryCompletion":2296,"completion":2296,"start":2297,"enrollment":2298,"conditions":2299,"interventions":2300},"NCT01579968","Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery",[],"2010-03-09","1999-03-10",86,[30,2136,2138],[2122],{"nctId":2302,"briefTitle":2303,"status":105,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":2252,"conditions":2307,"interventions":2311},"NCT00697320","Observational Study on the Efficacy and Safety of NovoSeven® During \"Real-life\" Usage in Germany",[],"2010-12","2008-06",[30,2308,2309,2197,2310],"Congenital FVII Deficiency","Glanzmann's Disease","Acquired Haemophilia",[2122],{"nctId":2313,"briefTitle":2314,"status":105,"phases":2315,"primaryCompletion":2296,"completion":2296,"start":2297,"enrollment":2316,"conditions":2317,"interventions":2318},"NCT01579955","Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice",[],321,[30,2136,2138],[2122],{"nctId":2320,"briefTitle":2321,"status":105,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":713,"conditions":2325,"interventions":2326},"NCT01876745","A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan",[],"2017-06-01","2014-10-07",[30,2309],[2122],{"nctId":2328,"briefTitle":2329,"status":105,"phases":2330,"primaryCompletion":2331,"completion":2331,"start":488,"enrollment":2298,"conditions":2332,"interventions":2333},"NCT00882778","PROPACT: Retrospective Prophylaxis Patient Case Collection",[],"2010-05",[30,2136,2138],[2122],{"nctId":2335,"briefTitle":2336,"status":105,"phases":2337,"primaryCompletion":2296,"completion":2296,"start":2297,"enrollment":2338,"conditions":2339,"interventions":2340},"NCT01586936","Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors",[],9,[30,2136,2138],[2122],{"intervention":70,"totalTrials":354,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2420,"PHASE3":2430,"PHASE4":2506,"NA":2508},{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":1827,"soonestReadout":2355},[2347,2351,2361,2370,2374,2383,2387,2391,2401,2405,2416],{"nctId":156,"briefTitle":157,"status":105,"phases":2348,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":2349,"interventions":2350},[88],[164],[70,112,166],{"nctId":2352,"briefTitle":2353,"status":380,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":528,"conditions":2357,"interventions":2359},"NCT07411560","A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese",[88],"2027-01-26","2026-02-09",[33,2358],"Obese",[2360,70],"Glucose-dependent Insulinotropic Polypeptide",{"nctId":2362,"briefTitle":2363,"status":380,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2369},"NCT07557953","A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity",[88],"2027-04-13","2026-04-30",120,[33,24],[70],{"nctId":238,"briefTitle":239,"status":105,"phases":2371,"primaryCompletion":241,"completion":242,"start":243,"enrollment":37,"conditions":2372,"interventions":2373},[88],[24],[70,75],{"nctId":2375,"briefTitle":2376,"status":1346,"phases":2377,"primaryCompletion":2378,"completion":2378,"start":2379,"enrollment":2380,"conditions":2381,"interventions":2382},"NCT07607587","Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events",[88],"2027-11-19","2026-05-29",114,[24,33],[70],{"nctId":446,"briefTitle":447,"status":380,"phases":2384,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":2385,"interventions":2386},[88],[24],[70,75],{"nctId":522,"briefTitle":523,"status":380,"phases":2388,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":2389,"interventions":2390},[88],[24],[70,75],{"nctId":2392,"briefTitle":2393,"status":105,"phases":2394,"primaryCompletion":2395,"completion":2396,"start":2397,"enrollment":223,"conditions":2398,"interventions":2400},"NCT05564104","A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body",[88],"2024-09-06","2024-12-19","2023-04-05",[2399,142],"Hepatic Impairment",[70],{"nctId":630,"briefTitle":631,"status":105,"phases":2402,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":2403,"interventions":2404},[88],[18],[75,70],{"nctId":2406,"briefTitle":2407,"status":105,"phases":2408,"primaryCompletion":570,"completion":2409,"start":2410,"enrollment":152,"conditions":2411,"interventions":2412},"NCT05804162","A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants",[88],"2023-09-18","2023-04-12",[24],[70,2413,2414,2415],"Cagrilintide Placebo","Moxifloxacin","Moxifloxacin Placebo",{"nctId":703,"briefTitle":704,"status":105,"phases":2417,"primaryCompletion":241,"completion":706,"start":707,"enrollment":708,"conditions":2418,"interventions":2419},[88],[24],[70,75,711,712],{"trials":2421,"activeCount":99},[2422,2426],{"nctId":799,"briefTitle":800,"status":105,"phases":2423,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":2424,"interventions":2425},[89],[806],[257,75,808,809,810,70,811,809],{"nctId":854,"briefTitle":855,"status":105,"phases":2427,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":2428,"interventions":2429},[89],[840,862,24],[70,75],{"trials":2431,"activeCount":422,"soonestReadout":69},[2432,2436,2440,2444,2454,2458,2462,2466,2474,2478,2482,2486,2490,2494,2498,2502],{"nctId":887,"briefTitle":888,"status":457,"phases":2433,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":2434,"interventions":2435},[90],[895],[70,75],{"nctId":938,"briefTitle":939,"status":105,"phases":2437,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":2438,"interventions":2439},[90],[24],[70,75],{"nctId":1025,"briefTitle":1026,"status":105,"phases":2441,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":2442,"interventions":2443},[90],[24],[70,75,1034],{"nctId":2445,"briefTitle":2446,"status":457,"phases":2447,"primaryCompletion":2448,"completion":2449,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2453},"NCT07220759","Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide",[90],"2027-05-12","2027-06-30","2025-11-05",330,[33,24,862],[70],{"nctId":1162,"briefTitle":1163,"status":105,"phases":2455,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":1168,"conditions":2456,"interventions":2457},[90],[862],[70,75],{"nctId":1172,"briefTitle":1173,"status":105,"phases":2459,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":2460,"interventions":2461},[90],[862],[70,75],{"nctId":1192,"briefTitle":1193,"status":380,"phases":2463,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":1198,"conditions":2464,"interventions":2465},[90],[33,24],[70,75],{"nctId":2467,"briefTitle":2468,"status":457,"phases":2469,"primaryCompletion":2470,"completion":2471,"start":2450,"enrollment":943,"conditions":2472,"interventions":2473},"NCT07220642","Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide",[90],"2027-05-11","2027-06-29",[24,33],[70],{"nctId":1256,"briefTitle":1257,"status":105,"phases":2475,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":1262,"conditions":2476,"interventions":2477},[90],[862],[70,75,1034],{"nctId":1284,"briefTitle":1285,"status":105,"phases":2479,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":943,"conditions":2480,"interventions":2481},[90],[1291],[70,75],{"nctId":1375,"briefTitle":1376,"status":457,"phases":2483,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":1381,"conditions":2484,"interventions":2485},[90],[24],[70,75],{"nctId":1422,"briefTitle":1423,"status":105,"phases":2487,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":2488,"interventions":2489},[90],[1291],[70,75],{"nctId":1459,"briefTitle":1460,"status":105,"phases":2491,"primaryCompletion":1462,"completion":1463,"start":1464,"enrollment":1465,"conditions":2492,"interventions":2493},[90],[1467],[70,75],{"nctId":1499,"briefTitle":1500,"status":457,"phases":2495,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":1505,"conditions":2496,"interventions":2497},[90],[18],[70,75,1034],{"nctId":67,"briefTitle":68,"status":457,"phases":2499,"primaryCompletion":69,"completion":1521,"start":1522,"enrollment":1523,"conditions":2500,"interventions":2501},[90],[24],[70,75],{"nctId":1527,"briefTitle":1528,"status":105,"phases":2503,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":1533,"conditions":2504,"interventions":2505},[90],[33,24,1467],[70,75],{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[],{"intervention":1354,"totalTrials":1846,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2579,"PHASE3":2599,"PHASE4":2677,"NA":2679},{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":2578,"soonestReadout":2529},[2516,2525,2535,2543,2552,2561,2570],{"nctId":2517,"briefTitle":2518,"status":105,"phases":2519,"primaryCompletion":2520,"completion":461,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2524},"NCT06478563","A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity",[88],"2025-06-05","2024-06-27",133,[24,33],[1354,1354],{"nctId":2526,"briefTitle":2527,"status":380,"phases":2528,"primaryCompletion":2529,"completion":2530,"start":527,"enrollment":2531,"conditions":2532,"interventions":2534},"NCT07535307","Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes",[88],"2027-11-11","2027-12-06",80,[2533],"Diabetes Mellitus",[1354],{"nctId":2536,"briefTitle":2537,"status":105,"phases":2538,"primaryCompletion":2539,"completion":1049,"start":2540,"enrollment":173,"conditions":2541,"interventions":2542},"NCT06559527","A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function",[88],"2025-02-24","2024-08-20",[18,24,33],[1354],{"nctId":2544,"briefTitle":2545,"status":105,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":2549,"conditions":2550,"interventions":2551},"NCT06049329","A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity",[88],"2023-12-15","2023-09-14",36,[24],[1354],{"nctId":2553,"briefTitle":2554,"status":1346,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":2558,"conditions":2559,"interventions":2560},"NCT07587710","A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function",[88],"2027-12-01","2026-05-13",35,[33,24],[1354],{"nctId":2562,"briefTitle":2563,"status":380,"phases":2564,"primaryCompletion":2565,"completion":2566,"start":2567,"enrollment":2367,"conditions":2568,"interventions":2569},"NCT07508020","A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity",[88],"2028-01-19","2028-01-22","2026-03-30",[24],[1354],{"nctId":2571,"briefTitle":2572,"status":105,"phases":2573,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":354,"conditions":2576,"interventions":2577},"NCT06820476","A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing",[88],"2025-05-14","2025-02-09",[33,24],[1354],3,{"trials":2580,"activeCount":99},[2581,2588],{"nctId":2582,"briefTitle":2583,"status":105,"phases":2584,"primaryCompletion":1588,"completion":1588,"start":1187,"enrollment":2585,"conditions":2586,"interventions":2587},"NCT06064006","A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin",[89],125,[24,33],[1354],{"nctId":2589,"briefTitle":2590,"status":105,"phases":2591,"primaryCompletion":1165,"completion":2592,"start":2593,"enrollment":2594,"conditions":2595,"interventions":2597},"NCT06542874","A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes",[89],"2025-10-24","2024-08-07",448,[2596],"Type 2 Diabetes (T2D)",[2598,1354],"NNC0487-0111 subcutanous",{"trials":2600,"activeCount":2338,"soonestReadout":2665},[2601,2611,2620,2628,2638,2649,2653,2661,2670],{"nctId":2602,"briefTitle":2603,"status":380,"phases":2604,"primaryCompletion":2605,"completion":2606,"start":2607,"enrollment":943,"conditions":2608,"interventions":2610},"NCT07571005","AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea",[90],"2028-07-12","2028-10-04","2026-05-05",[24,33,2609],"Obstructive Sleep Apnoea",[1354],{"nctId":2612,"briefTitle":2613,"status":380,"phases":2614,"primaryCompletion":2615,"completion":2615,"start":2616,"enrollment":1381,"conditions":2617,"interventions":2619},"NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain",[90],"2028-08-14","2026-04-20",[24,33,2618],"Osteoarthritis, Knee",[1354],{"nctId":2621,"briefTitle":2622,"status":380,"phases":2623,"primaryCompletion":2624,"completion":2625,"start":2607,"enrollment":943,"conditions":2626,"interventions":2627},"NCT07571109","AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea",[90],"2028-06-26","2028-08-21",[24,33,2609],[1354],{"nctId":2629,"briefTitle":2630,"status":380,"phases":2631,"primaryCompletion":2632,"completion":2633,"start":2634,"enrollment":2635,"conditions":2636,"interventions":2637},"NCT07339423","AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight",[90],"2029-06-26","2029-08-21","2026-02-24",1150,[24],[1354],{"nctId":2639,"briefTitle":2640,"status":1346,"phases":2641,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":2645,"conditions":2646,"interventions":2648},"NCT07567001","A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity",[90],"2029-07-23","2029-08-15","2026-05-11",5610,[24,2647],"Heart Failure",[1354],{"nctId":1344,"briefTitle":1345,"status":1346,"phases":2650,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":2651,"interventions":2652},[90],[24,33,18],[1354,75],{"nctId":2654,"briefTitle":2655,"status":380,"phases":2656,"primaryCompletion":2615,"completion":2615,"start":2657,"enrollment":1381,"conditions":2658,"interventions":2660},"NCT07481630","A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain",[90],"2026-04-13",[24,2659],"Knee Osteoarthritis (OA)",[1354],{"nctId":2662,"briefTitle":2663,"status":380,"phases":2664,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":1659,"conditions":2668,"interventions":2669},"NCT07503210","AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss",[90],"2028-06-06","2028-07-04","2026-04-21",[24],[1354],{"nctId":2671,"briefTitle":2672,"status":380,"phases":2673,"primaryCompletion":2674,"completion":2674,"start":2657,"enrollment":2100,"conditions":2675,"interventions":2676},"NCT07533175","AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight",[90],"2028-08-07",[2533,33,24],[1354],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"intervention":2682,"totalTrials":2683,"cells":2684},"CagriSema",8,{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2706,"PHASE3":2726,"PHASE4":2759,"NA":2761},{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":1606,"soonestReadout":2702},[2689,2698],{"nctId":2690,"briefTitle":2691,"status":105,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":837,"enrollment":1846,"conditions":2695,"interventions":2696},"NCT06716307","A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity",[88],"2025-03-28","2025-05-22",[24],[2682,2697],"CagriSema A",{"nctId":2699,"briefTitle":2700,"status":380,"phases":2701,"primaryCompletion":2702,"completion":2702,"start":2703,"enrollment":2531,"conditions":2704,"interventions":2705},"NCT07184086","A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet",[88],"2027-10-12","2025-09-26",[24],[2682],{"trials":2707,"activeCount":864,"soonestReadout":2712},[2708,2718],{"nctId":2709,"briefTitle":2710,"status":457,"phases":2711,"primaryCompletion":2712,"completion":2712,"start":2713,"enrollment":2714,"conditions":2715,"interventions":2717},"NCT06797869","A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy",[89],"2026-08-21","2025-01-29",142,[18,2716],"Diabetic Peripheral Neuropathy",[2682],{"nctId":2719,"briefTitle":2720,"status":1346,"phases":2721,"primaryCompletion":2722,"completion":891,"start":2723,"enrollment":1381,"conditions":2724,"interventions":2725},"NCT07357740","A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes",[89],"2027-08-25","2026-08-27",[18],[2682],{"trials":2727,"activeCount":713,"soonestReadout":2033},[2728,2737,2745,2749],{"nctId":2729,"briefTitle":2730,"status":457,"phases":2731,"primaryCompletion":2033,"completion":2732,"start":2733,"enrollment":2734,"conditions":2735,"interventions":2736},"NCT07011667","A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term",[90],"2028-10-17","2025-06-03",609,[24],[2682],{"nctId":2738,"briefTitle":2739,"status":1346,"phases":2740,"primaryCompletion":2741,"completion":2742,"start":2077,"enrollment":2531,"conditions":2743,"interventions":2744},"NCT07282613","A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes",[90],"2029-09-07","2030-03-30",[18],[2682],{"nctId":1084,"briefTitle":1085,"status":380,"phases":2746,"primaryCompletion":1087,"completion":1088,"start":1089,"enrollment":1090,"conditions":2747,"interventions":2748},[90],[24,862],[1093,75],{"nctId":2750,"briefTitle":2751,"status":1346,"phases":2752,"primaryCompletion":2753,"completion":2754,"start":2755,"enrollment":2756,"conditions":2757,"interventions":2758},"NCT07357766","A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight",[90],"2027-11-29","2028-01-17","2026-06-22",1400,[33,24],[1093],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"intervention":43,"totalTrials":372,"cells":2764},{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2832,"PHASE3":2852,"PHASE4":2918,"NA":2920},{"trials":2766,"activeCount":99},[],{"trials":2768,"activeCount":99},[2769,2780,2790,2798,2807,2814,2823],{"nctId":2770,"briefTitle":2771,"status":105,"phases":2772,"primaryCompletion":2773,"completion":2773,"start":2774,"enrollment":182,"conditions":2775,"interventions":2779},"NCT03186495","Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function",[88],"2018-05-17","2017-06-20",[2776,2777,2778],"Growth Hormone Disorder","Adult Growth Hormone Deficiency","Growth Hormone Deficiency in Children",[43],{"nctId":2781,"briefTitle":2782,"status":105,"phases":2783,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":2558,"conditions":2786,"interventions":2787},"NCT01706783","A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency",[88],"2013-11-18","2012-10-12",[2776,2777],[2788,2789],"somapacitan","Norditropin NordiFlex®",{"nctId":2791,"briefTitle":2792,"status":105,"phases":2793,"primaryCompletion":2794,"completion":2794,"start":2795,"enrollment":422,"conditions":2796,"interventions":2797},"NCT02962440","A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects",[88],"2017-01","2016-11",[27],[2788],{"nctId":2799,"briefTitle":2800,"status":105,"phases":2801,"primaryCompletion":353,"completion":353,"start":2802,"enrollment":2803,"conditions":2804,"interventions":2806},"NCT03905850","A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects",[88],"2019-03-29",33,[142,2805],"Growth Hormone Deficiency",[2788],{"nctId":2808,"briefTitle":2809,"status":105,"phases":2810,"primaryCompletion":1099,"completion":1099,"start":2811,"enrollment":708,"conditions":2812,"interventions":2813},"NCT03212131","Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.",[88],"2017-08-16",[2776,2777,2778],[43],{"nctId":2815,"briefTitle":2816,"status":105,"phases":2817,"primaryCompletion":2818,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2822},"NCT01514500","First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects",[88],"2013-03-18","2012-01-16",105,[2776,2777,2778,27],[2788],{"nctId":2824,"briefTitle":2825,"status":105,"phases":2826,"primaryCompletion":2827,"completion":2827,"start":2828,"enrollment":223,"conditions":2829,"interventions":2830},"NCT01973244","A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency",[88],"2014-11-04","2013-12-16",[2776,2778],[2788,2831],"somatropin",{"trials":2833,"activeCount":1606,"soonestReadout":42},[2834,2844],{"nctId":2835,"briefTitle":2836,"status":105,"phases":2837,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":2840,"conditions":2841,"interventions":2842},"NCT02616562","Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency",[89],"2024-09-26","2016-03-31",76,[2776,2778],[2788,2843],"Norditropin® FlexPro® pen",{"nctId":40,"briefTitle":41,"status":457,"phases":2845,"primaryCompletion":42,"completion":2846,"start":2847,"enrollment":37,"conditions":2848,"interventions":2850},[89],"2026-12-23","2019-07-04",[2849],"Short Stature Children Born Small for Gestational Age (SGA)",[43,2851],"Norditropin®",{"trials":2853,"activeCount":864,"soonestReadout":61},[2854,2864,2873,2882,2892,2902,2909],{"nctId":2855,"briefTitle":2856,"status":105,"phases":2857,"primaryCompletion":2858,"completion":2859,"start":2860,"enrollment":2861,"conditions":2862,"interventions":2863},"NCT02229851","Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.",[90],"2017-04-21","2018-05-07","2014-10-31",301,[2776,2777],[2788,2831],{"nctId":2865,"briefTitle":2866,"status":105,"phases":2867,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":1110,"conditions":2871,"interventions":2872},"NCT03811535","A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)",[90],"2021-11-10","2025-09-30","2019-05-20",[2778],[43,2851],{"nctId":2874,"briefTitle":2875,"status":105,"phases":2876,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":2879,"conditions":2880,"interventions":2881},"NCT02382939","A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency",[90],"2016-01-04","2015-02-12",92,[2777,2776],[2788,2831],{"nctId":59,"briefTitle":60,"status":457,"phases":2883,"primaryCompletion":61,"completion":2884,"start":1532,"enrollment":2885,"conditions":2886,"interventions":2891},[90],"2027-10-29",47,[2887,2888,2889,2890],"SGA","Turner Syndrome","Noonan Syndrome","ISS",[43],{"nctId":2893,"briefTitle":2894,"status":105,"phases":2895,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2901},"NCT04970654","A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.",[90],"2023-11-17","2023-12-18","2021-07-22",110,[2778],[2788,2851],{"nctId":63,"briefTitle":64,"status":457,"phases":2903,"primaryCompletion":65,"completion":2884,"start":2904,"enrollment":2905,"conditions":2906,"interventions":2908},[90],"2022-08-10",412,[2907],"SGA, Turner Syndrome, Noonan Syndrome, ISS",[43,2851],{"nctId":2910,"briefTitle":2911,"status":105,"phases":2912,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":37,"conditions":2915,"interventions":2916},"NCT03075644","A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency",[90],"2018-10-04","2017-03-03",[2776,2777],[2788,2917],"Norditropin",{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":713,"soonestReadout":2951},[2922,2930,2939,2947],{"nctId":2923,"briefTitle":2924,"status":457,"phases":2925,"primaryCompletion":2926,"completion":2926,"start":2927,"enrollment":1110,"conditions":2928,"interventions":2929},"NCT05230550","Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®",[],"2026-12-31","2022-02-03",[2777],[43],{"nctId":2931,"briefTitle":2932,"status":1700,"phases":2933,"primaryCompletion":2934,"completion":2934,"start":1408,"enrollment":795,"conditions":2935,"interventions":2938},"NCT06709040","A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters",[],"2034-04-14",[2805,2936,2937],"Neoplasms","Diabetes Mellitus Type 2",[43],{"nctId":2940,"briefTitle":2941,"status":1700,"phases":2942,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":1381,"conditions":2945,"interventions":2946},"NCT05718570","A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information",[],"2032-12-15","2023-02-03",[2777],[43],{"nctId":2948,"briefTitle":2949,"status":1700,"phases":2950,"primaryCompletion":2951,"completion":2926,"start":2952,"enrollment":1110,"conditions":2953,"interventions":2954},"NCT06109935","Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed",[],"2026-07-31","2023-10-04",[2778],[43],{"intervention":48,"totalTrials":2338,"cells":2956},{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2969,"PHASE3":2983,"PHASE4":3010,"NA":3012},{"trials":2958,"activeCount":99},[],{"trials":2960,"activeCount":99},[2961],{"nctId":2962,"briefTitle":2963,"status":105,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":306,"conditions":2967,"interventions":2968},"NCT02490787","Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects",[88],"2016-10-14","2015-09-10",[30,36],[48],{"trials":2970,"activeCount":99},[2971,2975],{"nctId":2179,"briefTitle":2180,"status":105,"phases":2972,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2973,"interventions":2974},[89],[30,2136,2138],[48,2188],{"nctId":2976,"briefTitle":2977,"status":105,"phases":2978,"primaryCompletion":2979,"completion":2980,"start":2811,"enrollment":2549,"conditions":2981,"interventions":2982},"NCT03196297","A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors",[89],"2018-06-22","2020-06-03",[2165,36],[48,85],{"trials":2984,"activeCount":2578,"soonestReadout":47},[2985,2992,3001],{"nctId":45,"briefTitle":46,"status":457,"phases":2986,"primaryCompletion":47,"completion":2987,"start":2988,"enrollment":2989,"conditions":2990,"interventions":2991},[90],"2027-02-21","2019-10-21",134,[2136,2138],[48],{"nctId":50,"briefTitle":51,"status":457,"phases":2993,"primaryCompletion":52,"completion":2994,"start":2995,"enrollment":2996,"conditions":2997,"interventions":3000},[90],"2028-02-21","2019-11-13",156,[2998,2999],"Haemophilia A Without Inhibitors","Haemophilia B Without Inhibitors",[48],{"nctId":3002,"briefTitle":3003,"status":457,"phases":3004,"primaryCompletion":2667,"completion":3005,"start":1875,"enrollment":3006,"conditions":3007,"interventions":3009},"NCT05135559","A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors",[90],"2029-11-02",153,[3008],"Haemophilia A and B With and Without Inhibitors",[48],{"trials":3011,"activeCount":99},[],{"trials":3013,"activeCount":864,"soonestReadout":3027},[3014,3023,3031],{"nctId":3015,"briefTitle":3016,"status":1700,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":3019,"enrollment":119,"conditions":3020,"interventions":3022},"NCT06831734","Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo",[],"2031-01-31","2025-05-02",[3021],"Haemophilia A, Haemophilia B",[48],{"nctId":3024,"briefTitle":3025,"status":1700,"phases":3026,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":992,"conditions":3029,"interventions":3030},"NCT06285071","Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors",[],"2030-04-30","2024-08-08",[36,2137],[48],{"nctId":3032,"briefTitle":3033,"status":3034,"phases":3035,"conditions":3036,"interventions":3038},"NCT04921956","Compassionate Use of Concizumab if You Have Haemophilia","AVAILABLE",[],[3037],"Congenital Haemophilia",[48],{"intervention":3040,"totalTrials":422,"cells":3041},"Ziltivekimab",{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3056,"PHASE3":3078,"PHASE4":3120,"NA":3122},{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[3046],{"nctId":3047,"briefTitle":3048,"status":105,"phases":3049,"primaryCompletion":3050,"completion":3051,"start":3052,"enrollment":306,"conditions":3053,"interventions":3055},"NCT05379829","A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation",[88],"2024-06-12","2024-09-02","2022-05-30",[3054],"Chronic Kidney Disease and Systemic Inflammation",[3040],{"trials":3057,"activeCount":99},[3058,3069],{"nctId":3059,"briefTitle":3060,"status":105,"phases":3061,"primaryCompletion":3062,"completion":3063,"start":3064,"enrollment":2549,"conditions":3065,"interventions":3068},"NCT04626505","Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.",[89],"2021-08-03","2021-09-28","2020-10-22",[840,3066,3067],"Inflammation","Cardiovascular Risk",[3040],{"nctId":3070,"briefTitle":3071,"status":105,"phases":3072,"primaryCompletion":1865,"completion":1865,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3077},"NCT03926117","Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition",[89],"2019-06-03",264,[3076,3066],"Chronic Kidney Diseases",[3040],{"trials":3079,"activeCount":713,"soonestReadout":3084},[3080,3090,3099,3110],{"nctId":3081,"briefTitle":3082,"status":380,"phases":3083,"primaryCompletion":3084,"completion":3085,"start":859,"enrollment":3086,"conditions":3087,"interventions":3089},"NCT06200207","A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation",[90],"2026-10-01","2027-01-08",680,[2647,3088],"Systemic Inflammation",[3040],{"nctId":3091,"briefTitle":3092,"status":380,"phases":3093,"primaryCompletion":3094,"completion":3094,"start":3095,"enrollment":3096,"conditions":3097,"interventions":3098},"NCT05636176","A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation",[90],"2027-07-02","2023-05-08",5600,[2647],[3040],{"nctId":3100,"briefTitle":3101,"status":380,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":1745,"enrollment":3105,"conditions":3106,"interventions":3108},"NCT07301034","A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack",[90],"2028-11-14","2029-02-24",332,[3107],"Myocardial Infarction",[3040,3109],"Ziltivekimab Placebo",{"nctId":3111,"briefTitle":3112,"status":380,"phases":3113,"primaryCompletion":3114,"completion":3114,"start":3115,"enrollment":3116,"conditions":3117,"interventions":3119},"NCT06118281","ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack",[90],"2026-12-14","2024-06-25",10000,[3067,3118],"Acute Myocardial Infarction (AMI)",[3040],{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"intervention":3125,"totalTrials":2185,"cells":3126},"Oral semaglutide",{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3191,"PHASE3":3193,"PHASE4":3252,"NA":3254},{"trials":3128,"activeCount":99},[],{"trials":3130,"activeCount":1606,"soonestReadout":382},[3131,3141,3151,3160,3164,3173,3182],{"nctId":3132,"briefTitle":3133,"status":105,"phases":3134,"primaryCompletion":3135,"completion":3136,"start":3137,"enrollment":3138,"conditions":3139,"interventions":3140},"NCT04109508","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets",[88],"2020-12-24","2021-01-27","2019-10-02",278,[142,862],[3125],{"nctId":3142,"briefTitle":3143,"status":105,"phases":3144,"primaryCompletion":3145,"completion":3146,"start":3147,"enrollment":3148,"conditions":3149,"interventions":3150},"NCT04817644","A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets",[88],"2023-05-26","2023-07-03","2021-09-10",14,[18],[3125],{"nctId":3152,"briefTitle":3153,"status":105,"phases":3154,"primaryCompletion":3155,"completion":3156,"start":3157,"enrollment":1178,"conditions":3158,"interventions":3159},"NCT04097600","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets",[88],"2020-12-16","2021-01-20","2019-09-30",[142,862],[3125],{"nctId":378,"briefTitle":379,"status":380,"phases":3161,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":3162,"interventions":3163},[88],[24],[57,388,75],{"nctId":3165,"briefTitle":3166,"status":105,"phases":3167,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":223,"conditions":3171,"interventions":3172},"NCT04016974","A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese",[88],"2021-01-23","2021-02-26","2019-10-08",[142,18],[3125],{"nctId":3174,"briefTitle":3175,"status":105,"phases":3176,"primaryCompletion":3177,"completion":3177,"start":3178,"enrollment":3179,"conditions":3180,"interventions":3181},"NCT04524832","Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People",[88],"2022-02-25","2020-09-29",290,[18],[3125],{"nctId":3183,"briefTitle":3184,"status":105,"phases":3185,"primaryCompletion":3186,"completion":3187,"start":3188,"enrollment":2996,"conditions":3189,"interventions":3190},"NCT04513704","A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times",[88],"2021-04-20","2021-05-26","2020-08-28",[664],[388],{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":1606,"soonestReadout":3229},[3195,3205,3215,3225,3234,3242],{"nctId":3196,"briefTitle":3197,"status":105,"phases":3198,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":3201,"conditions":3202,"interventions":3203},"NCT04017832","A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes",[90],"2021-10-27","2019-07-29",1441,[18],[3125,3204],"Sitagliptin",{"nctId":3206,"briefTitle":3207,"status":105,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3214},"NCT05035095","Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)",[90],"2023-03-24","2023-05-12","2021-09-13",667,[24,33],[3125],{"nctId":3216,"briefTitle":3217,"status":105,"phases":3218,"primaryCompletion":3219,"completion":3220,"start":3221,"enrollment":3222,"conditions":3223,"interventions":3224},"NCT04596631","A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes",[90],"2025-04-29","2026-02-03","2020-11-02",132,[18],[3125],{"nctId":3226,"briefTitle":3227,"status":457,"phases":3228,"primaryCompletion":3229,"completion":3230,"start":3231,"enrollment":3074,"conditions":3232,"interventions":3233},"NCT07271251","A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes",[90],"2026-06-29","2026-08-03","2025-12-01",[862],[3125],{"nctId":3235,"briefTitle":3236,"status":105,"phases":3237,"primaryCompletion":3238,"completion":3199,"start":3239,"enrollment":1815,"conditions":3240,"interventions":3241},"NCT04109547","A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes",[90],"2021-09-23","2019-10-01",[18],[3125],{"nctId":3243,"briefTitle":3244,"status":105,"phases":3245,"primaryCompletion":3246,"completion":3247,"start":3248,"enrollment":3249,"conditions":3250,"interventions":3251},"NCT04707469","Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes",[90],"2023-03-07","2023-03-08","2021-01-15",1606,[18],[3125],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":1606,"soonestReadout":3301},[3256,3265,3272,3280,3289,3297,3306,3315,3323,3331,3339,3346,3355],{"nctId":3257,"briefTitle":3258,"status":105,"phases":3259,"primaryCompletion":3260,"completion":3260,"start":3261,"enrollment":3262,"conditions":3263,"interventions":3264},"NCT04601753","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice",[],"2023-03-03","2020-11-12",194,[18],[388],{"nctId":3266,"briefTitle":3267,"status":105,"phases":3268,"primaryCompletion":3095,"completion":3095,"start":3188,"enrollment":3269,"conditions":3270,"interventions":3271},"NCT04537637","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice",[],99,[18],[388],{"nctId":3273,"briefTitle":3274,"status":105,"phases":3275,"primaryCompletion":3276,"completion":3276,"start":3277,"enrollment":1061,"conditions":3278,"interventions":3279},"NCT05230615","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",[],"2023-10-31","2022-04-01",[18],[3125],{"nctId":3281,"briefTitle":3282,"status":105,"phases":3283,"primaryCompletion":3284,"completion":3285,"start":3286,"enrollment":3262,"conditions":3287,"interventions":3288},"NCT04537624","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice",[],"2023-01-11","2023-05-31","2020-08-24",[18],[388],{"nctId":3290,"briefTitle":3291,"status":105,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":883,"conditions":3295,"interventions":3296},"NCT05502562","A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India",[],"2024-06-03","2023-02-24",[18],[3125],{"nctId":3298,"briefTitle":3299,"status":380,"phases":3300,"primaryCompletion":3301,"completion":3301,"start":3302,"enrollment":3303,"conditions":3304,"interventions":3305},"NCT06269120","SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary",[],"2026-03-31","2024-09-30",470,[862],[388],{"nctId":3307,"briefTitle":3308,"status":105,"phases":3309,"primaryCompletion":3310,"completion":3310,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3314},"NCT04862923","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice",[],"2023-08-31","2021-05-12",336,[18],[3125],{"nctId":3316,"briefTitle":3317,"status":105,"phases":3318,"primaryCompletion":3319,"completion":3319,"start":3320,"enrollment":3262,"conditions":3321,"interventions":3322},"NCT04559815","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice",[],"2022-09-14","2020-10-21",[18],[388],{"nctId":3324,"briefTitle":3325,"status":105,"phases":3326,"primaryCompletion":3327,"completion":3327,"start":1974,"enrollment":3328,"conditions":3329,"interventions":3330},"NCT04878393","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice",[],"2023-02-09",650,[18],[3125],{"nctId":3332,"briefTitle":3333,"status":1135,"phases":3334,"primaryCompletion":3335,"completion":3335,"start":3336,"enrollment":99,"conditions":3337,"interventions":3338},"NCT05473286","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice",[],"2024-05-16","2022-09-30",[18],[388],{"nctId":3340,"briefTitle":3341,"status":105,"phases":3342,"primaryCompletion":3343,"completion":3343,"start":1554,"enrollment":3262,"conditions":3344,"interventions":3345},"NCT05230589","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice",[],"2023-03-13",[18],[3125],{"nctId":3347,"briefTitle":3348,"status":105,"phases":3349,"primaryCompletion":3350,"completion":3350,"start":3351,"enrollment":3352,"conditions":3353,"interventions":3354},"NCT05443568","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice",[],"2024-11-16","2023-03-09",155,[18],[3125],{"nctId":3356,"briefTitle":3357,"status":105,"phases":3358,"primaryCompletion":3359,"completion":3359,"start":3360,"enrollment":3361,"conditions":3362,"interventions":3363},"NCT04601740","A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice",[],"2022-12-19","2020-11-17",145,[18],[388],{"intervention":2851,"totalTrials":713,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3376,"PHASE4":3390,"NA":3392},{"trials":3367,"activeCount":99},[],{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":1606,"soonestReadout":42},[3372],{"nctId":40,"briefTitle":41,"status":457,"phases":3373,"primaryCompletion":42,"completion":2846,"start":2847,"enrollment":37,"conditions":3374,"interventions":3375},[89],[2849],[43,2851],{"trials":3377,"activeCount":1606,"soonestReadout":65},[3378,3382,3386],{"nctId":2865,"briefTitle":2866,"status":105,"phases":3379,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":1110,"conditions":3380,"interventions":3381},[90],[2778],[43,2851],{"nctId":2893,"briefTitle":2894,"status":105,"phases":3383,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":2899,"conditions":3384,"interventions":3385},[90],[2778],[2788,2851],{"nctId":63,"briefTitle":64,"status":457,"phases":3387,"primaryCompletion":65,"completion":2884,"start":2904,"enrollment":2905,"conditions":3388,"interventions":3389},[90],[2907],[43,2851],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"intervention":3395,"totalTrials":2578,"cells":3396},"NNC6019-0001",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3421,"PHASE4":3432,"NA":3434},{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":1606,"soonestReadout":3417},[3403,3413],{"nctId":3404,"briefTitle":3405,"status":105,"phases":3406,"primaryCompletion":3407,"completion":3408,"start":3409,"enrollment":2820,"conditions":3410,"interventions":3412},"NCT05442047","A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis",[89],"2025-02-17","2025-05-13","2022-08-02",[3411],"Transthyretin Amyloid Cardiomyopathy (ATTR CM)",[3395],{"nctId":3414,"briefTitle":3415,"status":457,"phases":3416,"primaryCompletion":3417,"completion":1702,"start":3418,"enrollment":2531,"conditions":3419,"interventions":3420},"NCT06260709","A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis",[89],"2028-02-29","2024-02-20",[3411],[3395],{"trials":3422,"activeCount":1606,"soonestReadout":3427},[3423],{"nctId":3424,"briefTitle":3425,"status":380,"phases":3426,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":3429,"conditions":3430,"interventions":3431},"NCT07207811","CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis",[90],"2029-06-29","2025-10-02",1280,[3411],[3395],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"intervention":768,"totalTrials":8,"cells":3437},{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3742,"PHASE3":3847,"PHASE4":4176,"NA":4229},{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":1606,"soonestReadout":382},[3442,3450,3457,3465,3472,3480,3488,3496,3504,3512,3522,3530,3538,3546,3554,3558,3565,3573,3581,3590,3598,3605,3614,3622,3630,3637,3646,3653,3659,3667,3673,3680,3688,3695,3702,3710,3719,3727,3734],{"nctId":3443,"briefTitle":3444,"status":105,"phases":3445,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":507,"conditions":3448,"interventions":3449},"NCT01789086","A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years",[88],"2014-05","2013-02",[204,24],[768],{"nctId":3451,"briefTitle":3452,"status":105,"phases":3453,"primaryCompletion":2193,"completion":2193,"start":2163,"enrollment":3454,"conditions":3455,"interventions":3456},"NCT01515553","Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers",[88],22,[15,27],[768],{"nctId":3458,"briefTitle":3459,"status":105,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":507,"conditions":3463,"interventions":3464},"NCT00943501","Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes",[88],"2011-09","2009-11",[15,18],[768,768],{"nctId":3466,"briefTitle":3467,"status":105,"phases":3468,"primaryCompletion":172,"completion":172,"start":3469,"enrollment":306,"conditions":3470,"interventions":3471},"NCT02207348","Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors",[88],"2014-08",[204,24],[768],{"nctId":3473,"briefTitle":3474,"status":105,"phases":3475,"primaryCompletion":3476,"completion":3476,"start":3477,"enrollment":363,"conditions":3478,"interventions":3479},"NCT02717858","A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.",[88],"2017-02-27","2016-03-16",[204,24],[768],{"nctId":3481,"briefTitle":3482,"status":105,"phases":3483,"primaryCompletion":3484,"completion":3484,"start":652,"enrollment":306,"conditions":3485,"interventions":3486},"NCT01319240","Safety and Tolerability of Insulin Degludec\u002FLiraglutide (A3) in Healthy Subjects",[88],"2011-05",[15,27],[1919,3487,768],"insulin degludec\u002Fliraglutide",{"nctId":3489,"briefTitle":3490,"status":105,"phases":3491,"primaryCompletion":3492,"completion":3492,"start":3493,"enrollment":306,"conditions":3494,"interventions":3495},"NCT01507389","Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function",[88],"2006-06","2006-03",[15,18],[768],{"nctId":3497,"briefTitle":3498,"status":105,"phases":3499,"primaryCompletion":3500,"completion":3500,"start":3501,"enrollment":306,"conditions":3502,"interventions":3503},"NCT01620476","Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers",[88],"2004-03","2003-09",[15,27],[768,768,768],{"nctId":3505,"briefTitle":3506,"status":105,"phases":3507,"primaryCompletion":3508,"completion":3508,"start":3509,"enrollment":306,"conditions":3510,"interventions":3511},"NCT01514487","Comparison of Three Liraglutide Formulations in Healthy Volunteers",[88],"2005-03-30","2005-01-13",[15,27],[768],{"nctId":3513,"briefTitle":3514,"status":105,"phases":3515,"primaryCompletion":3516,"completion":3516,"start":3517,"enrollment":3518,"conditions":3519,"interventions":3520},"NCT02235961","Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects",[88],"2016-07-06","2014-09-04",163,[204,24],[3521,768],"NNC9204-0530",{"nctId":3523,"briefTitle":3524,"status":105,"phases":3525,"primaryCompletion":3526,"completion":3526,"start":3527,"enrollment":708,"conditions":3528,"interventions":3529},"NCT01507272","Safety and Tolerability of Liraglutide in Healthy Male Volunteers",[88],"1999-12","1999-03",[15,27],[768,768],{"nctId":3531,"briefTitle":3532,"status":105,"phases":3533,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":3534,"conditions":3535,"interventions":3536},"NCT01518166","Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH",[88],70,[15,27],[768,557,366,3537,227],"griseofulvin",{"nctId":3539,"briefTitle":3540,"status":105,"phases":3541,"primaryCompletion":3542,"completion":3542,"start":3543,"enrollment":306,"conditions":3544,"interventions":3545},"NCT03292185","A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec\u002FLiraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects",[88],"2018-01-02","2017-09-29",[15,18],[3487,1919,768],{"nctId":3547,"briefTitle":3548,"status":105,"phases":3549,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":223,"conditions":3552,"interventions":3553},"NCT01507337","Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers",[88],"2004-06","2004-04",[15,27],[768],{"nctId":378,"briefTitle":379,"status":380,"phases":3555,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":3556,"interventions":3557},[88],[24],[57,388,75],{"nctId":3559,"briefTitle":3560,"status":105,"phases":3561,"primaryCompletion":3493,"completion":3493,"start":3562,"enrollment":119,"conditions":3563,"interventions":3564},"NCT01508806","Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function",[88],"2005-08",[15,18],[768],{"nctId":3566,"briefTitle":3567,"status":105,"phases":3568,"primaryCompletion":3569,"completion":3569,"start":3570,"enrollment":306,"conditions":3571,"interventions":3572},"NCT02696148","A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years",[88],"2017-04-13","2016-03-14",[204,24],[768],{"nctId":3574,"briefTitle":3575,"status":105,"phases":3576,"primaryCompletion":3526,"completion":3526,"start":3577,"enrollment":3578,"conditions":3579,"interventions":3580},"NCT01507311","Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes",[88],"1999-09",11,[15,18],[768],{"nctId":3582,"briefTitle":3583,"status":105,"phases":3584,"primaryCompletion":3585,"completion":3585,"start":3586,"enrollment":2803,"conditions":3587,"interventions":3588},"NCT00873223","Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir",[88],"2009-09","2009-03",[15,18],[768,3589],"insulin detemir",{"nctId":3591,"briefTitle":3592,"status":105,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":2145,"enrollment":653,"conditions":3595,"interventions":3596},"NCT01511692","Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes",[88],"2007-09",[15,18],[768,3597],"glimepiride",{"nctId":3599,"briefTitle":3600,"status":105,"phases":3601,"primaryCompletion":3492,"completion":3492,"start":3602,"enrollment":3454,"conditions":3603,"interventions":3604},"NCT01515579","Comparison of Two Liraglutide Formulations in Healthy Subjects",[88],"2006-04",[15,27],[768,768],{"nctId":3606,"briefTitle":3607,"status":105,"phases":3608,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":223,"conditions":3611,"interventions":3612},"NCT01511159","Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers",[88],"2001-12","2001-10",[15,27],[768,768,768,3613,3613,768],"insulin human",{"nctId":3615,"briefTitle":3616,"status":105,"phases":3617,"primaryCompletion":3618,"completion":3618,"start":3619,"enrollment":2252,"conditions":3620,"interventions":3621},"NCT01516255","Effect of Liraglutide on Heart Frequency in Healthy Volunteers",[88],"2006-11","2006-07",[15,18],[768,607],{"nctId":3623,"briefTitle":3624,"status":105,"phases":3625,"primaryCompletion":3626,"completion":3626,"start":3627,"enrollment":306,"conditions":3628,"interventions":3629},"NCT01507285","Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes",[88],"1999-11","1999-08",[15,18,27],[768],{"nctId":3631,"briefTitle":3632,"status":105,"phases":3633,"primaryCompletion":3500,"completion":3500,"start":3634,"enrollment":518,"conditions":3635,"interventions":3636},"NCT01615978","Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes",[88],"2003-12",[15,18],[768,768],{"nctId":3638,"briefTitle":3639,"status":105,"phases":3640,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":3643,"conditions":3644,"interventions":3645},"NCT01509742","Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes",[88],"2001-11","2001-04",19,[15,18],[768],{"nctId":3647,"briefTitle":3648,"status":105,"phases":3649,"primaryCompletion":3610,"completion":3610,"start":3650,"enrollment":372,"conditions":3651,"interventions":3652},"NCT01511185","Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group",[88],"2001-02",[15,18],[768],{"nctId":3654,"briefTitle":3655,"status":105,"phases":3656,"primaryCompletion":2305,"completion":2305,"start":128,"enrollment":372,"conditions":3657,"interventions":3658},"NCT00993304","A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics",[88],[15,18],[768],{"nctId":3660,"briefTitle":3661,"status":105,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":3454,"conditions":3665,"interventions":3666},"NCT01508897","Comparison of Two Liraglutide Formulations in Healthy Volunteers",[88],"2004-06-30","2004-05-28",[15,27],[768,768],{"nctId":3668,"briefTitle":3669,"status":105,"phases":3670,"primaryCompletion":3602,"completion":3602,"start":2194,"enrollment":306,"conditions":3671,"interventions":3672},"NCT01515592","Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers",[88],[15,18],[768,768,768],{"nctId":3674,"briefTitle":3675,"status":105,"phases":3676,"primaryCompletion":333,"completion":333,"start":3677,"enrollment":266,"conditions":3678,"interventions":3679},"NCT01536665","The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes",[88],"2012-02",[15,21],[768],{"nctId":3681,"briefTitle":3682,"status":105,"phases":3683,"primaryCompletion":3684,"completion":3684,"start":3685,"enrollment":1926,"conditions":3686,"interventions":3687},"NCT00978393","A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers",[88],"2011-06-08","2009-09-16",[204,24],[768,768,768,768,768,768],{"nctId":3689,"briefTitle":3690,"status":105,"phases":3691,"primaryCompletion":2193,"completion":2193,"start":3618,"enrollment":507,"conditions":3692,"interventions":3693},"NCT01508858","Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women",[88],[15,18],[768,3694],"levonorgestrel \u002F ethinylestradiol",{"nctId":3696,"briefTitle":3697,"status":105,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":3585,"enrollment":306,"conditions":3700,"interventions":3701},"NCT00983021","Safety and Tolerability of NN9068 in Healthy Male Volunteers",[88],"2009-12",[15,27],[3487,1919,768],{"nctId":3703,"briefTitle":3704,"status":105,"phases":3705,"primaryCompletion":3706,"completion":3706,"start":3707,"enrollment":223,"conditions":3708,"interventions":3709},"NCT01620463","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers",[88],"2003-03","2002-12",[15,18],[768],{"nctId":3711,"briefTitle":3712,"status":105,"phases":3713,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":1846,"conditions":3716,"interventions":3717},"NCT01517555","Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes",[88],"2007-05","2006-10",[15,18],[768,3718],"paracetamol",{"nctId":3720,"briefTitle":3721,"status":105,"phases":3722,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":1668,"conditions":3725,"interventions":3726},"NCT02870231","Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity",[88],"2017-09-03","2016-08-18",[204,24],[3521,768],{"nctId":3728,"briefTitle":3729,"status":105,"phases":3730,"primaryCompletion":3714,"completion":3714,"start":3731,"enrollment":507,"conditions":3732,"interventions":3733},"NCT01513525","Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers",[88],"2007-02",[15,27],[768],{"nctId":3735,"briefTitle":3736,"status":105,"phases":3737,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":285,"conditions":3740,"interventions":3741},"NCT00761540","To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo",[88],"2008-12","2008-10",[15,27],[768,768,768],{"trials":3743,"activeCount":99},[3744,3752,3760,3767,3775,3779,3787,3794,3798,3806,3817,3821,3827,3837],{"nctId":3745,"briefTitle":3746,"status":105,"phases":3747,"primaryCompletion":2144,"completion":2144,"start":3748,"enrollment":3749,"conditions":3750,"interventions":3751},"NCT00154414","Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes",[89],"2005-01",226,[15,18],[768],{"nctId":3753,"briefTitle":3754,"status":105,"phases":3755,"primaryCompletion":3756,"completion":3756,"start":3757,"enrollment":2146,"conditions":3758,"interventions":3759},"NCT01508923","Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes",[89],"2002-02","2001-05",[15,18],[768],{"nctId":3761,"briefTitle":3762,"status":105,"phases":3763,"primaryCompletion":3707,"completion":3707,"start":3764,"enrollment":3361,"conditions":3765,"interventions":3766},"NCT01511172","Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes",[89],"2002-08",[15,18],[768,226,3597],{"nctId":3768,"briefTitle":3769,"status":105,"phases":3770,"primaryCompletion":3610,"completion":3610,"start":3771,"enrollment":3772,"conditions":3773,"interventions":3774},"NCT01509755","Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes",[89],"2000-10",196,[15,18],[768,3597],{"nctId":760,"briefTitle":761,"status":105,"phases":3776,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":3777,"interventions":3778},[89],[15,18],[112,768],{"nctId":3780,"briefTitle":3781,"status":349,"phases":3782,"primaryCompletion":3783,"completion":3783,"start":3784,"enrollment":2578,"conditions":3785,"interventions":3786},"NCT01206101","Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation",[89],"2013-06-03","2012-03-21",[15,21],[768],{"nctId":3788,"briefTitle":3789,"status":105,"phases":3790,"primaryCompletion":2225,"completion":2225,"start":3748,"enrollment":3791,"conditions":3792,"interventions":3793},"NCT00154401","Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes",[89],177,[15,18],[768],{"nctId":813,"briefTitle":814,"status":105,"phases":3795,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":3796,"interventions":3797},[89],[15,18],[112,112,112,112,112,112,768,768],{"nctId":3799,"briefTitle":3800,"status":105,"phases":3801,"primaryCompletion":3802,"completion":3802,"start":3803,"enrollment":2558,"conditions":3804,"interventions":3805},"NCT01508949","Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes",[89],"2002-03","2001-06",[15,18],[768],{"nctId":3807,"briefTitle":3808,"status":105,"phases":3809,"primaryCompletion":3810,"completion":3811,"start":3812,"enrollment":3813,"conditions":3814,"interventions":3815},"NCT00422058","The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes",[89],"2007-09-13","2009-04-30","2007-01-10",564,[204,24],[768,3816],"orlistat",{"nctId":844,"briefTitle":845,"status":105,"phases":3818,"primaryCompletion":847,"completion":848,"start":849,"enrollment":850,"conditions":3819,"interventions":3820},[89],[204,24],[112,768],{"nctId":3822,"briefTitle":3823,"status":105,"phases":3824,"primaryCompletion":3610,"completion":3610,"start":3650,"enrollment":22,"conditions":3825,"interventions":3826},"NCT01511198","Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent",[89],[15,18],[768,226],{"nctId":3828,"briefTitle":3829,"status":105,"phases":3830,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":1071,"conditions":3834,"interventions":3835},"NCT02443155","A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function",[89],"2018-08-31","2019-02-27","2015-11-10",[15,21],[3836,768],"NNC0114-0006",{"nctId":3838,"briefTitle":3839,"status":105,"phases":3840,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":3843,"conditions":3844,"interventions":3845},"NCT02205528","A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin",[89],"2015-09-15","2014-08-18",108,[15,2937],[57,1478,3846],"NNC0090-2746",{"trials":3848,"activeCount":1606,"soonestReadout":56},[3849,3856,3864,3868,3877,3886,3890,3897,3905,3915,3919,3929,3937,3948,3957,3965,3975,3985,3992,4001,4005,4011,4018,4025,4035,4045,4053,4062,4071,4080,4088,4097,4106,4115,4124,4132,4140,4149,4160,4170],{"nctId":3850,"briefTitle":3789,"status":105,"phases":3851,"primaryCompletion":3852,"completion":2171,"start":3618,"enrollment":1381,"conditions":3853,"interventions":3854},"NCT00393718",[90],"2007-11",[15,18],[768,3855],"glibenclamide",{"nctId":3857,"briefTitle":3858,"status":105,"phases":3859,"primaryCompletion":3714,"completion":3860,"start":2144,"enrollment":3861,"conditions":3862,"interventions":3863},"NCT00318461","To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together",[90],"2008-11",1091,[15,18],[768,226,3597,768,768],{"nctId":947,"briefTitle":948,"status":105,"phases":3865,"primaryCompletion":950,"completion":951,"start":952,"enrollment":953,"conditions":3866,"interventions":3867},[90],[15,18],[75,57],{"nctId":3869,"briefTitle":3870,"status":105,"phases":3871,"primaryCompletion":3872,"completion":3873,"start":3586,"enrollment":3874,"conditions":3875,"interventions":3876},"NCT00856986","The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes",[90],"2010-04","2010-11",987,[15,18],[768,3589,226],{"nctId":3878,"briefTitle":3879,"status":105,"phases":3880,"primaryCompletion":2818,"completion":3881,"start":3882,"enrollment":3883,"conditions":3884,"interventions":3885},"NCT01272219","Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes",[90],"2015-03-02","2011-06-01",3731,[204,24],[768,768],{"nctId":966,"briefTitle":967,"status":105,"phases":3887,"primaryCompletion":969,"completion":970,"start":971,"enrollment":972,"conditions":3888,"interventions":3889},[90],[15,18],[75,57],{"nctId":3891,"briefTitle":3789,"status":105,"phases":3892,"primaryCompletion":3714,"completion":3714,"start":2144,"enrollment":3893,"conditions":3894,"interventions":3895},"NCT00318422",[90],1041,[15,18],[768,3896,3597],"rosiglitazone",{"nctId":3898,"briefTitle":3899,"status":105,"phases":3900,"primaryCompletion":129,"completion":129,"start":3901,"enrollment":3902,"conditions":3903,"interventions":3904},"NCT00614120","Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],"2008-01",929,[15,18],[768,768,768,3597,226],{"nctId":3906,"briefTitle":3907,"status":105,"phases":3908,"primaryCompletion":3909,"completion":3910,"start":3911,"enrollment":3912,"conditions":3913,"interventions":3914},"NCT01336023","Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec\u002FLiraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",[90],"2012-05-24","2012-11-22","2011-05-23",1663,[15,18],[3487,1919,768],{"nctId":1007,"briefTitle":1008,"status":105,"phases":3916,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":3917,"interventions":3918},[90],[15,18],[112,768],{"nctId":3920,"briefTitle":3921,"status":105,"phases":3922,"primaryCompletion":3923,"completion":3924,"start":3925,"enrollment":3926,"conditions":3927,"interventions":3928},"NCT02607306","A Trial Comparing the Efficacy and Safety of Insulin Degludec\u002FLiraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.",[90],"2017-12-15","2017-12-22","2015-11-18",819,[15,18],[3487,1919,768],{"nctId":3930,"briefTitle":3931,"status":105,"phases":3932,"primaryCompletion":3933,"completion":2204,"start":2306,"enrollment":3934,"conditions":3935,"interventions":3936},"NCT00700817","The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",[90],"2009-06",665,[15,18],[768,984,226,768],{"nctId":3938,"briefTitle":3939,"status":105,"phases":3940,"primaryCompletion":3941,"completion":3942,"start":3943,"enrollment":3944,"conditions":3945,"interventions":3946},"NCT01572740","Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes",[90],"2012-11-01","2013-03-27","2012-04-05",257,[15,18],[768,3947],"insulin",{"nctId":3949,"briefTitle":3950,"status":105,"phases":3951,"primaryCompletion":3952,"completion":3952,"start":3953,"enrollment":3954,"conditions":3955,"interventions":3956},"NCT01620489","Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment",[90],"2013-08-20","2012-06-14",279,[15,18],[768],{"nctId":3958,"briefTitle":3959,"status":105,"phases":3960,"primaryCompletion":3961,"completion":2171,"start":3715,"enrollment":3074,"conditions":3962,"interventions":3963},"NCT00395746","Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],"2007-10",[15,18],[3964,768,768],"sulfonylurea",{"nctId":3966,"briefTitle":3967,"status":105,"phases":3968,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":3973,"interventions":3974},"NCT01557166","Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea",[90],"2013-06-01","2013-06-17","2012-06-07",359,[204,24,2609],[768],{"nctId":3976,"briefTitle":3977,"status":105,"phases":3978,"primaryCompletion":3979,"completion":3980,"start":3981,"enrollment":3982,"conditions":3983,"interventions":3984},"NCT02963935","Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting",[90],"2018-05-23","2018-06-19","2017-02-06",282,[204,24],[768],{"nctId":3986,"briefTitle":3789,"status":105,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":2144,"enrollment":3989,"conditions":3990,"interventions":3991},"NCT00333151",[90],"2007-08",576,[15,18],[768,3896,226],{"nctId":3993,"briefTitle":3994,"status":105,"phases":3995,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":673,"conditions":3999,"interventions":4000},"NCT02527200","Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome",[90],"2020-11-04","2020-11-19","2015-11-09",[204,24],[768],{"nctId":1152,"briefTitle":1153,"status":105,"phases":4002,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":4003,"interventions":4004},[90],[33,24],[75,57],{"nctId":54,"briefTitle":55,"status":457,"phases":4006,"primaryCompletion":56,"completion":4007,"start":4008,"enrollment":404,"conditions":4009,"interventions":4010},[90],"2027-02-08","2021-03-04",[24],[57],{"nctId":4012,"briefTitle":4013,"status":105,"phases":4014,"primaryCompletion":2331,"completion":2331,"start":4015,"enrollment":1926,"conditions":4016,"interventions":4017},"NCT00620282","The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus",[90],"2008-02",[15,18],[768,3597],{"nctId":4019,"briefTitle":4020,"status":349,"phases":4021,"primaryCompletion":3860,"completion":3860,"start":2213,"enrollment":4022,"conditions":4023,"interventions":4024},"NCT00294723","To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c",[90],746,[15,18],[768,3597,768],{"nctId":4026,"briefTitle":4027,"status":105,"phases":4028,"primaryCompletion":4029,"completion":4030,"start":4031,"enrollment":4032,"conditions":4033,"interventions":4034},"NCT02918279","Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity",[90],"2019-02-14","2019-08-08","2016-09-29",251,[204,24],[57],{"nctId":4036,"briefTitle":4037,"status":105,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":4041,"conditions":4042,"interventions":4043},"NCT01512108","Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone",[90],"2013-04-26","2012-01-10",363,[15,18],[768,4044],"oral anti-diabetic drug",{"nctId":4046,"briefTitle":4047,"status":105,"phases":4048,"primaryCompletion":4049,"completion":488,"start":3988,"enrollment":4050,"conditions":4051,"interventions":4052},"NCT00518882","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],"2008-04",467,[15,18],[768,1131],{"nctId":4054,"briefTitle":4055,"status":105,"phases":4056,"primaryCompletion":4057,"completion":4057,"start":4058,"enrollment":4059,"conditions":4060,"interventions":4061},"NCT01617434","The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes",[90],"2013-10","2012-09",451,[15,18],[768],{"nctId":4063,"briefTitle":4064,"status":105,"phases":4065,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":4068,"conditions":4069,"interventions":4070},"NCT01676116","The Efficacy of Insulin Degludec\u002FLiraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy",[90],"2014-03-11","2012-08-29",438,[15,18],[3487,768,1131],{"nctId":4072,"briefTitle":4073,"status":105,"phases":4074,"primaryCompletion":4075,"completion":4076,"start":4077,"enrollment":16,"conditions":4078,"interventions":4079},"NCT02505334","A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg\u002FDay to Liraglutide 0.9 mg\u002FDay in Japanese Subjects With Type 2 Diabetes Mellitus.",[90],"2017-05-02","2017-11-09","2015-07-21",[15,18],[768],{"nctId":4081,"briefTitle":4082,"status":105,"phases":4083,"primaryCompletion":4084,"completion":4084,"start":3446,"enrollment":4085,"conditions":4086,"interventions":4087},"NCT02098395","The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes",[90],"2015-04",835,[15,21],[768,768,768],{"nctId":4089,"briefTitle":4090,"status":105,"phases":4091,"primaryCompletion":4092,"completion":4093,"start":3882,"enrollment":4094,"conditions":4095,"interventions":4096},"NCT01272232","Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes",[90],"2013-01-01","2013-01-25",846,[204,24],[768,768],{"nctId":4098,"briefTitle":4099,"status":105,"phases":4100,"primaryCompletion":4101,"completion":4102,"start":2914,"enrollment":4103,"conditions":4104,"interventions":4105},"NCT02964247","LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.",[90],"2018-05-04","2018-05-08",303,[15,18],[768],{"nctId":4107,"briefTitle":4108,"status":105,"phases":4109,"primaryCompletion":4110,"completion":4110,"start":4111,"enrollment":4112,"conditions":4113,"interventions":4114},"NCT01664247","The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification",[90],"2013-12-31","2012-10-01",346,[15,18],[1919,768],{"nctId":4116,"briefTitle":4117,"status":105,"phases":4118,"primaryCompletion":4119,"completion":4119,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4123},"NCT01179048","Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results",[90],"2015-12-17","2010-08-31",9341,[15,18],[768],{"nctId":4125,"briefTitle":4126,"status":105,"phases":4127,"primaryCompletion":4128,"completion":4128,"start":3461,"enrollment":4129,"conditions":4130,"interventions":4131},"NCT01388361","Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin",[90],"2012-07",413,[15,18],[1919,1978,768],{"nctId":4133,"briefTitle":4134,"status":105,"phases":4135,"primaryCompletion":4136,"completion":4136,"start":2132,"enrollment":4137,"conditions":4138,"interventions":4139},"NCT01836523","The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes",[90],"2015-06",1398,[15,21],[768,768,768],{"nctId":4141,"briefTitle":4142,"status":105,"phases":4143,"primaryCompletion":4144,"completion":4144,"start":4145,"enrollment":4146,"conditions":4147,"interventions":4148},"NCT00781937","Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance",[90],"2010-09-01","2008-10-30",422,[204,24],[768],{"nctId":4150,"briefTitle":4151,"status":105,"phases":4152,"primaryCompletion":4153,"completion":4154,"start":4155,"enrollment":4156,"conditions":4157,"interventions":4158},"NCT03172494","A Trial Comparing Insulin Degludec\u002FLiraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)",[90],"2019-06-14","2019-07-13","2017-05-26",720,[15,18],[4159,1887,57],"Insulin degludec\u002Fliraglutide",{"nctId":4161,"briefTitle":4162,"status":105,"phases":4163,"primaryCompletion":4164,"completion":4165,"start":4166,"enrollment":4167,"conditions":4168,"interventions":4169},"NCT01541215","Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",[90],"2017-11-15","2020-05-20","2012-11-13",135,[15,18],[768,226],{"nctId":4171,"briefTitle":3789,"status":105,"phases":4172,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":4173,"conditions":4174,"interventions":4175},"NCT00331851",[90],584,[15,18],[768,876,226,3597],{"trials":4177,"activeCount":99},[4178,4186,4200,4208,4212,4220],{"nctId":4179,"briefTitle":4180,"status":105,"phases":4181,"primaryCompletion":698,"completion":698,"start":4057,"enrollment":4182,"conditions":4183,"interventions":4184},"NCT01973231","Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes",[91],404,[15,18],[768,4185],"lixisenatide",{"nctId":4187,"briefTitle":4188,"status":105,"phases":4189,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":4192,"interventions":4193},"NCT02730377","Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes",[91],"2016-03-28",1991,[15,18],[768,4194,4195,4196,4197,4198,4199],"alpha-glucosidase inhibitors","DPP-4 inhibitors","meglitinides","SGLT-2 inhibitors","sulphonylurea","thiazolidinediones",{"nctId":4201,"briefTitle":4202,"status":105,"phases":4203,"primaryCompletion":698,"completion":698,"start":4204,"enrollment":4205,"conditions":4206,"interventions":4207},"NCT02008682","The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes",[91],"2013-12",368,[15,18],[768,984],{"nctId":1585,"briefTitle":1586,"status":105,"phases":4209,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":795,"conditions":4210,"interventions":4211},[91],[24],[75,1592,1593,1594,57],{"nctId":4213,"briefTitle":4214,"status":105,"phases":4215,"primaryCompletion":4216,"completion":4216,"start":826,"enrollment":4217,"conditions":4218,"interventions":4219},"NCT01907854","Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin",[91],"2015-06-15",407,[15,18],[768,984],{"nctId":4221,"briefTitle":4222,"status":105,"phases":4223,"primaryCompletion":4224,"completion":3517,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4228},"NCT01917656","Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes",[91],"2014-09-01","2014-01-09",343,[15,18],[768,226,4198],{"trials":4230,"activeCount":99},[4231,4239,4248,4257,4266,4275,4283,4292,4300,4308,4316,4324,4332,4340,4348,4356,4365],{"nctId":4232,"briefTitle":4233,"status":105,"phases":4234,"primaryCompletion":4235,"completion":4235,"start":4236,"enrollment":943,"conditions":4237,"interventions":4238},"NCT06283641","Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.",[],"2025-01-13","2024-04-08",[24],[57],{"nctId":4240,"briefTitle":4241,"status":105,"phases":4242,"primaryCompletion":4243,"completion":4243,"start":4244,"enrollment":4245,"conditions":4246,"interventions":4247},"NCT02077946","A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden",[],"2014-09-03","2014-02-10",1059,[15,18],[768,984],{"nctId":4249,"briefTitle":4250,"status":105,"phases":4251,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":4254,"conditions":4255,"interventions":4256},"NCT02255266","Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice",[],"2015-11-16","2015-03-26",1788,[15,18],[768],{"nctId":4258,"briefTitle":4259,"status":105,"phases":4260,"primaryCompletion":4261,"completion":4261,"start":4262,"enrollment":4263,"conditions":4264,"interventions":4265},"NCT01288326","Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes",[],"2013-03","2011-02",254,[15,18],[768],{"nctId":4267,"briefTitle":4268,"status":105,"phases":4269,"primaryCompletion":4270,"completion":4270,"start":4271,"enrollment":4272,"conditions":4273,"interventions":4274},"NCT03560336","A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.",[],"2020-12-02","2018-07-05",758,[24,33],[57],{"nctId":4276,"briefTitle":4277,"status":105,"phases":4278,"primaryCompletion":264,"completion":264,"start":4279,"enrollment":4280,"conditions":4281,"interventions":4282},"NCT02321878","Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)",[],"2014-12-15",1092,[15,18],[768],{"nctId":4284,"briefTitle":4285,"status":105,"phases":4286,"primaryCompletion":4287,"completion":4287,"start":4288,"enrollment":4289,"conditions":4290,"interventions":4291},"NCT01403025","Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes",[],"2015-12-28","2011-07-19",4121,[15,18],[768],{"nctId":4293,"briefTitle":4294,"status":105,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":4297,"enrollment":2820,"conditions":4298,"interventions":4299},"NCT03479762","In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database",[],"2022-09-12","2018-04-20",[24,33],[57],{"nctId":4301,"briefTitle":4302,"status":105,"phases":4303,"primaryCompletion":3320,"completion":3320,"start":4304,"enrollment":4305,"conditions":4306,"interventions":4307},"NCT03888157","A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine",[],"2019-03-10",839,[18],[57],{"nctId":4309,"briefTitle":4310,"status":105,"phases":4311,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":2252,"conditions":4314,"interventions":4315},"NCT01821846","Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus",[],"2017-03-08","2013-11-20",[15,18],[768],{"nctId":4317,"briefTitle":4318,"status":105,"phases":4319,"primaryCompletion":4320,"completion":4320,"start":3873,"enrollment":4321,"conditions":4322,"interventions":4323},"NCT01212133","A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India",[],"2012-04",1386,[15,18],[768],{"nctId":4325,"briefTitle":4326,"status":105,"phases":4327,"primaryCompletion":1737,"completion":1737,"start":4328,"enrollment":4329,"conditions":4330,"interventions":4331},"NCT02967757","In-market Utilisation of Liraglutide Used for Weight Management in Europe",[],"2016-12-22",316,[204,24],[768],{"nctId":4333,"briefTitle":4334,"status":105,"phases":4335,"primaryCompletion":403,"completion":403,"start":4336,"enrollment":4337,"conditions":4338,"interventions":4339},"NCT01890993","Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe",[],"2013-08",952,[15,18],[768],{"nctId":4341,"briefTitle":4342,"status":105,"phases":4343,"primaryCompletion":2860,"completion":2860,"start":4344,"enrollment":4345,"conditions":4346,"interventions":4347},"NCT01484262","Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2",[],"2011-11-14",1344,[15,18],[768,3947],{"nctId":4349,"briefTitle":4350,"status":1135,"phases":4351,"primaryCompletion":3336,"completion":4352,"start":4353,"enrollment":99,"conditions":4354,"interventions":4355},"NCT05438186","INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records",[],"2022-10-31","2022-09-01",[24],[57],{"nctId":4357,"briefTitle":4358,"status":105,"phases":4359,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":4363,"interventions":4364},"NCT01345734","Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes",[],"2013-07-26","2011-09-01",1056,[15,18],[768],{"nctId":4366,"briefTitle":4367,"status":105,"phases":4368,"primaryCompletion":2132,"completion":2132,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4372},"NCT01226966","Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes",[],"2010-09",3152,[15,18],[768],{"intervention":876,"totalTrials":2531,"cells":4374},{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4573,"PHASE3":4610,"PHASE4":4918,"NA":4982},{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[4379,4387,4394,4401,4409,4417,4426,4433,4442,4448,4456,4465,4473,4480,4487,4496,4505,4514,4522,4530,4538,4545,4549,4557,4566],{"nctId":4380,"briefTitle":4381,"status":105,"phases":4382,"primaryCompletion":4383,"completion":4383,"start":961,"enrollment":162,"conditions":4384,"interventions":4385},"NCT01796366","A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes",[88],"2013-08-19",[15,18],[4386,876],"insulin 338",{"nctId":4388,"briefTitle":4389,"status":105,"phases":4390,"primaryCompletion":4261,"completion":4261,"start":4391,"enrollment":162,"conditions":4392,"interventions":4393},"NCT01704417","A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine",[88],"2012-10",[15,21],[1919,876],{"nctId":4395,"briefTitle":4396,"status":105,"phases":4397,"primaryCompletion":3618,"completion":3618,"start":4398,"enrollment":162,"conditions":4399,"interventions":4400},"NCT01865292","Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes",[88],"2006-08",[15,21,18],[1919,876],{"nctId":4402,"briefTitle":4403,"status":105,"phases":4404,"primaryCompletion":4405,"completion":4405,"start":4136,"enrollment":130,"conditions":4406,"interventions":4407},"NCT02479022","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects",[88],"2015-12",[15,18,27],[4408,876],"Insulin 320",{"nctId":4410,"briefTitle":4411,"status":105,"phases":4412,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":325,"conditions":4415,"interventions":4416},"NCT00961324","A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes",[88],"2009-10-26","2009-07-27",[15,21],[1919,876],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4420,"primaryCompletion":4421,"completion":4421,"start":4422,"enrollment":2549,"conditions":4423,"interventions":4424},"NCT04136067","A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes",[88],"2020-08-23","2019-10-29",[18],[4425,876],"NNC0268-0965",{"nctId":4427,"briefTitle":4428,"status":105,"phases":4429,"primaryCompletion":2331,"completion":2331,"start":3699,"enrollment":4430,"conditions":4431,"interventions":4432},"NCT01030926","A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes",[88],39,[15,21],[1919,876],{"nctId":4434,"briefTitle":4435,"status":105,"phases":4436,"primaryCompletion":4437,"completion":4437,"start":4438,"enrollment":4439,"conditions":4440,"interventions":4441},"NCT02536859","Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U\u002FmL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus",[88],"2016-04-14","2015-08-31",60,[15,21],[1919,876],{"nctId":4443,"briefTitle":4444,"status":105,"phases":4445,"primaryCompletion":2225,"completion":2225,"start":2234,"enrollment":223,"conditions":4446,"interventions":4447},"NCT01497574","Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes",[88],[15,21],[3589,876],{"nctId":4449,"briefTitle":4450,"status":105,"phases":4451,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":404,"conditions":4454,"interventions":4455},"NCT03965013","A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes",[88],"2019-12-14","2019-06-05",[21,142],[4425,876],{"nctId":4457,"briefTitle":4458,"status":105,"phases":4459,"primaryCompletion":4460,"completion":4460,"start":4461,"enrollment":130,"conditions":4462,"interventions":4463},"NCT01809184","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects",[88],"2013-09-06","2013-03-04",[15,18],[4464,876],"insulin 287",{"nctId":4466,"briefTitle":4467,"status":105,"phases":4468,"primaryCompletion":3961,"completion":3961,"start":3988,"enrollment":306,"conditions":4469,"interventions":4470},"NCT00824668","Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes",[88],[15,18],[4471,876,4472],"biphasic insulin aspart 30","insulin glulisine",{"nctId":4474,"briefTitle":4475,"status":105,"phases":4476,"primaryCompletion":2194,"completion":2194,"start":2234,"enrollment":3454,"conditions":4477,"interventions":4479},"NCT00184613","Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes",[88],[15,18,4478],"Delivery Systems",[876,1978],{"nctId":4481,"briefTitle":4482,"status":105,"phases":4483,"primaryCompletion":3462,"completion":3462,"start":4484,"enrollment":335,"conditions":4485,"interventions":4486},"NCT00964418","A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes",[88],"2009-08",[15,21],[1919,876],{"nctId":4488,"briefTitle":4489,"status":105,"phases":4490,"primaryCompletion":4391,"completion":4391,"start":4491,"enrollment":4492,"conditions":4493,"interventions":4494},"NCT01597713","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects",[88],"2012-05",83,[15,18,27],[4495,876,4495,4495,4495],"NNC 0148-0000-0362",{"nctId":4497,"briefTitle":4498,"status":105,"phases":4499,"primaryCompletion":4500,"completion":4500,"start":4391,"enrollment":3534,"conditions":4501,"interventions":4502},"NCT01730014","A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes",[88],"2013-07",[15,21,27],[4503,4503,876,4504],"148-0287-A-4.2mM-cartridge","sodium chloride 0.9% w\u002Fv",{"nctId":4506,"briefTitle":4507,"status":105,"phases":4508,"primaryCompletion":4509,"completion":4509,"start":4510,"enrollment":3534,"conditions":4511,"interventions":4512},"NCT01334034","Safety of NNC 0123-0000-0338 in Healthy Subjects",[88],"2011-09-16","2011-04-11",[15,27],[4513,876],"NNC 0123-0000-0338",{"nctId":4515,"briefTitle":4516,"status":105,"phases":4517,"primaryCompletion":4518,"completion":4518,"start":4519,"enrollment":162,"conditions":4520,"interventions":4521},"NCT01497535","Within-subject Variability of Insulin Detemir in Healthy Volunteers",[88],"2004-10-31","2004-05-27",[15,27],[3589,876],{"nctId":4523,"briefTitle":4524,"status":105,"phases":4525,"primaryCompletion":4526,"completion":4526,"start":361,"enrollment":37,"conditions":4527,"interventions":4528},"NCT02220296","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus",[88],"2015-03-31",[27,15,21],[4529,4529,876],"Insulin 338",{"nctId":4531,"briefTitle":4532,"status":105,"phases":4533,"primaryCompletion":4534,"completion":4534,"start":4535,"enrollment":1867,"conditions":4536,"interventions":4537},"NCT01114542","A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes",[88],"2010-08-10","2010-05-03",[15,21],[1919,876],{"nctId":4539,"briefTitle":4540,"status":105,"phases":4541,"primaryCompletion":2306,"completion":2306,"start":3901,"enrollment":4542,"conditions":4543,"interventions":4544},"NCT01868529","Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus",[88],63,[15,21],[1919,876],{"nctId":1904,"briefTitle":1905,"status":105,"phases":4546,"primaryCompletion":1813,"completion":1813,"start":1907,"enrollment":653,"conditions":4547,"interventions":4548},[88],[18],[376,1910],{"nctId":4550,"briefTitle":4551,"status":105,"phases":4552,"primaryCompletion":4553,"completion":4554,"start":3320,"enrollment":2298,"conditions":4555,"interventions":4556},"NCT04575181","A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine",[88],"2021-12-10","2021-12-24",[18],[4425,1910],{"nctId":4558,"briefTitle":4559,"status":105,"phases":4560,"primaryCompletion":4561,"completion":4561,"start":4562,"enrollment":2549,"conditions":4563,"interventions":4564},"NCT04262661","A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes",[88],"2020-09-25","2020-03-02",[142,18],[4565,876],"NNC0472-0147",{"nctId":4567,"briefTitle":4568,"status":105,"phases":4569,"primaryCompletion":4570,"completion":4570,"start":128,"enrollment":413,"conditions":4571,"interventions":4572},"NCT01002768","Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics",[88],"2010-03",[15,21],[1919,876],{"trials":4574,"activeCount":99},[4575,4582,4588,4595,4599,4606],{"nctId":4576,"briefTitle":4577,"status":105,"phases":4578,"primaryCompletion":4579,"completion":4579,"start":1924,"enrollment":1624,"conditions":4580,"interventions":4581},"NCT02470039","Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy",[89],"2015-12-31",[15,18],[4386,876],{"nctId":4583,"briefTitle":4584,"status":105,"phases":4585,"primaryCompletion":2306,"completion":2306,"start":3901,"enrollment":95,"conditions":4586,"interventions":4587},"NCT00612040","Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes",[89],[15,21],[1919,1919,876,1978],{"nctId":4589,"briefTitle":4590,"status":105,"phases":4591,"primaryCompletion":2162,"completion":2162,"start":3901,"enrollment":95,"conditions":4592,"interventions":4593},"NCT00614055","Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes",[89],[15,18],[4594,4594,876,226],"insulin degludec\u002Finsulin aspart",{"nctId":1949,"briefTitle":1950,"status":105,"phases":4596,"primaryCompletion":1952,"completion":1953,"start":1944,"enrollment":1954,"conditions":4597,"interventions":4598},[89],[18],[1829,1957],{"nctId":4600,"briefTitle":4601,"status":105,"phases":4602,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":734,"conditions":4604,"interventions":4605},"NCT00611884","Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes",[89],"2008-08",[15,18],[876,1919,1919,1919,226],{"nctId":1959,"briefTitle":1960,"status":105,"phases":4607,"primaryCompletion":595,"completion":1953,"start":1866,"enrollment":1962,"conditions":4608,"interventions":4609},[89],[18],[1829,1478,1965,1910],{"trials":4611,"activeCount":1606,"soonestReadout":2032},[4612,4616,4622,4631,4639,4647,4654,4663,4668,4677,4684,4694,4700,4710,4717,4724,4733,4740,4744,4753,4761,4769,4779,4783,4790,4798,4805,4815,4819,4828,4837,4845,4853,4862,4871,4880,4890,4897,4901,4907,4914],{"nctId":868,"briefTitle":869,"status":105,"phases":4613,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":4614,"interventions":4615},[90],[15,18],[112,876],{"nctId":4617,"briefTitle":4618,"status":105,"phases":4619,"primaryCompletion":3873,"completion":3873,"start":4570,"enrollment":1198,"conditions":4620,"interventions":4621},"NCT01068665","Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes",[90],[15,18],[1919,876],{"nctId":4623,"briefTitle":4624,"status":105,"phases":4625,"primaryCompletion":4626,"completion":4626,"start":4627,"enrollment":4628,"conditions":4629,"interventions":4630},"NCT01959529","A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events",[90],"2016-10-16","2013-10-29",7637,[15,18],[1919,876],{"nctId":4632,"briefTitle":4633,"status":105,"phases":4634,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":838,"conditions":4637,"interventions":4638},"NCT01045447","Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes",[90],"2010-10","2010-01",[15,18],[4594,876],{"nctId":4640,"briefTitle":4641,"status":105,"phases":4642,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":1495,"conditions":4645,"interventions":4646},"NCT00097084","Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes",[90],"2005-12","2004-09",[15,18],[3589,876,1978],{"nctId":4648,"briefTitle":4649,"status":105,"phases":4650,"primaryCompletion":3873,"completion":3873,"start":2204,"enrollment":4651,"conditions":4652,"interventions":4653},"NCT01135992","Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)",[90],143,[15,18],[1919,876],{"nctId":4655,"briefTitle":4656,"status":105,"phases":4657,"primaryCompletion":4658,"completion":4658,"start":4659,"enrollment":4660,"conditions":4661,"interventions":4662},"NCT01059799","Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes",[90],"2010-12-16","2010-02-01",435,[15,18],[1919,876],{"nctId":4664,"briefTitle":4618,"status":105,"phases":4665,"primaryCompletion":2305,"completion":2305,"start":4570,"enrollment":4050,"conditions":4666,"interventions":4667},"NCT01076647",[90],[15,18],[1919,876],{"nctId":4669,"briefTitle":4670,"status":105,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4674,"conditions":4675,"interventions":4676},"NCT05013229","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",[90],"2023-11-14","2021-11-30",679,[18],[375,1910,1978],{"nctId":4678,"briefTitle":4679,"status":105,"phases":4680,"primaryCompletion":4369,"completion":4369,"start":3462,"enrollment":4681,"conditions":4682,"interventions":4683},"NCT01006291","Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes",[90],687,[15,18],[1919,1919,876],{"nctId":4685,"briefTitle":4686,"status":105,"phases":4687,"primaryCompletion":4688,"completion":4689,"start":923,"enrollment":4690,"conditions":4691,"interventions":4692},"NCT02906917","A 38 Week Trial Comparing Effect and Safety of Insulin Degludec\u002FInsulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification",[90],"2017-08-31","2017-12-24",532,[15,18],[4693,1910,1311],"Insulin degludec\u002Finsulin aspart",{"nctId":4695,"briefTitle":4656,"status":105,"phases":4696,"primaryCompletion":2305,"completion":2305,"start":3585,"enrollment":4697,"conditions":4698,"interventions":4699},"NCT00982644",[90],1030,[15,18],[1919,876],{"nctId":4701,"briefTitle":4702,"status":105,"phases":4703,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":4706,"conditions":4707,"interventions":4708},"NCT01819129","Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes",[90],"2015-01-22","2013-09-09",881,[15,18],[4709,1311,1910],"Faster-acting insulin aspart",{"nctId":4711,"briefTitle":4712,"status":105,"phases":4713,"primaryCompletion":3873,"completion":3484,"start":4570,"enrollment":4714,"conditions":4715,"interventions":4716},"NCT01079234","Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes",[90],493,[15,21],[1919,876,1978],{"nctId":4718,"briefTitle":4719,"status":105,"phases":4720,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4721,"conditions":4722,"interventions":4723},"NCT01045707","Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",[90],530,[15,18],[4594,876],{"nctId":4725,"briefTitle":4726,"status":105,"phases":4727,"primaryCompletion":4728,"completion":4728,"start":4729,"enrollment":4730,"conditions":4731,"interventions":4732},"NCT02501161","A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec\u002FLiraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus",[90],"2018-10-03","2016-01-31",1012,[15,18],[3487,876],{"nctId":4734,"briefTitle":4735,"status":105,"phases":4736,"primaryCompletion":3461,"completion":3461,"start":233,"enrollment":4737,"conditions":4738,"interventions":4739},"NCT01272193","Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes",[90],296,[15,18],[4594,876],{"nctId":2002,"briefTitle":2003,"status":105,"phases":4741,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":4742,"interventions":4743},[90],[18],[1829,1910],{"nctId":4745,"briefTitle":4746,"status":105,"phases":4747,"primaryCompletion":3500,"completion":3500,"start":4748,"enrollment":1188,"conditions":4749,"interventions":4750},"NCT00598793","Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy",[90],"2002-11",[15,18],[4751,876,226,4752],"biphasic insulin aspart","pioglitazone",{"nctId":4754,"briefTitle":4755,"status":105,"phases":4756,"primaryCompletion":2827,"completion":2827,"start":4757,"enrollment":4758,"conditions":4759,"interventions":4760},"NCT01952145","A Trial Comparing the Efficacy and Safety of Insulin Degludec\u002FLiraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus",[90],"2013-09-20",557,[15,18],[3487,876],{"nctId":4762,"briefTitle":4763,"status":105,"phases":4764,"primaryCompletion":4643,"completion":4643,"start":4765,"enrollment":4766,"conditions":4767,"interventions":4768},"NCT00106366","Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes",[90],"2005-03",389,[15,18],[3589,876,1978],{"nctId":4770,"briefTitle":4771,"status":105,"phases":4772,"primaryCompletion":4773,"completion":4774,"start":4775,"enrollment":4776,"conditions":4777,"interventions":4778},"NCT03078478","A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units\u002FmL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs",[90],"2019-02-13","2019-03-04","2017-03-13",1609,[15,18],[1887,1910],{"nctId":2021,"briefTitle":2022,"status":105,"phases":4780,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":1975,"conditions":4781,"interventions":4782},[90],[18],[1829,1910,1311],{"nctId":4784,"briefTitle":4785,"status":105,"phases":4786,"primaryCompletion":4787,"completion":4787,"start":4320,"enrollment":3361,"conditions":4788,"interventions":4789},"NCT01570751","A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U\u002FmL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin",[90],"2014-01",[15,18],[1919,876],{"nctId":4791,"briefTitle":4792,"status":105,"phases":4793,"primaryCompletion":4794,"completion":4794,"start":3706,"enrollment":4795,"conditions":4796,"interventions":4797},"NCT00283751","Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes",[90],"2004-11",583,[15,18],[3589,876],{"nctId":4799,"briefTitle":4800,"status":105,"phases":4801,"primaryCompletion":4802,"completion":4802,"start":4320,"enrollment":306,"conditions":4803,"interventions":4804},"NCT01569841","A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes",[90],"2012-11",[15,21],[1919,876],{"nctId":4806,"briefTitle":4807,"status":105,"phases":4808,"primaryCompletion":4809,"completion":4810,"start":4811,"enrollment":4812,"conditions":4813,"interventions":4814},"NCT06269107","A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)",[90],"2025-05-27","2025-07-08","2024-02-15",485,[862],[375,1910],{"nctId":2029,"briefTitle":2030,"status":380,"phases":4816,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":2035,"conditions":4817,"interventions":4818},[90],[21],[1829,1910,1311],{"nctId":4820,"briefTitle":4821,"status":105,"phases":4822,"primaryCompletion":4823,"completion":4823,"start":4824,"enrollment":4825,"conditions":4826,"interventions":4827},"NCT02030600","A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes",[90],"2015-12-04","2014-01-06",721,[15,18],[1919,876],{"nctId":4829,"briefTitle":4830,"status":105,"phases":4831,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":4834,"conditions":4835,"interventions":4836},"NCT00982228","Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes",[90],"2010-11-08","2009-09-01",629,[15,21],[1919,876,1978],{"nctId":4838,"briefTitle":4839,"status":105,"phases":4840,"primaryCompletion":4841,"completion":4841,"start":4833,"enrollment":4842,"conditions":4843,"interventions":4844},"NCT00972283","Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With\u002FWithout Metformin and With\u002FWithout Pioglitazone in Type 2 Diabetes",[90],"2010-10-28",1006,[15,18],[1919,876,1978],{"nctId":4846,"briefTitle":4847,"status":105,"phases":4848,"primaryCompletion":3706,"completion":3706,"start":4849,"enrollment":4850,"conditions":4851,"interventions":4852},"NCT00312104","Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes",[90],"2002-04",325,[15,21],[3589,876,1978],{"nctId":4854,"briefTitle":4855,"status":105,"phases":4856,"primaryCompletion":4857,"completion":4857,"start":4858,"enrollment":4859,"conditions":4860,"interventions":4861},"NCT02034513","A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes",[90],"2016-01-11","2014-01-05",501,[15,21],[1919,876,1978],{"nctId":4863,"briefTitle":4864,"status":105,"phases":4865,"primaryCompletion":4866,"completion":4866,"start":4867,"enrollment":4868,"conditions":4869,"interventions":4870},"NCT02420262","A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec\u002FLiraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus",[90],"2016-10-05","2015-07-26",506,[15,18],[3487,876,1978],{"nctId":4872,"briefTitle":4873,"status":105,"phases":4874,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4878,"interventions":4879},"NCT01849289","A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes",[90],"2014-05-15","2013-06-02",833,[15,18],[1999,1957],{"nctId":4881,"briefTitle":4882,"status":105,"phases":4883,"primaryCompletion":4884,"completion":4885,"start":4886,"enrollment":4887,"conditions":4888,"interventions":4889},"NCT02773368","A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec\u002FLiraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus",[90],"2017-09-26","2017-10-23","2016-05-23",420,[15,18],[3487,876],{"nctId":4891,"briefTitle":4892,"status":105,"phases":4893,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4894,"conditions":4895,"interventions":4896},"NCT00095082","Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes",[90],447,[15,21],[3589,876,1978],{"nctId":2057,"briefTitle":2058,"status":105,"phases":4898,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":2063,"conditions":4899,"interventions":4900},[90],[2065],[1829,1910],{"nctId":4902,"briefTitle":4618,"status":105,"phases":4903,"primaryCompletion":3873,"completion":3873,"start":4904,"enrollment":1198,"conditions":4905,"interventions":4906},"NCT01068678",[90],"2010-02",[15,18],[1919,876],{"nctId":4908,"briefTitle":4909,"status":105,"phases":4910,"primaryCompletion":3618,"completion":3618,"start":3748,"enrollment":4911,"conditions":4912,"interventions":4913},"NCT00097877","Comparison of Biphasic Insulin Aspart 70\u002F30 Versus Insulin Glargine in Subjects With Type 2 Diabetes",[90],293,[15,18],[4751,876],{"nctId":4171,"briefTitle":3789,"status":105,"phases":4915,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":4173,"conditions":4916,"interventions":4917},[90],[15,18],[768,876,226,3597],{"trials":4919,"activeCount":99},[4920,4930,4937,4945,4954,4961,4968,4975],{"nctId":4921,"briefTitle":4922,"status":105,"phases":4923,"primaryCompletion":4924,"completion":4925,"start":4926,"enrollment":4927,"conditions":4928,"interventions":4929},"NCT03687827","A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study",[91],"2019-12-20","2019-12-27","2018-10-02",498,[18],[1887,1910],{"nctId":4931,"briefTitle":4932,"status":105,"phases":4933,"primaryCompletion":923,"completion":923,"start":4438,"enrollment":4934,"conditions":4935,"interventions":4936},"NCT02453685","A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients",[91],335,[15,18],[4471,876,1978],{"nctId":4938,"briefTitle":4939,"status":105,"phases":4940,"primaryCompletion":2204,"completion":2204,"start":4941,"enrollment":4942,"conditions":4943,"interventions":4944},"NCT00909480","Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes",[91],"2009-05",457,[15,18],[3589,876],{"nctId":4946,"briefTitle":4947,"status":105,"phases":4948,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":4951,"conditions":4952,"interventions":4953},"NCT00184626","Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30\u002F70 or Biphasic Insulin Aspart 30\u002F70 in Combination With Metformin in Subjects With Type 2 Diabetes.",[91],"2005-10-24","2004-09-10",97,[15,18],[4751,876,226],{"nctId":4955,"briefTitle":4956,"status":105,"phases":4957,"primaryCompletion":4958,"completion":4958,"start":2331,"enrollment":1815,"conditions":4959,"interventions":4960},"NCT01123980","Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment",[91],"2011-06",[15,18],[4471,226,3597,876],{"nctId":4962,"briefTitle":4963,"status":105,"phases":4964,"primaryCompletion":3618,"completion":3618,"start":3602,"enrollment":1986,"conditions":4965,"interventions":4966},"NCT00313742","The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins",[91],[15,21],[3589,876,4967],"insulin NPH",{"nctId":4969,"briefTitle":4970,"status":105,"phases":4971,"primaryCompletion":4765,"completion":4765,"start":3634,"enrollment":4972,"conditions":4973,"interventions":4974},"NCT00619697","Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes",[91],260,[15,18],[4751,876,226,3597],{"nctId":4976,"briefTitle":4977,"status":105,"phases":4978,"primaryCompletion":4049,"completion":4049,"start":3714,"enrollment":4979,"conditions":4980,"interventions":4981},"NCT00469092","Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes",[91],480,[15,18],[4751,876,226,3597],{"trials":4983,"activeCount":99},[],{"intervention":4985,"totalTrials":422,"cells":4986},"Etavopivat",{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":5039,"PHASE3":5050,"PHASE4":5061,"NA":5063},{"trials":4988,"activeCount":99},[],{"trials":4990,"activeCount":99},[4991,4999,5010,5021,5029],{"nctId":4992,"briefTitle":4993,"status":105,"phases":4994,"primaryCompletion":4995,"completion":4995,"start":804,"enrollment":699,"conditions":4996,"interventions":4998},"NCT06336018","A Research Study on Etavopivat in Participants With and Without Liver Disease",[88],"2025-08-01",[4997],"Liver Diseases",[4985],{"nctId":5000,"briefTitle":5001,"status":105,"phases":5002,"primaryCompletion":5003,"completion":5004,"start":5005,"enrollment":5006,"conditions":5007,"interventions":5009},"NCT06433661","A Research Study of the Effect of Food on Etavopivat in Healthy Participants",[88],"2024-07-06","2024-07-08","2024-05-28",16,[5008],"Healthy Volunteers Sickle Cell Disease, Thalassemia",[4985],{"nctId":5011,"briefTitle":5012,"status":105,"phases":5013,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":2803,"conditions":5017,"interventions":5020},"NCT07023029","A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants",[88],"2025-09-12","2025-09-22","2025-06-09",[142,5018,5019],"Sickle Cell Disease","Thalassemia",[4985,2414],{"nctId":5022,"briefTitle":5023,"status":105,"phases":5024,"primaryCompletion":5025,"completion":5025,"start":5026,"enrollment":306,"conditions":5027,"interventions":5028},"NCT06581627","A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants",[88],"2024-10-31","2024-08-26",[142,5018,5019],[4985],{"nctId":5030,"briefTitle":5031,"status":105,"phases":5032,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":5034,"interventions":5035},"NCT06813924","A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants",[88],"2025-02-06",[5008],[4985,5036,5037,1478,5038,628],"Digoxin","Pitavastatin","Midazolam",{"trials":5040,"activeCount":99},[5041],{"nctId":5042,"briefTitle":5043,"status":105,"phases":5044,"primaryCompletion":5045,"completion":5045,"start":5046,"enrollment":5047,"conditions":5048,"interventions":5049},"NCT05725902","Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease",[89],"2026-03-09","2024-03-09",12,[5018],[4985],{"trials":5051,"activeCount":1606,"soonestReadout":5056},[5052],{"nctId":5053,"briefTitle":5054,"status":380,"phases":5055,"primaryCompletion":5056,"completion":5057,"start":3407,"enrollment":5058,"conditions":5059,"interventions":5060},"NCT06612268","A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease",[90],"2027-08-27","2029-03-12",408,[5018],[4985],{"trials":5062,"activeCount":99},[],{"trials":5064,"activeCount":99},[],{"intervention":1034,"totalTrials":713,"cells":5066},{"EARLY_PHASE1":5067,"PHASE1":5069,"PHASE2":5071,"PHASE3":5082,"PHASE4":5096,"NA":5098},{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"trials":5072,"activeCount":99},[5073],{"nctId":5074,"briefTitle":5075,"status":105,"phases":5076,"primaryCompletion":5077,"completion":1703,"start":5078,"enrollment":5079,"conditions":5080,"interventions":5081},"NCT06326060","A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight",[89],"2025-04-10","2024-03-18",354,[24],[842,1034],{"trials":5083,"activeCount":1606,"soonestReadout":1502},[5084,5088,5092],{"nctId":1025,"briefTitle":1026,"status":105,"phases":5085,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":5086,"interventions":5087},[90],[24],[70,75,1034],{"nctId":1256,"briefTitle":1257,"status":105,"phases":5089,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":1262,"conditions":5090,"interventions":5091},[90],[862],[70,75,1034],{"nctId":1499,"briefTitle":1500,"status":457,"phases":5093,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":1505,"conditions":5094,"interventions":5095},[90],[18],[70,75,1034],{"trials":5097,"activeCount":99},[],{"trials":5099,"activeCount":99},[],{"intervention":5101,"totalTrials":864,"cells":5102},"Mim8",{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5109,"PHASE4":5127,"NA":5129},{"trials":5104,"activeCount":99},[],{"trials":5106,"activeCount":99},[],{"trials":5108,"activeCount":99},[],{"trials":5110,"activeCount":1606,"soonestReadout":5124},[5111,5120],{"nctId":5112,"briefTitle":5113,"status":105,"phases":5114,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":3534,"conditions":5117,"interventions":5119},"NCT05306418","A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors",[90],"2024-11-13","2022-04-04",[5118],"Haemophilia A With or Without Inhibitors",[5101],{"nctId":5121,"briefTitle":5122,"status":457,"phases":5123,"primaryCompletion":5124,"completion":5124,"start":792,"enrollment":4059,"conditions":5125,"interventions":5126},"NCT05685238","A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)",[90],"2028-06-30",[36,2136],[5101],{"trials":5128,"activeCount":99},[],{"trials":5130,"activeCount":99},[],{"intervention":5132,"totalTrials":864,"cells":5133},"Ziltivekimab B",{"EARLY_PHASE1":5134,"PHASE1":5136,"PHASE2":5148,"PHASE3":5150,"PHASE4":5161,"NA":5163},{"trials":5135,"activeCount":99},[],{"trials":5137,"activeCount":99},[5138],{"nctId":5139,"briefTitle":5140,"status":105,"phases":5141,"primaryCompletion":5142,"completion":5142,"start":2944,"enrollment":5143,"conditions":5144,"interventions":5145},"NCT05721989","A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab",[88],"2024-01-08",267,[482],[5132,5146,5147],"Ziltivekimab D","Ziltivekimab C",{"trials":5149,"activeCount":99},[],{"trials":5151,"activeCount":1606,"soonestReadout":5156},[5152],{"nctId":5153,"briefTitle":5154,"status":457,"phases":5155,"primaryCompletion":5156,"completion":5156,"start":5157,"enrollment":5158,"conditions":5159,"interventions":5160},"NCT05021835","ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation",[90],"2026-06-09","2021-08-30",6200,[3067,840,3066],[5132,5147],{"trials":5162,"activeCount":99},[],{"trials":5164,"activeCount":99},[],{"intervention":5147,"totalTrials":864,"cells":5166},{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5175,"PHASE3":5177,"PHASE4":5183,"NA":5185},{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[5171],{"nctId":5139,"briefTitle":5140,"status":105,"phases":5172,"primaryCompletion":5142,"completion":5142,"start":2944,"enrollment":5143,"conditions":5173,"interventions":5174},[88],[482],[5132,5146,5147],{"trials":5176,"activeCount":99},[],{"trials":5178,"activeCount":1606,"soonestReadout":5156},[5179],{"nctId":5153,"briefTitle":5154,"status":457,"phases":5180,"primaryCompletion":5156,"completion":5156,"start":5157,"enrollment":5158,"conditions":5181,"interventions":5182},[90],[3067,840,3066],[5132,5147],{"trials":5184,"activeCount":99},[],{"trials":5186,"activeCount":99},[],{"intervention":5188,"totalTrials":1606,"cells":5189},"Etavopivat A",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5194,"PHASE3":5196,"PHASE4":5208,"NA":5210},{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[],{"trials":5195,"activeCount":99},[],{"trials":5197,"activeCount":1606,"soonestReadout":5202},[5198],{"nctId":5199,"briefTitle":5200,"status":380,"phases":5201,"primaryCompletion":5202,"completion":5202,"start":5203,"enrollment":4979,"conditions":5204,"interventions":5205},"NCT06609226","A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia",[90],"2030-12-30","2025-01-10",[5018,5019],[5188,5206,5207],"Etavopivat B","Etavopivat C",{"trials":5209,"activeCount":99},[],{"trials":5211,"activeCount":99},[],{"intervention":5206,"totalTrials":1606,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5226,"NA":5228},{"trials":5215,"activeCount":99},[],{"trials":5217,"activeCount":99},[],{"trials":5219,"activeCount":99},[],{"trials":5221,"activeCount":1606,"soonestReadout":5202},[5222],{"nctId":5199,"briefTitle":5200,"status":380,"phases":5223,"primaryCompletion":5202,"completion":5202,"start":5203,"enrollment":4979,"conditions":5224,"interventions":5225},[90],[5018,5019],[5188,5206,5207],{"trials":5227,"activeCount":99},[],{"trials":5229,"activeCount":99},[],{"intervention":5207,"totalTrials":1606,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5238,"PHASE4":5244,"NA":5246},{"trials":5233,"activeCount":99},[],{"trials":5235,"activeCount":99},[],{"trials":5237,"activeCount":99},[],{"trials":5239,"activeCount":1606,"soonestReadout":5202},[5240],{"nctId":5199,"briefTitle":5200,"status":380,"phases":5241,"primaryCompletion":5202,"completion":5202,"start":5203,"enrollment":4979,"conditions":5242,"interventions":5243},[90],[5018,5019],[5188,5206,5207],{"trials":5245,"activeCount":99},[],{"trials":5247,"activeCount":99},[],{"intervention":3109,"totalTrials":1606,"cells":5249},{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5254,"PHASE3":5256,"PHASE4":5262,"NA":5264},{"trials":5251,"activeCount":99},[],{"trials":5253,"activeCount":99},[],{"trials":5255,"activeCount":99},[],{"trials":5257,"activeCount":1606,"soonestReadout":3103},[5258],{"nctId":3100,"briefTitle":3101,"status":380,"phases":5259,"primaryCompletion":3103,"completion":3104,"start":1745,"enrollment":3105,"conditions":5260,"interventions":5261},[90],[3107],[3040,3109],{"trials":5263,"activeCount":99},[],{"trials":5265,"activeCount":99},[],{"intervention":1978,"totalTrials":5267,"cells":5268},137,{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5548,"PHASE3":5560,"PHASE4":5951,"NA":6099},{"trials":5270,"activeCount":99},[],{"trials":5272,"activeCount":99},[5273,5282,5290,5298,5306,5312,5319,5325,5335,5341,5348,5356,5362,5369,5375,5381,5389,5396,5402,5413,5421,5432,5440,5448,5458,5466,5474,5478,5484,5492,5499,5507,5515,5522,5530,5536,5542],{"nctId":5274,"briefTitle":5275,"status":105,"phases":5276,"primaryCompletion":5277,"completion":5277,"start":2965,"enrollment":5278,"conditions":5279,"interventions":5280},"NCT02933853","A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus",[88],"2017-12-21",61,[15,18],[4709,5281],"Insulin Aspart",{"nctId":5283,"briefTitle":5284,"status":105,"phases":5285,"primaryCompletion":5286,"completion":5286,"start":5287,"enrollment":1624,"conditions":5288,"interventions":5289},"NCT01934712","A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes",[88],"2014-01-28","2013-08-30",[15,21],[4709,1978],{"nctId":5291,"briefTitle":5292,"status":105,"phases":5293,"primaryCompletion":5294,"completion":5294,"start":5295,"enrollment":212,"conditions":5296,"interventions":5297},"NCT02003677","A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes",[88],"2014-08-14","2013-11-29",[15,21],[4709,1978],{"nctId":5299,"briefTitle":5300,"status":105,"phases":5301,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":109,"conditions":5304,"interventions":5305},"NCT03215498","A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes",[88],"2017-11-20","2017-07-03",[15,21],[4709,1311],{"nctId":5307,"briefTitle":5308,"status":105,"phases":5309,"primaryCompletion":3860,"completion":3860,"start":2306,"enrollment":306,"conditions":5310,"interventions":5311},"NCT01464099","Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes",[88],[15,21],[1978,1978],{"nctId":5313,"briefTitle":5314,"status":105,"phases":5315,"primaryCompletion":652,"completion":652,"start":233,"enrollment":5316,"conditions":5317,"interventions":5318},"NCT01269606","Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes",[88],13,[15,21],[1978,3613,1978,3613],{"nctId":5320,"briefTitle":5321,"status":105,"phases":5322,"primaryCompletion":403,"completion":403,"start":4787,"enrollment":1894,"conditions":5323,"interventions":5324},"NCT02033239","A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes",[88],[15,21],[4709,1978],{"nctId":5326,"briefTitle":5327,"status":105,"phases":5328,"primaryCompletion":5329,"completion":5330,"start":5331,"enrollment":2885,"conditions":5332,"interventions":5333},"NCT02938572","A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus",[88],"2017-06-17","2017-07-04","2016-10-19",[15,21],[5334,5281],"NNC0143-0406",{"nctId":5336,"briefTitle":5337,"status":105,"phases":5338,"primaryCompletion":4261,"completion":4261,"start":4058,"enrollment":653,"conditions":5339,"interventions":5340},"NCT01682902","A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes",[88],[15,21],[4709,4709,1978],{"nctId":5342,"briefTitle":5343,"status":105,"phases":5344,"primaryCompletion":2204,"completion":2204,"start":3462,"enrollment":130,"conditions":5345,"interventions":5346},"NCT01028404","A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes",[88],[15,21,18,27],[5347,1978,5347,1978],"NN1952",{"nctId":5349,"briefTitle":5350,"status":105,"phases":5351,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":413,"conditions":5354,"interventions":5355},"NCT01486914","Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process",[88],"2003-02-24","2003-01-19",[15,27],[1978],{"nctId":5357,"briefTitle":5358,"status":105,"phases":5359,"primaryCompletion":2132,"completion":2132,"start":4336,"enrollment":2549,"conditions":5360,"interventions":5361},"NCT01924637","A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes",[88],[15,21],[4709,1978],{"nctId":5363,"briefTitle":5364,"status":105,"phases":5365,"primaryCompletion":651,"completion":651,"start":5366,"enrollment":162,"conditions":5367,"interventions":5368},"NCT01469143","A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes",[88],"2011-11",[15,21],[4709,1978],{"nctId":5370,"briefTitle":5371,"status":105,"phases":5372,"primaryCompletion":2153,"completion":2153,"start":3446,"enrollment":2803,"conditions":5373,"interventions":5374},"NCT02131246","A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes",[88],[15,21],[4709,1978],{"nctId":5376,"briefTitle":5377,"status":105,"phases":5378,"primaryCompletion":4636,"completion":4636,"start":128,"enrollment":335,"conditions":5379,"interventions":5380},"NCT00992537","Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics",[88],[15,21],[1919,4594,1978],{"nctId":5382,"briefTitle":5383,"status":105,"phases":5384,"primaryCompletion":5385,"completion":5385,"start":5386,"enrollment":363,"conditions":5387,"interventions":5388},"NCT01618188","A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes",[88],"2012-09-07","2012-06-11",[15,21],[4709,1978],{"nctId":5390,"briefTitle":5391,"status":105,"phases":5392,"primaryCompletion":2278,"completion":2278,"start":3872,"enrollment":2185,"conditions":5393,"interventions":5394},"NCT01121289","A Trial Investigating NN1218 in Subjects With Type 1 Diabetes",[88],[15,21],[5395,1978,5395,5395,5395,5395],"NN1218",{"nctId":5397,"briefTitle":5398,"status":105,"phases":5399,"primaryCompletion":2144,"completion":2144,"start":3493,"enrollment":708,"conditions":5400,"interventions":5401},"NCT01530048","Bioequivalence of Two Insulin Aspart Formulations (100 U\u002FmL Versus 200 U\u002FmL)",[88],[15,27],[1978],{"nctId":5403,"briefTitle":5404,"status":105,"phases":5405,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":5408,"interventions":5409},"NCT01865305","Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes",[88],"2006-09",59,[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],"insulin degludec\u002Finsulin aspart 30","insulin degludec\u002Finsulin aspart 40","insulin degludec\u002Finsulin aspart 50",{"nctId":5414,"briefTitle":5415,"status":105,"phases":5416,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":306,"conditions":5419,"interventions":5420},"NCT01698697","Comparison of Two Insulin Aspart Formulations in Healthy Volunteers",[88],"2002-10-18","2002-09-02",[15,27],[1978],{"nctId":5422,"briefTitle":5423,"status":105,"phases":5424,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":5428,"conditions":5429,"interventions":5430},"NCT07068295","A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump",[88],"2026-02-22","2026-03-10","2025-07-11",65,[18],[5431,5281],"NNC0471-0119 H",{"nctId":5433,"briefTitle":5434,"status":105,"phases":5435,"primaryCompletion":4271,"completion":4271,"start":5436,"enrollment":1894,"conditions":5437,"interventions":5438},"NCT03407599","A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes",[88],"2018-01-08",[15,21],[5439,1311],"Faster aspart",{"nctId":5441,"briefTitle":5442,"status":105,"phases":5443,"primaryCompletion":5444,"completion":5444,"start":5445,"enrollment":624,"conditions":5446,"interventions":5447},"NCT02035371","A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes",[88],"2014-07-24","2014-01-13",[15,21],[4709,1978],{"nctId":5449,"briefTitle":5450,"status":105,"phases":5451,"primaryCompletion":5452,"completion":5452,"start":5453,"enrollment":2558,"conditions":5454,"interventions":5455},"NCT01520831","Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects",[88],"2000-05","1999-04",[15,27],[4471,5456,5457,1978],"biphasic insulin aspart 50","biphasic insulin aspart 70",{"nctId":5459,"briefTitle":5460,"status":105,"phases":5461,"primaryCompletion":5462,"completion":5462,"start":5463,"enrollment":173,"conditions":5464,"interventions":5465},"NCT02568280","Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes",[88],"2016-04-25","2015-10-06",[15,21],[4709,1978],{"nctId":5467,"briefTitle":5468,"status":105,"phases":5469,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":5470,"interventions":5471},"NCT01868568","Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes",[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],"insulin degludec\u002Finsulin aspart 45","insulin degludec\u002Finsulin aspart 55",{"nctId":4474,"briefTitle":4475,"status":105,"phases":5475,"primaryCompletion":2194,"completion":2194,"start":2234,"enrollment":3454,"conditions":5476,"interventions":5477},[88],[15,18,4478],[876,1978],{"nctId":5479,"briefTitle":5480,"status":105,"phases":5481,"primaryCompletion":652,"completion":652,"start":4262,"enrollment":162,"conditions":5482,"interventions":5483},"NCT01296438","A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1",[88],[15,21],[4709,1978],{"nctId":5485,"briefTitle":5486,"status":105,"phases":5487,"primaryCompletion":5488,"completion":5488,"start":5489,"enrollment":699,"conditions":5490,"interventions":5491},"NCT02612844","A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol\u002FL in Subjects With Type 1 Diabetes",[88],"2016-06","2015-11",[15,21],[5334,1978],{"nctId":5493,"briefTitle":5494,"status":105,"phases":5495,"primaryCompletion":2194,"completion":2194,"start":5496,"enrollment":498,"conditions":5497,"interventions":5498},"NCT00115973","A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump",[88],"2005-06",[15,18,4478],[1978],{"nctId":5500,"briefTitle":5501,"status":105,"phases":5502,"primaryCompletion":5503,"completion":5504,"start":2713,"enrollment":653,"conditions":5505,"interventions":5506},"NCT06809621","A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump",[88],"2025-07-16","2025-07-28",[21],[5431,1311],{"nctId":5508,"briefTitle":5509,"status":105,"phases":5510,"primaryCompletion":4336,"completion":4336,"start":5511,"enrollment":2803,"conditions":5512,"interventions":5513},"NCT01773798","A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec\u002FInsulin Aspart 15 in Subjects With Type 1 Diabetes",[88],"2013-01",[15,21],[5514,4594,1919,1978],"insulin degludec\u002Finsulin aspart 15",{"nctId":5516,"briefTitle":5517,"status":105,"phases":5518,"primaryCompletion":4369,"completion":4369,"start":3872,"enrollment":5519,"conditions":5520,"interventions":5521},"NCT01121276","A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes",[88],82,[15,21,18],[4709,1978,4709,4709,4709],{"nctId":5523,"briefTitle":5524,"status":105,"phases":5525,"primaryCompletion":5526,"completion":5526,"start":5527,"enrollment":1894,"conditions":5528,"interventions":5529},"NCT02594033","A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles",[88],"2016-01-28","2015-10-27",[15],[1978],{"nctId":5531,"briefTitle":5532,"status":105,"phases":5533,"primaryCompletion":3873,"completion":3873,"start":2278,"enrollment":335,"conditions":5534,"interventions":5535},"NCT01173926","Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes",[88],[15,21],[1919,4594,1978],{"nctId":5537,"briefTitle":5538,"status":105,"phases":5539,"primaryCompletion":3619,"completion":3619,"start":3602,"enrollment":223,"conditions":5540,"interventions":5541},"NCT01536028","Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes",[88],[15,21],[4471,5456,5457,1978],{"nctId":5543,"briefTitle":5544,"status":105,"phases":5545,"primaryCompletion":2154,"completion":2154,"start":2132,"enrollment":699,"conditions":5546,"interventions":5547},"NCT01992588","A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes",[88],[15,21],[4709,1978],{"trials":5549,"activeCount":99},[5550,5554],{"nctId":4583,"briefTitle":4584,"status":105,"phases":5551,"primaryCompletion":2306,"completion":2306,"start":3901,"enrollment":95,"conditions":5552,"interventions":5553},[89],[15,21],[1919,1919,876,1978],{"nctId":5555,"briefTitle":5556,"status":105,"phases":5557,"primaryCompletion":4941,"completion":4941,"start":489,"enrollment":5428,"conditions":5558,"interventions":5559},"NCT00841087","Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes",[89],[15,21],[1919,3589,1978],{"trials":5561,"activeCount":1606,"soonestReadout":2032},[5562,5566,5576,5583,5591,5595,5604,5611,5620,5626,5630,5638,5642,5648,5652,5656,5665,5671,5680,5688,5697,5706,5714,5724,5728,5735,5743,5747,5753,5761,5770,5777,5781,5789,5798,5802,5811,5820,5824,5828,5835,5839,5848,5856,5860,5867,5875,5883,5887,5891,5898,5905,5909,5915,5924,5932,5942],{"nctId":1969,"briefTitle":1970,"status":105,"phases":5563,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":1975,"conditions":5564,"interventions":5565},[90],[21],[376,1919,1978],{"nctId":5567,"briefTitle":5568,"status":349,"phases":5569,"primaryCompletion":5570,"completion":5570,"start":5571,"enrollment":5572,"conditions":5573,"interventions":5574},"NCT00322257","Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes",[90],"2008-04-02","2006-05-01",596,[15,21],[5575,3589,1978],"inhaled human insulin",{"nctId":5577,"briefTitle":5578,"status":105,"phases":5579,"primaryCompletion":2162,"completion":2162,"start":5580,"enrollment":2451,"conditions":5581,"interventions":5582},"NCT00447382","Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes",[90],"2007-03",[15,21],[3589,1978,3589],{"nctId":5584,"briefTitle":5585,"status":105,"phases":5586,"primaryCompletion":1693,"completion":5587,"start":5588,"enrollment":1428,"conditions":5589,"interventions":5590},"NCT04588259","Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes",[90],"2022-08-05","2020-10-09",[21,18],[5439,1311,1887],{"nctId":4640,"briefTitle":4641,"status":105,"phases":5592,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":1495,"conditions":5593,"interventions":5594},[90],[15,18],[3589,876,1978],{"nctId":5596,"briefTitle":5597,"status":105,"phases":5598,"primaryCompletion":2144,"completion":2144,"start":5599,"enrollment":5600,"conditions":5601,"interventions":5602},"NCT00097071","Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents",[90],"2004-10",299,[15,21],[5603,1978],"insulin lispro",{"nctId":5605,"briefTitle":5606,"status":105,"phases":5607,"primaryCompletion":2305,"completion":2305,"start":4904,"enrollment":5608,"conditions":5609,"interventions":5610},"NCT01074268","Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes",[90],456,[15,21],[1919,3589,1978],{"nctId":5612,"briefTitle":5613,"status":349,"phases":5614,"primaryCompletion":5615,"completion":5615,"start":5616,"enrollment":578,"conditions":5617,"interventions":5619},"NCT00472953","Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)",[90],"2008-03-05","2007-05-15",[15,21,18,5618],"Chronic Obstructive Pulmonary Disease",[5575,1978],{"nctId":5621,"briefTitle":5622,"status":105,"phases":5623,"primaryCompletion":4084,"completion":4084,"start":274,"enrollment":554,"conditions":5624,"interventions":5625},"NCT02100475","A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec\u002FLiraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec\u002FLiraglutide and Metformin and in Need of Further Intensification",[90],[15,18],[3487,1978],{"nctId":4669,"briefTitle":4670,"status":105,"phases":5627,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4674,"conditions":5628,"interventions":5629},[90],[18],[375,1910,1978],{"nctId":5631,"briefTitle":5632,"status":105,"phases":5633,"primaryCompletion":5634,"completion":5634,"start":5418,"enrollment":5635,"conditions":5636,"interventions":5637},"NCT00725036","Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes",[90],"2004-12-14",305,[15,21],[5575,1978,4967],{"nctId":4685,"briefTitle":4686,"status":105,"phases":5639,"primaryCompletion":4688,"completion":4689,"start":923,"enrollment":4690,"conditions":5640,"interventions":5641},[90],[15,18],[4693,1910,1311],{"nctId":5643,"briefTitle":5644,"status":105,"phases":5645,"primaryCompletion":5406,"completion":5406,"start":3550,"enrollment":4859,"conditions":5646,"interventions":5647},"NCT00184665","Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes",[90],[15,21],[3589,4967,1978],{"nctId":4701,"briefTitle":4702,"status":105,"phases":5649,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":4706,"conditions":5650,"interventions":5651},[90],[15,18],[4709,1311,1910],{"nctId":4711,"briefTitle":4712,"status":105,"phases":5653,"primaryCompletion":3873,"completion":3484,"start":4570,"enrollment":4714,"conditions":5654,"interventions":5655},[90],[15,21],[1919,876,1978],{"nctId":5657,"briefTitle":5658,"status":349,"phases":5659,"primaryCompletion":5660,"completion":5660,"start":5661,"enrollment":5662,"conditions":5663,"interventions":5664},"NCT00331604","Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes",[90],"2008-05-05","2006-08-31",618,[15,18],[5575,3589,1978,1978],{"nctId":5666,"briefTitle":5667,"status":105,"phases":5668,"primaryCompletion":2154,"completion":2154,"start":4261,"enrollment":162,"conditions":5669,"interventions":5670},"NCT01814137","A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec\u002FInsulin Aspart Twice Daily",[90],[15,18],[4594,1919,1978,1978],{"nctId":5672,"briefTitle":5673,"status":105,"phases":5674,"primaryCompletion":5675,"completion":5675,"start":5676,"enrollment":5677,"conditions":5678,"interventions":5679},"NCT00604656","Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes",[90],"2004-01-29","2003-05-05",241,[15,21],[1978],{"nctId":5681,"briefTitle":5682,"status":105,"phases":5683,"primaryCompletion":2774,"completion":5684,"start":3516,"enrollment":5685,"conditions":5686,"interventions":5687},"NCT02825251","Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes",[90],"2017-07-21",472,[15,21],[4709,1978],{"nctId":5689,"briefTitle":5690,"status":349,"phases":5691,"primaryCompletion":5692,"completion":5692,"start":5693,"enrollment":1546,"conditions":5694,"interventions":5696},"NCT00523042","Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma",[90],"2008-02-28","2007-08-30",[15,21,18,5695],"Asthma",[1978,5575],{"nctId":5698,"briefTitle":5699,"status":105,"phases":5700,"primaryCompletion":5452,"completion":5452,"start":5701,"enrollment":5702,"conditions":5703,"interventions":5704},"NCT01707134","Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes",[90],"1997-09",753,[15,21],[1978,5705,4967],"human soluble insulin",{"nctId":5707,"briefTitle":5708,"status":105,"phases":5709,"primaryCompletion":5710,"completion":5710,"start":3802,"enrollment":5711,"conditions":5712,"interventions":5713},"NCT01486940","Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes",[90],"2002-10",598,[15,21],[3589,1978,4967,5705],{"nctId":5715,"briefTitle":5716,"status":105,"phases":5717,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":5721,"conditions":5722,"interventions":5723},"NCT03268005","Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"\u002F\"NovoLog\" in People With Type 2 Diabetes",[90],"2019-01-07","2019-01-29","2017-09-19",1264,[15,18],[4709,1311,1887,1478],{"nctId":4762,"briefTitle":4763,"status":105,"phases":5725,"primaryCompletion":4643,"completion":4643,"start":4765,"enrollment":4766,"conditions":5726,"interventions":5727},[90],[15,18],[3589,876,1978],{"nctId":5729,"briefTitle":5730,"status":105,"phases":5731,"primaryCompletion":3585,"completion":3585,"start":4015,"enrollment":5732,"conditions":5733,"interventions":5734},"NCT00623194","Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689",[90],146,[15,21],[3589,1978],{"nctId":5736,"briefTitle":5737,"status":105,"phases":5738,"primaryCompletion":2214,"completion":2214,"start":5739,"enrollment":5740,"conditions":5741,"interventions":5742},"NCT00600626","Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes",[90],"2004-01",394,[15,18],[4751,4967,1978],{"nctId":2021,"briefTitle":2022,"status":105,"phases":5744,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":1975,"conditions":5745,"interventions":5746},[90],[18],[1829,1910,1311],{"nctId":5748,"briefTitle":5749,"status":105,"phases":5750,"primaryCompletion":4225,"completion":4225,"start":961,"enrollment":1178,"conditions":5751,"interventions":5752},"NCT01713530","A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin",[90],[15,18],[4594,1919,1978],{"nctId":5754,"briefTitle":5755,"status":105,"phases":5756,"primaryCompletion":5757,"completion":5757,"start":3764,"enrollment":5758,"conditions":5759,"interventions":5760},"NCT00312156","Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes",[90],"2003-08",347,[15,21],[3589,4967,1978],{"nctId":5762,"briefTitle":5763,"status":105,"phases":5764,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":5767,"conditions":5768,"interventions":5769},"NCT00504673","Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes",[90],"2006-12","2005-04",277,[15,18],[3589,4967,1978],{"nctId":5771,"briefTitle":5772,"status":105,"phases":5773,"primaryCompletion":4748,"completion":4748,"start":2260,"enrollment":5774,"conditions":5775,"interventions":5776},"NCT01697657","Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes",[90],131,[15,21],[3589,4967,1978],{"nctId":1303,"briefTitle":1304,"status":105,"phases":5778,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5779,"interventions":5780},[90],[18],[75,1311,1312],{"nctId":5782,"briefTitle":5783,"status":105,"phases":5784,"primaryCompletion":5785,"completion":5785,"start":2819,"enrollment":5786,"conditions":5787,"interventions":5788},"NCT01513473","A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus",[90],"2013-07-30",350,[15,21],[1919,3589,1978],{"nctId":5790,"briefTitle":5791,"status":105,"phases":5792,"primaryCompletion":3634,"completion":3634,"start":5793,"enrollment":335,"conditions":5794,"interventions":5796},"NCT00065130","Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes",[90],"2000-04",[15,5795],"Gestational Diabetes",[5797,4967,1978],"human insulin",{"nctId":2029,"briefTitle":2030,"status":380,"phases":5799,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":2035,"conditions":5800,"interventions":5801},[90],[21],[1829,1910,1311],{"nctId":5803,"briefTitle":5804,"status":105,"phases":5805,"primaryCompletion":5806,"completion":5806,"start":5807,"enrollment":2289,"conditions":5808,"interventions":5809},"NCT03377699","Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes",[90],"2020-12-17","2017-11-22",[15,21],[1887,5281,5810],"Insulin detemir",{"nctId":5812,"briefTitle":5813,"status":105,"phases":5814,"primaryCompletion":5815,"completion":2811,"start":5816,"enrollment":5817,"conditions":5818,"interventions":5819},"NCT02500706","Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes",[90],"2017-07-17","2016-05-04",1108,[15,21],[4709,1978,1919],{"nctId":4829,"briefTitle":4830,"status":105,"phases":5821,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":4834,"conditions":5822,"interventions":5823},[90],[15,21],[1919,876,1978],{"nctId":4125,"briefTitle":4126,"status":105,"phases":5825,"primaryCompletion":4128,"completion":4128,"start":3461,"enrollment":4129,"conditions":5826,"interventions":5827},[90],[15,18],[1919,1978,768],{"nctId":5829,"briefTitle":5830,"status":105,"phases":5831,"primaryCompletion":4484,"completion":4484,"start":4794,"enrollment":5832,"conditions":5833,"interventions":5834},"NCT00184600","Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes",[90],708,[15,18],[4751,3589,1978],{"nctId":4838,"briefTitle":4839,"status":105,"phases":5836,"primaryCompletion":4841,"completion":4841,"start":4833,"enrollment":4842,"conditions":5837,"interventions":5838},[90],[15,18],[1919,876,1978],{"nctId":5840,"briefTitle":5841,"status":105,"phases":5842,"primaryCompletion":5843,"completion":5843,"start":5844,"enrollment":5845,"conditions":5846,"interventions":5847},"NCT00605020","Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes",[90],"2005-03-03","2003-12-02",719,[15,18],[3589,1978],{"nctId":5849,"briefTitle":5850,"status":105,"phases":5851,"primaryCompletion":5852,"completion":5852,"start":3714,"enrollment":3303,"conditions":5853,"interventions":5854},"NCT00474045","Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes",[90],"2010-08",[15,21],[3589,5855,1978],"NPH insulin",{"nctId":4846,"briefTitle":4847,"status":105,"phases":5857,"primaryCompletion":3706,"completion":3706,"start":4849,"enrollment":4850,"conditions":5858,"interventions":5859},[90],[15,21],[3589,876,1978],{"nctId":5861,"briefTitle":5862,"status":105,"phases":5863,"primaryCompletion":2224,"completion":2224,"start":3731,"enrollment":5864,"conditions":5865,"interventions":5866},"NCT00435019","Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes",[90],348,[15,21],[3589,4967,1978],{"nctId":5868,"briefTitle":5869,"status":105,"phases":5870,"primaryCompletion":5871,"completion":5871,"start":5872,"enrollment":285,"conditions":5873,"interventions":5874},"NCT01999322","A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes",[90],"2014-05-14","2013-11-19",[15,21],[4709,1978],{"nctId":5876,"briefTitle":5877,"status":105,"phases":5878,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":385,"conditions":5881,"interventions":5882},"NCT00832182","Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes",[90],"2002-11-25","1999-12-22",[15,21],[1978,4967],{"nctId":4854,"briefTitle":4855,"status":105,"phases":5884,"primaryCompletion":4857,"completion":4857,"start":4858,"enrollment":4859,"conditions":5885,"interventions":5886},[90],[15,21],[1919,876,1978],{"nctId":4863,"briefTitle":4864,"status":105,"phases":5888,"primaryCompletion":4866,"completion":4866,"start":4867,"enrollment":4868,"conditions":5889,"interventions":5890},[90],[15,18],[3487,876,1978],{"nctId":5892,"briefTitle":5893,"status":105,"phases":5894,"primaryCompletion":2331,"completion":2331,"start":4484,"enrollment":5895,"conditions":5896,"interventions":5897},"NCT00978627","Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes",[90],548,[15,21],[4594,3589,1978,1978],{"nctId":5899,"briefTitle":5900,"status":105,"phases":5901,"primaryCompletion":5902,"completion":5902,"start":5844,"enrollment":2380,"conditions":5903,"interventions":5904},"NCT00595374","Efficacy and Safety of Insulin Detemir in Type 1 Diabetes",[90],"2004-10-07",[15,21],[3589,4967,1978],{"nctId":4891,"briefTitle":4892,"status":105,"phases":5906,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4894,"conditions":5907,"interventions":5908},[90],[15,21],[3589,876,1978],{"nctId":5910,"briefTitle":5911,"status":349,"phases":5912,"primaryCompletion":3602,"completion":3602,"start":4643,"enrollment":2338,"conditions":5913,"interventions":5914},"NCT00267683","Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes",[90],[15,18],[1978,3855],{"nctId":5916,"briefTitle":5917,"status":105,"phases":5918,"primaryCompletion":5919,"completion":5920,"start":5816,"enrollment":5921,"conditions":5922,"interventions":5923},"NCT02670915","Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes",[90],"2018-02-05","2018-03-03",834,[15,21],[4709,1978,1919],{"nctId":5925,"briefTitle":5926,"status":105,"phases":5927,"primaryCompletion":3550,"completion":3550,"start":5928,"enrollment":5929,"conditions":5930,"interventions":5931},"NCT00071448","Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population",[90],"2002-06",378,[15,21],[3613,5603,1978],{"nctId":5933,"briefTitle":5934,"status":105,"phases":5935,"primaryCompletion":5936,"completion":5937,"start":5938,"enrollment":5939,"conditions":5940,"interventions":5941},"NCT01831765","Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes",[90],"2015-05-12","2015-06-11","2013-08-26",1290,[15,21],[4709,3589,1978,4709],{"nctId":5943,"briefTitle":5944,"status":105,"phases":5945,"primaryCompletion":5946,"completion":5946,"start":5947,"enrollment":5948,"conditions":5949,"interventions":5950},"NCT01835431","A Trial Investigating the Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus",[90],"2014-11-07","2013-10-17",362,[15,21],[4594,1978,3589,1978],{"trials":5952,"activeCount":99},[5953,5960,5968,5974,5982,5988,5992,5999,6005,6012,6018,6025,6032,6039,6046,6054,6061,6068,6074,6082,6091],{"nctId":5954,"briefTitle":5955,"status":105,"phases":5956,"primaryCompletion":4765,"completion":4765,"start":2214,"enrollment":5957,"conditions":5958,"interventions":5959},"NCT00095446","NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes",[91],513,[15,21,18],[1978],{"nctId":5961,"briefTitle":5962,"status":105,"phases":5963,"primaryCompletion":5766,"completion":5766,"start":5964,"enrollment":5965,"conditions":5966,"interventions":5967},"NCT00365170","Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes",[91],"2002-09",419,[15,21],[5797,1978],{"nctId":5969,"briefTitle":5970,"status":105,"phases":5971,"primaryCompletion":3586,"completion":3586,"start":3961,"enrollment":4737,"conditions":5972,"interventions":5973},"NCT00537303","Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes",[91],[15,18],[3589,1978,1978],{"nctId":5975,"briefTitle":5976,"status":105,"phases":5977,"primaryCompletion":3618,"completion":3618,"start":5978,"enrollment":5979,"conditions":5980,"interventions":5981},"NCT00274274","Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes",[91],"2005-09",373,[15,18],[3589,1978],{"nctId":5983,"briefTitle":5984,"status":349,"phases":5985,"primaryCompletion":334,"completion":334,"start":5366,"enrollment":109,"conditions":5986,"interventions":5987},"NCT01486966","Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes",[91],[15,18],[3589,1978,4967,5705,226],{"nctId":4931,"briefTitle":4932,"status":105,"phases":5989,"primaryCompletion":923,"completion":923,"start":4438,"enrollment":4934,"conditions":5990,"interventions":5991},[91],[15,18],[4471,876,1978],{"nctId":5993,"briefTitle":5994,"status":105,"phases":5995,"primaryCompletion":4491,"completion":4491,"start":4570,"enrollment":5996,"conditions":5997,"interventions":5998},"NCT01068652","Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs",[91],403,[15,18],[3589,1978,4471,226],{"nctId":6000,"briefTitle":6001,"status":105,"phases":6002,"primaryCompletion":3586,"completion":3586,"start":3594,"enrollment":192,"conditions":6003,"interventions":6004},"NCT00542620","Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial",[91],[15,21],[3589,1978,3589,1978],{"nctId":6006,"briefTitle":6007,"status":105,"phases":6008,"primaryCompletion":5599,"completion":5599,"start":5757,"enrollment":5278,"conditions":6009,"interventions":6010},"NCT00571935","Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes",[91],[15,21],[1978,6011],"soluble human insulin",{"nctId":6013,"briefTitle":6014,"status":105,"phases":6015,"primaryCompletion":4320,"completion":4320,"start":4635,"enrollment":1418,"conditions":6016,"interventions":6017},"NCT01165684","Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen",[91],[15,18],[1978,1978,3589],{"nctId":6019,"briefTitle":6020,"status":349,"phases":6021,"primaryCompletion":2162,"completion":2162,"start":6022,"enrollment":992,"conditions":6023,"interventions":6024},"NCT00509925","Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes",[91],"2007-07",[15,21],[3589,4967,1978],{"nctId":6026,"briefTitle":6027,"status":105,"phases":6028,"primaryCompletion":4398,"completion":4398,"start":2213,"enrollment":6029,"conditions":6030,"interventions":6031},"NCT00282451","Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes",[91],79,[15,18],[4751,1978],{"nctId":6033,"briefTitle":6034,"status":105,"phases":6035,"primaryCompletion":5757,"completion":5757,"start":3802,"enrollment":6036,"conditions":6037,"interventions":6038},"NCT01649570","Safety and Efficacy of Insulin Aspart in Type 2 Diabetes",[91],123,[15,18],[1978],{"nctId":6040,"briefTitle":6041,"status":105,"phases":6042,"primaryCompletion":3715,"completion":3715,"start":5496,"enrollment":6043,"conditions":6044,"interventions":6045},"NCT00117780","Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes",[91],520,[15,21],[3589,1978],{"nctId":6047,"briefTitle":6048,"status":105,"phases":6049,"primaryCompletion":6050,"completion":6050,"start":6051,"enrollment":3643,"conditions":6052,"interventions":6053},"NCT00676819","Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes",[91],"2002-07-19","2002-01-10",[15,18],[1978,5797],{"nctId":6055,"briefTitle":6056,"status":105,"phases":6057,"primaryCompletion":3602,"completion":3602,"start":6058,"enrollment":2803,"conditions":6059,"interventions":6060},"NCT00494988","Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart",[91],"2004-12",[15,18],[1978,4967],{"nctId":6062,"briefTitle":6063,"status":105,"phases":6064,"primaryCompletion":5766,"completion":5766,"start":2214,"enrollment":6065,"conditions":6066,"interventions":6067},"NCT00593255","Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes",[91],220,[15,21,18],[6011,1978,4967],{"nctId":6069,"briefTitle":6070,"status":105,"phases":6071,"primaryCompletion":3707,"completion":3707,"start":5710,"enrollment":2172,"conditions":6072,"interventions":6073},"NCT00597233","Human Insulin NPH and Insulin Aspart in Type 1 Diabetes",[91],[15,21],[1978,6011,4967],{"nctId":6075,"briefTitle":6076,"status":105,"phases":6077,"primaryCompletion":6078,"completion":6078,"start":6079,"enrollment":2134,"conditions":6080,"interventions":6081},"NCT00572806","Initiation of Insulin Aspart in Type 2 Diabetes",[91],"2004-02-02","2003-02-05",[15,18],[1978],{"nctId":6083,"briefTitle":6084,"status":105,"phases":6085,"primaryCompletion":6086,"completion":6086,"start":6087,"enrollment":2185,"conditions":6088,"interventions":6089},"NCT01467141","Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes",[91],"2003-10-15","2002-06-19",[15,21],[1978,5797,6090],"isophane human insulin",{"nctId":6092,"briefTitle":6093,"status":105,"phases":6094,"primaryCompletion":6095,"completion":6095,"start":6096,"enrollment":5774,"conditions":6097,"interventions":6098},"NCT01697631","Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes",[91],"2003-04-24","2002-07-22",[15,18],[4471,1978],{"trials":6100,"activeCount":99},[6101,6108,6115,6121,6127,6134,6141,6147,6154,6161,6167,6173,6180,6187,6196,6203,6211,6218,6225,6233],{"nctId":6102,"briefTitle":6103,"status":105,"phases":6104,"primaryCompletion":652,"completion":652,"start":3860,"enrollment":6105,"conditions":6106,"interventions":6107},"NCT00869908","Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication",[],66726,[15,18],[1978,3589,4751],{"nctId":6109,"briefTitle":6110,"status":105,"phases":6111,"primaryCompletion":3715,"completion":3715,"start":2194,"enrollment":6112,"conditions":6113,"interventions":6114},"NCT01548248","Efficacy and Safety of Levemir® Used as Basal Insulin",[],631,[15,21,18],[3589,1978],{"nctId":6116,"briefTitle":6117,"status":1135,"phases":6118,"primaryCompletion":3462,"completion":3462,"start":129,"enrollment":99,"conditions":6119,"interventions":6120},"NCT00849316","Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease",[],[15,21,18,840],[1978],{"nctId":6122,"briefTitle":6123,"status":105,"phases":6124,"primaryCompletion":128,"completion":128,"start":3634,"enrollment":498,"conditions":6125,"interventions":6126},"NCT01538576","Paediatric Subjects - Special Survey",[],[15,21,18],[1978],{"nctId":6128,"briefTitle":6129,"status":105,"phases":6130,"primaryCompletion":2331,"completion":2331,"start":4015,"enrollment":6131,"conditions":6132,"interventions":6133},"NCT00676741","Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin",[],3809,[15,18],[1978,4471,3589],{"nctId":6135,"briefTitle":6136,"status":105,"phases":6137,"primaryCompletion":4484,"completion":4484,"start":4015,"enrollment":6138,"conditions":6139,"interventions":6140},"NCT00698269","An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment",[],5926,[15,21,18],[3589,4471,1978],{"nctId":6142,"briefTitle":6143,"status":105,"phases":6144,"primaryCompletion":2193,"completion":2193,"start":3715,"enrollment":4979,"conditions":6145,"interventions":6146},"NCT01542489","Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos",[],[15,21,18],[3589,1978,5705],{"nctId":6148,"briefTitle":6149,"status":105,"phases":6150,"primaryCompletion":128,"completion":128,"start":4849,"enrollment":6151,"conditions":6152,"interventions":6153},"NCT01487369","Special Survey of Production of Insulin Aspart Specific Antibody",[],204,[15,21,18],[1978],{"nctId":6155,"briefTitle":6156,"status":105,"phases":6157,"primaryCompletion":2278,"completion":2278,"start":3739,"enrollment":6158,"conditions":6159,"interventions":6160},"NCT00771680","Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes",[],10408,[15,18],[3589,4471,1978],{"nctId":6162,"briefTitle":6163,"status":105,"phases":6164,"primaryCompletion":128,"completion":128,"start":4849,"enrollment":5677,"conditions":6165,"interventions":6166},"NCT01487382","Special Survey for Paediatric Subjects",[],[15,21,18],[1978],{"nctId":6168,"briefTitle":6129,"status":105,"phases":6169,"primaryCompletion":3699,"completion":3699,"start":3901,"enrollment":6170,"conditions":6171,"interventions":6172},"NCT00670722",[],6500,[15,18],[1978,3589,4471],{"nctId":6174,"briefTitle":6175,"status":105,"phases":6176,"primaryCompletion":6177,"completion":6177,"start":2205,"enrollment":5979,"conditions":6178,"interventions":6179},"NCT00675220","Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™",[],"2007-12",[15,21,18,4478],[1978],{"nctId":6181,"briefTitle":6182,"status":105,"phases":6183,"primaryCompletion":3492,"completion":3492,"start":3748,"enrollment":6184,"conditions":6185,"interventions":6186},"NCT01490112","Surveillance Study of NovoRapid® for New Drug Re-examination",[],1239,[15,21,18],[1978],{"nctId":6188,"briefTitle":6189,"status":105,"phases":6190,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":6193,"interventions":6194},"NCT00715780","Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents",[],"2009-07",1667,[15,18],[6011,6195,4967,1978,4751,3589],"biphasic human insulin",{"nctId":6197,"briefTitle":6198,"status":105,"phases":6199,"primaryCompletion":128,"completion":128,"start":4849,"enrollment":6200,"conditions":6201,"interventions":6202},"NCT01487408","Special Survey for Type 1 or Type 2 Diabetic Patients",[],1463,[15,21,18],[1978],{"nctId":6204,"briefTitle":6205,"status":105,"phases":6206,"primaryCompletion":2144,"completion":2144,"start":6207,"enrollment":6208,"conditions":6209,"interventions":6210},"NCT00410033","Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin",[92],"1989-12",74,[15,21],[6011,6090,1978],{"nctId":6212,"briefTitle":6213,"status":105,"phases":6214,"primaryCompletion":2224,"completion":2224,"start":2279,"enrollment":6215,"conditions":6216,"interventions":6217},"NCT00700648","An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects",[],3024,[15,21,18],[1978],{"nctId":6219,"briefTitle":6220,"status":105,"phases":6221,"primaryCompletion":3462,"completion":3462,"start":488,"enrollment":6222,"conditions":6223,"interventions":6224},"NCT00873639","Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues",[],417,[15,21],[1978,3589],{"nctId":6226,"briefTitle":6227,"status":105,"phases":6228,"primaryCompletion":3715,"completion":3715,"start":6229,"enrollment":6230,"conditions":6231,"interventions":6232},"NCT01487421","An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime",[],"2003-07",2134,[15,18],[1978,3589],{"nctId":6234,"briefTitle":6235,"status":105,"phases":6236,"primaryCompletion":128,"completion":128,"start":3634,"enrollment":6237,"conditions":6238,"interventions":6239},"NCT01538589","Special Survey for Patients With Type 1 or Type 2 Diabetes",[],1582,[15,21,18],[1978],{"intervention":726,"totalTrials":1827,"cells":6241},{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6272,"PHASE3":6285,"PHASE4":6287,"NA":6289},{"trials":6243,"activeCount":99},[],{"trials":6245,"activeCount":1606,"soonestReadout":6250},[6246,6257,6265],{"nctId":6247,"briefTitle":6248,"status":380,"phases":6249,"primaryCompletion":6250,"completion":6251,"start":6252,"enrollment":266,"conditions":6253,"interventions":6254},"NCT07525791","A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight",[88],"2027-04-08","2027-05-04","2026-04-07",[33,24],[726,6255,6256],"Oral contraceptive","Acetaminophen",{"nctId":6258,"briefTitle":6259,"status":105,"phases":6260,"primaryCompletion":6261,"completion":6261,"start":6262,"enrollment":528,"conditions":6263,"interventions":6264},"NCT06737536","A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity",[88],"2025-07-26","2024-12-18",[33,24],[726],{"nctId":6266,"briefTitle":6267,"status":105,"phases":6268,"primaryCompletion":6269,"completion":6269,"start":4995,"enrollment":528,"conditions":6270,"interventions":6271},"NCT07101783","A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity",[88],"2025-10-31",[33,24],[726],{"trials":6273,"activeCount":864,"soonestReadout":3114},[6274,6278],{"nctId":717,"briefTitle":718,"status":380,"phases":6275,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":6276,"interventions":6277},[89],[18],[726,75],{"nctId":6279,"briefTitle":6280,"status":457,"phases":6281,"primaryCompletion":3114,"completion":3114,"start":1165,"enrollment":6282,"conditions":6283,"interventions":6284},"NCT07184632","A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity",[89],224,[33,24],[726],{"trials":6286,"activeCount":99},[],{"trials":6288,"activeCount":99},[],{"trials":6290,"activeCount":99},[],{"intervention":6292,"totalTrials":864,"cells":6293},"CDR132L",{"EARLY_PHASE1":6294,"PHASE1":6296,"PHASE2":6298,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6295,"activeCount":99},[],{"trials":6297,"activeCount":99},[],{"trials":6299,"activeCount":864,"soonestReadout":6304},[6300,6309],{"nctId":6301,"briefTitle":6302,"status":380,"phases":6303,"primaryCompletion":6304,"completion":6305,"start":6306,"enrollment":1110,"conditions":6307,"interventions":6308},"NCT06979362","A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy",[89],"2027-05-16","2028-01-23","2025-06-27",[2647],[6292],{"nctId":6310,"briefTitle":6311,"status":380,"phases":6312,"primaryCompletion":6304,"completion":6305,"start":6313,"enrollment":1110,"conditions":6314,"interventions":6315},"NCT06979375","A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced\u002FMildly Reduced Ejection Fraction and Left Ventricular Hypertrophy",[89],"2025-06-30",[2647],[6292],{"trials":6317,"activeCount":99},[],{"trials":6319,"activeCount":99},[],{"trials":6321,"activeCount":99},[],{"intervention":842,"totalTrials":1546,"cells":6323},{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6385,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6325,"activeCount":99},[],{"trials":6327,"activeCount":99},[6328,6337,6345,6355,6364,6371,6378],{"nctId":6329,"briefTitle":6330,"status":105,"phases":6331,"primaryCompletion":6332,"completion":6333,"start":6334,"enrollment":3454,"conditions":6335,"interventions":6336},"NCT05870670","A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men",[88],"2023-10-07","2023-10-16","2023-05-15",[18],[842],{"nctId":6338,"briefTitle":6339,"status":105,"phases":6340,"primaryCompletion":6341,"completion":6341,"start":6342,"enrollment":372,"conditions":6343,"interventions":6344},"NCT07004322","A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight",[88],"2026-01-28","2025-05-26",[18,24],[842],{"nctId":6346,"briefTitle":6347,"status":105,"phases":6348,"primaryCompletion":6349,"completion":2869,"start":6350,"enrollment":2885,"conditions":6351,"interventions":6352},"NCT06513104","A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause",[88],"2025-09-10","2024-07-18",[18],[842,6353,6354],"Levonorgestrel + Ethinylestradiol","Paracetamol",{"nctId":6356,"briefTitle":6357,"status":105,"phases":6358,"primaryCompletion":6359,"completion":6359,"start":6360,"enrollment":442,"conditions":6361,"interventions":6363},"NCT05363774","A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.",[88],"2024-04-02","2022-04-20",[6362],"Healthy Volunteers (Diabetes Mellitus, Type 2)",[842],{"nctId":6365,"briefTitle":6366,"status":105,"phases":6367,"primaryCompletion":1588,"completion":1588,"start":6368,"enrollment":2549,"conditions":6369,"interventions":6370},"NCT06370819","A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function",[88],"2024-04-15",[18],[842],{"nctId":6372,"briefTitle":6373,"status":105,"phases":6374,"primaryCompletion":803,"completion":803,"start":6375,"enrollment":2989,"conditions":6376,"interventions":6377},"NCT06718998","A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity",[88],"2024-11-20",[24],[842],{"nctId":6379,"briefTitle":6380,"status":105,"phases":6381,"primaryCompletion":6382,"completion":6382,"start":2593,"enrollment":5519,"conditions":6383,"interventions":6384},"NCT06567041","A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes",[88],"2025-12-10",[18,24],[842],{"trials":6386,"activeCount":1606,"soonestReadout":835},[6387,6396,6400],{"nctId":6388,"briefTitle":6389,"status":105,"phases":6390,"primaryCompletion":6391,"completion":6392,"start":5078,"enrollment":5600,"conditions":6393,"interventions":6394},"NCT06326047","A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes",[89],"2025-09-19","2025-10-13",[18],[842,6395],"Trizepatide",{"nctId":5074,"briefTitle":5075,"status":105,"phases":6397,"primaryCompletion":5077,"completion":1703,"start":5078,"enrollment":5079,"conditions":6398,"interventions":6399},[89],[24],[842,1034],{"nctId":832,"briefTitle":833,"status":380,"phases":6401,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":6402,"interventions":6403},[89],[840],[842,75],{"trials":6405,"activeCount":99},[],{"trials":6407,"activeCount":99},[],{"trials":6409,"activeCount":99},[],{"intervention":6411,"totalTrials":1606,"cells":6412},"UBT251",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6414,"activeCount":99},[],{"trials":6416,"activeCount":99},[],{"trials":6418,"activeCount":1606,"soonestReadout":6423},[6419],{"nctId":6420,"briefTitle":6421,"status":380,"phases":6422,"primaryCompletion":6423,"completion":6424,"start":634,"enrollment":1772,"conditions":6425,"interventions":6426},"NCT07395687","A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity",[89],"2027-01-14","2027-02-18",[33,24],[6411],{"trials":6428,"activeCount":99},[],{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[],{"intervention":6434,"totalTrials":2578,"cells":6435},"NNC0442-0344 A",{"EARLY_PHASE1":6436,"PHASE1":6438,"PHASE2":6464,"PHASE3":6466,"PHASE4":6468,"NA":6470},{"trials":6437,"activeCount":99},[],{"trials":6439,"activeCount":864,"soonestReadout":6460},[6440,6449,6456],{"nctId":6441,"briefTitle":6442,"status":105,"phases":6443,"primaryCompletion":6444,"completion":6444,"start":6445,"enrollment":6446,"conditions":6447,"interventions":6448},"NCT06649630","A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men",[88],"2026-03-26","2024-09-23",95,[36],[6434],{"nctId":6450,"briefTitle":6451,"status":380,"phases":6452,"primaryCompletion":6453,"completion":6453,"start":1176,"enrollment":119,"conditions":6454,"interventions":6455},"NCT07220564","A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A",[88],"2027-02-05",[36],[6434],{"nctId":6457,"briefTitle":6458,"status":380,"phases":6459,"primaryCompletion":6460,"completion":6460,"start":6461,"enrollment":2531,"conditions":6462,"interventions":6463},"NCT07238816","A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People",[88],"2026-04-29","2025-11-18",[36],[6434],{"trials":6465,"activeCount":99},[],{"trials":6467,"activeCount":99},[],{"trials":6469,"activeCount":99},[],{"trials":6471,"activeCount":99},[],{"intervention":6473,"totalTrials":864,"cells":6474},"Cagrilintide D",{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6496,"PHASE3":6498,"PHASE4":6500,"NA":6502},{"trials":6476,"activeCount":99},[],{"trials":6478,"activeCount":864,"soonestReadout":6492},[6479,6488],{"nctId":6480,"briefTitle":6481,"status":1346,"phases":6482,"primaryCompletion":1474,"completion":1474,"start":6483,"enrollment":6484,"conditions":6485,"interventions":6486},"NCT07597018","A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity",[88],"2026-05-18",234,[24,33],[6473,6487],"Cagrilintide B and placebo semaglutide I",{"nctId":6489,"briefTitle":6490,"status":1346,"phases":6491,"primaryCompletion":6492,"completion":6492,"start":1350,"enrollment":1624,"conditions":6493,"interventions":6494},"NCT07605052","A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight",[88],"2026-09-03",[33,24],[6495,6473],"Cagrilintide B",{"trials":6497,"activeCount":99},[],{"trials":6499,"activeCount":99},[],{"trials":6501,"activeCount":99},[],{"trials":6503,"activeCount":99},[],{"intervention":6495,"totalTrials":864,"cells":6505},{"EARLY_PHASE1":6506,"PHASE1":6508,"PHASE2":6523,"PHASE3":6525,"PHASE4":6527,"NA":6529},{"trials":6507,"activeCount":99},[],{"trials":6509,"activeCount":864,"soonestReadout":6444},[6510,6514],{"nctId":6489,"briefTitle":6490,"status":1346,"phases":6511,"primaryCompletion":6492,"completion":6492,"start":1350,"enrollment":1624,"conditions":6512,"interventions":6513},[88],[33,24],[6495,6473],{"nctId":6515,"briefTitle":6516,"status":380,"phases":6517,"primaryCompletion":6444,"completion":6518,"start":6519,"enrollment":3791,"conditions":6520,"interventions":6521},"NCT06719011","A Study on How NNC0174-1213 Works in People With Overweight or Obesity.",[88],"2026-05-17","2024-12-03",[24,33],[6522,6495],"NNC0174-1213 A",{"trials":6524,"activeCount":99},[],{"trials":6526,"activeCount":99},[],{"trials":6528,"activeCount":99},[],{"trials":6530,"activeCount":99},[],{"intervention":257,"totalTrials":1546,"cells":6532},{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6604,"PHASE3":6610,"PHASE4":6612,"NA":6614},{"trials":6534,"activeCount":99},[],{"trials":6536,"activeCount":1606,"soonestReadout":459},[6537,6546,6555,6559,6563,6572,6580,6588,6596],{"nctId":6538,"briefTitle":6539,"status":105,"phases":6540,"primaryCompletion":6541,"completion":6541,"start":6542,"enrollment":173,"conditions":6543,"interventions":6545},"NCT05727644","A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function",[88],"2023-11-10","2023-02-15",[6544],"Non-alcoholic Steatohepatitis (NASH)",[257],{"nctId":6547,"briefTitle":6548,"status":105,"phases":6549,"primaryCompletion":6550,"completion":6550,"start":6551,"enrollment":306,"conditions":6552,"interventions":6553},"NCT05742919","A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men",[88],"2023-06-13","2023-02-16",[215],[257,257,6554],"NC0194-0499",{"nctId":247,"briefTitle":248,"status":105,"phases":6556,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":6557,"interventions":6558},[88],[255],[257,75,258,258],{"nctId":455,"briefTitle":456,"status":457,"phases":6560,"primaryCompletion":459,"completion":460,"start":461,"enrollment":234,"conditions":6561,"interventions":6562},[88],[21],[257,75],{"nctId":6564,"briefTitle":6565,"status":105,"phases":6566,"primaryCompletion":6567,"completion":6567,"start":2897,"enrollment":708,"conditions":6568,"interventions":6570},"NCT06188026","A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.",[88],"2024-12-30",[6569],"Healthy Volunteers (Non-alcoholic Steatohepatitis)",[257,6571],"ethinylestradiol\u002Flevonorgestrel",{"nctId":6573,"briefTitle":6574,"status":105,"phases":6575,"primaryCompletion":6576,"completion":6576,"start":6577,"enrollment":673,"conditions":6578,"interventions":6579},"NCT03015207","First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity",[88],"2017-10-26","2017-01-06",[204,24],[257],{"nctId":6581,"briefTitle":6582,"status":105,"phases":6583,"primaryCompletion":6584,"completion":6584,"start":6585,"enrollment":173,"conditions":6586,"interventions":6587},"NCT04722653","A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men",[88],"2021-04-27","2021-02-02",[255],[257],{"nctId":6589,"briefTitle":6590,"status":105,"phases":6591,"primaryCompletion":6592,"completion":6592,"start":6593,"enrollment":2803,"conditions":6594,"interventions":6595},"NCT05917938","A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function",[88],"2024-12-16","2023-07-04",[2399,142],[257],{"nctId":6597,"briefTitle":6598,"status":105,"phases":6599,"primaryCompletion":6600,"completion":6600,"start":6601,"enrollment":11,"conditions":6602,"interventions":6603},"NCT03479892","A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity",[88],"2019-06-04","2018-03-13",[204,24],[257],{"trials":6605,"activeCount":99},[6606],{"nctId":799,"briefTitle":800,"status":105,"phases":6607,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":6608,"interventions":6609},[89],[806],[257,75,808,809,810,70,811,809],{"trials":6611,"activeCount":99},[],{"trials":6613,"activeCount":99},[],{"trials":6615,"activeCount":99},[],{"intervention":6617,"totalTrials":864,"cells":6618},"NNC0581-0001",{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6640,"PHASE3":6642,"PHASE4":6644,"NA":6646},{"trials":6620,"activeCount":99},[],{"trials":6622,"activeCount":1606,"soonestReadout":6635},[6623,6631],{"nctId":6624,"briefTitle":6625,"status":105,"phases":6626,"primaryCompletion":1214,"completion":1214,"start":6627,"enrollment":699,"conditions":6628,"interventions":6630},"NCT05599945","First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases",[88],"2022-11-23",[142,6629],"Hepatic Steatosis",[6617],{"nctId":6632,"briefTitle":6633,"status":380,"phases":6634,"primaryCompletion":6635,"completion":6636,"start":6637,"enrollment":699,"conditions":6638,"interventions":6639},"NCT06891365","Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases",[88],"2027-10-11","2027-11-15","2025-03-12",[142,6629],[6617],{"trials":6641,"activeCount":99},[],{"trials":6643,"activeCount":99},[],{"trials":6645,"activeCount":99},[],{"trials":6647,"activeCount":99},[],{"intervention":6649,"totalTrials":864,"cells":6650},"NNC0537-1482",{"EARLY_PHASE1":6651,"PHASE1":6653,"PHASE2":6670,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6652,"activeCount":99},[],{"trials":6654,"activeCount":1606,"soonestReadout":6667},[6655,6663],{"nctId":6656,"briefTitle":6657,"status":105,"phases":6658,"primaryCompletion":6659,"completion":6659,"start":6660,"enrollment":554,"conditions":6661,"interventions":6662},"NCT06625307","A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin",[88],"2025-05-04","2024-10-03",[142,2647],[6649],{"nctId":6664,"briefTitle":6665,"status":380,"phases":6666,"primaryCompletion":6667,"completion":6667,"start":1176,"enrollment":2549,"conditions":6668,"interventions":6669},"NCT07218627","A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure",[88],"2027-01-15",[2647],[6649],{"trials":6671,"activeCount":99},[],{"trials":6673,"activeCount":99},[],{"trials":6675,"activeCount":99},[],{"trials":6677,"activeCount":99},[],{"intervention":6679,"totalTrials":864,"cells":6680},"NNC0363-1063",{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6701,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6682,"activeCount":99},[],{"trials":6684,"activeCount":1606,"soonestReadout":6518},[6685,6692],{"nctId":6686,"briefTitle":6687,"status":380,"phases":6688,"primaryCompletion":6518,"completion":1089,"start":6689,"enrollment":2549,"conditions":6690,"interventions":6691},"NCT07305805","A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes",[88],"2025-12-15",[21],[6679],{"nctId":6693,"briefTitle":6694,"status":105,"phases":6695,"primaryCompletion":6696,"completion":6697,"start":6698,"enrollment":12,"conditions":6699,"interventions":6700},"NCT06685185","A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes",[88],"2026-03-08","2026-03-18","2024-11-12",[21],[6679,1887,5810],{"trials":6702,"activeCount":99},[],{"trials":6704,"activeCount":99},[],{"trials":6706,"activeCount":99},[],{"trials":6708,"activeCount":99},[],{"intervention":6255,"totalTrials":864,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6728,"PHASE3":6730,"PHASE4":6732,"NA":6734},{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":1606,"soonestReadout":6250},[6715,6719],{"nctId":6247,"briefTitle":6248,"status":380,"phases":6716,"primaryCompletion":6250,"completion":6251,"start":6252,"enrollment":266,"conditions":6717,"interventions":6718},[88],[33,24],[726,6255,6256],{"nctId":6720,"briefTitle":6721,"status":105,"phases":6722,"primaryCompletion":6723,"completion":6723,"start":6724,"enrollment":554,"conditions":6725,"interventions":6726},"NCT04074174","Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant",[88],"2020-03-06","2019-09-12",[33,24],[539,6727,6256],"Oral contraceptive (OC)",{"trials":6729,"activeCount":99},[],{"trials":6731,"activeCount":99},[],{"trials":6733,"activeCount":99},[],{"trials":6735,"activeCount":99},[],{"intervention":6256,"totalTrials":864,"cells":6737},{"EARLY_PHASE1":6738,"PHASE1":6740,"PHASE2":6750,"PHASE3":6752,"PHASE4":6754,"NA":6756},{"trials":6739,"activeCount":99},[],{"trials":6741,"activeCount":1606,"soonestReadout":6250},[6742,6746],{"nctId":6247,"briefTitle":6248,"status":380,"phases":6743,"primaryCompletion":6250,"completion":6251,"start":6252,"enrollment":266,"conditions":6744,"interventions":6745},[88],[33,24],[726,6255,6256],{"nctId":6720,"briefTitle":6721,"status":105,"phases":6747,"primaryCompletion":6723,"completion":6723,"start":6724,"enrollment":554,"conditions":6748,"interventions":6749},[88],[33,24],[539,6727,6256],{"trials":6751,"activeCount":99},[],{"trials":6753,"activeCount":99},[],{"trials":6755,"activeCount":99},[],{"trials":6757,"activeCount":99},[],{"intervention":6759,"totalTrials":1606,"cells":6760},"NNC1679-0001",{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6773,"PHASE3":6775,"PHASE4":6777,"NA":6779},{"trials":6762,"activeCount":99},[],{"trials":6764,"activeCount":1606,"soonestReadout":6769},[6765],{"nctId":6766,"briefTitle":6767,"status":380,"phases":6768,"primaryCompletion":6769,"completion":6769,"start":6770,"enrollment":2531,"conditions":6771,"interventions":6772},"NCT07570992","A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM",[88],"2028-06-25","2026-05-04",[142,18],[6759],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"trials":6778,"activeCount":99},[],{"trials":6780,"activeCount":99},[],{"intervention":2360,"totalTrials":1606,"cells":6782},{"EARLY_PHASE1":6783,"PHASE1":6785,"PHASE2":6791,"PHASE3":6793,"PHASE4":6795,"NA":6797},{"trials":6784,"activeCount":99},[],{"trials":6786,"activeCount":1606,"soonestReadout":2355},[6787],{"nctId":2352,"briefTitle":2353,"status":380,"phases":6788,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":528,"conditions":6789,"interventions":6790},[88],[33,2358],[2360,70],{"trials":6792,"activeCount":99},[],{"trials":6794,"activeCount":99},[],{"trials":6796,"activeCount":99},[],{"trials":6798,"activeCount":99},[],{"intervention":6800,"totalTrials":1606,"cells":6801},"NNC6989-0001 A",{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6813,"PHASE3":6815,"PHASE4":6817,"NA":6819},{"trials":6803,"activeCount":99},[],{"trials":6805,"activeCount":1606,"soonestReadout":6810},[6806],{"nctId":6807,"briefTitle":6808,"status":380,"phases":6809,"primaryCompletion":6810,"completion":6810,"start":2634,"enrollment":234,"conditions":6811,"interventions":6812},"NCT07437079","A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity",[88],"2027-01-21",[33,24],[6800],{"trials":6814,"activeCount":99},[],{"trials":6816,"activeCount":99},[],{"trials":6818,"activeCount":99},[],{"trials":6820,"activeCount":99},[],{"intervention":6822,"totalTrials":1606,"cells":6823},"NNC0638-0355",{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6836,"PHASE3":6838,"PHASE4":6840,"NA":6842},{"trials":6825,"activeCount":99},[],{"trials":6827,"activeCount":1606,"soonestReadout":6832},[6828],{"nctId":6829,"briefTitle":6830,"status":457,"phases":6831,"primaryCompletion":6832,"completion":6832,"start":6833,"enrollment":4542,"conditions":6834,"interventions":6835},"NCT06577766","A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity",[88],"2026-09-24","2024-09-03",[24,33],[6822],{"trials":6837,"activeCount":99},[],{"trials":6839,"activeCount":99},[],{"trials":6841,"activeCount":99},[],{"trials":6843,"activeCount":99},[],{"intervention":6845,"totalTrials":1606,"cells":6846},"NNC9733-0001",{"EARLY_PHASE1":6847,"PHASE1":6849,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6848,"activeCount":99},[],{"trials":6850,"activeCount":1606,"soonestReadout":6855},[6851],{"nctId":6852,"briefTitle":6853,"status":380,"phases":6854,"primaryCompletion":6855,"completion":6856,"start":6857,"enrollment":587,"conditions":6858,"interventions":6860},"NCT07270731","A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes",[88],"2027-08-30","2027-11-12","2025-11-25",[6859,862],"Healthy Volunteer",[6845],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[],{"trials":6866,"activeCount":99},[],{"trials":6868,"activeCount":99},[],{"intervention":6870,"totalTrials":1606,"cells":6871},"NNC0113-5840",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6884,"PHASE3":6886,"PHASE4":6888,"NA":6890},{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":1606,"soonestReadout":6880},[6876],{"nctId":6877,"briefTitle":6878,"status":1346,"phases":6879,"primaryCompletion":6880,"completion":6880,"start":6881,"enrollment":699,"conditions":6882,"interventions":6883},"NCT07566390","A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity",[88],"2026-11-26","2026-05-01",[24,33],[6870],{"trials":6885,"activeCount":99},[],{"trials":6887,"activeCount":99},[],{"trials":6889,"activeCount":99},[],{"trials":6891,"activeCount":99},[],{"intervention":6893,"totalTrials":1606,"cells":6894},"Coramitug",{"EARLY_PHASE1":6895,"PHASE1":6897,"PHASE2":6909,"PHASE3":6911,"PHASE4":6913,"NA":6915},{"trials":6896,"activeCount":99},[],{"trials":6898,"activeCount":1606,"soonestReadout":6903},[6899],{"nctId":6900,"briefTitle":6901,"status":380,"phases":6902,"primaryCompletion":6903,"completion":6904,"start":6905,"enrollment":3148,"conditions":6906,"interventions":6908},"NCT07448623","A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET\u002FCT Imaging in People With ATTR Amyloidosis.",[88],"2027-05-30","2028-07-25","2026-03-02",[6907],"Transthyretin Amyloid Cardiomyopathy",[6893],{"trials":6910,"activeCount":99},[],{"trials":6912,"activeCount":99},[],{"trials":6914,"activeCount":99},[],{"trials":6916,"activeCount":99},[],{"intervention":6487,"totalTrials":1606,"cells":6918},{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6927,"PHASE3":6929,"PHASE4":6931,"NA":6933},{"trials":6920,"activeCount":99},[],{"trials":6922,"activeCount":1606,"soonestReadout":1474},[6923],{"nctId":6480,"briefTitle":6481,"status":1346,"phases":6924,"primaryCompletion":1474,"completion":1474,"start":6483,"enrollment":6484,"conditions":6925,"interventions":6926},[88],[24,33],[6473,6487],{"trials":6928,"activeCount":99},[],{"trials":6930,"activeCount":99},[],{"trials":6932,"activeCount":99},[],{"trials":6934,"activeCount":99},[],{"intervention":6936,"totalTrials":1606,"cells":6937},"NNC4004-0002",{"EARLY_PHASE1":6938,"PHASE1":6940,"PHASE2":6950,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6939,"activeCount":99},[],{"trials":6941,"activeCount":1606,"soonestReadout":6946},[6942],{"nctId":6943,"briefTitle":6944,"status":380,"phases":6945,"primaryCompletion":6946,"completion":6946,"start":5115,"enrollment":4439,"conditions":6947,"interventions":6949},"NCT06859073","A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia",[88],"2026-06-01",[142,6948],"Hyperuricemia",[6936],{"trials":6951,"activeCount":99},[],{"trials":6953,"activeCount":99},[],{"trials":6955,"activeCount":99},[],{"trials":6957,"activeCount":99},[],{"intervention":6959,"totalTrials":1606,"cells":6960},"NNC0497-0040",{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6974,"PHASE3":6976,"PHASE4":6978,"NA":6980},{"trials":6962,"activeCount":99},[],{"trials":6964,"activeCount":1606,"soonestReadout":6969},[6965],{"nctId":6966,"briefTitle":6967,"status":1346,"phases":6968,"primaryCompletion":6969,"completion":6969,"start":6970,"enrollment":5732,"conditions":6971,"interventions":6973},"NCT07578584","A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity",[88],"2028-02-18","2026-05-07",[6972,33,24,142],"Type 1 Diabetes (T1D)",[6959],{"trials":6975,"activeCount":99},[],{"trials":6977,"activeCount":99},[],{"trials":6979,"activeCount":99},[],{"trials":6981,"activeCount":99},[],{"intervention":6983,"totalTrials":1606,"cells":6984},"NNC4005-001",{"EARLY_PHASE1":6985,"PHASE1":6987,"PHASE2":6998,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6986,"activeCount":99},[],{"trials":6988,"activeCount":1606,"soonestReadout":6993},[6989],{"nctId":6990,"briefTitle":6991,"status":380,"phases":6992,"primaryCompletion":6993,"completion":6993,"start":6994,"enrollment":4439,"conditions":6995,"interventions":6997},"NCT07214870","A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat",[88],"2027-05-14","2025-10-08",[6996],"Fatty Liver Disease",[6983],{"trials":6999,"activeCount":99},[],{"trials":7001,"activeCount":99},[],{"trials":7003,"activeCount":99},[],{"trials":7005,"activeCount":99},[],{"intervention":6522,"totalTrials":1606,"cells":7007},{"EARLY_PHASE1":7008,"PHASE1":7010,"PHASE2":7016,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":7009,"activeCount":99},[],{"trials":7011,"activeCount":1606,"soonestReadout":6444},[7012],{"nctId":6515,"briefTitle":6516,"status":380,"phases":7013,"primaryCompletion":6444,"completion":6518,"start":6519,"enrollment":3791,"conditions":7014,"interventions":7015},[88],[24,33],[6522,6495],{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":99},[],{"trials":7021,"activeCount":99},[],{"trials":7023,"activeCount":99},[],{"intervention":7025,"totalTrials":1606,"cells":7026},"INV-347",{"EARLY_PHASE1":7027,"PHASE1":7029,"PHASE2":7039,"PHASE3":7041,"PHASE4":7043,"NA":7045},{"trials":7028,"activeCount":99},[],{"trials":7030,"activeCount":1606,"soonestReadout":7035},[7031],{"nctId":7032,"briefTitle":7033,"status":380,"phases":7034,"primaryCompletion":7035,"completion":7035,"start":7036,"enrollment":2172,"conditions":7037,"interventions":7038},"NCT07153172","Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108",[88],"2027-09-15","2025-08-06",[24],[7025],{"trials":7040,"activeCount":99},[],{"trials":7042,"activeCount":99},[],{"trials":7044,"activeCount":99},[],{"trials":7046,"activeCount":99},[],{"intervention":7048,"totalTrials":5047,"cells":7049},"turoctocog alfa pegol",{"EARLY_PHASE1":7050,"PHASE1":7052,"PHASE2":7075,"PHASE3":7077,"PHASE4":7129,"NA":7131},{"trials":7051,"activeCount":99},[],{"trials":7053,"activeCount":99},[7054,7060,7068],{"nctId":7055,"briefTitle":7056,"status":105,"phases":7057,"primaryCompletion":2271,"completion":2271,"start":4369,"enrollment":335,"conditions":7058,"interventions":7059},"NCT01205724","Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A",[88],[30,36],[7048,7048,7048],{"nctId":7061,"briefTitle":7062,"status":105,"phases":7063,"primaryCompletion":7064,"completion":7064,"start":7065,"enrollment":507,"conditions":7066,"interventions":7067},"NCT02920398","A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A",[88],"2017-04-07","2016-10-04",[30,36],[7048],{"nctId":7069,"briefTitle":7070,"status":105,"phases":7071,"primaryCompletion":430,"completion":430,"start":7072,"enrollment":1624,"conditions":7073,"interventions":7074},"NCT02994407","Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A",[88],"2017-01-30",[30,36],[7048],{"trials":7076,"activeCount":99},[],{"trials":7078,"activeCount":99},[7079,7088,7097,7104,7113,7122],{"nctId":7080,"briefTitle":7081,"status":105,"phases":7082,"primaryCompletion":7083,"completion":7083,"start":7084,"enrollment":7085,"conditions":7086,"interventions":7087},"NCT02137850","Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A",[90],"2023-06-07","2014-06-26",124,[30,36],[7048],{"nctId":7089,"briefTitle":7090,"status":105,"phases":7091,"primaryCompletion":7092,"completion":7092,"start":7093,"enrollment":7094,"conditions":7095,"interventions":7096},"NCT01480180","Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A",[90],"2018-12-10","2012-01-30",186,[30,36],[7048],{"nctId":7098,"briefTitle":7099,"status":105,"phases":7100,"primaryCompletion":7101,"completion":7101,"start":1813,"enrollment":2549,"conditions":7102,"interventions":7103},"NCT05082116","Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)",[90],"2022-12-28",[36],[7048],{"nctId":7105,"briefTitle":7106,"status":105,"phases":7107,"primaryCompletion":7108,"completion":7108,"start":7109,"enrollment":7110,"conditions":7111,"interventions":7112},"NCT03528551","A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A",[90],"2020-12-03","2018-04-30",160,[30,36],[80,80,80],{"nctId":7114,"briefTitle":7115,"status":105,"phases":7116,"primaryCompletion":7117,"completion":7118,"start":7119,"enrollment":34,"conditions":7120,"interventions":7121},"NCT01731600","A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A",[90],"2014-09-15","2018-09-28","2013-02-20",[30,36],[7048],{"nctId":7123,"briefTitle":7124,"status":105,"phases":7125,"primaryCompletion":7092,"completion":7092,"start":7126,"enrollment":2549,"conditions":7127,"interventions":7128},"NCT01489111","Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.",[90],"2012-08-03",[30,36],[7048],{"trials":7130,"activeCount":99},[],{"trials":7132,"activeCount":864,"soonestReadout":79},[7133,7141,7150],{"nctId":7134,"briefTitle":7135,"status":1700,"phases":7136,"primaryCompletion":7137,"completion":7137,"start":7138,"enrollment":4439,"conditions":7139,"interventions":7140},"NCT04574076","A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®",[],"2027-06-03","2020-10-23",[36],[80],{"nctId":7142,"briefTitle":7143,"status":105,"phases":7144,"primaryCompletion":7145,"completion":7146,"start":7147,"enrollment":992,"conditions":7148,"interventions":7149},"NCT04334057","Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®",[],"2023-11-30","2024-01-10","2021-03-31",[36],[80],{"nctId":77,"briefTitle":78,"status":1700,"phases":7151,"primaryCompletion":79,"completion":79,"start":7152,"enrollment":1624,"conditions":7153,"interventions":7154},[],"2020-12-09",[36],[80],{"intervention":7156,"totalTrials":2338,"cells":7157},"nonacog beta pegol",{"EARLY_PHASE1":7158,"PHASE1":7160,"PHASE2":7168,"PHASE3":7170,"PHASE4":7219,"NA":7221},{"trials":7159,"activeCount":99},[],{"trials":7161,"activeCount":99},[7162],{"nctId":7163,"briefTitle":7164,"status":105,"phases":7165,"primaryCompletion":2278,"completion":2278,"start":4484,"enrollment":1846,"conditions":7166,"interventions":7167},"NCT00956345","Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B",[88],[30,2137],[7156,7156,7156],{"trials":7169,"activeCount":99},[],{"trials":7171,"activeCount":99},[7172,7179,7187,7195,7204,7211],{"nctId":7173,"briefTitle":7174,"status":105,"phases":7175,"primaryCompletion":7176,"completion":7176,"start":3971,"enrollment":5316,"conditions":7177,"interventions":7178},"NCT01386528","Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B",[90],"2013-12-01",[30,2137],[7156],{"nctId":7180,"briefTitle":7181,"status":105,"phases":7182,"primaryCompletion":7183,"completion":7183,"start":7184,"enrollment":498,"conditions":7185,"interventions":7186},"NCT01395810","Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773",[90],"2014-03-30","2012-04-15",[30,2137],[7156,7156,7156],{"nctId":7188,"briefTitle":7189,"status":105,"phases":7190,"primaryCompletion":7191,"completion":7191,"start":7192,"enrollment":6208,"conditions":7193,"interventions":7194},"NCT01333111","Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients",[90],"2013-03-31","2011-04-27",[30,2137],[7156,7156,7156],{"nctId":7196,"briefTitle":7197,"status":105,"phases":7198,"primaryCompletion":1984,"completion":7199,"start":7200,"enrollment":119,"conditions":7201,"interventions":7202},"NCT05365217","A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B",[90],"2024-05-11","2022-05-18",[2137],[7203],"Nonacog beta pegol",{"nctId":7205,"briefTitle":7206,"status":105,"phases":7207,"primaryCompletion":2896,"completion":2896,"start":7208,"enrollment":192,"conditions":7209,"interventions":7210},"NCT01467427","Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.",[90],"2012-05-16",[30,2137],[7156],{"nctId":7212,"briefTitle":7213,"status":105,"phases":7214,"primaryCompletion":7215,"completion":7215,"start":7216,"enrollment":325,"conditions":7217,"interventions":7218},"NCT02141074","Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B",[90],"2022-10-27","2014-07-02",[30,2137],[7156],{"trials":7220,"activeCount":99},[],{"trials":7222,"activeCount":864,"soonestReadout":721},[7223,7231],{"nctId":7224,"briefTitle":7225,"status":1700,"phases":7226,"primaryCompletion":7227,"completion":7227,"start":7228,"enrollment":4439,"conditions":7229,"interventions":7230},"NCT03745924","A Study Following Males With Haemophilia B on Prophylaxis With Refixia\u002FREBINYN",[],"2027-12-15","2019-04-01",[2137],[7203],{"nctId":7232,"briefTitle":7233,"status":1700,"phases":7234,"primaryCompletion":721,"completion":721,"start":1307,"enrollment":1546,"conditions":7235,"interventions":7236},"NCT03690336","Adverse Event Data Collection From External Registries on Nonacog Beta Pegol",[],[2137],[7203],{"intervention":7238,"totalTrials":1846,"cells":7239},"turoctocog alfa",{"EARLY_PHASE1":7240,"PHASE1":7242,"PHASE2":7276,"PHASE3":7282,"PHASE4":7330,"NA":7341},{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[7244,7251,7257,7264,7270],{"nctId":7245,"briefTitle":7246,"status":105,"phases":7247,"primaryCompletion":128,"completion":128,"start":3586,"enrollment":992,"conditions":7248,"interventions":7249},"NCT00837356","Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects",[88],[30,36],[7250,7238],"Advate®",{"nctId":7252,"briefTitle":7253,"status":105,"phases":7254,"primaryCompletion":3461,"completion":3461,"start":4958,"enrollment":713,"conditions":7255,"interventions":7256},"NCT01365520","A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A",[88],[30,36],[7238],{"nctId":7258,"briefTitle":7259,"status":105,"phases":7260,"primaryCompletion":7261,"completion":7261,"start":3873,"enrollment":2134,"conditions":7262,"interventions":7263},"NCT01238367","A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543",[88],"2011-10",[30,36],[7238],{"nctId":7265,"briefTitle":7266,"status":105,"phases":7267,"primaryCompletion":4261,"completion":4261,"start":562,"enrollment":518,"conditions":7268,"interventions":7269},"NCT01692925","Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A",[88],[30,36],[7238,7238],{"nctId":7271,"briefTitle":7272,"status":105,"phases":7273,"primaryCompletion":2774,"completion":2774,"start":265,"enrollment":2558,"conditions":7274,"interventions":7275},"NCT02941354","Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A",[88],[30,36],[7238],{"trials":7277,"activeCount":99},[7278],{"nctId":2976,"briefTitle":2977,"status":105,"phases":7279,"primaryCompletion":2979,"completion":2980,"start":2811,"enrollment":2549,"conditions":7280,"interventions":7281},[89],[2165,36],[48,85],{"trials":7283,"activeCount":99},[7284,7293,7299,7306,7313,7321],{"nctId":7285,"briefTitle":7286,"status":105,"phases":7287,"primaryCompletion":7288,"completion":7289,"start":7290,"enrollment":34,"conditions":7291,"interventions":7292},"NCT02938585","Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A",[90],"2018-03-16","2018-12-12","2016-12-12",[30,36],[7238,7238],{"nctId":7294,"briefTitle":7295,"status":105,"phases":7296,"primaryCompletion":5366,"completion":5366,"start":2204,"enrollment":5428,"conditions":7297,"interventions":7298},"NCT01138501","Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A",[90],[30,36],[7238,7238],{"nctId":7300,"briefTitle":7301,"status":105,"phases":7302,"primaryCompletion":3461,"completion":3461,"start":488,"enrollment":7303,"conditions":7304,"interventions":7305},"NCT00840086","Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects",[90],150,[30,36],[7238],{"nctId":7307,"briefTitle":7308,"status":349,"phases":7309,"primaryCompletion":1002,"completion":1002,"start":7310,"enrollment":1606,"conditions":7311,"interventions":7312},"NCT03588741","Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial",[90],"2018-06-12",[36],[85],{"nctId":7314,"briefTitle":7315,"status":105,"phases":7316,"primaryCompletion":2811,"completion":7317,"start":7318,"enrollment":4439,"conditions":7319,"interventions":7320},"NCT01493778","Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A",[90],"2018-12-05","2012-09-17",[30,36],[7238],{"nctId":7322,"briefTitle":7323,"status":105,"phases":7324,"primaryCompletion":7325,"completion":7326,"start":4413,"enrollment":7327,"conditions":7328,"interventions":7329},"NCT00984126","Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015",[90],"2016-06-28","2016-06-29",214,[30,36],[7238,7238],{"trials":7331,"activeCount":99},[7332],{"nctId":7333,"briefTitle":7334,"status":105,"phases":7335,"primaryCompletion":7336,"completion":7337,"start":7338,"enrollment":4439,"conditions":7339,"interventions":7340},"NCT03449342","Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period",[91],"2019-03-25","2019-04-22","2018-03-01",[30,36],[7238],{"trials":7342,"activeCount":1606,"soonestReadout":84},[7343,7351,7358,7367,7373],{"nctId":7344,"briefTitle":7345,"status":105,"phases":7346,"primaryCompletion":7347,"completion":7347,"start":7348,"enrollment":1546,"conditions":7349,"interventions":7350},"NCT03179748","Study Investigating Novoeight®\u002FNovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients",[],"2021-06-16","2018-06-20",[30,36],[7238],{"nctId":7352,"briefTitle":7353,"status":105,"phases":7354,"primaryCompletion":7355,"completion":7355,"start":872,"enrollment":162,"conditions":7356,"interventions":7357},"NCT02207218","To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan",[],"2020-11-10",[30,36],[7238],{"nctId":7359,"briefTitle":7360,"status":105,"phases":7361,"primaryCompletion":7362,"completion":7362,"start":7363,"enrollment":7364,"conditions":7365,"interventions":7366},"NCT02035384","Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A",[],"2020-01-15","2014-06-05",69,[30,36],[7238],{"nctId":82,"briefTitle":83,"status":380,"phases":7368,"primaryCompletion":84,"completion":2366,"start":7369,"enrollment":7370,"conditions":7371,"interventions":7372},[],"2024-11-10",900,[30,36],[85],{"nctId":7374,"briefTitle":7375,"status":105,"phases":7376,"primaryCompletion":7377,"completion":7377,"start":7378,"enrollment":1846,"conditions":7379,"interventions":7380},"NCT04584892","Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities",[],"2023-03-27","2021-04-12",[36],[85],{"intervention":2917,"totalTrials":864,"cells":7382},{"EARLY_PHASE1":7383,"PHASE1":7385,"PHASE2":7387,"PHASE3":7389,"PHASE4":7395,"NA":7397},{"trials":7384,"activeCount":99},[],{"trials":7386,"activeCount":99},[],{"trials":7388,"activeCount":99},[],{"trials":7390,"activeCount":99},[7391],{"nctId":2910,"briefTitle":2911,"status":105,"phases":7392,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":37,"conditions":7393,"interventions":7394},[90],[2776,2777],[2788,2917],{"trials":7396,"activeCount":99},[],{"trials":7398,"activeCount":1606,"soonestReadout":7403},[7399],{"nctId":7400,"briefTitle":7401,"status":1700,"phases":7402,"primaryCompletion":7403,"completion":7403,"start":680,"enrollment":7404,"conditions":7405,"interventions":7406},"NCT05308927","French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome",[],"2028-03-17",221,[2889],[2917],{"intervention":7408,"totalTrials":1606,"cells":7409},"Esperoct",{"EARLY_PHASE1":7410,"PHASE1":7412,"PHASE2":7414,"PHASE3":7416,"PHASE4":7418,"NA":7420},{"trials":7411,"activeCount":99},[],{"trials":7413,"activeCount":99},[],{"trials":7415,"activeCount":99},[],{"trials":7417,"activeCount":99},[],{"trials":7419,"activeCount":99},[],{"trials":7421,"activeCount":1606,"soonestReadout":7426},[7422],{"nctId":7423,"briefTitle":7424,"status":380,"phases":7425,"primaryCompletion":7426,"completion":7426,"start":6627,"enrollment":528,"conditions":7427,"interventions":7428},"NCT05621746","An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct",[],"2026-06-30",[36],[7408],{"intervention":7430,"totalTrials":1606,"cells":7431},"Norditropin® FlexPro®",{"EARLY_PHASE1":7432,"PHASE1":7434,"PHASE2":7436,"PHASE3":7438,"PHASE4":7440,"NA":7442},{"trials":7433,"activeCount":99},[],{"trials":7435,"activeCount":99},[],{"trials":7437,"activeCount":99},[],{"trials":7439,"activeCount":99},[],{"trials":7441,"activeCount":99},[],{"trials":7443,"activeCount":1606,"soonestReadout":7448},[7444],{"nctId":7445,"briefTitle":7446,"status":1700,"phases":7447,"primaryCompletion":7448,"completion":7449,"start":7450,"enrollment":7451,"conditions":7452,"interventions":7454},"NCT03972345","Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)",[],"2029-06-30","2031-06-30","2019-06-21",750,[2778,7453],"Born Small for Gestational Age",[7430],{"intervention":3597,"totalTrials":518,"cells":7456},{"EARLY_PHASE1":7457,"PHASE1":7459,"PHASE2":7465,"PHASE3":7475,"PHASE4":7526,"NA":7540},{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[7461],{"nctId":3591,"briefTitle":3592,"status":105,"phases":7462,"primaryCompletion":3594,"completion":3594,"start":2145,"enrollment":653,"conditions":7463,"interventions":7464},[88],[15,18],[768,3597],{"trials":7466,"activeCount":99},[7467,7471],{"nctId":3761,"briefTitle":3762,"status":105,"phases":7468,"primaryCompletion":3707,"completion":3707,"start":3764,"enrollment":3361,"conditions":7469,"interventions":7470},[89],[15,18],[768,226,3597],{"nctId":3768,"briefTitle":3769,"status":105,"phases":7472,"primaryCompletion":3610,"completion":3610,"start":3771,"enrollment":3772,"conditions":7473,"interventions":7474},[89],[15,18],[768,3597],{"trials":7476,"activeCount":99},[7477,7481,7485,7489,7497,7501,7505,7513,7522],{"nctId":3857,"briefTitle":3858,"status":105,"phases":7478,"primaryCompletion":3714,"completion":3860,"start":2144,"enrollment":3861,"conditions":7479,"interventions":7480},[90],[15,18],[768,226,3597,768,768],{"nctId":3891,"briefTitle":3789,"status":105,"phases":7482,"primaryCompletion":3714,"completion":3714,"start":2144,"enrollment":3893,"conditions":7483,"interventions":7484},[90],[15,18],[768,3896,3597],{"nctId":3898,"briefTitle":3899,"status":105,"phases":7486,"primaryCompletion":129,"completion":129,"start":3901,"enrollment":3902,"conditions":7487,"interventions":7488},[90],[15,18],[768,768,768,3597,226],{"nctId":7490,"briefTitle":7491,"status":349,"phases":7492,"primaryCompletion":7493,"completion":7493,"start":3812,"enrollment":7494,"conditions":7495,"interventions":7496},"NCT00427154","Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes",[90],"2008-03-11",227,[15,18],[3896,5575,226,3597],{"nctId":4012,"briefTitle":4013,"status":105,"phases":7498,"primaryCompletion":2331,"completion":2331,"start":4015,"enrollment":1926,"conditions":7499,"interventions":7500},[90],[15,18],[768,3597],{"nctId":4019,"briefTitle":4020,"status":349,"phases":7502,"primaryCompletion":3860,"completion":3860,"start":2213,"enrollment":4022,"conditions":7503,"interventions":7504},[90],[15,18],[768,3597,768],{"nctId":7506,"briefTitle":7507,"status":349,"phases":7508,"primaryCompletion":7509,"completion":7509,"start":7510,"enrollment":4041,"conditions":7511,"interventions":7512},"NCT00343980","Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes",[90],"2008-03-10","2006-10-10",[15,18],[3896,5575,3597],{"nctId":7514,"briefTitle":7515,"status":349,"phases":7516,"primaryCompletion":7517,"completion":7517,"start":7518,"enrollment":7519,"conditions":7520,"interventions":7521},"NCT00469586","Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes",[90],"2008-04-24","2007-04-26",174,[15,18],[5575,226,3597,5575],{"nctId":4171,"briefTitle":3789,"status":105,"phases":7523,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":4173,"conditions":7524,"interventions":7525},[90],[15,18],[768,876,226,3597],{"trials":7527,"activeCount":99},[7528,7532,7536],{"nctId":4955,"briefTitle":4956,"status":105,"phases":7529,"primaryCompletion":4958,"completion":4958,"start":2331,"enrollment":1815,"conditions":7530,"interventions":7531},[91],[15,18],[4471,226,3597,876],{"nctId":4969,"briefTitle":4970,"status":105,"phases":7533,"primaryCompletion":4765,"completion":4765,"start":3634,"enrollment":4972,"conditions":7534,"interventions":7535},[91],[15,18],[4751,876,226,3597],{"nctId":4976,"briefTitle":4977,"status":105,"phases":7537,"primaryCompletion":4049,"completion":4049,"start":3714,"enrollment":4979,"conditions":7538,"interventions":7539},[91],[15,18],[4751,876,226,3597],{"trials":7541,"activeCount":99},[],{"intervention":4198,"totalTrials":2578,"cells":7543},{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7550,"PHASE4":7559,"NA":7569},{"trials":7545,"activeCount":99},[],{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[],{"trials":7551,"activeCount":99},[7552],{"nctId":7553,"briefTitle":7554,"status":105,"phases":7555,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":7556,"conditions":7557,"interventions":7558},"NCT00789191","Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes",[90],222,[15,18],[3589,984,226,4198],{"trials":7560,"activeCount":99},[7561,7565],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7562,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7563,"interventions":7564},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"nctId":4221,"briefTitle":4222,"status":105,"phases":7566,"primaryCompletion":4224,"completion":3517,"start":4225,"enrollment":4226,"conditions":7567,"interventions":7568},[91],[15,18],[768,226,4198],{"trials":7570,"activeCount":99},[],{"intervention":1064,"totalTrials":2578,"cells":7572},{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7577,"PHASE3":7579,"PHASE4":7589,"NA":7595},{"trials":7574,"activeCount":99},[],{"trials":7576,"activeCount":99},[],{"trials":7578,"activeCount":99},[],{"trials":7580,"activeCount":99},[7581,7585],{"nctId":1057,"briefTitle":1058,"status":105,"phases":7582,"primaryCompletion":1060,"completion":1060,"start":952,"enrollment":1061,"conditions":7583,"interventions":7584},[90],[15,18],[75,1064],{"nctId":1314,"briefTitle":1315,"status":105,"phases":7586,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":1320,"conditions":7587,"interventions":7588},[90],[15,18],[112,1064],{"trials":7590,"activeCount":99},[7591],{"nctId":1558,"briefTitle":1559,"status":105,"phases":7592,"primaryCompletion":412,"completion":1561,"start":1562,"enrollment":753,"conditions":7593,"interventions":7594},[91],[142,18,33,24],[75,1064],{"trials":7596,"activeCount":99},[],{"intervention":7598,"totalTrials":864,"cells":7599},"glyburide",{"EARLY_PHASE1":7600,"PHASE1":7602,"PHASE2":7604,"PHASE3":7606,"PHASE4":7608,"NA":7627},{"trials":7601,"activeCount":99},[],{"trials":7603,"activeCount":99},[],{"trials":7605,"activeCount":99},[],{"trials":7607,"activeCount":99},[],{"trials":7609,"activeCount":99},[7610,7619],{"nctId":7611,"briefTitle":7612,"status":105,"phases":7613,"primaryCompletion":7614,"completion":7614,"start":7615,"enrollment":2338,"conditions":7616,"interventions":7617},"NCT01698931","Efficacy of Repaglinide in Subjects With Type 2 Diabetes",[91],"2003-03-06","2002-04-26",[15,18],[7618,7598],"repaglinide",{"nctId":7620,"briefTitle":7621,"status":105,"phases":7622,"primaryCompletion":7623,"completion":7623,"start":7624,"enrollment":1986,"conditions":7625,"interventions":7626},"NCT01605773","Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes",[91],"2003-03-13","2001-11-08",[15,18],[7618,7598],{"trials":7628,"activeCount":99},[],{"intervention":7630,"totalTrials":864,"cells":7631},"1.0 mg estradiol \u002F 0.5 mg norethisterone acetate",{"EARLY_PHASE1":7632,"PHASE1":7634,"PHASE2":7645,"PHASE3":7647,"PHASE4":7649,"NA":7660},{"trials":7633,"activeCount":99},[],{"trials":7635,"activeCount":99},[7636],{"nctId":7637,"briefTitle":7638,"status":105,"phases":7639,"primaryCompletion":5496,"completion":5496,"start":4765,"enrollment":306,"conditions":7640,"interventions":7642},"NCT01477632","Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women",[88],[7641,27],"Menopause",[7643,7644,7630],"0.5 mg estradiol \u002F 0.1 mg norethisterone acetate","0.5 mg estradiol \u002F 0.25 mg norethisterone acetate",{"trials":7646,"activeCount":99},[],{"trials":7648,"activeCount":99},[],{"trials":7650,"activeCount":99},[7651],{"nctId":7652,"briefTitle":7653,"status":105,"phases":7654,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":7657,"conditions":7658,"interventions":7659},"NCT01705249","Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women",[91],"2003-06-06","2001-08-14",191,[7641,27],[7630],{"trials":7661,"activeCount":99},[],{"intervention":7663,"totalTrials":864,"cells":7664},"biphasic human insulin 50",{"EARLY_PHASE1":7665,"PHASE1":7667,"PHASE2":7669,"PHASE3":7671,"PHASE4":7681,"NA":7690},{"trials":7666,"activeCount":99},[],{"trials":7668,"activeCount":99},[],{"trials":7670,"activeCount":99},[],{"trials":7672,"activeCount":99},[7673],{"nctId":7674,"briefTitle":7675,"status":105,"phases":7676,"primaryCompletion":7677,"completion":7677,"start":7678,"enrollment":4492,"conditions":7679,"interventions":7680},"NCT01650129","Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes",[90],"2001-10-18","2000-12-13",[15,18],[5456,7663],{"trials":7682,"activeCount":99},[7683],{"nctId":7684,"briefTitle":7685,"status":105,"phases":7686,"primaryCompletion":3446,"completion":3446,"start":7687,"enrollment":442,"conditions":7688,"interventions":7689},"NCT01892020","Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus",[91],"2013-06",[15,18],[5456,7663],{"trials":7691,"activeCount":99},[],{"intervention":3816,"totalTrials":864,"cells":7693},{"EARLY_PHASE1":7694,"PHASE1":7696,"PHASE2":7698,"PHASE3":7704,"PHASE4":7706,"NA":7712},{"trials":7695,"activeCount":99},[],{"trials":7697,"activeCount":99},[],{"trials":7699,"activeCount":99},[7700],{"nctId":3807,"briefTitle":3808,"status":105,"phases":7701,"primaryCompletion":3810,"completion":3811,"start":3812,"enrollment":3813,"conditions":7702,"interventions":7703},[89],[204,24],[768,3816],{"trials":7705,"activeCount":99},[],{"trials":7707,"activeCount":99},[7708],{"nctId":1585,"briefTitle":1586,"status":105,"phases":7709,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":795,"conditions":7710,"interventions":7711},[91],[24],[75,1592,1593,1594,57],{"trials":7713,"activeCount":99},[],{"intervention":7715,"totalTrials":1606,"cells":7716},"gliclazide",{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7721,"PHASE3":7723,"PHASE4":7725,"NA":7734},{"trials":7718,"activeCount":99},[],{"trials":7720,"activeCount":99},[],{"trials":7722,"activeCount":99},[],{"trials":7724,"activeCount":99},[],{"trials":7726,"activeCount":99},[7727],{"nctId":7728,"briefTitle":7729,"status":105,"phases":7730,"primaryCompletion":3873,"completion":3873,"start":3462,"enrollment":7731,"conditions":7732,"interventions":7733},"NCT01022762","Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment",[91],440,[15,18],[7618,7715],{"trials":7735,"activeCount":99},[],{"intervention":7737,"totalTrials":1606,"cells":7738},"Medication for chronic weight management",{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7745,"PHASE4":7747,"NA":7756},{"trials":7740,"activeCount":99},[],{"trials":7742,"activeCount":99},[],{"trials":7744,"activeCount":99},[],{"trials":7746,"activeCount":99},[],{"trials":7748,"activeCount":99},[7749],{"nctId":7750,"briefTitle":7751,"status":105,"phases":7752,"primaryCompletion":7753,"completion":7753,"start":5718,"enrollment":1110,"conditions":7754,"interventions":7755},"NCT03799198","Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity",[91],"2020-05-22",[24],[7737],{"trials":7757,"activeCount":99},[],{"intervention":7759,"totalTrials":1606,"cells":7760},"factor VIII",{"EARLY_PHASE1":7761,"PHASE1":7763,"PHASE2":7765,"PHASE3":7767,"PHASE4":7769,"NA":7779},{"trials":7762,"activeCount":99},[],{"trials":7764,"activeCount":99},[],{"trials":7766,"activeCount":99},[],{"trials":7768,"activeCount":99},[],{"trials":7770,"activeCount":99},[7771],{"nctId":7772,"briefTitle":7773,"status":105,"phases":7774,"primaryCompletion":7775,"completion":7775,"start":7776,"enrollment":2549,"conditions":7777,"interventions":7778},"NCT01561391","Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",[91],"2004-05","1998-04",[30,2136,2138],[2157,2157,7759],{"trials":7780,"activeCount":99},[],{"intervention":7782,"totalTrials":1606,"cells":7783},"Insulin-Levemir",{"EARLY_PHASE1":7784,"PHASE1":7786,"PHASE2":7788,"PHASE3":7790,"PHASE4":7792,"NA":7803},{"trials":7785,"activeCount":99},[],{"trials":7787,"activeCount":99},[],{"trials":7789,"activeCount":99},[],{"trials":7791,"activeCount":99},[],{"trials":7793,"activeCount":99},[7794],{"nctId":7795,"briefTitle":7796,"status":105,"phases":7797,"primaryCompletion":2271,"completion":2271,"start":4049,"enrollment":385,"conditions":7798,"interventions":7800},"NCT01076842","Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment",[91],[7799],"Diabetes Type 2",[7782,7801,7802],"Exenatide-Bayetta","Insulin-Levemir and Exenatide-Bayetta",{"trials":7804,"activeCount":99},[],{"intervention":7801,"totalTrials":1606,"cells":7806},{"EARLY_PHASE1":7807,"PHASE1":7809,"PHASE2":7811,"PHASE3":7813,"PHASE4":7815,"NA":7821},{"trials":7808,"activeCount":99},[],{"trials":7810,"activeCount":99},[],{"trials":7812,"activeCount":99},[],{"trials":7814,"activeCount":99},[],{"trials":7816,"activeCount":99},[7817],{"nctId":7795,"briefTitle":7796,"status":105,"phases":7818,"primaryCompletion":2271,"completion":2271,"start":4049,"enrollment":385,"conditions":7819,"interventions":7820},[91],[7799],[7782,7801,7802],{"trials":7822,"activeCount":99},[],{"intervention":7802,"totalTrials":1606,"cells":7824},{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7831,"PHASE4":7833,"NA":7839},{"trials":7826,"activeCount":99},[],{"trials":7828,"activeCount":99},[],{"trials":7830,"activeCount":99},[],{"trials":7832,"activeCount":99},[],{"trials":7834,"activeCount":99},[7835],{"nctId":7795,"briefTitle":7796,"status":105,"phases":7836,"primaryCompletion":2271,"completion":2271,"start":4049,"enrollment":385,"conditions":7837,"interventions":7838},[91],[7799],[7782,7801,7802],{"trials":7840,"activeCount":99},[],{"intervention":4185,"totalTrials":1606,"cells":7842},{"EARLY_PHASE1":7843,"PHASE1":7845,"PHASE2":7847,"PHASE3":7849,"PHASE4":7851,"NA":7857},{"trials":7844,"activeCount":99},[],{"trials":7846,"activeCount":99},[],{"trials":7848,"activeCount":99},[],{"trials":7850,"activeCount":99},[],{"trials":7852,"activeCount":99},[7853],{"nctId":4179,"briefTitle":4180,"status":105,"phases":7854,"primaryCompletion":698,"completion":698,"start":4057,"enrollment":4182,"conditions":7855,"interventions":7856},[91],[15,18],[768,4185],{"trials":7858,"activeCount":99},[],{"intervention":4194,"totalTrials":1606,"cells":7860},{"EARLY_PHASE1":7861,"PHASE1":7863,"PHASE2":7865,"PHASE3":7867,"PHASE4":7869,"NA":7875},{"trials":7862,"activeCount":99},[],{"trials":7864,"activeCount":99},[],{"trials":7866,"activeCount":99},[],{"trials":7868,"activeCount":99},[],{"trials":7870,"activeCount":99},[7871],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7872,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7873,"interventions":7874},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"trials":7876,"activeCount":99},[],{"intervention":4195,"totalTrials":1606,"cells":7878},{"EARLY_PHASE1":7879,"PHASE1":7881,"PHASE2":7883,"PHASE3":7885,"PHASE4":7887,"NA":7893},{"trials":7880,"activeCount":99},[],{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[],{"trials":7888,"activeCount":99},[7889],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7890,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7891,"interventions":7892},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"trials":7894,"activeCount":99},[],{"intervention":4196,"totalTrials":1606,"cells":7896},{"EARLY_PHASE1":7897,"PHASE1":7899,"PHASE2":7901,"PHASE3":7903,"PHASE4":7905,"NA":7911},{"trials":7898,"activeCount":99},[],{"trials":7900,"activeCount":99},[],{"trials":7902,"activeCount":99},[],{"trials":7904,"activeCount":99},[],{"trials":7906,"activeCount":99},[7907],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7908,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7909,"interventions":7910},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"trials":7912,"activeCount":99},[],{"intervention":4197,"totalTrials":1606,"cells":7914},{"EARLY_PHASE1":7915,"PHASE1":7917,"PHASE2":7919,"PHASE3":7921,"PHASE4":7923,"NA":7929},{"trials":7916,"activeCount":99},[],{"trials":7918,"activeCount":99},[],{"trials":7920,"activeCount":99},[],{"trials":7922,"activeCount":99},[],{"trials":7924,"activeCount":99},[7925],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7926,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7927,"interventions":7928},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"trials":7930,"activeCount":99},[],{"intervention":4199,"totalTrials":1606,"cells":7932},{"EARLY_PHASE1":7933,"PHASE1":7935,"PHASE2":7937,"PHASE3":7939,"PHASE4":7941,"NA":7947},{"trials":7934,"activeCount":99},[],{"trials":7936,"activeCount":99},[],{"trials":7938,"activeCount":99},[],{"trials":7940,"activeCount":99},[],{"trials":7942,"activeCount":99},[7943],{"nctId":4187,"briefTitle":4188,"status":105,"phases":7944,"primaryCompletion":1789,"completion":690,"start":4190,"enrollment":4191,"conditions":7945,"interventions":7946},[91],[15,18],[768,4194,4195,4196,4197,4198,4199],{"trials":7948,"activeCount":99},[],{"intervention":7950,"totalTrials":1606,"cells":7951},"oestrogen",{"EARLY_PHASE1":7952,"PHASE1":7954,"PHASE2":7956,"PHASE3":7958,"PHASE4":7960,"NA":7970},{"trials":7953,"activeCount":99},[],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"trials":7959,"activeCount":99},[],{"trials":7961,"activeCount":99},[7962],{"nctId":7963,"briefTitle":7964,"status":105,"phases":7965,"primaryCompletion":3501,"completion":3501,"start":7966,"enrollment":5428,"conditions":7967,"interventions":7969},"NCT01518062","Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome",[91],"1989-11",[7968,2888],"Genetic Disorder",[2831,2831,2831,7950],{"trials":7971,"activeCount":99},[],{"intervention":7973,"totalTrials":1606,"cells":7974},"glicazide",{"EARLY_PHASE1":7975,"PHASE1":7977,"PHASE2":7979,"PHASE3":7981,"PHASE4":7983,"NA":7993},{"trials":7976,"activeCount":99},[],{"trials":7978,"activeCount":99},[],{"trials":7980,"activeCount":99},[],{"trials":7982,"activeCount":99},[],{"trials":7984,"activeCount":99},[7985],{"nctId":7986,"briefTitle":7987,"status":105,"phases":7988,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":1495,"conditions":7991,"interventions":7992},"NCT00568984","Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes",[91],"2003-11-10","2002-11-21",[15,18],[7618,226,7973],{"trials":7994,"activeCount":99},[],{"intervention":7996,"totalTrials":1606,"cells":7997},"Glurenorm®",{"EARLY_PHASE1":7998,"PHASE1":8000,"PHASE2":8002,"PHASE3":8004,"PHASE4":8006,"NA":8017},{"trials":7999,"activeCount":99},[],{"trials":8001,"activeCount":99},[],{"trials":8003,"activeCount":99},[],{"trials":8005,"activeCount":99},[],{"trials":8007,"activeCount":99},[8008],{"nctId":8009,"briefTitle":8010,"status":105,"phases":8011,"primaryCompletion":8012,"completion":8012,"start":8013,"enrollment":5774,"conditions":8014,"interventions":8015},"NCT00568074","Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes",[91],"2004-09-02","2003-12-16",[15,18],[7618,7996,8016],"Glucobay®",{"trials":8018,"activeCount":99},[],{"intervention":8016,"totalTrials":1606,"cells":8020},{"EARLY_PHASE1":8021,"PHASE1":8023,"PHASE2":8025,"PHASE3":8027,"PHASE4":8029,"NA":8035},{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"trials":8026,"activeCount":99},[],{"trials":8028,"activeCount":99},[],{"trials":8030,"activeCount":99},[8031],{"nctId":8009,"briefTitle":8010,"status":105,"phases":8032,"primaryCompletion":8012,"completion":8012,"start":8013,"enrollment":5774,"conditions":8033,"interventions":8034},[91],[15,18],[7618,7996,8016],{"trials":8036,"activeCount":99},[],{"intervention":1583,"totalTrials":1606,"cells":8038},{"EARLY_PHASE1":8039,"PHASE1":8041,"PHASE2":8043,"PHASE3":8045,"PHASE4":8047,"NA":8053},{"trials":8040,"activeCount":99},[],{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"trials":8046,"activeCount":99},[],{"trials":8048,"activeCount":99},[8049],{"nctId":1575,"briefTitle":1576,"status":105,"phases":8050,"primaryCompletion":1578,"completion":1578,"start":1579,"enrollment":1580,"conditions":8051,"interventions":8052},[91],[18],[112,1583],{"trials":8054,"activeCount":99},[],{"intervention":1593,"totalTrials":1606,"cells":8056},{"EARLY_PHASE1":8057,"PHASE1":8059,"PHASE2":8061,"PHASE3":8063,"PHASE4":8065,"NA":8071},{"trials":8058,"activeCount":99},[],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[],{"trials":8064,"activeCount":99},[],{"trials":8066,"activeCount":99},[8067],{"nctId":1585,"briefTitle":1586,"status":105,"phases":8068,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":795,"conditions":8069,"interventions":8070},[91],[24],[75,1592,1593,1594,57],{"trials":8072,"activeCount":99},[],{"intervention":1594,"totalTrials":1606,"cells":8074},{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8079,"PHASE3":8081,"PHASE4":8083,"NA":8089},{"trials":8076,"activeCount":99},[],{"trials":8078,"activeCount":99},[],{"trials":8080,"activeCount":99},[],{"trials":8082,"activeCount":99},[],{"trials":8084,"activeCount":99},[8085],{"nctId":1585,"briefTitle":1586,"status":105,"phases":8086,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":795,"conditions":8087,"interventions":8088},[91],[24],[75,1592,1593,1594,57],{"trials":8090,"activeCount":99},[],{"intervention":1605,"totalTrials":1606,"cells":8092},{"EARLY_PHASE1":8093,"PHASE1":8095,"PHASE2":8097,"PHASE3":8099,"PHASE4":8101,"NA":8107},{"trials":8094,"activeCount":99},[],{"trials":8096,"activeCount":99},[],{"trials":8098,"activeCount":99},[],{"trials":8100,"activeCount":99},[],{"trials":8102,"activeCount":99},[8103],{"nctId":1596,"briefTitle":1597,"status":105,"phases":8104,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":8105,"interventions":8106},[91],[18],[75,1605],{"trials":8108,"activeCount":99},[],{"intervention":5575,"totalTrials":5047,"cells":8110},{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8121,"PHASE3":8131,"PHASE4":8180,"NA":8182},{"trials":8112,"activeCount":99},[],{"trials":8114,"activeCount":99},[8115],{"nctId":8116,"briefTitle":8117,"status":105,"phases":8118,"primaryCompletion":2145,"completion":2145,"start":2225,"enrollment":992,"conditions":8119,"interventions":8120},"NCT00419718","Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes",[88],[15,21],[5575],{"trials":8122,"activeCount":99},[8123],{"nctId":8124,"briefTitle":8125,"status":105,"phases":8126,"primaryCompletion":8127,"completion":8127,"start":8128,"enrollment":335,"conditions":8129,"interventions":8130},"NCT00567775","Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes",[89],"2002-11-20","2002-10-21",[15,21],[5797,5575],{"trials":8132,"activeCount":99},[8133,8137,8145,8149,8153,8157,8161,8165,8169,8176],{"nctId":5567,"briefTitle":5568,"status":349,"phases":8134,"primaryCompletion":5570,"completion":5570,"start":5571,"enrollment":5572,"conditions":8135,"interventions":8136},[90],[15,21],[5575,3589,1978],{"nctId":8138,"briefTitle":8139,"status":349,"phases":8140,"primaryCompletion":8141,"completion":8141,"start":8142,"enrollment":3772,"conditions":8143,"interventions":8144},"NCT00411892","Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes",[90],"2008-03-18","2006-11-29",[15,18],[4752,5575],{"nctId":7490,"briefTitle":7491,"status":349,"phases":8146,"primaryCompletion":7493,"completion":7493,"start":3812,"enrollment":7494,"conditions":8147,"interventions":8148},[90],[15,18],[3896,5575,226,3597],{"nctId":5612,"briefTitle":5613,"status":349,"phases":8150,"primaryCompletion":5615,"completion":5615,"start":5616,"enrollment":578,"conditions":8151,"interventions":8152},[90],[15,21,18,5618],[5575,1978],{"nctId":5631,"briefTitle":5632,"status":105,"phases":8154,"primaryCompletion":5634,"completion":5634,"start":5418,"enrollment":5635,"conditions":8155,"interventions":8156},[90],[15,21],[5575,1978,4967],{"nctId":5657,"briefTitle":5658,"status":349,"phases":8158,"primaryCompletion":5660,"completion":5660,"start":5661,"enrollment":5662,"conditions":8159,"interventions":8160},[90],[15,18],[5575,3589,1978,1978],{"nctId":5689,"briefTitle":5690,"status":349,"phases":8162,"primaryCompletion":5692,"completion":5692,"start":5693,"enrollment":1546,"conditions":8163,"interventions":8164},[90],[15,21,18,5695],[1978,5575],{"nctId":7506,"briefTitle":7507,"status":349,"phases":8166,"primaryCompletion":7509,"completion":7509,"start":7510,"enrollment":4041,"conditions":8167,"interventions":8168},[90],[15,18],[3896,5575,3597],{"nctId":8170,"briefTitle":8171,"status":349,"phases":8172,"primaryCompletion":5615,"completion":5615,"start":8173,"enrollment":2861,"conditions":8174,"interventions":8175},"NCT00348712","Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes",[90],"2006-10-30",[15,18],[3896,5575,226],{"nctId":7514,"briefTitle":7515,"status":349,"phases":8177,"primaryCompletion":7517,"completion":7517,"start":7518,"enrollment":7519,"conditions":8178,"interventions":8179},[90],[15,18],[5575,226,3597,5575],{"trials":8181,"activeCount":99},[],{"trials":8183,"activeCount":99},[],{"intervention":3896,"totalTrials":1827,"cells":8185},{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8192,"PHASE4":8214,"NA":8216},{"trials":8187,"activeCount":99},[],{"trials":8189,"activeCount":99},[],{"trials":8191,"activeCount":99},[],{"trials":8193,"activeCount":99},[8194,8198,8202,8206,8210],{"nctId":3891,"briefTitle":3789,"status":105,"phases":8195,"primaryCompletion":3714,"completion":3714,"start":2144,"enrollment":3893,"conditions":8196,"interventions":8197},[90],[15,18],[768,3896,3597],{"nctId":7490,"briefTitle":7491,"status":349,"phases":8199,"primaryCompletion":7493,"completion":7493,"start":3812,"enrollment":7494,"conditions":8200,"interventions":8201},[90],[15,18],[3896,5575,226,3597],{"nctId":3986,"briefTitle":3789,"status":105,"phases":8203,"primaryCompletion":3988,"completion":3988,"start":2144,"enrollment":3989,"conditions":8204,"interventions":8205},[90],[15,18],[768,3896,226],{"nctId":7506,"briefTitle":7507,"status":349,"phases":8207,"primaryCompletion":7509,"completion":7509,"start":7510,"enrollment":4041,"conditions":8208,"interventions":8209},[90],[15,18],[3896,5575,3597],{"nctId":8170,"briefTitle":8171,"status":349,"phases":8211,"primaryCompletion":5615,"completion":5615,"start":8173,"enrollment":2861,"conditions":8212,"interventions":8213},[90],[15,18],[3896,5575,226],{"trials":8215,"activeCount":99},[],{"trials":8217,"activeCount":99},[],{"intervention":375,"totalTrials":1827,"cells":8219},{"EARLY_PHASE1":8220,"PHASE1":8222,"PHASE2":8228,"PHASE3":8230,"PHASE4":8253,"NA":8255},{"trials":8221,"activeCount":99},[],{"trials":8223,"activeCount":99},[8224],{"nctId":368,"briefTitle":369,"status":105,"phases":8225,"primaryCompletion":371,"completion":371,"start":139,"enrollment":372,"conditions":8226,"interventions":8227},[88],[18],[375,376,112],{"trials":8229,"activeCount":99},[],{"trials":8231,"activeCount":99},[8232,8236,8240,8249],{"nctId":4669,"briefTitle":4670,"status":105,"phases":8233,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4674,"conditions":8234,"interventions":8235},[90],[18],[375,1910,1978],{"nctId":2012,"briefTitle":2013,"status":105,"phases":8237,"primaryCompletion":1167,"completion":2015,"start":2016,"enrollment":2017,"conditions":8238,"interventions":8239},[90],[18],[375,1829],{"nctId":8241,"briefTitle":8242,"status":105,"phases":8243,"primaryCompletion":732,"completion":1261,"start":8244,"enrollment":8245,"conditions":8246,"interventions":8247},"NCT05259033","A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)",[90],"2022-04-11",683,[18],[375,8248],"Semaglutide 1 mg",{"nctId":4806,"briefTitle":4807,"status":105,"phases":8250,"primaryCompletion":4809,"completion":4810,"start":4811,"enrollment":4812,"conditions":8251,"interventions":8252},[90],[862],[375,1910],{"trials":8254,"activeCount":99},[],{"trials":8256,"activeCount":99},[],{"intervention":8258,"totalTrials":1827,"cells":8259},"Semaglutide 2.4 mg",{"EARLY_PHASE1":8260,"PHASE1":8262,"PHASE2":8264,"PHASE3":8275,"PHASE4":8315,"NA":8317},{"trials":8261,"activeCount":99},[],{"trials":8263,"activeCount":99},[],{"trials":8265,"activeCount":99},[8266],{"nctId":8267,"briefTitle":8268,"status":105,"phases":8269,"primaryCompletion":8270,"completion":8270,"start":8271,"enrollment":2879,"conditions":8272,"interventions":8273},"NCT04982575","Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes",[89],"2022-07-07","2021-08-02",[18],[8258,8274],"Cagrilintide 2.4 mg",{"trials":8276,"activeCount":99},[8277,8285,8295,8305],{"nctId":8278,"briefTitle":8279,"status":105,"phases":8280,"primaryCompletion":6333,"completion":8281,"start":8282,"enrollment":7303,"conditions":8283,"interventions":8284},"NCT04998136","Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity",[90],"2023-11-20","2022-08-15",[24],[8258],{"nctId":8286,"briefTitle":8287,"status":105,"phases":8288,"primaryCompletion":8289,"completion":8290,"start":933,"enrollment":8291,"conditions":8292,"interventions":8293},"NCT03552757","Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity",[90],"2020-03-24","2020-05-01",1210,[24,33],[8294,8258],"Semaglutide 1.0 mg",{"nctId":8296,"briefTitle":8297,"status":105,"phases":8298,"primaryCompletion":8299,"completion":8300,"start":8301,"enrollment":8302,"conditions":8303,"interventions":8304},"NCT05040971","Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes",[90],"2023-01-06","2023-07-14","2021-09-06",207,[24],[8258],{"nctId":8306,"briefTitle":8307,"status":105,"phases":8308,"primaryCompletion":8309,"completion":8310,"start":8311,"enrollment":4217,"conditions":8312,"interventions":8313},"NCT05064735","Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis",[90],"2023-07-24","2023-09-08","2021-10-01",[24],[8314,8314],"semaglutide 2.4 mg",{"trials":8316,"activeCount":99},[],{"trials":8318,"activeCount":99},[],{"intervention":8320,"totalTrials":713,"cells":8321},"estradiol, 10 mcg",{"EARLY_PHASE1":8322,"PHASE1":8324,"PHASE2":8334,"PHASE3":8336,"PHASE4":8359,"NA":8361},{"trials":8323,"activeCount":99},[],{"trials":8325,"activeCount":99},[8326],{"nctId":8327,"briefTitle":8328,"status":105,"phases":8329,"primaryCompletion":3714,"completion":3714,"start":2163,"enrollment":109,"conditions":8330,"interventions":8332},"NCT01486979","Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis",[88],[7641,8331],"Postmenopausal Vaginal Atrophy",[8320,8333],"estradiol, 25 mcg",{"trials":8335,"activeCount":99},[],{"trials":8337,"activeCount":99},[8338,8346,8352],{"nctId":8339,"briefTitle":8340,"status":105,"phases":8341,"primaryCompletion":8342,"completion":8342,"start":8343,"enrollment":1790,"conditions":8344,"interventions":8345},"NCT00465192","Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis",[90],"1995-11-30","1994-08-31",[7641,8331],[8320,8333],{"nctId":8347,"briefTitle":8348,"status":105,"phases":8349,"primaryCompletion":3860,"completion":3860,"start":2163,"enrollment":3312,"conditions":8350,"interventions":8351},"NCT00431132","Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis",[90],[7641,8331],[8320],{"nctId":8353,"briefTitle":8354,"status":105,"phases":8355,"primaryCompletion":3714,"completion":3714,"start":4765,"enrollment":8356,"conditions":8357,"interventions":8358},"NCT00108849","Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms",[90],309,[7641,8331],[8320],{"trials":8360,"activeCount":99},[],{"trials":8362,"activeCount":99},[],{"intervention":5439,"totalTrials":713,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8394,"PHASE3":8396,"PHASE4":8402,"NA":8404},{"trials":8366,"activeCount":99},[],{"trials":8368,"activeCount":99},[8369,8379,8390],{"nctId":8370,"briefTitle":8371,"status":105,"phases":8372,"primaryCompletion":8373,"completion":8374,"start":3186,"enrollment":992,"conditions":8375,"interventions":8376},"NCT04698018","A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes",[88],"2022-07-20","2022-07-22",[21,18],[8377,8378],"Faster Aspart","Novo Rapid",{"nctId":8380,"briefTitle":8381,"status":105,"phases":8382,"primaryCompletion":1051,"completion":8383,"start":8384,"enrollment":3643,"conditions":8385,"interventions":8386},"NCT05262595","A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump",[88],"2022-09-05","2022-03-03",[21],[8387,8388,8389,5439],"NNC0471-0119 A","NNC0471-0119 B","NNC0471-0119 D",{"nctId":5433,"briefTitle":5434,"status":105,"phases":8391,"primaryCompletion":4271,"completion":4271,"start":5436,"enrollment":1894,"conditions":8392,"interventions":8393},[88],[15,21],[5439,1311],{"trials":8395,"activeCount":99},[],{"trials":8397,"activeCount":99},[8398],{"nctId":5584,"briefTitle":5585,"status":105,"phases":8399,"primaryCompletion":1693,"completion":5587,"start":5588,"enrollment":1428,"conditions":8400,"interventions":8401},[90],[21,18],[5439,1311,1887],{"trials":8403,"activeCount":99},[],{"trials":8405,"activeCount":99},[],{"intervention":8407,"totalTrials":713,"cells":8408},"repaglinide and metformin combination",{"EARLY_PHASE1":8409,"PHASE1":8411,"PHASE2":8432,"PHASE3":8434,"PHASE4":8444,"NA":8446},{"trials":8410,"activeCount":99},[],{"trials":8412,"activeCount":99},[8413,8420,8426],{"nctId":8414,"briefTitle":8415,"status":105,"phases":8416,"primaryCompletion":4398,"completion":4398,"start":3492,"enrollment":8417,"conditions":8418,"interventions":8419},"NCT01490658","Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers",[88],93,[15,18],[7618,226,8407],{"nctId":8421,"briefTitle":8422,"status":105,"phases":8423,"primaryCompletion":3619,"completion":3619,"start":3492,"enrollment":37,"conditions":8424,"interventions":8425},"NCT01489644","Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers",[88],[15,18],[7618,226,8407],{"nctId":8427,"briefTitle":8428,"status":105,"phases":8429,"primaryCompletion":128,"completion":128,"start":4484,"enrollment":173,"conditions":8430,"interventions":8431},"NCT00959101","Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers",[88],[15,27],[8407,8407,7618,226],{"trials":8433,"activeCount":99},[],{"trials":8435,"activeCount":99},[8436],{"nctId":8437,"briefTitle":8438,"status":105,"phases":8439,"primaryCompletion":3852,"completion":3852,"start":3618,"enrollment":8440,"conditions":8441,"interventions":8442},"NCT00399711","Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes",[90],560,[15,18],[8407,8443],"rosiglitazone and metformin combination",{"trials":8445,"activeCount":99},[],{"trials":8447,"activeCount":99},[],{"intervention":1131,"totalTrials":713,"cells":8449},{"EARLY_PHASE1":8450,"PHASE1":8452,"PHASE2":8454,"PHASE3":8456,"PHASE4":8476,"NA":8478},{"trials":8451,"activeCount":99},[],{"trials":8453,"activeCount":99},[],{"trials":8455,"activeCount":99},[],{"trials":8457,"activeCount":99},[8458,8462,8466,8472],{"nctId":1124,"briefTitle":1125,"status":105,"phases":8459,"primaryCompletion":1127,"completion":1127,"start":826,"enrollment":1128,"conditions":8460,"interventions":8461},[90],[15,18],[112,1131],{"nctId":4046,"briefTitle":4047,"status":105,"phases":8463,"primaryCompletion":4049,"completion":488,"start":3988,"enrollment":4050,"conditions":8464,"interventions":8465},[90],[15,18],[768,1131],{"nctId":8467,"briefTitle":8468,"status":105,"phases":8469,"primaryCompletion":6022,"completion":6022,"start":3602,"enrollment":5979,"conditions":8470,"interventions":8471},"NCT00313001","Effects of Biphasic Insulin Aspart 70\u002F30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.",[90],[15,18],[4751,1131],{"nctId":4063,"briefTitle":4064,"status":105,"phases":8473,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":4068,"conditions":8474,"interventions":8475},[90],[15,18],[3487,768,1131],{"trials":8477,"activeCount":99},[],{"trials":8479,"activeCount":99},[],{"intervention":2208,"totalTrials":2578,"cells":8481},{"EARLY_PHASE1":8482,"PHASE1":8484,"PHASE2":8492,"PHASE3":8498,"PHASE4":8504,"NA":8506},{"trials":8483,"activeCount":99},[],{"trials":8485,"activeCount":99},[8486],{"nctId":8487,"briefTitle":8488,"status":105,"phases":8489,"primaryCompletion":6191,"completion":6191,"start":489,"enrollment":223,"conditions":8490,"interventions":8491},"NCT00822185","Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers",[88],[30,27],[2208,2208,2208,2208],{"trials":8493,"activeCount":99},[8494],{"nctId":2201,"briefTitle":2202,"status":105,"phases":8495,"primaryCompletion":2204,"completion":2204,"start":2205,"enrollment":1986,"conditions":8496,"interventions":8497},[89],[30,36,2137],[2122,2208,2208,2208,2208,2208],{"trials":8499,"activeCount":99},[8500],{"nctId":2239,"briefTitle":2240,"status":105,"phases":8501,"primaryCompletion":333,"completion":333,"start":232,"enrollment":587,"conditions":8502,"interventions":8503},[90],[30,2136,2138],[2208,2122],{"trials":8505,"activeCount":99},[],{"trials":8507,"activeCount":99},[],{"intervention":1312,"totalTrials":2578,"cells":8509},{"EARLY_PHASE1":8510,"PHASE1":8512,"PHASE2":8518,"PHASE3":8524,"PHASE4":8530,"NA":8532},{"trials":8511,"activeCount":99},[],{"trials":8513,"activeCount":99},[8514],{"nctId":1930,"briefTitle":1931,"status":105,"phases":8515,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":306,"conditions":8516,"interventions":8517},[88],[21],[376,1312],{"trials":8519,"activeCount":99},[8520],{"nctId":1940,"briefTitle":1941,"status":105,"phases":8521,"primaryCompletion":1822,"completion":1943,"start":1944,"enrollment":1945,"conditions":8522,"interventions":8523},[89],[18],[1829,1312],{"trials":8525,"activeCount":99},[8526],{"nctId":1303,"briefTitle":1304,"status":105,"phases":8527,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":8528,"interventions":8529},[90],[18],[75,1311,1312],{"trials":8531,"activeCount":99},[],{"trials":8533,"activeCount":99},[],{"intervention":4752,"totalTrials":2578,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8542,"PHASE4":8559,"NA":8561},{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[],{"trials":8541,"activeCount":99},[],{"trials":8543,"activeCount":99},[8544,8548,8555],{"nctId":8138,"briefTitle":8139,"status":349,"phases":8545,"primaryCompletion":8141,"completion":8141,"start":8142,"enrollment":3772,"conditions":8546,"interventions":8547},[90],[15,18],[4752,5575],{"nctId":8549,"briefTitle":8550,"status":105,"phases":8551,"primaryCompletion":3562,"completion":3562,"start":8552,"enrollment":1790,"conditions":8553,"interventions":8554},"NCT00097279","Comparison of Biphasic Insulin Aspart 70\u002F30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes",[90],"2004-08",[15,18],[4751,4752,226],{"nctId":4745,"briefTitle":4746,"status":105,"phases":8556,"primaryCompletion":3500,"completion":3500,"start":4748,"enrollment":1188,"conditions":8557,"interventions":8558},[90],[15,18],[4751,876,226,4752],{"trials":8560,"activeCount":99},[],{"trials":8562,"activeCount":99},[],{"intervention":8564,"totalTrials":2578,"cells":8565},"Semaglutide J",{"EARLY_PHASE1":8566,"PHASE1":8568,"PHASE2":8591,"PHASE3":8593,"PHASE4":8603,"NA":8605},{"trials":8567,"activeCount":99},[],{"trials":8569,"activeCount":99},[8570,8578],{"nctId":8571,"briefTitle":8572,"status":105,"phases":8573,"primaryCompletion":243,"completion":1613,"start":8574,"enrollment":3074,"conditions":8575,"interventions":8576},"NCT05784402","A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants",[88],"2023-03-16",[482],[8564,8577],"Semaglutide C",{"nctId":8579,"briefTitle":8580,"status":105,"phases":8581,"primaryCompletion":8582,"completion":8583,"start":8584,"enrollment":2195,"conditions":8585,"interventions":8586},"NCT06642584","A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV",[88],"2025-07-10","2025-08-13","2024-10-15",[664],[8587,8564,8588,8589,8590],"Semaglutide B","Semaglutide L","Semaglutide M","Semaglutide N",{"trials":8592,"activeCount":99},[],{"trials":8594,"activeCount":99},[8595],{"nctId":8596,"briefTitle":8597,"status":105,"phases":8598,"primaryCompletion":8599,"completion":2409,"start":8600,"enrollment":883,"conditions":8601,"interventions":8602},"NCT05478252","A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes",[90],"2023-08-09","2022-08-03",[18],[8564,8587],{"trials":8604,"activeCount":99},[],{"trials":8606,"activeCount":99},[],{"intervention":8294,"totalTrials":2578,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8622,"PHASE3":8624,"PHASE4":8643,"NA":8645},{"trials":8610,"activeCount":99},[],{"trials":8612,"activeCount":99},[8613],{"nctId":8614,"briefTitle":8615,"status":105,"phases":8616,"primaryCompletion":505,"completion":8617,"start":8618,"enrollment":2549,"conditions":8619,"interventions":8620},"NCT03288740","A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects",[88],"2018-08-07","2017-09-21",[15,18],[8621,8294],"Semaglutide 0.5 mg",{"trials":8623,"activeCount":99},[],{"trials":8625,"activeCount":99},[8626,8639],{"nctId":8627,"briefTitle":8628,"status":105,"phases":8629,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":8634,"interventions":8635},"NCT03061214","Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)",[90],"2019-03-14","2019-04-15","2017-08-28",868,[15,18],[8621,8294,8636,3204,8637,8638],"Sitagliptin placebo","Semaglutide placebo 0.5 mg","Semaglutide placebo 1.0 mg",{"nctId":8286,"briefTitle":8287,"status":105,"phases":8640,"primaryCompletion":8289,"completion":8290,"start":933,"enrollment":8291,"conditions":8641,"interventions":8642},[90],[24,33],[8294,8258],{"trials":8644,"activeCount":99},[],{"trials":8646,"activeCount":99},[],{"intervention":8648,"totalTrials":2578,"cells":8649},"NNC0365-3769",{"EARLY_PHASE1":8650,"PHASE1":8652,"PHASE2":8662,"PHASE3":8672,"PHASE4":8684,"NA":8686},{"trials":8651,"activeCount":99},[],{"trials":8653,"activeCount":99},[8654],{"nctId":8655,"briefTitle":8656,"status":105,"phases":8657,"primaryCompletion":8658,"completion":8658,"start":8659,"enrollment":1954,"conditions":8660,"interventions":8661},"NCT05681845","A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge",[88],"2023-10-13","2023-01-02",[36],[8648],{"trials":8663,"activeCount":99},[8664],{"nctId":8665,"briefTitle":8666,"status":105,"phases":8667,"primaryCompletion":8668,"completion":8668,"start":1770,"enrollment":8669,"conditions":8670,"interventions":8671},"NCT04204408","A Research Study Investigating Mim8 in People With Haemophilia A",[89],"2023-10-06",275,[142,5118],[8648],{"trials":8673,"activeCount":99},[8674],{"nctId":8675,"briefTitle":8676,"status":105,"phases":8677,"primaryCompletion":8678,"completion":8679,"start":8680,"enrollment":8681,"conditions":8682,"interventions":8683},"NCT05053139","A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors",[90],"2024-03-11","2024-12-17","2021-12-02",281,[36,2136],[8648],{"trials":8685,"activeCount":99},[],{"trials":8687,"activeCount":99},[],{"intervention":1218,"totalTrials":2578,"cells":8689},{"EARLY_PHASE1":8690,"PHASE1":8692,"PHASE2":8694,"PHASE3":8696,"PHASE4":8710,"NA":8712},{"trials":8691,"activeCount":99},[],{"trials":8693,"activeCount":99},[],{"trials":8695,"activeCount":99},[],{"trials":8697,"activeCount":99},[8698,8702,8706],{"nctId":1095,"briefTitle":1096,"status":105,"phases":8699,"primaryCompletion":1098,"completion":1099,"start":1012,"enrollment":1100,"conditions":8700,"interventions":8701},[90],[15,18],[112,1103],{"nctId":1210,"briefTitle":1211,"status":1135,"phases":8703,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":99,"conditions":8704,"interventions":8705},[90],[18],[75,1218],{"nctId":1470,"briefTitle":1471,"status":1135,"phases":8707,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":99,"conditions":8708,"interventions":8709},[90],[18],[75,1218,1478],{"trials":8711,"activeCount":99},[],{"trials":8713,"activeCount":99},[],{"intervention":809,"totalTrials":2578,"cells":8715},{"EARLY_PHASE1":8716,"PHASE1":8718,"PHASE2":8720,"PHASE3":8739,"PHASE4":8745,"NA":8747},{"trials":8717,"activeCount":99},[],{"trials":8719,"activeCount":99},[],{"trials":8721,"activeCount":99},[8722,8735],{"nctId":8723,"briefTitle":8724,"status":105,"phases":8725,"primaryCompletion":8679,"completion":8726,"start":8727,"enrollment":8728,"conditions":8729,"interventions":8730},"NCT05016882","Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)",[89],"2025-03-14","2021-08-31",698,[255],[8731,8732,809,8733,8734],"NNC0194 0499 50 mg\u002FmL","Semaglutide 3 mg\u002FmL","NNC0174 0833 10 mg\u002FmL","NNC0174 0833 placebo",{"nctId":799,"briefTitle":800,"status":105,"phases":8736,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":8737,"interventions":8738},[89],[806],[257,75,808,809,810,70,811,809],{"trials":8740,"activeCount":99},[8741],{"nctId":1105,"briefTitle":1106,"status":105,"phases":8742,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":8743,"interventions":8744},[90],[33,24],[75,1113],{"trials":8746,"activeCount":99},[],{"trials":8748,"activeCount":99},[],{"intervention":3855,"totalTrials":864,"cells":8750},{"EARLY_PHASE1":8751,"PHASE1":8753,"PHASE2":8755,"PHASE3":8757,"PHASE4":8767,"NA":8769},{"trials":8752,"activeCount":99},[],{"trials":8754,"activeCount":99},[],{"trials":8756,"activeCount":99},[],{"trials":8758,"activeCount":99},[8759,8763],{"nctId":3850,"briefTitle":3789,"status":105,"phases":8760,"primaryCompletion":3852,"completion":2171,"start":3618,"enrollment":1381,"conditions":8761,"interventions":8762},[90],[15,18],[768,3855],{"nctId":5910,"briefTitle":5911,"status":349,"phases":8764,"primaryCompletion":3602,"completion":3602,"start":4643,"enrollment":2338,"conditions":8765,"interventions":8766},[90],[15,18],[1978,3855],{"trials":8768,"activeCount":99},[],{"trials":8770,"activeCount":99},[],{"intervention":5603,"totalTrials":864,"cells":8772},{"EARLY_PHASE1":8773,"PHASE1":8775,"PHASE2":8777,"PHASE3":8779,"PHASE4":8789,"NA":8791},{"trials":8774,"activeCount":99},[],{"trials":8776,"activeCount":99},[],{"trials":8778,"activeCount":99},[],{"trials":8780,"activeCount":99},[8781,8785],{"nctId":5596,"briefTitle":5597,"status":105,"phases":8782,"primaryCompletion":2144,"completion":2144,"start":5599,"enrollment":5600,"conditions":8783,"interventions":8784},[90],[15,21],[5603,1978],{"nctId":5925,"briefTitle":5926,"status":105,"phases":8786,"primaryCompletion":3550,"completion":3550,"start":5928,"enrollment":5929,"conditions":8787,"interventions":8788},[90],[15,21],[3613,5603,1978],{"trials":8790,"activeCount":99},[],{"trials":8792,"activeCount":99},[],{"intervention":8621,"totalTrials":864,"cells":8794},{"EARLY_PHASE1":8795,"PHASE1":8797,"PHASE2":8803,"PHASE3":8805,"PHASE4":8811,"NA":8813},{"trials":8796,"activeCount":99},[],{"trials":8798,"activeCount":99},[8799],{"nctId":8614,"briefTitle":8615,"status":105,"phases":8800,"primaryCompletion":505,"completion":8617,"start":8618,"enrollment":2549,"conditions":8801,"interventions":8802},[88],[15,18],[8621,8294],{"trials":8804,"activeCount":99},[],{"trials":8806,"activeCount":99},[8807],{"nctId":8627,"briefTitle":8628,"status":105,"phases":8808,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":8809,"interventions":8810},[90],[15,18],[8621,8294,8636,3204,8637,8638],{"trials":8812,"activeCount":99},[],{"trials":8814,"activeCount":99},[],{"intervention":8587,"totalTrials":864,"cells":8816},{"EARLY_PHASE1":8817,"PHASE1":8819,"PHASE2":8825,"PHASE3":8827,"PHASE4":8833,"NA":8835},{"trials":8818,"activeCount":99},[],{"trials":8820,"activeCount":99},[8821],{"nctId":8579,"briefTitle":8580,"status":105,"phases":8822,"primaryCompletion":8582,"completion":8583,"start":8584,"enrollment":2195,"conditions":8823,"interventions":8824},[88],[664],[8587,8564,8588,8589,8590],{"trials":8826,"activeCount":99},[],{"trials":8828,"activeCount":99},[8829],{"nctId":8596,"briefTitle":8597,"status":105,"phases":8830,"primaryCompletion":8599,"completion":2409,"start":8600,"enrollment":883,"conditions":8831,"interventions":8832},[90],[18],[8564,8587],{"trials":8834,"activeCount":99},[],{"trials":8836,"activeCount":99},[],{"intervention":5855,"totalTrials":864,"cells":8838},{"EARLY_PHASE1":8839,"PHASE1":8841,"PHASE2":8843,"PHASE3":8845,"PHASE4":8860,"NA":8862},{"trials":8840,"activeCount":99},[],{"trials":8842,"activeCount":99},[],{"trials":8844,"activeCount":99},[],{"trials":8846,"activeCount":99},[8847,8856],{"nctId":8848,"briefTitle":8849,"status":105,"phases":8850,"primaryCompletion":8851,"completion":8851,"start":8852,"enrollment":8853,"conditions":8854,"interventions":8855},"NCT03220425","Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.",[90],"2001-11-12","2001-02-01",752,[21],[5810,5855],{"nctId":5849,"briefTitle":5850,"status":105,"phases":8857,"primaryCompletion":5852,"completion":5852,"start":3714,"enrollment":3303,"conditions":8858,"interventions":8859},[90],[15,21],[3589,5855,1978],{"trials":8861,"activeCount":99},[],{"trials":8863,"activeCount":99},[],{"intervention":7644,"totalTrials":864,"cells":8865},{"EARLY_PHASE1":8866,"PHASE1":8868,"PHASE2":8874,"PHASE3":8876,"PHASE4":8886,"NA":8888},{"trials":8867,"activeCount":99},[],{"trials":8869,"activeCount":99},[8870],{"nctId":7637,"briefTitle":7638,"status":105,"phases":8871,"primaryCompletion":5496,"completion":5496,"start":4765,"enrollment":306,"conditions":8872,"interventions":8873},[88],[7641,27],[7643,7644,7630],{"trials":8875,"activeCount":99},[],{"trials":8877,"activeCount":99},[8878],{"nctId":8879,"briefTitle":8880,"status":105,"phases":8881,"primaryCompletion":8882,"completion":8882,"start":3664,"enrollment":3989,"conditions":8883,"interventions":8885},"NCT00184795","Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations",[90],"2005-05-04",[7641,8884],"Menopausal Vasomotor Symptoms",[7643,7644],{"trials":8887,"activeCount":99},[],{"trials":8889,"activeCount":99},[],{"intervention":1998,"totalTrials":1606,"cells":8891},{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8898,"PHASE4":8904,"NA":8906},{"trials":8893,"activeCount":99},[],{"trials":8895,"activeCount":99},[],{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[8900],{"nctId":1990,"briefTitle":1991,"status":105,"phases":8901,"primaryCompletion":1993,"completion":1051,"start":1994,"enrollment":1995,"conditions":8902,"interventions":8903},[90],[18],[1829,1998,1999,2000],{"trials":8905,"activeCount":99},[],{"trials":8907,"activeCount":99},[],{"intervention":2000,"totalTrials":1606,"cells":8909},{"EARLY_PHASE1":8910,"PHASE1":8912,"PHASE2":8914,"PHASE3":8916,"PHASE4":8922,"NA":8924},{"trials":8911,"activeCount":99},[],{"trials":8913,"activeCount":99},[],{"trials":8915,"activeCount":99},[],{"trials":8917,"activeCount":99},[8918],{"nctId":1990,"briefTitle":1991,"status":105,"phases":8919,"primaryCompletion":1993,"completion":1051,"start":1994,"enrollment":1995,"conditions":8920,"interventions":8921},[90],[18],[1829,1998,1999,2000],{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[],{"intervention":1055,"totalTrials":1606,"cells":8927},{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8932,"PHASE3":8934,"PHASE4":8940,"NA":8942},{"trials":8929,"activeCount":99},[],{"trials":8931,"activeCount":99},[],{"trials":8933,"activeCount":99},[],{"trials":8935,"activeCount":99},[8936],{"nctId":1046,"briefTitle":1047,"status":105,"phases":8937,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":8938,"interventions":8939},[90],[18,24],[75,1055,1055],{"trials":8941,"activeCount":99},[],{"trials":8943,"activeCount":99},[],{"intervention":8636,"totalTrials":1606,"cells":8945},{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8952,"PHASE4":8958,"NA":8960},{"trials":8947,"activeCount":99},[],{"trials":8949,"activeCount":99},[],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[8954],{"nctId":8627,"briefTitle":8628,"status":105,"phases":8955,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":8956,"interventions":8957},[90],[15,18],[8621,8294,8636,3204,8637,8638],{"trials":8959,"activeCount":99},[],{"trials":8961,"activeCount":99},[],{"intervention":8637,"totalTrials":1606,"cells":8963},{"EARLY_PHASE1":8964,"PHASE1":8966,"PHASE2":8968,"PHASE3":8970,"PHASE4":8976,"NA":8978},{"trials":8965,"activeCount":99},[],{"trials":8967,"activeCount":99},[],{"trials":8969,"activeCount":99},[],{"trials":8971,"activeCount":99},[8972],{"nctId":8627,"briefTitle":8628,"status":105,"phases":8973,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":8974,"interventions":8975},[90],[15,18],[8621,8294,8636,3204,8637,8638],{"trials":8977,"activeCount":99},[],{"trials":8979,"activeCount":99},[],{"intervention":8638,"totalTrials":1606,"cells":8981},{"EARLY_PHASE1":8982,"PHASE1":8984,"PHASE2":8986,"PHASE3":8988,"PHASE4":8994,"NA":8996},{"trials":8983,"activeCount":99},[],{"trials":8985,"activeCount":99},[],{"trials":8987,"activeCount":99},[],{"trials":8989,"activeCount":99},[8990],{"nctId":8627,"briefTitle":8628,"status":105,"phases":8991,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":8992,"interventions":8993},[90],[15,18],[8621,8294,8636,3204,8637,8638],{"trials":8995,"activeCount":99},[],{"trials":8997,"activeCount":99},[],{"intervention":8443,"totalTrials":1606,"cells":8999},{"EARLY_PHASE1":9000,"PHASE1":9002,"PHASE2":9004,"PHASE3":9006,"PHASE4":9012,"NA":9014},{"trials":9001,"activeCount":99},[],{"trials":9003,"activeCount":99},[],{"trials":9005,"activeCount":99},[],{"trials":9007,"activeCount":99},[9008],{"nctId":8437,"briefTitle":8438,"status":105,"phases":9009,"primaryCompletion":3852,"completion":3852,"start":3618,"enrollment":8440,"conditions":9010,"interventions":9011},[90],[15,18],[8407,8443],{"trials":9013,"activeCount":99},[],{"trials":9015,"activeCount":99},[],{"intervention":9017,"totalTrials":1606,"cells":9018},"NNC0365-3769 (Mim8) PPX",{"EARLY_PHASE1":9019,"PHASE1":9021,"PHASE2":9023,"PHASE3":9025,"PHASE4":9035,"NA":9037},{"trials":9020,"activeCount":99},[],{"trials":9022,"activeCount":99},[],{"trials":9024,"activeCount":99},[],{"trials":9026,"activeCount":99},[9027],{"nctId":9028,"briefTitle":9029,"status":105,"phases":9030,"primaryCompletion":6350,"completion":9031,"start":9032,"enrollment":5278,"conditions":9033,"interventions":9034},"NCT05878938","A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)",[90],"2024-07-19","2023-06-26",[36,2136],[9017],{"trials":9036,"activeCount":99},[],{"trials":9038,"activeCount":99},[],{"intervention":9040,"totalTrials":1606,"cells":9041},"semaglutide 50 mg",{"EARLY_PHASE1":9042,"PHASE1":9044,"PHASE2":9046,"PHASE3":9048,"PHASE4":9060,"NA":9062},{"trials":9043,"activeCount":99},[],{"trials":9045,"activeCount":99},[],{"trials":9047,"activeCount":99},[],{"trials":9049,"activeCount":99},[9050],{"nctId":9051,"briefTitle":9052,"status":105,"phases":9053,"primaryCompletion":9054,"completion":9055,"start":9056,"enrollment":1042,"conditions":9057,"interventions":9059},"NCT05132088","Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity",[90],"2023-07-11","2023-09-01","2021-11-16",[9058],"Overweight and Obesity",[9040],{"trials":9061,"activeCount":99},[],{"trials":9063,"activeCount":99},[],{"intervention":3964,"totalTrials":1606,"cells":9065},{"EARLY_PHASE1":9066,"PHASE1":9068,"PHASE2":9070,"PHASE3":9072,"PHASE4":9078,"NA":9080},{"trials":9067,"activeCount":99},[],{"trials":9069,"activeCount":99},[],{"trials":9071,"activeCount":99},[],{"trials":9073,"activeCount":99},[9074],{"nctId":3958,"briefTitle":3959,"status":105,"phases":9075,"primaryCompletion":3961,"completion":2171,"start":3715,"enrollment":3074,"conditions":9076,"interventions":9077},[90],[15,18],[3964,768,768],{"trials":9079,"activeCount":99},[],{"trials":9081,"activeCount":99},[],{"intervention":9083,"totalTrials":1606,"cells":9084},"Semagludtide",{"EARLY_PHASE1":9085,"PHASE1":9087,"PHASE2":9089,"PHASE3":9091,"PHASE4":9101,"NA":9103},{"trials":9086,"activeCount":99},[],{"trials":9088,"activeCount":99},[],{"trials":9090,"activeCount":99},[],{"trials":9092,"activeCount":99},[9093],{"nctId":9094,"briefTitle":9095,"status":105,"phases":9096,"primaryCompletion":9097,"completion":1328,"start":662,"enrollment":1329,"conditions":9098,"interventions":9100},"NCT04777396","A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)",[90],"2025-09-16",[9099],"Early Alzheimer's Disease",[9083],{"trials":9102,"activeCount":99},[],{"trials":9104,"activeCount":99},[],{"intervention":9106,"totalTrials":1606,"cells":9107},"17-beta estradiol",{"EARLY_PHASE1":9108,"PHASE1":9110,"PHASE2":9112,"PHASE3":9114,"PHASE4":9124,"NA":9126},{"trials":9109,"activeCount":99},[],{"trials":9111,"activeCount":99},[],{"trials":9113,"activeCount":99},[],{"trials":9115,"activeCount":99},[9116],{"nctId":9117,"briefTitle":9118,"status":105,"phases":9119,"primaryCompletion":9120,"completion":9120,"start":9121,"enrollment":1624,"conditions":9122,"interventions":9123},"NCT01710696","Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome",[90],"2004-07-26","1998-07-23",[7968,2888],[9106,9106],{"trials":9125,"activeCount":99},[],{"trials":9127,"activeCount":99},[],{"intervention":8248,"totalTrials":1606,"cells":9129},{"EARLY_PHASE1":9130,"PHASE1":9132,"PHASE2":9134,"PHASE3":9136,"PHASE4":9142,"NA":9144},{"trials":9131,"activeCount":99},[],{"trials":9133,"activeCount":99},[],{"trials":9135,"activeCount":99},[],{"trials":9137,"activeCount":99},[9138],{"nctId":8241,"briefTitle":8242,"status":105,"phases":9139,"primaryCompletion":732,"completion":1261,"start":8244,"enrollment":8245,"conditions":9140,"interventions":9141},[90],[18],[375,8248],{"trials":9143,"activeCount":99},[],{"trials":9145,"activeCount":99},[],{"intervention":4044,"totalTrials":1606,"cells":9147},{"EARLY_PHASE1":9148,"PHASE1":9150,"PHASE2":9152,"PHASE3":9154,"PHASE4":9160,"NA":9162},{"trials":9149,"activeCount":99},[],{"trials":9151,"activeCount":99},[],{"trials":9153,"activeCount":99},[],{"trials":9155,"activeCount":99},[9156],{"nctId":4036,"briefTitle":4037,"status":105,"phases":9157,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":4041,"conditions":9158,"interventions":9159},[90],[15,18],[768,4044],{"trials":9161,"activeCount":99},[],{"trials":9163,"activeCount":99},[],{"intervention":1282,"totalTrials":1606,"cells":9165},{"EARLY_PHASE1":9166,"PHASE1":9168,"PHASE2":9170,"PHASE3":9172,"PHASE4":9178,"NA":9180},{"trials":9167,"activeCount":99},[],{"trials":9169,"activeCount":99},[],{"trials":9171,"activeCount":99},[],{"trials":9173,"activeCount":99},[9174],{"nctId":1275,"briefTitle":1276,"status":105,"phases":9175,"primaryCompletion":1278,"completion":1278,"start":872,"enrollment":1279,"conditions":9176,"interventions":9177},[90],[15,18],[112,1282],{"trials":9179,"activeCount":99},[],{"trials":9181,"activeCount":99},[],{"intervention":1488,"totalTrials":1606,"cells":9183},{"EARLY_PHASE1":9184,"PHASE1":9186,"PHASE2":9188,"PHASE3":9190,"PHASE4":9196,"NA":9198},{"trials":9185,"activeCount":99},[],{"trials":9187,"activeCount":99},[],{"trials":9189,"activeCount":99},[],{"trials":9191,"activeCount":99},[9192],{"nctId":1480,"briefTitle":1481,"status":105,"phases":9193,"primaryCompletion":1483,"completion":1484,"start":1446,"enrollment":1485,"conditions":9194,"interventions":9195},[90],[15,18],[75,1488],{"trials":9197,"activeCount":99},[],{"trials":9199,"activeCount":99},[],{"intervention":539,"totalTrials":422,"cells":9201},{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9242,"PHASE3":9253,"PHASE4":9255,"NA":9257},{"trials":9203,"activeCount":99},[],{"trials":9205,"activeCount":99},[9206,9213,9217,9224,9228,9236],{"nctId":9207,"briefTitle":9208,"status":105,"phases":9209,"primaryCompletion":9210,"completion":9210,"start":7362,"enrollment":2803,"conditions":9211,"interventions":9212},"NCT04209049","A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function",[88],"2021-01-05",[33,24],[539],{"nctId":532,"briefTitle":533,"status":105,"phases":9214,"primaryCompletion":535,"completion":535,"start":536,"enrollment":234,"conditions":9215,"interventions":9216},[88],[24,33],[539,75],{"nctId":9218,"briefTitle":9219,"status":105,"phases":9220,"primaryCompletion":9221,"completion":9221,"start":1399,"enrollment":325,"conditions":9222,"interventions":9223},"NCT02300844","Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects",[88],"2016-03-21",[204,24],[539],{"nctId":6720,"briefTitle":6721,"status":105,"phases":9225,"primaryCompletion":6723,"completion":6723,"start":6724,"enrollment":554,"conditions":9226,"interventions":9227},[88],[33,24],[539,6727,6256],{"nctId":9229,"briefTitle":9230,"status":105,"phases":9231,"primaryCompletion":9232,"completion":9232,"start":9233,"enrollment":234,"conditions":9234,"interventions":9235},"NCT02958085","Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight",[88],"2018-01-24","2016-11-04",[204,24],[539],{"nctId":9237,"briefTitle":9238,"status":105,"phases":9239,"primaryCompletion":6600,"completion":6600,"start":5718,"enrollment":1867,"conditions":9240,"interventions":9241},"NCT03787225","A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity",[88],[24,33],[539],{"trials":9243,"activeCount":99},[9244],{"nctId":9245,"briefTitle":9246,"status":105,"phases":9247,"primaryCompletion":4562,"completion":9248,"start":9249,"enrollment":765,"conditions":9250,"interventions":9251},"NCT03856047","Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.",[89],"2021-03-25","2019-03-01",[33,24],[539,9252],"Liraglutide 3.0 mg",{"trials":9254,"activeCount":99},[],{"trials":9256,"activeCount":99},[],{"trials":9258,"activeCount":99},[],{"intervention":3836,"totalTrials":1827,"cells":9260},{"EARLY_PHASE1":9261,"PHASE1":9263,"PHASE2":9281,"PHASE3":9301,"PHASE4":9303,"NA":9305},{"trials":9262,"activeCount":99},[],{"trials":9264,"activeCount":99},[9265,9273],{"nctId":9266,"briefTitle":9267,"status":349,"phases":9268,"primaryCompletion":9269,"completion":9269,"start":4058,"enrollment":1546,"conditions":9270,"interventions":9272},"NCT01689025","An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)",[88],"2014-02",[3066,9271],"Systemic Lupus Erythematosus",[3836],{"nctId":9274,"briefTitle":9275,"status":105,"phases":9276,"primaryCompletion":4057,"completion":4057,"start":9277,"enrollment":223,"conditions":9278,"interventions":9280},"NCT01565408","Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis",[88],"2012-03",[3066,9279],"Rheumatoid Arthritis",[3836],{"trials":9282,"activeCount":99},[9283,9289,9297],{"nctId":9284,"briefTitle":9285,"status":105,"phases":9286,"primaryCompletion":4336,"completion":4336,"start":4058,"enrollment":37,"conditions":9287,"interventions":9288},"NCT01647451","A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis",[89],[3066,9279],[3836],{"nctId":9290,"briefTitle":9291,"status":105,"phases":9292,"primaryCompletion":9293,"completion":9293,"start":3447,"enrollment":253,"conditions":9294,"interventions":9296},"NCT01751152","A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease",[89],"2014-12",[3066,9295],"Crohn's Disease",[3836],{"nctId":3828,"briefTitle":3829,"status":105,"phases":9298,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":1071,"conditions":9299,"interventions":9300},[89],[15,21],[3836,768],{"trials":9302,"activeCount":99},[],{"trials":9304,"activeCount":99},[],{"trials":9306,"activeCount":99},[],{"intervention":4386,"totalTrials":1827,"cells":9308},{"EARLY_PHASE1":9309,"PHASE1":9311,"PHASE2":9335,"PHASE3":9341,"PHASE4":9343,"NA":9345},{"trials":9310,"activeCount":99},[],{"trials":9312,"activeCount":99},[9313,9317,9325,9331],{"nctId":4380,"briefTitle":4381,"status":105,"phases":9314,"primaryCompletion":4383,"completion":4383,"start":961,"enrollment":162,"conditions":9315,"interventions":9316},[88],[15,18],[4386,876],{"nctId":9318,"briefTitle":9319,"status":105,"phases":9320,"primaryCompletion":9321,"completion":9321,"start":9322,"enrollment":266,"conditions":9323,"interventions":9324},"NCT02304627","Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects",[88],"2015-07-31","2014-11-24",[15,27],[4386],{"nctId":9326,"briefTitle":9327,"status":105,"phases":9328,"primaryCompletion":4204,"completion":4204,"start":4336,"enrollment":266,"conditions":9329,"interventions":9330},"NCT01931137","A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects",[88],[15,27],[4386],{"nctId":4523,"briefTitle":4524,"status":105,"phases":9332,"primaryCompletion":4526,"completion":4526,"start":361,"enrollment":37,"conditions":9333,"interventions":9334},[88],[27,15,21],[4529,4529,876],{"trials":9336,"activeCount":99},[9337],{"nctId":4576,"briefTitle":4577,"status":105,"phases":9338,"primaryCompletion":4579,"completion":4579,"start":1924,"enrollment":1624,"conditions":9339,"interventions":9340},[89],[15,18],[4386,876],{"trials":9342,"activeCount":99},[],{"trials":9344,"activeCount":99},[],{"trials":9346,"activeCount":99},[],{"intervention":9348,"totalTrials":713,"cells":9349},"NNC126-0083",{"EARLY_PHASE1":9350,"PHASE1":9352,"PHASE2":9367,"PHASE3":9381,"PHASE4":9383,"NA":9385},{"trials":9351,"activeCount":99},[],{"trials":9353,"activeCount":99},[9354,9360],{"nctId":9355,"briefTitle":9356,"status":105,"phases":9357,"primaryCompletion":488,"completion":488,"start":2162,"enrollment":162,"conditions":9358,"interventions":9359},"NCT00722540","Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083",[88],[2776,27],[9348,9348,9348,9348,9348],{"nctId":9361,"briefTitle":9362,"status":105,"phases":9363,"primaryCompletion":3901,"completion":3901,"start":3988,"enrollment":673,"conditions":9364,"interventions":9365},"NCT01034202","Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®",[88],[2776,27],[9348,9366,9348,9366],"Norditropin® SimpleXx®",{"trials":9368,"activeCount":99},[9369,9375],{"nctId":9370,"briefTitle":9371,"status":105,"phases":9372,"primaryCompletion":3586,"completion":3586,"start":2162,"enrollment":2803,"conditions":9373,"interventions":9374},"NCT00715689","Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083",[89],[2776,2777],[9348,9348,9348,9348],{"nctId":9376,"briefTitle":9377,"status":105,"phases":9378,"primaryCompletion":2278,"completion":2278,"start":4484,"enrollment":554,"conditions":9379,"interventions":9380},"NCT00936403","A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone",[89],[2776,2778],[9348,2831],{"trials":9382,"activeCount":99},[],{"trials":9384,"activeCount":99},[],{"trials":9386,"activeCount":99},[],{"intervention":9388,"totalTrials":713,"cells":9389},"recombinant interleukin-21",{"EARLY_PHASE1":9390,"PHASE1":9392,"PHASE2":9394,"PHASE3":9432,"PHASE4":9434,"NA":9436},{"trials":9391,"activeCount":99},[],{"trials":9393,"activeCount":99},[],{"trials":9395,"activeCount":99},[9396,9407,9414,9424],{"nctId":9397,"briefTitle":9398,"status":105,"phases":9399,"primaryCompletion":9400,"completion":9400,"start":9401,"enrollment":1546,"conditions":9402,"interventions":9405},"NCT00523380","Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer",[89],"2009-01-07","2007-10-04",[9403,9404],"Cancer","Ovarian Cancer",[9388,9406],"caelyx",{"nctId":9408,"briefTitle":9409,"status":105,"phases":9410,"primaryCompletion":3961,"completion":3961,"start":4644,"enrollment":325,"conditions":9411,"interventions":9413},"NCT00336986","Efficacy Study of IL-21 to Treat Metastatic Melanoma",[89],[9403,9412],"Malignant Melanoma",[9388],{"nctId":9415,"briefTitle":9416,"status":105,"phases":9417,"primaryCompletion":9418,"completion":9418,"start":9419,"enrollment":2338,"conditions":9420,"interventions":9422},"NCT00617253","Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients",[89],"2008-06-30","2007-07-12",[9403,9421],"Renal Cell Carcinoma",[9388,9423,9388,9388,9388],"sunitinib",{"nctId":9425,"briefTitle":9426,"status":349,"phases":9427,"primaryCompletion":9428,"completion":9428,"start":9429,"enrollment":1606,"conditions":9430,"interventions":9431},"NCT00601861","Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer",[89],"2008-06-25","2008-02-13",[9403,9412],[9388],{"trials":9433,"activeCount":99},[],{"trials":9435,"activeCount":99},[],{"trials":9437,"activeCount":99},[],{"intervention":666,"totalTrials":713,"cells":9439},{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9458,"PHASE3":9464,"PHASE4":9466,"NA":9468},{"trials":9441,"activeCount":99},[],{"trials":9443,"activeCount":99},[9444,9450,9454],{"nctId":9445,"briefTitle":9446,"status":105,"phases":9447,"primaryCompletion":3409,"completion":3409,"start":5157,"enrollment":173,"conditions":9448,"interventions":9449},"NCT05015894","A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function",[88],[18],[666],{"nctId":658,"briefTitle":659,"status":105,"phases":9451,"primaryCompletion":661,"completion":661,"start":662,"enrollment":306,"conditions":9452,"interventions":9453},[88],[664],[666,75],{"nctId":677,"briefTitle":678,"status":105,"phases":9455,"primaryCompletion":680,"completion":680,"start":681,"enrollment":140,"conditions":9456,"interventions":9457},[88],[142,33,24,18],[666,75],{"trials":9459,"activeCount":99},[9460],{"nctId":789,"briefTitle":790,"status":105,"phases":9461,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":9462,"interventions":9463},[89],[18],[666,75],{"trials":9465,"activeCount":99},[],{"trials":9467,"activeCount":99},[],{"trials":9469,"activeCount":99},[],{"intervention":9471,"totalTrials":2578,"cells":9472},"activated recombinant human factor VII, long acting",{"EARLY_PHASE1":9473,"PHASE1":9475,"PHASE2":9489,"PHASE3":9498,"PHASE4":9500,"NA":9502},{"trials":9474,"activeCount":99},[],{"trials":9476,"activeCount":99},[9477,9483],{"nctId":9478,"briefTitle":9479,"status":105,"phases":9480,"primaryCompletion":3585,"completion":3585,"start":3933,"enrollment":2683,"conditions":9481,"interventions":9482},"NCT00922792","Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B",[88],[30,36,2137],[9471,9471],{"nctId":9484,"briefTitle":9485,"status":105,"phases":9486,"primaryCompletion":3872,"completion":3872,"start":6191,"enrollment":578,"conditions":9487,"interventions":9488},"NCT00951873","A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers",[88],[30,36,2137,27],[9471,9471],{"trials":9490,"activeCount":99},[9491],{"nctId":9492,"briefTitle":9493,"status":105,"phases":9494,"primaryCompletion":9495,"completion":9495,"start":4833,"enrollment":992,"conditions":9496,"interventions":9497},"NCT00951405","Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors",[89],"2011-03-29",[30,2136,2138],[9471,9471,9471],{"trials":9499,"activeCount":99},[],{"trials":9501,"activeCount":99},[],{"trials":9503,"activeCount":99},[],{"intervention":9505,"totalTrials":2578,"cells":9506},"NNC 0151-0000-0000",{"EARLY_PHASE1":9507,"PHASE1":9509,"PHASE2":9523,"PHASE3":9531,"PHASE4":9533,"NA":9535},{"trials":9508,"activeCount":99},[],{"trials":9510,"activeCount":99},[9511,9517],{"nctId":9512,"briefTitle":9513,"status":1135,"phases":9514,"primaryCompletion":3462,"completion":3462,"start":3462,"enrollment":99,"conditions":9515,"interventions":9516},"NCT01018238","An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)",[88],[3066,9271],[9505],{"nctId":9518,"briefTitle":9519,"status":105,"phases":9520,"primaryCompletion":128,"completion":128,"start":2306,"enrollment":4439,"conditions":9521,"interventions":9522},"NCT02151409","Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects",[88],[3066,9271,9279,27],[9505,9505],{"trials":9524,"activeCount":99},[9525],{"nctId":9526,"briefTitle":9527,"status":105,"phases":9528,"primaryCompletion":3447,"completion":3447,"start":233,"enrollment":708,"conditions":9529,"interventions":9530},"NCT01223911","A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis",[89],[3066,9279],[9505],{"trials":9532,"activeCount":99},[],{"trials":9534,"activeCount":99},[],{"trials":9536,"activeCount":99},[],{"intervention":9538,"totalTrials":2578,"cells":9539},"NNC0109-0012",{"EARLY_PHASE1":9540,"PHASE1":9542,"PHASE2":9544,"PHASE3":9569,"PHASE4":9571,"NA":9573},{"trials":9541,"activeCount":99},[],{"trials":9543,"activeCount":99},[],{"trials":9545,"activeCount":99},[9546,9553,9560],{"nctId":9547,"briefTitle":9548,"status":1135,"phases":9549,"primaryCompletion":296,"completion":296,"start":172,"enrollment":99,"conditions":9550,"interventions":9551},"NCT02097264","A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate",[89],[3066,9279],[9538,9552],"Adalimumab",{"nctId":9554,"briefTitle":9555,"status":349,"phases":9556,"primaryCompletion":698,"completion":698,"start":333,"enrollment":9557,"conditions":9558,"interventions":9559},"NCT01636817","A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics",[89],239,[3066,9279],[9538],{"nctId":9561,"briefTitle":9562,"status":349,"phases":9563,"primaryCompletion":9564,"completion":9564,"start":9565,"enrollment":9566,"conditions":9567,"interventions":9568},"NCT01636843","A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate",[89],"2014-11-10","2012-10-30",298,[3066,9279],[9538],{"trials":9570,"activeCount":99},[],{"trials":9572,"activeCount":99},[],{"trials":9574,"activeCount":99},[],{"intervention":2843,"totalTrials":864,"cells":9576},{"EARLY_PHASE1":9577,"PHASE1":9579,"PHASE2":9589,"PHASE3":9595,"PHASE4":9597,"NA":9599},{"trials":9578,"activeCount":99},[],{"trials":9580,"activeCount":99},[9581],{"nctId":9582,"briefTitle":9583,"status":105,"phases":9584,"primaryCompletion":4057,"completion":4057,"start":2133,"enrollment":223,"conditions":9585,"interventions":9587},"NCT01943084","A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects",[88],[9586,27],"Growth Disorder",[2843,9588],"Genotropin Pen®",{"trials":9590,"activeCount":99},[9591],{"nctId":2835,"briefTitle":2836,"status":105,"phases":9592,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":2840,"conditions":9593,"interventions":9594},[89],[2776,2778],[2788,2843],{"trials":9596,"activeCount":99},[],{"trials":9598,"activeCount":99},[],{"trials":9600,"activeCount":99},[],{"intervention":9602,"totalTrials":864,"cells":9603},"NNC0385-0434 A 100 mg",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9617,"PHASE3":9631,"PHASE4":9633,"NA":9635},{"trials":9605,"activeCount":99},[],{"trials":9607,"activeCount":99},[9608],{"nctId":9609,"briefTitle":9610,"status":349,"phases":9611,"primaryCompletion":9612,"completion":9613,"start":9614,"enrollment":4439,"conditions":9615,"interventions":9616},"NCT05094934","A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function",[88],"2022-07-15","2022-08-24","2021-11-09",[840],[9602],{"trials":9618,"activeCount":99},[9619],{"nctId":9620,"briefTitle":9621,"status":105,"phases":9622,"primaryCompletion":9623,"completion":9624,"start":3062,"enrollment":5143,"conditions":9625,"interventions":9627},"NCT04992065","A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease",[89],"2022-04-26","2022-06-20",[9626],"Atherosclerotic Cardiovascular Disease",[9628,9629,9602,9630],"NNC0385-0434 A 15 mg","NNC0385-0434 A 40 mg","Evolocumab 140 mg\u002FmL, Repatha®",{"trials":9632,"activeCount":99},[],{"trials":9634,"activeCount":99},[],{"trials":9636,"activeCount":99},[],{"intervention":830,"totalTrials":864,"cells":9638},{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9651,"PHASE3":9657,"PHASE4":9659,"NA":9661},{"trials":9640,"activeCount":99},[],{"trials":9642,"activeCount":99},[9643],{"nctId":9644,"briefTitle":9645,"status":105,"phases":9646,"primaryCompletion":4491,"completion":4491,"start":2270,"enrollment":691,"conditions":9647,"interventions":9648},"NCT01405261","Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects",[88],[15,18,27],[9649,9649,9650,830],"oral NNC 0113-0987","I.v. NNC 0113-0987",{"trials":9652,"activeCount":99},[9653],{"nctId":822,"briefTitle":823,"status":105,"phases":9654,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":9655,"interventions":9656},[89],[15,18],[112,112,830],{"trials":9658,"activeCount":99},[],{"trials":9660,"activeCount":99},[],{"trials":9662,"activeCount":99},[],{"intervention":9664,"totalTrials":864,"cells":9665},"EX1000",{"EARLY_PHASE1":9666,"PHASE1":9668,"PHASE2":9670,"PHASE3":9685,"PHASE4":9687,"NA":9689},{"trials":9667,"activeCount":99},[],{"trials":9669,"activeCount":99},[],{"trials":9671,"activeCount":99},[9672,9679],{"nctId":9673,"briefTitle":9674,"status":105,"phases":9675,"primaryCompletion":3586,"completion":3586,"start":4015,"enrollment":9676,"conditions":9677,"interventions":9678},"NCT00660374","Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes",[89],402,[15,18],[4967,9664],{"nctId":9680,"briefTitle":9681,"status":105,"phases":9682,"primaryCompletion":3586,"completion":3586,"start":2306,"enrollment":1400,"conditions":9683,"interventions":9684},"NCT00698802","Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes",[89],[15,18],[9664,6195],{"trials":9686,"activeCount":99},[],{"trials":9688,"activeCount":99},[],{"trials":9690,"activeCount":99},[],{"intervention":811,"totalTrials":864,"cells":9692},{"EARLY_PHASE1":9693,"PHASE1":9695,"PHASE2":9701,"PHASE3":9707,"PHASE4":9709,"NA":9711},{"trials":9694,"activeCount":99},[],{"trials":9696,"activeCount":99},[9697],{"nctId":2406,"briefTitle":2407,"status":105,"phases":9698,"primaryCompletion":570,"completion":2409,"start":2410,"enrollment":152,"conditions":9699,"interventions":9700},[88],[24],[70,2413,2414,2415],{"trials":9702,"activeCount":99},[9703],{"nctId":799,"briefTitle":800,"status":105,"phases":9704,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":9705,"interventions":9706},[89],[806],[257,75,808,809,810,70,811,809],{"trials":9708,"activeCount":99},[],{"trials":9710,"activeCount":99},[],{"trials":9712,"activeCount":99},[],{"intervention":9714,"totalTrials":1606,"cells":9715},"DCR-PHXC",{"EARLY_PHASE1":9716,"PHASE1":9718,"PHASE2":9720,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9717,"activeCount":99},[],{"trials":9719,"activeCount":99},[],{"trials":9721,"activeCount":99},[9722],{"nctId":9723,"briefTitle":9724,"status":105,"phases":9725,"primaryCompletion":9726,"completion":9727,"start":752,"enrollment":2558,"conditions":9728,"interventions":9734},"NCT03847909","A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2",[89],"2021-06-21","2021-06-29",[9729,9730,9731,9732,9733],"Primary Hyperoxaluria Type 1 (PH1)","Primary Hyperoxaluria Type 2 (PH2)","Kidney Diseases","Urologic Diseases","Genetic Disease",[9714,9735],"Sterile Normal Saline",{"trials":9737,"activeCount":99},[],{"trials":9739,"activeCount":99},[],{"trials":9741,"activeCount":99},[],{"intervention":9735,"totalTrials":1606,"cells":9743},{"EARLY_PHASE1":9744,"PHASE1":9746,"PHASE2":9748,"PHASE3":9754,"PHASE4":9756,"NA":9758},{"trials":9745,"activeCount":99},[],{"trials":9747,"activeCount":99},[],{"trials":9749,"activeCount":99},[9750],{"nctId":9723,"briefTitle":9724,"status":105,"phases":9751,"primaryCompletion":9726,"completion":9727,"start":752,"enrollment":2558,"conditions":9752,"interventions":9753},[89],[9729,9730,9731,9732,9733],[9714,9735],{"trials":9755,"activeCount":99},[],{"trials":9757,"activeCount":99},[],{"trials":9759,"activeCount":99},[],{"intervention":9761,"totalTrials":1606,"cells":9762},"COR-001",{"EARLY_PHASE1":9763,"PHASE1":9765,"PHASE2":9767,"PHASE3":9778,"PHASE4":9780,"NA":9782},{"trials":9764,"activeCount":99},[],{"trials":9766,"activeCount":99},[],{"trials":9768,"activeCount":99},[9769],{"nctId":9770,"briefTitle":9771,"status":105,"phases":9772,"primaryCompletion":9773,"completion":9773,"start":9774,"enrollment":5278,"conditions":9775,"interventions":9777},"NCT02868229","Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001",[88,89],"2018-12-11","2016-09-12",[9776],"Anemia",[9761],{"trials":9779,"activeCount":99},[],{"trials":9781,"activeCount":99},[],{"trials":9783,"activeCount":99},[],{"intervention":9785,"totalTrials":1606,"cells":9786},"NDec - oral decitabine-tetrahydrouridine",{"EARLY_PHASE1":9787,"PHASE1":9789,"PHASE2":9791,"PHASE3":9801,"PHASE4":9803,"NA":9805},{"trials":9788,"activeCount":99},[],{"trials":9790,"activeCount":99},[],{"trials":9792,"activeCount":99},[9793],{"nctId":9794,"briefTitle":9795,"status":105,"phases":9796,"primaryCompletion":9797,"completion":9797,"start":8270,"enrollment":234,"conditions":9798,"interventions":9799},"NCT05405114","Research Study Investigating How Well NDec Works in People With Sickle Cell Disease",[89],"2025-07-24",[5018],[9785,9800],"HU - Hydroxyurea",{"trials":9802,"activeCount":99},[],{"trials":9804,"activeCount":99},[],{"trials":9806,"activeCount":99},[],{"intervention":9800,"totalTrials":1606,"cells":9808},{"EARLY_PHASE1":9809,"PHASE1":9811,"PHASE2":9813,"PHASE3":9819,"PHASE4":9821,"NA":9823},{"trials":9810,"activeCount":99},[],{"trials":9812,"activeCount":99},[],{"trials":9814,"activeCount":99},[9815],{"nctId":9794,"briefTitle":9795,"status":105,"phases":9816,"primaryCompletion":9797,"completion":9797,"start":8270,"enrollment":234,"conditions":9817,"interventions":9818},[89],[5018],[9785,9800],{"trials":9820,"activeCount":99},[],{"trials":9822,"activeCount":99},[],{"trials":9824,"activeCount":99},[],{"intervention":9552,"totalTrials":1606,"cells":9826},{"EARLY_PHASE1":9827,"PHASE1":9829,"PHASE2":9831,"PHASE3":9837,"PHASE4":9839,"NA":9841},{"trials":9828,"activeCount":99},[],{"trials":9830,"activeCount":99},[],{"trials":9832,"activeCount":99},[9833],{"nctId":9547,"briefTitle":9548,"status":1135,"phases":9834,"primaryCompletion":296,"completion":296,"start":172,"enrollment":99,"conditions":9835,"interventions":9836},[89],[3066,9279],[9538,9552],{"trials":9838,"activeCount":99},[],{"trials":9840,"activeCount":99},[],{"trials":9842,"activeCount":99},[],{"intervention":6395,"totalTrials":1606,"cells":9844},{"EARLY_PHASE1":9845,"PHASE1":9847,"PHASE2":9849,"PHASE3":9855,"PHASE4":9857,"NA":9859},{"trials":9846,"activeCount":99},[],{"trials":9848,"activeCount":99},[],{"trials":9850,"activeCount":99},[9851],{"nctId":6388,"briefTitle":6389,"status":105,"phases":9852,"primaryCompletion":6391,"completion":6392,"start":5078,"enrollment":5600,"conditions":9853,"interventions":9854},[89],[18],[842,6395],{"trials":9856,"activeCount":99},[],{"trials":9858,"activeCount":99},[],{"trials":9860,"activeCount":99},[],{"intervention":8731,"totalTrials":1606,"cells":9862},{"EARLY_PHASE1":9863,"PHASE1":9865,"PHASE2":9867,"PHASE3":9873,"PHASE4":9875,"NA":9877},{"trials":9864,"activeCount":99},[],{"trials":9866,"activeCount":99},[],{"trials":9868,"activeCount":99},[9869],{"nctId":8723,"briefTitle":8724,"status":105,"phases":9870,"primaryCompletion":8679,"completion":8726,"start":8727,"enrollment":8728,"conditions":9871,"interventions":9872},[89],[255],[8731,8732,809,8733,8734],{"trials":9874,"activeCount":99},[],{"trials":9876,"activeCount":99},[],{"trials":9878,"activeCount":99},[],{"intervention":8732,"totalTrials":1606,"cells":9880},{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9891,"PHASE4":9893,"NA":9895},{"trials":9882,"activeCount":99},[],{"trials":9884,"activeCount":99},[],{"trials":9886,"activeCount":99},[9887],{"nctId":8723,"briefTitle":8724,"status":105,"phases":9888,"primaryCompletion":8679,"completion":8726,"start":8727,"enrollment":8728,"conditions":9889,"interventions":9890},[89],[255],[8731,8732,809,8733,8734],{"trials":9892,"activeCount":99},[],{"trials":9894,"activeCount":99},[],{"trials":9896,"activeCount":99},[],{"intervention":8733,"totalTrials":1606,"cells":9898},{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9903,"PHASE3":9909,"PHASE4":9911,"NA":9913},{"trials":9900,"activeCount":99},[],{"trials":9902,"activeCount":99},[],{"trials":9904,"activeCount":99},[9905],{"nctId":8723,"briefTitle":8724,"status":105,"phases":9906,"primaryCompletion":8679,"completion":8726,"start":8727,"enrollment":8728,"conditions":9907,"interventions":9908},[89],[255],[8731,8732,809,8733,8734],{"trials":9910,"activeCount":99},[],{"trials":9912,"activeCount":99},[],{"trials":9914,"activeCount":99},[],{"intervention":8734,"totalTrials":1606,"cells":9916},{"EARLY_PHASE1":9917,"PHASE1":9919,"PHASE2":9921,"PHASE3":9927,"PHASE4":9929,"NA":9931},{"trials":9918,"activeCount":99},[],{"trials":9920,"activeCount":99},[],{"trials":9922,"activeCount":99},[9923],{"nctId":8723,"briefTitle":8724,"status":105,"phases":9924,"primaryCompletion":8679,"completion":8726,"start":8727,"enrollment":8728,"conditions":9925,"interventions":9926},[89],[255],[8731,8732,809,8733,8734],{"trials":9928,"activeCount":99},[],{"trials":9930,"activeCount":99},[],{"trials":9932,"activeCount":99},[],{"intervention":9934,"totalTrials":1606,"cells":9935},"standard therapy",{"EARLY_PHASE1":9936,"PHASE1":9938,"PHASE2":9940,"PHASE3":9951,"PHASE4":9953,"NA":9955},{"trials":9937,"activeCount":99},[],{"trials":9939,"activeCount":99},[],{"trials":9941,"activeCount":99},[9942],{"nctId":9943,"briefTitle":9944,"status":349,"phases":9945,"primaryCompletion":9946,"completion":9946,"start":9947,"enrollment":3578,"conditions":9948,"interventions":9950},"NCT01564563","Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation",[89],"2003-10-27","2002-06-28",[2197,9949],"Bleeding During\u002FFollowing Surgery",[9934,2157,2157],{"trials":9952,"activeCount":99},[],{"trials":9954,"activeCount":99},[],{"trials":9956,"activeCount":99},[],{"intervention":2598,"totalTrials":1606,"cells":9958},{"EARLY_PHASE1":9959,"PHASE1":9961,"PHASE2":9963,"PHASE3":9969,"PHASE4":9971,"NA":9973},{"trials":9960,"activeCount":99},[],{"trials":9962,"activeCount":99},[],{"trials":9964,"activeCount":99},[9965],{"nctId":2589,"briefTitle":2590,"status":105,"phases":9966,"primaryCompletion":1165,"completion":2592,"start":2593,"enrollment":2594,"conditions":9967,"interventions":9968},[89],[2596],[2598,1354],{"trials":9970,"activeCount":99},[],{"trials":9972,"activeCount":99},[],{"trials":9974,"activeCount":99},[],{"intervention":9406,"totalTrials":1606,"cells":9976},{"EARLY_PHASE1":9977,"PHASE1":9979,"PHASE2":9981,"PHASE3":9987,"PHASE4":9989,"NA":9991},{"trials":9978,"activeCount":99},[],{"trials":9980,"activeCount":99},[],{"trials":9982,"activeCount":99},[9983],{"nctId":9397,"briefTitle":9398,"status":105,"phases":9984,"primaryCompletion":9400,"completion":9400,"start":9401,"enrollment":1546,"conditions":9985,"interventions":9986},[89],[9403,9404],[9388,9406],{"trials":9988,"activeCount":99},[],{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":99},[],{"intervention":9628,"totalTrials":1606,"cells":9994},{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10005,"PHASE4":10007,"NA":10009},{"trials":9996,"activeCount":99},[],{"trials":9998,"activeCount":99},[],{"trials":10000,"activeCount":99},[10001],{"nctId":9620,"briefTitle":9621,"status":105,"phases":10002,"primaryCompletion":9623,"completion":9624,"start":3062,"enrollment":5143,"conditions":10003,"interventions":10004},[89],[9626],[9628,9629,9602,9630],{"trials":10006,"activeCount":99},[],{"trials":10008,"activeCount":99},[],{"trials":10010,"activeCount":99},[],{"intervention":9629,"totalTrials":1606,"cells":10012},{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10017,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10014,"activeCount":99},[],{"trials":10016,"activeCount":99},[],{"trials":10018,"activeCount":99},[10019],{"nctId":9620,"briefTitle":9621,"status":105,"phases":10020,"primaryCompletion":9623,"completion":9624,"start":3062,"enrollment":5143,"conditions":10021,"interventions":10022},[89],[9626],[9628,9629,9602,9630],{"trials":10024,"activeCount":99},[],{"trials":10026,"activeCount":99},[],{"trials":10028,"activeCount":99},[],{"intervention":9630,"totalTrials":1606,"cells":10030},{"EARLY_PHASE1":10031,"PHASE1":10033,"PHASE2":10035,"PHASE3":10041,"PHASE4":10043,"NA":10045},{"trials":10032,"activeCount":99},[],{"trials":10034,"activeCount":99},[],{"trials":10036,"activeCount":99},[10037],{"nctId":9620,"briefTitle":9621,"status":105,"phases":10038,"primaryCompletion":9623,"completion":9624,"start":3062,"enrollment":5143,"conditions":10039,"interventions":10040},[89],[9626],[9628,9629,9602,9630],{"trials":10042,"activeCount":99},[],{"trials":10044,"activeCount":99},[],{"trials":10046,"activeCount":99},[],{"intervention":9423,"totalTrials":1606,"cells":10048},{"EARLY_PHASE1":10049,"PHASE1":10051,"PHASE2":10053,"PHASE3":10059,"PHASE4":10061,"NA":10063},{"trials":10050,"activeCount":99},[],{"trials":10052,"activeCount":99},[],{"trials":10054,"activeCount":99},[10055],{"nctId":9415,"briefTitle":9416,"status":105,"phases":10056,"primaryCompletion":9418,"completion":9418,"start":9419,"enrollment":2338,"conditions":10057,"interventions":10058},[89],[9403,9421],[9388,9423,9388,9388,9388],{"trials":10060,"activeCount":99},[],{"trials":10062,"activeCount":99},[],{"trials":10064,"activeCount":99},[],{"intervention":10066,"totalTrials":1606,"cells":10067},"Semaglutide 2.4 mg and NNC0165-1875 2.0 mg",{"EARLY_PHASE1":10068,"PHASE1":10070,"PHASE2":10072,"PHASE3":10086,"PHASE4":10088,"NA":10090},{"trials":10069,"activeCount":99},[],{"trials":10071,"activeCount":99},[],{"trials":10073,"activeCount":99},[10074],{"nctId":10075,"briefTitle":10076,"status":105,"phases":10077,"primaryCompletion":10078,"completion":10079,"start":10080,"enrollment":2367,"conditions":10081,"interventions":10082},"NCT04969939","A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity",[89],"2022-12-06","2023-01-30","2021-07-15",[24],[10066,10083,10084,10085],"Semaglutide 2.4 mg and placebo 2.0 mg","Semaglutide 2.4 mg and NNC0165-1875 1.0 mg","Semaglutide 2.4 mg and placebo 1.0 mg",{"trials":10087,"activeCount":99},[],{"trials":10089,"activeCount":99},[],{"trials":10091,"activeCount":99},[],{"intervention":10083,"totalTrials":1606,"cells":10093},{"EARLY_PHASE1":10094,"PHASE1":10096,"PHASE2":10098,"PHASE3":10104,"PHASE4":10106,"NA":10108},{"trials":10095,"activeCount":99},[],{"trials":10097,"activeCount":99},[],{"trials":10099,"activeCount":99},[10100],{"nctId":10075,"briefTitle":10076,"status":105,"phases":10101,"primaryCompletion":10078,"completion":10079,"start":10080,"enrollment":2367,"conditions":10102,"interventions":10103},[89],[24],[10066,10083,10084,10085],{"trials":10105,"activeCount":99},[],{"trials":10107,"activeCount":99},[],{"trials":10109,"activeCount":99},[],{"intervention":10084,"totalTrials":1606,"cells":10111},{"EARLY_PHASE1":10112,"PHASE1":10114,"PHASE2":10116,"PHASE3":10122,"PHASE4":10124,"NA":10126},{"trials":10113,"activeCount":99},[],{"trials":10115,"activeCount":99},[],{"trials":10117,"activeCount":99},[10118],{"nctId":10075,"briefTitle":10076,"status":105,"phases":10119,"primaryCompletion":10078,"completion":10079,"start":10080,"enrollment":2367,"conditions":10120,"interventions":10121},[89],[24],[10066,10083,10084,10085],{"trials":10123,"activeCount":99},[],{"trials":10125,"activeCount":99},[],{"trials":10127,"activeCount":99},[],{"intervention":10085,"totalTrials":1606,"cells":10129},{"EARLY_PHASE1":10130,"PHASE1":10132,"PHASE2":10134,"PHASE3":10140,"PHASE4":10142,"NA":10144},{"trials":10131,"activeCount":99},[],{"trials":10133,"activeCount":99},[],{"trials":10135,"activeCount":99},[10136],{"nctId":10075,"briefTitle":10076,"status":105,"phases":10137,"primaryCompletion":10078,"completion":10079,"start":10080,"enrollment":2367,"conditions":10138,"interventions":10139},[89],[24],[10066,10083,10084,10085],{"trials":10141,"activeCount":99},[],{"trials":10143,"activeCount":99},[],{"trials":10145,"activeCount":99},[],{"intervention":808,"totalTrials":1606,"cells":10147},{"EARLY_PHASE1":10148,"PHASE1":10150,"PHASE2":10152,"PHASE3":10158,"PHASE4":10160,"NA":10162},{"trials":10149,"activeCount":99},[],{"trials":10151,"activeCount":99},[],{"trials":10153,"activeCount":99},[10154],{"nctId":799,"briefTitle":800,"status":105,"phases":10155,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":10156,"interventions":10157},[89],[806],[257,75,808,809,810,70,811,809],{"trials":10159,"activeCount":99},[],{"trials":10161,"activeCount":99},[],{"trials":10163,"activeCount":99},[],{"intervention":810,"totalTrials":1606,"cells":10165},{"EARLY_PHASE1":10166,"PHASE1":10168,"PHASE2":10170,"PHASE3":10176,"PHASE4":10178,"NA":10180},{"trials":10167,"activeCount":99},[],{"trials":10169,"activeCount":99},[],{"trials":10171,"activeCount":99},[10172],{"nctId":799,"briefTitle":800,"status":105,"phases":10173,"primaryCompletion":802,"completion":803,"start":804,"enrollment":723,"conditions":10174,"interventions":10175},[89],[806],[257,75,808,809,810,70,811,809],{"trials":10177,"activeCount":99},[],{"trials":10179,"activeCount":99},[],{"trials":10181,"activeCount":99},[],{"intervention":1965,"totalTrials":1606,"cells":10183},{"EARLY_PHASE1":10184,"PHASE1":10186,"PHASE2":10188,"PHASE3":10194,"PHASE4":10196,"NA":10198},{"trials":10185,"activeCount":99},[],{"trials":10187,"activeCount":99},[],{"trials":10189,"activeCount":99},[10190],{"nctId":1959,"briefTitle":1960,"status":105,"phases":10191,"primaryCompletion":595,"completion":1953,"start":1866,"enrollment":1962,"conditions":10192,"interventions":10193},[89],[18],[1829,1478,1965,1910],{"trials":10195,"activeCount":99},[],{"trials":10197,"activeCount":99},[],{"trials":10199,"activeCount":99},[],{"intervention":10201,"totalTrials":1606,"cells":10202},"NNC109-0012",{"EARLY_PHASE1":10203,"PHASE1":10205,"PHASE2":10207,"PHASE3":10215,"PHASE4":10217,"NA":10219},{"trials":10204,"activeCount":99},[],{"trials":10206,"activeCount":99},[],{"trials":10208,"activeCount":99},[10209],{"nctId":10210,"briefTitle":10211,"status":105,"phases":10212,"primaryCompletion":651,"completion":651,"start":4262,"enrollment":212,"conditions":10213,"interventions":10214},"NCT01282255","Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis",[89],[3066,9279],[10201],{"trials":10216,"activeCount":99},[],{"trials":10218,"activeCount":99},[],{"trials":10220,"activeCount":99},[],{"intervention":3846,"totalTrials":1606,"cells":10222},{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10227,"PHASE3":10233,"PHASE4":10235,"NA":10237},{"trials":10224,"activeCount":99},[],{"trials":10226,"activeCount":99},[],{"trials":10228,"activeCount":99},[10229],{"nctId":3838,"briefTitle":3839,"status":105,"phases":10230,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":3843,"conditions":10231,"interventions":10232},[89],[15,2937],[57,1478,3846],{"trials":10234,"activeCount":99},[],{"trials":10236,"activeCount":99},[],{"trials":10238,"activeCount":99},[],{"intervention":8274,"totalTrials":1606,"cells":10240},{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10251,"PHASE4":10253,"NA":10255},{"trials":10242,"activeCount":99},[],{"trials":10244,"activeCount":99},[],{"trials":10246,"activeCount":99},[10247],{"nctId":8267,"briefTitle":8268,"status":105,"phases":10248,"primaryCompletion":8270,"completion":8270,"start":8271,"enrollment":2879,"conditions":10249,"interventions":10250},[89],[18],[8258,8274],{"trials":10252,"activeCount":99},[],{"trials":10254,"activeCount":99},[],{"trials":10256,"activeCount":99},[],{"intervention":2414,"totalTrials":1827,"cells":10258},{"EARLY_PHASE1":10259,"PHASE1":10261,"PHASE2":10288,"PHASE3":10290,"PHASE4":10292,"NA":10294},{"trials":10260,"activeCount":99},[],{"trials":10262,"activeCount":99},[10263,10267,10271,10275,10284],{"nctId":5011,"briefTitle":5012,"status":105,"phases":10264,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":2803,"conditions":10265,"interventions":10266},[88],[142,5018,5019],[4985,2414],{"nctId":3615,"briefTitle":3616,"status":105,"phases":10268,"primaryCompletion":3618,"completion":3618,"start":3619,"enrollment":2252,"conditions":10269,"interventions":10270},[88],[15,18],[768,607],{"nctId":599,"briefTitle":600,"status":105,"phases":10272,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":10273,"interventions":10274},[88],[15,27],[112,607],{"nctId":10276,"briefTitle":10277,"status":105,"phases":10278,"primaryCompletion":10279,"completion":10280,"start":10281,"enrollment":130,"conditions":10282,"interventions":10283},"NCT02911870","A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.",[88],"2017-05-04","2017-05-11","2016-09-23",[27],[195,2414],{"nctId":2406,"briefTitle":2407,"status":105,"phases":10285,"primaryCompletion":570,"completion":2409,"start":2410,"enrollment":152,"conditions":10286,"interventions":10287},[88],[24],[70,2413,2414,2415],{"trials":10289,"activeCount":99},[],{"trials":10291,"activeCount":99},[],{"trials":10293,"activeCount":99},[],{"trials":10295,"activeCount":99},[],{"intervention":195,"totalTrials":713,"cells":10297},{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10318,"PHASE3":10320,"PHASE4":10322,"NA":10324},{"trials":10299,"activeCount":99},[],{"trials":10301,"activeCount":99},[10302,10306,10310,10314],{"nctId":187,"briefTitle":188,"status":105,"phases":10303,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":10304,"interventions":10305},[88],[15,18],[112,195,196],{"nctId":260,"briefTitle":261,"status":105,"phases":10307,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":10308,"interventions":10309},[88],[15,27],[75,195,269],{"nctId":618,"briefTitle":619,"status":105,"phases":10311,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":10312,"interventions":10313},[88],[15,27],[627,628,195,75],{"nctId":10276,"briefTitle":10277,"status":105,"phases":10315,"primaryCompletion":10279,"completion":10280,"start":10281,"enrollment":130,"conditions":10316,"interventions":10317},[88],[27],[195,2414],{"trials":10319,"activeCount":99},[],{"trials":10321,"activeCount":99},[],{"trials":10323,"activeCount":99},[],{"trials":10325,"activeCount":99},[],{"intervention":227,"totalTrials":713,"cells":10327},{"EARLY_PHASE1":10328,"PHASE1":10330,"PHASE2":10348,"PHASE3":10350,"PHASE4":10352,"NA":10354},{"trials":10329,"activeCount":99},[],{"trials":10331,"activeCount":99},[10332,10336,10340,10344],{"nctId":218,"briefTitle":219,"status":105,"phases":10333,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":10334,"interventions":10335},[88],[15,27],[112,226,227],{"nctId":3531,"briefTitle":3532,"status":105,"phases":10337,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":3534,"conditions":10338,"interventions":10339},[88],[15,27],[768,557,366,3537,227],{"nctId":549,"briefTitle":550,"status":105,"phases":10341,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":10342,"interventions":10343},[88],[15,27],[112,227,557],{"nctId":5030,"briefTitle":5031,"status":105,"phases":10345,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":10346,"interventions":10347},[88],[5008],[4985,5036,5037,1478,5038,628],{"trials":10349,"activeCount":99},[],{"trials":10351,"activeCount":99},[],{"trials":10353,"activeCount":99},[],{"trials":10355,"activeCount":99},[],{"intervention":309,"totalTrials":713,"cells":10357},{"EARLY_PHASE1":10358,"PHASE1":10360,"PHASE2":10378,"PHASE3":10380,"PHASE4":10382,"NA":10384},{"trials":10359,"activeCount":99},[],{"trials":10361,"activeCount":99},[10362,10366,10370,10374],{"nctId":301,"briefTitle":302,"status":105,"phases":10363,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":10364,"interventions":10365},[88],[15,18,27],[112,226,309],{"nctId":358,"briefTitle":359,"status":105,"phases":10367,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":10368,"interventions":10369},[88],[15,27],[112,366,309],{"nctId":2159,"briefTitle":2160,"status":105,"phases":10371,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":28,"conditions":10372,"interventions":10373},[88],[2165,27],[309,2122],{"nctId":703,"briefTitle":704,"status":105,"phases":10375,"primaryCompletion":241,"completion":706,"start":707,"enrollment":708,"conditions":10376,"interventions":10377},[88],[24],[70,75,711,712],{"trials":10379,"activeCount":99},[],{"trials":10381,"activeCount":99},[],{"trials":10383,"activeCount":99},[],{"trials":10385,"activeCount":99},[],{"intervention":10387,"totalTrials":713,"cells":10388},"NNC0113-0987",{"EARLY_PHASE1":10389,"PHASE1":10391,"PHASE2":10420,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10390,"activeCount":99},[],{"trials":10392,"activeCount":99},[10393,10401,10408,10414],{"nctId":10394,"briefTitle":10395,"status":105,"phases":10396,"primaryCompletion":10397,"completion":10397,"start":10398,"enrollment":266,"conditions":10399,"interventions":10400},"NCT01690169","Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects",[88],"2012-12-11","2012-09-14",[15,18,27],[10387],{"nctId":10402,"briefTitle":10403,"status":105,"phases":10404,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":10405,"conditions":10406,"interventions":10407},"NCT02094521","Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects",[88],122,[15,27],[10387],{"nctId":10409,"briefTitle":10410,"status":105,"phases":10411,"primaryCompletion":3446,"completion":3446,"start":4057,"enrollment":5519,"conditions":10412,"interventions":10413},"NCT01967589","Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects",[88],[15,27],[10387],{"nctId":10415,"briefTitle":10416,"status":105,"phases":10417,"primaryCompletion":403,"completion":403,"start":2132,"enrollment":528,"conditions":10418,"interventions":10419},"NCT01978613","Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects",[88],[15,27],[10387],{"trials":10421,"activeCount":99},[],{"trials":10423,"activeCount":99},[],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"intervention":10429,"totalTrials":2578,"cells":10430},"NNC0487-0111 A",{"EARLY_PHASE1":10431,"PHASE1":10433,"PHASE2":10462,"PHASE3":10464,"PHASE4":10466,"NA":10468},{"trials":10432,"activeCount":99},[],{"trials":10434,"activeCount":99},[10435,10443,10450],{"nctId":10436,"briefTitle":10437,"status":105,"phases":10438,"primaryCompletion":1205,"completion":1205,"start":10439,"enrollment":451,"conditions":10440,"interventions":10441},"NCT05369390","A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity",[88],"2022-05-11",[24],[10429,10442],"NNC0487-0111 B",{"nctId":10444,"briefTitle":10445,"status":105,"phases":10446,"primaryCompletion":10447,"completion":10447,"start":2034,"enrollment":2549,"conditions":10448,"interventions":10449},"NCT07121153","A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.",[88],"2025-12-20",[33,24],[10429],{"nctId":10451,"briefTitle":10452,"status":105,"phases":10453,"primaryCompletion":10454,"completion":10455,"start":10456,"enrollment":653,"conditions":10457,"interventions":10458},"NCT06461039","A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant",[88],"2025-03-16","2025-04-04","2024-06-14",[24],[10429,10459,10460,10461],"NNC0487-0111 C","Levonorgestrel 150 μg + Ethinylestradiol 30 μg","Acetaminophen - 500 mg\u002F15 ml",{"trials":10463,"activeCount":99},[],{"trials":10465,"activeCount":99},[],{"trials":10467,"activeCount":99},[],{"trials":10469,"activeCount":99},[],{"intervention":3521,"totalTrials":2578,"cells":10471},{"EARLY_PHASE1":10472,"PHASE1":10474,"PHASE2":10492,"PHASE3":10494,"PHASE4":10496,"NA":10498},{"trials":10473,"activeCount":99},[],{"trials":10475,"activeCount":99},[10476,10484,10488],{"nctId":10477,"briefTitle":10478,"status":105,"phases":10479,"primaryCompletion":10480,"completion":10480,"start":10481,"enrollment":699,"conditions":10482,"interventions":10483},"NCT02835235","A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity",[88],"2017-07-07","2016-07-26",[204,24],[3521],{"nctId":3513,"briefTitle":3514,"status":105,"phases":10485,"primaryCompletion":3516,"completion":3516,"start":3517,"enrollment":3518,"conditions":10486,"interventions":10487},[88],[204,24],[3521,768],{"nctId":3720,"briefTitle":3721,"status":105,"phases":10489,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":1668,"conditions":10490,"interventions":10491},[88],[204,24],[3521,768],{"trials":10493,"activeCount":99},[],{"trials":10495,"activeCount":99},[],{"trials":10497,"activeCount":99},[],{"trials":10499,"activeCount":99},[],{"intervention":557,"totalTrials":2578,"cells":10501},{"EARLY_PHASE1":10502,"PHASE1":10504,"PHASE2":10518,"PHASE3":10520,"PHASE4":10522,"NA":10524},{"trials":10503,"activeCount":99},[],{"trials":10505,"activeCount":99},[10506,10510,10514],{"nctId":3531,"briefTitle":3532,"status":105,"phases":10507,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":3534,"conditions":10508,"interventions":10509},[88],[15,27],[768,557,366,3537,227],{"nctId":549,"briefTitle":550,"status":105,"phases":10511,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":10512,"interventions":10513},[88],[15,27],[112,227,557],{"nctId":703,"briefTitle":704,"status":105,"phases":10515,"primaryCompletion":241,"completion":706,"start":707,"enrollment":708,"conditions":10516,"interventions":10517},[88],[24],[70,75,711,712],{"trials":10519,"activeCount":99},[],{"trials":10521,"activeCount":99},[],{"trials":10523,"activeCount":99},[],{"trials":10525,"activeCount":99},[],{"intervention":5410,"totalTrials":2578,"cells":10527},{"EARLY_PHASE1":10528,"PHASE1":10530,"PHASE2":10546,"PHASE3":10548,"PHASE4":10550,"NA":10552},{"trials":10529,"activeCount":99},[],{"trials":10531,"activeCount":99},[10532,10536,10540],{"nctId":5403,"briefTitle":5404,"status":105,"phases":10533,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":10534,"interventions":10535},[88],[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],{"nctId":5467,"briefTitle":5468,"status":105,"phases":10537,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":10538,"interventions":10539},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"nctId":10541,"briefTitle":10542,"status":105,"phases":10543,"primaryCompletion":4015,"completion":4015,"start":6177,"enrollment":223,"conditions":10544,"interventions":10545},"NCT01868555","Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects",[88],[15,27],[1919,5410,5472],{"trials":10547,"activeCount":99},[],{"trials":10549,"activeCount":99},[],{"trials":10551,"activeCount":99},[],{"trials":10553,"activeCount":99},[],{"intervention":4425,"totalTrials":2578,"cells":10555},{"EARLY_PHASE1":10556,"PHASE1":10558,"PHASE2":10572,"PHASE3":10574,"PHASE4":10576,"NA":10578},{"trials":10557,"activeCount":99},[],{"trials":10559,"activeCount":99},[10560,10564,10568],{"nctId":4418,"briefTitle":4419,"status":105,"phases":10561,"primaryCompletion":4421,"completion":4421,"start":4422,"enrollment":2549,"conditions":10562,"interventions":10563},[88],[18],[4425,876],{"nctId":4449,"briefTitle":4450,"status":105,"phases":10565,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":404,"conditions":10566,"interventions":10567},[88],[21,142],[4425,876],{"nctId":4550,"briefTitle":4551,"status":105,"phases":10569,"primaryCompletion":4553,"completion":4554,"start":3320,"enrollment":2298,"conditions":10570,"interventions":10571},[88],[18],[4425,1910],{"trials":10573,"activeCount":99},[],{"trials":10575,"activeCount":99},[],{"trials":10577,"activeCount":99},[],{"trials":10579,"activeCount":99},[],{"intervention":10581,"totalTrials":2578,"cells":10582},"anti-IL-20",{"EARLY_PHASE1":10583,"PHASE1":10585,"PHASE2":10606,"PHASE3":10608,"PHASE4":10610,"NA":10612},{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":99},[10587,10593,10600],{"nctId":10588,"briefTitle":10589,"status":105,"phases":10590,"primaryCompletion":4636,"completion":4636,"start":3738,"enrollment":223,"conditions":10591,"interventions":10592},"NCT00818064","Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis",[88],[3066,9279,27],[10581],{"nctId":10594,"briefTitle":10595,"status":349,"phases":10596,"primaryCompletion":233,"completion":233,"start":4049,"enrollment":614,"conditions":10597,"interventions":10599},"NCT01261767","First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects",[88],[3066,10598],"Psoriasis",[10581],{"nctId":10601,"briefTitle":10602,"status":105,"phases":10603,"primaryCompletion":2305,"completion":2305,"start":4904,"enrollment":5006,"conditions":10604,"interventions":10605},"NCT01038674","Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis",[88],[3066,9279],[10581],{"trials":10607,"activeCount":99},[],{"trials":10609,"activeCount":99},[],{"trials":10611,"activeCount":99},[],{"trials":10613,"activeCount":99},[],{"intervention":10615,"totalTrials":2578,"cells":10616},"NNC0385-0434",{"EARLY_PHASE1":10617,"PHASE1":10619,"PHASE2":10649,"PHASE3":10651,"PHASE4":10653,"NA":10655},{"trials":10618,"activeCount":99},[],{"trials":10620,"activeCount":99},[10621,10628,10640],{"nctId":10622,"briefTitle":10623,"status":105,"phases":10624,"primaryCompletion":159,"completion":159,"start":10625,"enrollment":2549,"conditions":10626,"interventions":10627},"NCT05003440","A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men",[88],"2021-08-19",[142,9626],[10615],{"nctId":10629,"briefTitle":10630,"status":105,"phases":10631,"primaryCompletion":10632,"completion":10633,"start":10634,"enrollment":10635,"conditions":10636,"interventions":10639},"NCT05091073","A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants",[88],"2022-04-07","2022-05-31","2021-12-09",73,[10637,10638,142],"Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk","Elevated Cholesterol",[10615],{"nctId":10641,"briefTitle":10642,"status":105,"phases":10643,"primaryCompletion":10644,"completion":10644,"start":10645,"enrollment":4430,"conditions":10646,"interventions":10648},"NCT04058834","A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels",[88],"2020-04-23","2019-08-20",[142,10647],"Hypercholesterolaemia",[10615],{"trials":10650,"activeCount":99},[],{"trials":10652,"activeCount":99},[],{"trials":10654,"activeCount":99},[],{"trials":10656,"activeCount":99},[],{"intervention":10658,"totalTrials":864,"cells":10659},"NNC 0128-0000-2011",{"EARLY_PHASE1":10660,"PHASE1":10662,"PHASE2":10677,"PHASE3":10679,"PHASE4":10681,"NA":10683},{"trials":10661,"activeCount":99},[],{"trials":10663,"activeCount":99},[10664,10670],{"nctId":10665,"briefTitle":10666,"status":105,"phases":10667,"primaryCompletion":232,"completion":232,"start":233,"enrollment":518,"conditions":10668,"interventions":10669},"NCT01288391","Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients",[88],[30,36,2137],[10658,10658],{"nctId":10671,"briefTitle":10672,"status":105,"phases":10673,"primaryCompletion":652,"completion":652,"start":233,"enrollment":5047,"conditions":10674,"interventions":10675},"NCT01272206","Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects",[88],[30,36,2137],[10658,10676],"NNC 0128-0000-2021",{"trials":10678,"activeCount":99},[],{"trials":10680,"activeCount":99},[],{"trials":10682,"activeCount":99},[],{"trials":10684,"activeCount":99},[],{"intervention":166,"totalTrials":864,"cells":10686},{"EARLY_PHASE1":10687,"PHASE1":10689,"PHASE2":10704,"PHASE3":10706,"PHASE4":10708,"NA":10710},{"trials":10688,"activeCount":99},[],{"trials":10690,"activeCount":99},[10691,10695],{"nctId":156,"briefTitle":157,"status":105,"phases":10692,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":10693,"interventions":10694},[88],[164],[70,112,166],{"nctId":10696,"briefTitle":10697,"status":105,"phases":10698,"primaryCompletion":10699,"completion":1028,"start":4811,"enrollment":10700,"conditions":10701,"interventions":10702},"NCT06267092","A Study of How CagriSema Works on Appetite in People With Excess Body Weight",[88],"2025-04-07",164,[33,24],[10703],"Cagrilintide and Semaglutide",{"trials":10705,"activeCount":99},[],{"trials":10707,"activeCount":99},[],{"trials":10709,"activeCount":99},[],{"trials":10711,"activeCount":99},[],{"intervention":196,"totalTrials":864,"cells":10713},{"EARLY_PHASE1":10714,"PHASE1":10716,"PHASE2":10734,"PHASE3":10736,"PHASE4":10738,"NA":10740},{"trials":10715,"activeCount":99},[],{"trials":10717,"activeCount":99},[10718,10722],{"nctId":187,"briefTitle":188,"status":105,"phases":10719,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":10720,"interventions":10721},[88],[15,18],[112,195,196],{"nctId":10723,"briefTitle":10724,"status":105,"phases":10725,"primaryCompletion":10726,"completion":4353,"start":10727,"enrollment":335,"conditions":10728,"interventions":10729},"NCT05153564","A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause",[88],"2022-08-13","2021-12-13",[18],[10730,10731,10732,10733,196],"Semaglutide 1.34 mg\u002FmL","Semaglutide 3.0 mg\u002FmL","NNC0480-0389 10 mg\u002FmL","NNC0480-0389 30 mg\u002FmL",{"trials":10735,"activeCount":99},[],{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[],{"trials":10741,"activeCount":99},[],{"intervention":10743,"totalTrials":864,"cells":10744},"NNC0113-6856",{"EARLY_PHASE1":10745,"PHASE1":10747,"PHASE2":10762,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10746,"activeCount":99},[],{"trials":10748,"activeCount":99},[10749,10755],{"nctId":10750,"briefTitle":10751,"status":105,"phases":10752,"primaryCompletion":1753,"completion":1753,"start":2952,"enrollment":276,"conditions":10753,"interventions":10754},"NCT06069895","Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants",[88],[482],[10743],{"nctId":10756,"briefTitle":10757,"status":105,"phases":10758,"primaryCompletion":7377,"completion":7377,"start":10759,"enrollment":3534,"conditions":10760,"interventions":10761},"NCT05521256","A Research Study of a New Medicine NNC0113-6856 in Healthy Males",[88],"2022-08-26",[142,862],[10743],{"trials":10763,"activeCount":99},[],{"trials":10765,"activeCount":99},[],{"trials":10767,"activeCount":99},[],{"trials":10769,"activeCount":99},[],{"intervention":5334,"totalTrials":864,"cells":10771},{"EARLY_PHASE1":10772,"PHASE1":10774,"PHASE2":10784,"PHASE3":10786,"PHASE4":10788,"NA":10790},{"trials":10773,"activeCount":99},[],{"trials":10775,"activeCount":99},[10776,10780],{"nctId":5326,"briefTitle":5327,"status":105,"phases":10777,"primaryCompletion":5329,"completion":5330,"start":5331,"enrollment":2885,"conditions":10778,"interventions":10779},[88],[15,21],[5334,5281],{"nctId":5485,"briefTitle":5486,"status":105,"phases":10781,"primaryCompletion":5488,"completion":5488,"start":5489,"enrollment":699,"conditions":10782,"interventions":10783},[88],[15,21],[5334,1978],{"trials":10785,"activeCount":99},[],{"trials":10787,"activeCount":99},[],{"trials":10789,"activeCount":99},[],{"trials":10791,"activeCount":99},[],{"intervention":10793,"totalTrials":864,"cells":10794},"Glucagon",{"EARLY_PHASE1":10795,"PHASE1":10797,"PHASE2":10816,"PHASE3":10818,"PHASE4":10820,"NA":10822},{"trials":10796,"activeCount":99},[],{"trials":10798,"activeCount":99},[10799,10807],{"nctId":10800,"briefTitle":10801,"status":105,"phases":10802,"primaryCompletion":10803,"completion":10803,"start":5919,"enrollment":2549,"conditions":10804,"interventions":10805},"NCT03444467","First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.",[88],"2018-05-24",[15,21,18],[10806,10793],"NNC9204-1513",{"nctId":10808,"briefTitle":10809,"status":105,"phases":10810,"primaryCompletion":10811,"completion":10811,"start":10812,"enrollment":578,"conditions":10813,"interventions":10814},"NCT06588504","Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents",[88],"2025-07-20","2024-09-10",[21],[10815,10793],"Dasiglucagon",{"trials":10817,"activeCount":99},[],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[],{"trials":10823,"activeCount":99},[],{"intervention":5412,"totalTrials":864,"cells":10825},{"EARLY_PHASE1":10826,"PHASE1":10828,"PHASE2":10840,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10827,"activeCount":99},[],{"trials":10829,"activeCount":99},[10830,10836],{"nctId":10831,"briefTitle":10832,"status":105,"phases":10833,"primaryCompletion":5580,"completion":5580,"start":5765,"enrollment":223,"conditions":10834,"interventions":10835},"NCT01865331","Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects",[88],[15,27],[1919,5412],{"nctId":5403,"briefTitle":5404,"status":105,"phases":10837,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":10838,"interventions":10839},[88],[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],{"trials":10841,"activeCount":99},[],{"trials":10843,"activeCount":99},[],{"trials":10845,"activeCount":99},[],{"trials":10847,"activeCount":99},[],{"intervention":10849,"totalTrials":864,"cells":10850},"NNC0363-0845",{"EARLY_PHASE1":10851,"PHASE1":10853,"PHASE2":10871,"PHASE3":10873,"PHASE4":10875,"NA":10877},{"trials":10852,"activeCount":99},[],{"trials":10854,"activeCount":99},[10855,10863],{"nctId":10856,"briefTitle":10857,"status":105,"phases":10858,"primaryCompletion":10859,"completion":10859,"start":10860,"enrollment":34,"conditions":10861,"interventions":10862},"NCT04569994","A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes",[88],"2021-06-23","2020-09-30",[142,21],[10849,1887],{"nctId":10864,"briefTitle":10865,"status":105,"phases":10866,"primaryCompletion":10867,"completion":10867,"start":10868,"enrollment":119,"conditions":10869,"interventions":10870},"NCT05134987","A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works",[88],"2022-05-06","2021-12-01",[21],[10849,5810],{"trials":10872,"activeCount":99},[],{"trials":10874,"activeCount":99},[],{"trials":10876,"activeCount":99},[],{"trials":10878,"activeCount":99},[],{"intervention":366,"totalTrials":864,"cells":10880},{"EARLY_PHASE1":10881,"PHASE1":10883,"PHASE2":10893,"PHASE3":10895,"PHASE4":10897,"NA":10899},{"trials":10882,"activeCount":99},[],{"trials":10884,"activeCount":99},[10885,10889],{"nctId":3531,"briefTitle":3532,"status":105,"phases":10886,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":3534,"conditions":10887,"interventions":10888},[88],[15,27],[768,557,366,3537,227],{"nctId":358,"briefTitle":359,"status":105,"phases":10890,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":10891,"interventions":10892},[88],[15,27],[112,366,309],{"trials":10894,"activeCount":99},[],{"trials":10896,"activeCount":99},[],{"trials":10898,"activeCount":99},[],{"trials":10900,"activeCount":99},[],{"intervention":290,"totalTrials":864,"cells":10902},{"EARLY_PHASE1":10903,"PHASE1":10905,"PHASE2":10919,"PHASE3":10921,"PHASE4":10923,"NA":10925},{"trials":10904,"activeCount":99},[],{"trials":10906,"activeCount":99},[10907,10911],{"nctId":280,"briefTitle":281,"status":105,"phases":10908,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":10909,"interventions":10910},[88],[287,288],[290,75],{"nctId":10912,"briefTitle":10913,"status":105,"phases":10914,"primaryCompletion":10915,"completion":10915,"start":10916,"enrollment":8417,"conditions":10917,"interventions":10918},"NCT02568306","A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects",[88],"2017-02-07","2015-10-05",[204,24],[290],{"trials":10920,"activeCount":99},[],{"trials":10922,"activeCount":99},[],{"trials":10924,"activeCount":99},[],{"trials":10926,"activeCount":99},[],{"intervention":6354,"totalTrials":864,"cells":10928},{"EARLY_PHASE1":10929,"PHASE1":10931,"PHASE2":10941,"PHASE3":10943,"PHASE4":10945,"NA":10947},{"trials":10930,"activeCount":99},[],{"trials":10932,"activeCount":99},[10933,10937],{"nctId":6346,"briefTitle":6347,"status":105,"phases":10934,"primaryCompletion":6349,"completion":2869,"start":6350,"enrollment":2885,"conditions":10935,"interventions":10936},[88],[18],[842,6353,6354],{"nctId":3711,"briefTitle":3712,"status":105,"phases":10938,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":1846,"conditions":10939,"interventions":10940},[88],[15,18],[768,3718],{"trials":10942,"activeCount":99},[],{"trials":10944,"activeCount":99},[],{"trials":10946,"activeCount":99},[],{"trials":10948,"activeCount":99},[],{"intervention":10950,"totalTrials":864,"cells":10951},"NNC0385-0434 B",{"EARLY_PHASE1":10952,"PHASE1":10954,"PHASE2":10985,"PHASE3":10987,"PHASE4":10989,"NA":10991},{"trials":10953,"activeCount":99},[],{"trials":10955,"activeCount":99},[10956,10974],{"nctId":10957,"briefTitle":10958,"status":105,"phases":10959,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":10964,"interventions":10966},"NCT05129891","A Research Study Looking at New Protein-based Tablets in Healthy Male Participants",[88],"2023-02-26","2023-05-04","2021-11-03",384,[142,10965,862],"High Blood Cholesterol Levels",[10967,10968,10969,10970,10950,10971,10972,10973],"Semaglutide D","Semaglutide G","Semaglutide H","Semaglutide I","NNC0385-0434 C","NNC0385-0434 D","NNC0385-0434 E",{"nctId":10975,"briefTitle":10976,"status":105,"phases":10977,"primaryCompletion":8374,"completion":10978,"start":10979,"enrollment":140,"conditions":10980,"interventions":10982},"NCT05333107","A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II",[88],"2022-09-23","2022-04-12",[10981],"Healthy Volunteers; High Cholesterol",[10983,10984,10950],"NNC0385-0434 G","NNC0385-0434 F",{"trials":10986,"activeCount":99},[],{"trials":10988,"activeCount":99},[],{"trials":10990,"activeCount":99},[],{"trials":10992,"activeCount":99},[],{"intervention":10994,"totalTrials":864,"cells":10995},"NNC0215-0384",{"EARLY_PHASE1":10996,"PHASE1":10998,"PHASE2":11013,"PHASE3":11015,"PHASE4":11017,"NA":11019},{"trials":10997,"activeCount":99},[],{"trials":10999,"activeCount":99},[11000,11007],{"nctId":11001,"briefTitle":11002,"status":105,"phases":11003,"primaryCompletion":3970,"completion":3970,"start":11004,"enrollment":2549,"conditions":11005,"interventions":11006},"NCT01611688","First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis",[88],"2012-06-04",[3066,9279],[10994,10994],{"nctId":11008,"briefTitle":11009,"status":105,"phases":11010,"primaryCompletion":402,"completion":402,"start":2133,"enrollment":306,"conditions":11011,"interventions":11012},"NCT01955603","A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis",[88],[3066,9279],[10994],{"trials":11014,"activeCount":99},[],{"trials":11016,"activeCount":99},[],{"trials":11018,"activeCount":99},[],{"trials":11020,"activeCount":99},[],{"intervention":11022,"totalTrials":864,"cells":11023},"Semaglutide B, 1.34 mg\u002FmL",{"EARLY_PHASE1":11024,"PHASE1":11026,"PHASE2":11044,"PHASE3":11046,"PHASE4":11048,"NA":11050},{"trials":11025,"activeCount":99},[],{"trials":11027,"activeCount":99},[11028,11036],{"nctId":11029,"briefTitle":11030,"status":105,"phases":11031,"primaryCompletion":1109,"completion":1109,"start":11032,"enrollment":372,"conditions":11033,"interventions":11034},"NCT05689099","A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose",[88],"2023-01-17",[18,482],[11022,11035],"Semaglutide B, 0.68 mg\u002FmL",{"nctId":11037,"briefTitle":11038,"status":105,"phases":11039,"primaryCompletion":11040,"completion":11040,"start":159,"enrollment":1846,"conditions":11041,"interventions":11042},"NCT05232708","A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide",[88],"2022-08-30",[6362],[11022,11043,11043,11022],"Semaglutide D, 1.0 mg\u002FmL",{"trials":11045,"activeCount":99},[],{"trials":11047,"activeCount":99},[],{"trials":11049,"activeCount":99},[],{"trials":11051,"activeCount":99},[],{"intervention":11053,"totalTrials":864,"cells":11054},"NNC172-2021",{"EARLY_PHASE1":11055,"PHASE1":11057,"PHASE2":11075,"PHASE3":11077,"PHASE4":11079,"NA":11081},{"trials":11056,"activeCount":99},[],{"trials":11058,"activeCount":99},[11059,11067],{"nctId":11060,"briefTitle":11061,"status":349,"phases":11062,"primaryCompletion":11063,"completion":11063,"start":11064,"enrollment":713,"conditions":11065,"interventions":11066},"NCT01631942","A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects",[88],"2012-09-04","2012-06-26",[30,36,27],[11053],{"nctId":11068,"briefTitle":11069,"status":105,"phases":11070,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":2683,"conditions":11073,"interventions":11074},"NCT01555749","Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects",[88],"2012-05-08","2012-03-12",[30,36,2137,27],[11053],{"trials":11076,"activeCount":99},[],{"trials":11078,"activeCount":99},[],{"trials":11080,"activeCount":99},[],{"trials":11082,"activeCount":99},[],{"intervention":5411,"totalTrials":864,"cells":11084},{"EARLY_PHASE1":11085,"PHASE1":11087,"PHASE2":11097,"PHASE3":11099,"PHASE4":11101,"NA":11103},{"trials":11086,"activeCount":99},[],{"trials":11088,"activeCount":99},[11089,11093],{"nctId":5403,"briefTitle":5404,"status":105,"phases":11090,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":11091,"interventions":11092},[88],[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],{"nctId":5467,"briefTitle":5468,"status":105,"phases":11094,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":11095,"interventions":11096},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"trials":11098,"activeCount":99},[],{"trials":11100,"activeCount":99},[],{"trials":11102,"activeCount":99},[],{"trials":11104,"activeCount":99},[],{"intervention":5431,"totalTrials":864,"cells":11106},{"EARLY_PHASE1":11107,"PHASE1":11109,"PHASE2":11119,"PHASE3":11121,"PHASE4":11123,"NA":11125},{"trials":11108,"activeCount":99},[],{"trials":11110,"activeCount":99},[11111,11115],{"nctId":5422,"briefTitle":5423,"status":105,"phases":11112,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":5428,"conditions":11113,"interventions":11114},[88],[18],[5431,5281],{"nctId":5500,"briefTitle":5501,"status":105,"phases":11116,"primaryCompletion":5503,"completion":5504,"start":2713,"enrollment":653,"conditions":11117,"interventions":11118},[88],[21],[5431,1311],{"trials":11120,"activeCount":99},[],{"trials":11122,"activeCount":99},[],{"trials":11124,"activeCount":99},[],{"trials":11126,"activeCount":99},[],{"intervention":11128,"totalTrials":864,"cells":11129},"Semaglutide D Dose 1",{"EARLY_PHASE1":11130,"PHASE1":11132,"PHASE2":11160,"PHASE3":11162,"PHASE4":11164,"NA":11166},{"trials":11131,"activeCount":99},[],{"trials":11133,"activeCount":99},[11134,11149],{"nctId":11135,"briefTitle":11136,"status":105,"phases":11137,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":11142,"interventions":11143},"NCT05227196","A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People",[88],"2023-06-28","2023-08-08","2022-02-04",546,[142,862],[11128,11144,11145,11146,11147,11148],"Semaglutide D Dose 2","Semaglutide D Dose 3","Semaglutide Dose 4","Semaglutide Dose 5","Semaglutide Dose 6",{"nctId":11150,"briefTitle":11151,"status":105,"phases":11152,"primaryCompletion":11153,"completion":11154,"start":11155,"enrollment":4439,"conditions":11156,"interventions":11157},"NCT05236517","A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity",[88],"2022-09-29","2022-11-07","2022-02-08",[24],[11128,11144,11145,11158,11159],"Semaglutide C Dose 4","Semaglutide C Dose 5",{"trials":11161,"activeCount":99},[],{"trials":11163,"activeCount":99},[],{"trials":11165,"activeCount":99},[],{"trials":11167,"activeCount":99},[],{"intervention":11144,"totalTrials":864,"cells":11169},{"EARLY_PHASE1":11170,"PHASE1":11172,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11188},{"trials":11171,"activeCount":99},[],{"trials":11173,"activeCount":99},[11174,11178],{"nctId":11135,"briefTitle":11136,"status":105,"phases":11175,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":11176,"interventions":11177},[88],[142,862],[11128,11144,11145,11146,11147,11148],{"nctId":11150,"briefTitle":11151,"status":105,"phases":11179,"primaryCompletion":11153,"completion":11154,"start":11155,"enrollment":4439,"conditions":11180,"interventions":11181},[88],[24],[11128,11144,11145,11158,11159],{"trials":11183,"activeCount":99},[],{"trials":11185,"activeCount":99},[],{"trials":11187,"activeCount":99},[],{"trials":11189,"activeCount":99},[],{"intervention":11145,"totalTrials":864,"cells":11191},{"EARLY_PHASE1":11192,"PHASE1":11194,"PHASE2":11204,"PHASE3":11206,"PHASE4":11208,"NA":11210},{"trials":11193,"activeCount":99},[],{"trials":11195,"activeCount":99},[11196,11200],{"nctId":11135,"briefTitle":11136,"status":105,"phases":11197,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":11198,"interventions":11199},[88],[142,862],[11128,11144,11145,11146,11147,11148],{"nctId":11150,"briefTitle":11151,"status":105,"phases":11201,"primaryCompletion":11153,"completion":11154,"start":11155,"enrollment":4439,"conditions":11202,"interventions":11203},[88],[24],[11128,11144,11145,11158,11159],{"trials":11205,"activeCount":99},[],{"trials":11207,"activeCount":99},[],{"trials":11209,"activeCount":99},[],{"trials":11211,"activeCount":99},[],{"intervention":11213,"totalTrials":864,"cells":11214},"semaglutide 1.34 mg\u002FmL",{"EARLY_PHASE1":11215,"PHASE1":11217,"PHASE2":11232,"PHASE3":11234,"PHASE4":11236,"NA":11238},{"trials":11216,"activeCount":99},[],{"trials":11218,"activeCount":99},[11219,11228],{"nctId":11220,"briefTitle":11221,"status":105,"phases":11222,"primaryCompletion":11223,"completion":11223,"start":8301,"enrollment":5006,"conditions":11224,"interventions":11225},"NCT05046873","A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People",[88],"2022-01-05",[18],[11226,11213,10730,11227],"Co-formulation NNC0480 0389+Semaglutide A 10\u002F1 mg\u002FmL","NNC0480-0389 A 10 mg\u002FmL",{"nctId":10723,"briefTitle":10724,"status":105,"phases":11229,"primaryCompletion":10726,"completion":4353,"start":10727,"enrollment":335,"conditions":11230,"interventions":11231},[88],[18],[10730,10731,10732,10733,196],{"trials":11233,"activeCount":99},[],{"trials":11235,"activeCount":99},[],{"trials":11237,"activeCount":99},[],{"trials":11239,"activeCount":99},[],{"intervention":5472,"totalTrials":864,"cells":11241},{"EARLY_PHASE1":11242,"PHASE1":11244,"PHASE2":11254,"PHASE3":11256,"PHASE4":11258,"NA":11260},{"trials":11243,"activeCount":99},[],{"trials":11245,"activeCount":99},[11246,11250],{"nctId":5467,"briefTitle":5468,"status":105,"phases":11247,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":11248,"interventions":11249},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"nctId":10541,"briefTitle":10542,"status":105,"phases":11251,"primaryCompletion":4015,"completion":4015,"start":6177,"enrollment":223,"conditions":11252,"interventions":11253},[88],[15,27],[1919,5410,5472],{"trials":11255,"activeCount":99},[],{"trials":11257,"activeCount":99},[],{"trials":11259,"activeCount":99},[],{"trials":11261,"activeCount":99},[],{"intervention":11263,"totalTrials":864,"cells":11264},"NNC9204-1177",{"EARLY_PHASE1":11265,"PHASE1":11267,"PHASE2":11285,"PHASE3":11287,"PHASE4":11289,"NA":11291},{"trials":11266,"activeCount":99},[],{"trials":11268,"activeCount":99},[11269,11278],{"nctId":11270,"briefTitle":11271,"status":105,"phases":11272,"primaryCompletion":11273,"completion":11273,"start":11274,"enrollment":266,"conditions":11275,"interventions":11276},"NCT04059367","Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People",[88],"2020-01-02","2019-08-15",[142,33,24],[11263,11277],"Cocktail of 5 already approved drugs",{"nctId":11279,"briefTitle":11280,"status":105,"phases":11281,"primaryCompletion":11282,"completion":11282,"start":265,"enrollment":1926,"conditions":11283,"interventions":11284},"NCT02941042","A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.",[88],"2017-09-30",[204,24],[11263],{"trials":11286,"activeCount":99},[],{"trials":11288,"activeCount":99},[],{"trials":11290,"activeCount":99},[],{"trials":11292,"activeCount":99},[],{"intervention":628,"totalTrials":864,"cells":11294},{"EARLY_PHASE1":11295,"PHASE1":11297,"PHASE2":11307,"PHASE3":11309,"PHASE4":11311,"NA":11313},{"trials":11296,"activeCount":99},[],{"trials":11298,"activeCount":99},[11299,11303],{"nctId":618,"briefTitle":619,"status":105,"phases":11300,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":11301,"interventions":11302},[88],[15,27],[627,628,195,75],{"nctId":5030,"briefTitle":5031,"status":105,"phases":11304,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":11305,"interventions":11306},[88],[5008],[4985,5036,5037,1478,5038,628],{"trials":11308,"activeCount":99},[],{"trials":11310,"activeCount":99},[],{"trials":11312,"activeCount":99},[],{"trials":11314,"activeCount":99},[],{"intervention":2175,"totalTrials":864,"cells":11316},{"EARLY_PHASE1":11317,"PHASE1":11319,"PHASE2":11331,"PHASE3":11333,"PHASE4":11335,"NA":11337},{"trials":11318,"activeCount":99},[],{"trials":11320,"activeCount":99},[11321,11325],{"nctId":2168,"briefTitle":2169,"status":349,"phases":11322,"primaryCompletion":489,"completion":489,"start":2171,"enrollment":2172,"conditions":11323,"interventions":11324},[88],[2165,27],[2122,2175],{"nctId":11326,"briefTitle":11327,"status":105,"phases":11328,"primaryCompletion":3901,"completion":3901,"start":6177,"enrollment":1846,"conditions":11329,"interventions":11330},"NCT01603342","A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers",[88],[2165,27],[2175],{"trials":11332,"activeCount":99},[],{"trials":11334,"activeCount":99},[],{"trials":11336,"activeCount":99},[],{"trials":11338,"activeCount":99},[],{"intervention":11340,"totalTrials":1606,"cells":11341},"MEDI5117",{"EARLY_PHASE1":11342,"PHASE1":11344,"PHASE2":11355,"PHASE3":11357,"PHASE4":11359,"NA":11361},{"trials":11343,"activeCount":99},[],{"trials":11345,"activeCount":99},[11346],{"nctId":11347,"briefTitle":11348,"status":349,"phases":11349,"primaryCompletion":11350,"completion":11350,"start":11351,"enrollment":4430,"conditions":11352,"interventions":11353},"NCT01559103","Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients",[88],"2014-02-28","2012-05-31",[9279],[11340,11354],"MEDI5117 Placebo",{"trials":11356,"activeCount":99},[],{"trials":11358,"activeCount":99},[],{"trials":11360,"activeCount":99},[],{"trials":11362,"activeCount":99},[],{"intervention":11354,"totalTrials":1606,"cells":11364},{"EARLY_PHASE1":11365,"PHASE1":11367,"PHASE2":11373,"PHASE3":11375,"PHASE4":11377,"NA":11379},{"trials":11366,"activeCount":99},[],{"trials":11368,"activeCount":99},[11369],{"nctId":11347,"briefTitle":11348,"status":349,"phases":11370,"primaryCompletion":11350,"completion":11350,"start":11351,"enrollment":4430,"conditions":11371,"interventions":11372},[88],[9279],[11340,11354],{"trials":11374,"activeCount":99},[],{"trials":11376,"activeCount":99},[],{"trials":11378,"activeCount":99},[],{"trials":11380,"activeCount":99},[],{"intervention":11382,"totalTrials":1606,"cells":11383},"sodium chloride 0.9% solution",{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11394,"PHASE3":11396,"PHASE4":11398,"NA":11400},{"trials":11385,"activeCount":99},[],{"trials":11387,"activeCount":99},[11388],{"nctId":11389,"briefTitle":11390,"status":105,"phases":11391,"primaryCompletion":4391,"completion":4391,"start":333,"enrollment":5519,"conditions":11392,"interventions":11393},"NCT01680328","Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations",[88],[15,21,18,4478],[11382],{"trials":11395,"activeCount":99},[],{"trials":11397,"activeCount":99},[],{"trials":11399,"activeCount":99},[],{"trials":11401,"activeCount":99},[],{"intervention":7250,"totalTrials":1606,"cells":11403},{"EARLY_PHASE1":11404,"PHASE1":11406,"PHASE2":11412,"PHASE3":11414,"PHASE4":11416,"NA":11418},{"trials":11405,"activeCount":99},[],{"trials":11407,"activeCount":99},[11408],{"nctId":7245,"briefTitle":7246,"status":105,"phases":11409,"primaryCompletion":128,"completion":128,"start":3586,"enrollment":992,"conditions":11410,"interventions":11411},[88],[30,36],[7250,7238],{"trials":11413,"activeCount":99},[],{"trials":11415,"activeCount":99},[],{"trials":11417,"activeCount":99},[],{"trials":11419,"activeCount":99},[],{"intervention":11421,"totalTrials":1606,"cells":11422},"Semaglutide, 0.5 mg\u002FmL",{"EARLY_PHASE1":11423,"PHASE1":11425,"PHASE2":11437,"PHASE3":11439,"PHASE4":11441,"NA":11443},{"trials":11424,"activeCount":99},[],{"trials":11426,"activeCount":99},[11427],{"nctId":11428,"briefTitle":11429,"status":105,"phases":11430,"primaryCompletion":118,"completion":118,"start":11431,"enrollment":34,"conditions":11432,"interventions":11433},"NCT03598621","A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools",[88],"2018-07-23",[18],[11421,11434,11435,11436],"Semaglutide, 1.0 mg\u002FmL","Semaglutide, 1.34 mg\u002FmL","Semaglutide, 2.0 mg\u002FmL",{"trials":11438,"activeCount":99},[],{"trials":11440,"activeCount":99},[],{"trials":11442,"activeCount":99},[],{"trials":11444,"activeCount":99},[],{"intervention":11434,"totalTrials":1606,"cells":11446},{"EARLY_PHASE1":11447,"PHASE1":11449,"PHASE2":11455,"PHASE3":11457,"PHASE4":11459,"NA":11461},{"trials":11448,"activeCount":99},[],{"trials":11450,"activeCount":99},[11451],{"nctId":11428,"briefTitle":11429,"status":105,"phases":11452,"primaryCompletion":118,"completion":118,"start":11431,"enrollment":34,"conditions":11453,"interventions":11454},[88],[18],[11421,11434,11435,11436],{"trials":11456,"activeCount":99},[],{"trials":11458,"activeCount":99},[],{"trials":11460,"activeCount":99},[],{"trials":11462,"activeCount":99},[],{"intervention":11435,"totalTrials":1606,"cells":11464},{"EARLY_PHASE1":11465,"PHASE1":11467,"PHASE2":11473,"PHASE3":11475,"PHASE4":11477,"NA":11479},{"trials":11466,"activeCount":99},[],{"trials":11468,"activeCount":99},[11469],{"nctId":11428,"briefTitle":11429,"status":105,"phases":11470,"primaryCompletion":118,"completion":118,"start":11431,"enrollment":34,"conditions":11471,"interventions":11472},[88],[18],[11421,11434,11435,11436],{"trials":11474,"activeCount":99},[],{"trials":11476,"activeCount":99},[],{"trials":11478,"activeCount":99},[],{"trials":11480,"activeCount":99},[],{"intervention":11436,"totalTrials":1606,"cells":11482},{"EARLY_PHASE1":11483,"PHASE1":11485,"PHASE2":11491,"PHASE3":11493,"PHASE4":11495,"NA":11497},{"trials":11484,"activeCount":99},[],{"trials":11486,"activeCount":99},[11487],{"nctId":11428,"briefTitle":11429,"status":105,"phases":11488,"primaryCompletion":118,"completion":118,"start":11431,"enrollment":34,"conditions":11489,"interventions":11490},[88],[18],[11421,11434,11435,11436],{"trials":11492,"activeCount":99},[],{"trials":11494,"activeCount":99},[],{"trials":11496,"activeCount":99},[],{"trials":11498,"activeCount":99},[],{"intervention":122,"totalTrials":1606,"cells":11500},{"EARLY_PHASE1":11501,"PHASE1":11503,"PHASE2":11509,"PHASE3":11511,"PHASE4":11513,"NA":11515},{"trials":11502,"activeCount":99},[],{"trials":11504,"activeCount":99},[11505],{"nctId":114,"briefTitle":115,"status":105,"phases":11506,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":11507,"interventions":11508},[88],[18],[122,75,123],{"trials":11510,"activeCount":99},[],{"trials":11512,"activeCount":99},[],{"trials":11514,"activeCount":99},[],{"trials":11516,"activeCount":99},[],{"intervention":123,"totalTrials":1606,"cells":11518},{"EARLY_PHASE1":11519,"PHASE1":11521,"PHASE2":11527,"PHASE3":11529,"PHASE4":11531,"NA":11533},{"trials":11520,"activeCount":99},[],{"trials":11522,"activeCount":99},[11523],{"nctId":114,"briefTitle":115,"status":105,"phases":11524,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":11525,"interventions":11526},[88],[18],[122,75,123],{"trials":11528,"activeCount":99},[],{"trials":11530,"activeCount":99},[],{"trials":11532,"activeCount":99},[],{"trials":11534,"activeCount":99},[],{"intervention":11536,"totalTrials":1606,"cells":11537},"NNC0113-6861",{"EARLY_PHASE1":11538,"PHASE1":11540,"PHASE2":11551,"PHASE3":11553,"PHASE4":11555,"NA":11557},{"trials":11539,"activeCount":99},[],{"trials":11541,"activeCount":99},[11542],{"nctId":11543,"briefTitle":11544,"status":105,"phases":11545,"primaryCompletion":1270,"completion":1270,"start":11546,"enrollment":1846,"conditions":11547,"interventions":11548},"NCT04676906","A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds",[88],"2020-11-26",[142,862],[11536,11549,11550],"NNC0113-6860","NNC0113-6891",{"trials":11552,"activeCount":99},[],{"trials":11554,"activeCount":99},[],{"trials":11556,"activeCount":99},[],{"trials":11558,"activeCount":99},[],{"intervention":11549,"totalTrials":1606,"cells":11560},{"EARLY_PHASE1":11561,"PHASE1":11563,"PHASE2":11569,"PHASE3":11571,"PHASE4":11573,"NA":11575},{"trials":11562,"activeCount":99},[],{"trials":11564,"activeCount":99},[11565],{"nctId":11543,"briefTitle":11544,"status":105,"phases":11566,"primaryCompletion":1270,"completion":1270,"start":11546,"enrollment":1846,"conditions":11567,"interventions":11568},[88],[142,862],[11536,11549,11550],{"trials":11570,"activeCount":99},[],{"trials":11572,"activeCount":99},[],{"trials":11574,"activeCount":99},[],{"trials":11576,"activeCount":99},[],{"intervention":11550,"totalTrials":1606,"cells":11578},{"EARLY_PHASE1":11579,"PHASE1":11581,"PHASE2":11587,"PHASE3":11589,"PHASE4":11591,"NA":11593},{"trials":11580,"activeCount":99},[],{"trials":11582,"activeCount":99},[11583],{"nctId":11543,"briefTitle":11544,"status":105,"phases":11584,"primaryCompletion":1270,"completion":1270,"start":11546,"enrollment":1846,"conditions":11585,"interventions":11586},[88],[142,862],[11536,11549,11550],{"trials":11588,"activeCount":99},[],{"trials":11590,"activeCount":99},[],{"trials":11592,"activeCount":99},[],{"trials":11594,"activeCount":99},[],{"intervention":144,"totalTrials":1606,"cells":11596},{"EARLY_PHASE1":11597,"PHASE1":11599,"PHASE2":11605,"PHASE3":11607,"PHASE4":11609,"NA":11611},{"trials":11598,"activeCount":99},[],{"trials":11600,"activeCount":99},[11601],{"nctId":134,"briefTitle":135,"status":105,"phases":11602,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":11603,"interventions":11604},[88],[142],[75,144,145],{"trials":11606,"activeCount":99},[],{"trials":11608,"activeCount":99},[],{"trials":11610,"activeCount":99},[],{"trials":11612,"activeCount":99},[],{"intervention":145,"totalTrials":1606,"cells":11614},{"EARLY_PHASE1":11615,"PHASE1":11617,"PHASE2":11623,"PHASE3":11625,"PHASE4":11627,"NA":11629},{"trials":11616,"activeCount":99},[],{"trials":11618,"activeCount":99},[11619],{"nctId":134,"briefTitle":135,"status":105,"phases":11620,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":11621,"interventions":11622},[88],[142],[75,144,145],{"trials":11624,"activeCount":99},[],{"trials":11626,"activeCount":99},[],{"trials":11628,"activeCount":99},[],{"trials":11630,"activeCount":99},[],{"intervention":11632,"totalTrials":1606,"cells":11633},"NNC 0172-0000-2021",{"EARLY_PHASE1":11634,"PHASE1":11636,"PHASE2":11646,"PHASE3":11648,"PHASE4":11650,"NA":11652},{"trials":11635,"activeCount":99},[],{"trials":11637,"activeCount":99},[11638],{"nctId":11639,"briefTitle":11640,"status":105,"phases":11641,"primaryCompletion":11642,"completion":11642,"start":11643,"enrollment":363,"conditions":11644,"interventions":11645},"NCT01228669","Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B",[88],"2012-09-10","2010-10-25",[30,36,2137,27],[11632,11632],{"trials":11647,"activeCount":99},[],{"trials":11649,"activeCount":99},[],{"trials":11651,"activeCount":99},[],{"trials":11653,"activeCount":99},[],{"intervention":10442,"totalTrials":1606,"cells":11655},{"EARLY_PHASE1":11656,"PHASE1":11658,"PHASE2":11664,"PHASE3":11666,"PHASE4":11668,"NA":11670},{"trials":11657,"activeCount":99},[],{"trials":11659,"activeCount":99},[11660],{"nctId":10436,"briefTitle":10437,"status":105,"phases":11661,"primaryCompletion":1205,"completion":1205,"start":10439,"enrollment":451,"conditions":11662,"interventions":11663},[88],[24],[10429,10442],{"trials":11665,"activeCount":99},[],{"trials":11667,"activeCount":99},[],{"trials":11669,"activeCount":99},[],{"trials":11671,"activeCount":99},[],{"intervention":8378,"totalTrials":1606,"cells":11673},{"EARLY_PHASE1":11674,"PHASE1":11676,"PHASE2":11682,"PHASE3":11684,"PHASE4":11686,"NA":11688},{"trials":11675,"activeCount":99},[],{"trials":11677,"activeCount":99},[11678],{"nctId":8370,"briefTitle":8371,"status":105,"phases":11679,"primaryCompletion":8373,"completion":8374,"start":3186,"enrollment":992,"conditions":11680,"interventions":11681},[88],[21,18],[8377,8378],{"trials":11683,"activeCount":99},[],{"trials":11685,"activeCount":99},[],{"trials":11687,"activeCount":99},[],{"trials":11689,"activeCount":99},[],{"intervention":6554,"totalTrials":1606,"cells":11691},{"EARLY_PHASE1":11692,"PHASE1":11694,"PHASE2":11700,"PHASE3":11702,"PHASE4":11704,"NA":11706},{"trials":11693,"activeCount":99},[],{"trials":11695,"activeCount":99},[11696],{"nctId":6547,"briefTitle":6548,"status":105,"phases":11697,"primaryCompletion":6550,"completion":6550,"start":6551,"enrollment":306,"conditions":11698,"interventions":11699},[88],[215],[257,257,6554],{"trials":11701,"activeCount":99},[],{"trials":11703,"activeCount":99},[],{"trials":11705,"activeCount":99},[],{"trials":11707,"activeCount":99},[],{"intervention":5347,"totalTrials":1606,"cells":11709},{"EARLY_PHASE1":11710,"PHASE1":11712,"PHASE2":11718,"PHASE3":11720,"PHASE4":11722,"NA":11724},{"trials":11711,"activeCount":99},[],{"trials":11713,"activeCount":99},[11714],{"nctId":5342,"briefTitle":5343,"status":105,"phases":11715,"primaryCompletion":2204,"completion":2204,"start":3462,"enrollment":130,"conditions":11716,"interventions":11717},[88],[15,21,18,27],[5347,1978,5347,1978],{"trials":11719,"activeCount":99},[],{"trials":11721,"activeCount":99},[],{"trials":11723,"activeCount":99},[],{"trials":11725,"activeCount":99},[],{"intervention":11727,"totalTrials":1606,"cells":11728},"NNC0582-0001",{"EARLY_PHASE1":11729,"PHASE1":11731,"PHASE2":11741,"PHASE3":11743,"PHASE4":11745,"NA":11747},{"trials":11730,"activeCount":99},[],{"trials":11732,"activeCount":99},[11733],{"nctId":11734,"briefTitle":11735,"status":105,"phases":11736,"primaryCompletion":11737,"completion":11737,"start":11738,"enrollment":673,"conditions":11739,"interventions":11740},"NCT05624580","A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults",[88],"2025-10-16","2022-11-15",[142],[11727],{"trials":11742,"activeCount":99},[],{"trials":11744,"activeCount":99},[],{"trials":11746,"activeCount":99},[],{"trials":11748,"activeCount":99},[],{"intervention":10806,"totalTrials":1606,"cells":11750},{"EARLY_PHASE1":11751,"PHASE1":11753,"PHASE2":11759,"PHASE3":11761,"PHASE4":11763,"NA":11765},{"trials":11752,"activeCount":99},[],{"trials":11754,"activeCount":99},[11755],{"nctId":10800,"briefTitle":10801,"status":105,"phases":11756,"primaryCompletion":10803,"completion":10803,"start":5919,"enrollment":2549,"conditions":11757,"interventions":11758},[88],[15,21,18],[10806,10793],{"trials":11760,"activeCount":99},[],{"trials":11762,"activeCount":99},[],{"trials":11764,"activeCount":99},[],{"trials":11766,"activeCount":99},[],{"intervention":258,"totalTrials":1606,"cells":11768},{"EARLY_PHASE1":11769,"PHASE1":11771,"PHASE2":11777,"PHASE3":11779,"PHASE4":11781,"NA":11783},{"trials":11770,"activeCount":99},[],{"trials":11772,"activeCount":99},[11773],{"nctId":247,"briefTitle":248,"status":105,"phases":11774,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":11775,"interventions":11776},[88],[255],[257,75,258,258],{"trials":11778,"activeCount":99},[],{"trials":11780,"activeCount":99},[],{"trials":11782,"activeCount":99},[],{"trials":11784,"activeCount":99},[],{"intervention":11786,"totalTrials":1606,"cells":11787},"NNC0174 0833",{"EARLY_PHASE1":11788,"PHASE1":11790,"PHASE2":11799,"PHASE3":11801,"PHASE4":11803,"NA":11805},{"trials":11789,"activeCount":99},[],{"trials":11791,"activeCount":99},[11792],{"nctId":11793,"briefTitle":11794,"status":105,"phases":11795,"primaryCompletion":11796,"completion":11796,"start":8384,"enrollment":306,"conditions":11797,"interventions":11798},"NCT05254158","A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity",[88],"2022-09-07",[9058],[11786],{"trials":11800,"activeCount":99},[],{"trials":11802,"activeCount":99},[],{"trials":11804,"activeCount":99},[],{"trials":11806,"activeCount":99},[],{"intervention":269,"totalTrials":1606,"cells":11808},{"EARLY_PHASE1":11809,"PHASE1":11811,"PHASE2":11817,"PHASE3":11819,"PHASE4":11821,"NA":11823},{"trials":11810,"activeCount":99},[],{"trials":11812,"activeCount":99},[11813],{"nctId":260,"briefTitle":261,"status":105,"phases":11814,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":11815,"interventions":11816},[88],[15,27],[75,195,269],{"trials":11818,"activeCount":99},[],{"trials":11820,"activeCount":99},[],{"trials":11822,"activeCount":99},[],{"trials":11824,"activeCount":99},[],{"intervention":11826,"totalTrials":1606,"cells":11827},"NNC9204-1706",{"EARLY_PHASE1":11828,"PHASE1":11830,"PHASE2":11840,"PHASE3":11842,"PHASE4":11844,"NA":11846},{"trials":11829,"activeCount":99},[],{"trials":11831,"activeCount":99},[11832],{"nctId":11833,"briefTitle":11834,"status":105,"phases":11835,"primaryCompletion":11836,"completion":11837,"start":1729,"enrollment":4439,"conditions":11838,"interventions":11839},"NCT03661879","Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity",[88],"2019-09-05","2019-10-09",[204,24],[11826],{"trials":11841,"activeCount":99},[],{"trials":11843,"activeCount":99},[],{"trials":11845,"activeCount":99},[],{"trials":11847,"activeCount":99},[],{"intervention":11849,"totalTrials":1606,"cells":11850},"NNC0113-2023",{"EARLY_PHASE1":11851,"PHASE1":11853,"PHASE2":11863,"PHASE3":11865,"PHASE4":11867,"NA":11869},{"trials":11852,"activeCount":99},[],{"trials":11854,"activeCount":99},[11855],{"nctId":11856,"briefTitle":11857,"status":105,"phases":11858,"primaryCompletion":11859,"completion":11859,"start":11860,"enrollment":162,"conditions":11861,"interventions":11862},"NCT03617081","First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.",[88],"2018-12-13","2018-08-09",[18],[11849],{"trials":11864,"activeCount":99},[],{"trials":11866,"activeCount":99},[],{"trials":11868,"activeCount":99},[],{"trials":11870,"activeCount":99},[],{"intervention":8577,"totalTrials":1606,"cells":11872},{"EARLY_PHASE1":11873,"PHASE1":11875,"PHASE2":11881,"PHASE3":11883,"PHASE4":11885,"NA":11887},{"trials":11874,"activeCount":99},[],{"trials":11876,"activeCount":99},[11877],{"nctId":8571,"briefTitle":8572,"status":105,"phases":11878,"primaryCompletion":243,"completion":1613,"start":8574,"enrollment":3074,"conditions":11879,"interventions":11880},[88],[482],[8564,8577],{"trials":11882,"activeCount":99},[],{"trials":11884,"activeCount":99},[],{"trials":11886,"activeCount":99},[],{"trials":11888,"activeCount":99},[],{"intervention":4408,"totalTrials":1606,"cells":11890},{"EARLY_PHASE1":11891,"PHASE1":11893,"PHASE2":11899,"PHASE3":11901,"PHASE4":11903,"NA":11905},{"trials":11892,"activeCount":99},[],{"trials":11894,"activeCount":99},[11895],{"nctId":4402,"briefTitle":4403,"status":105,"phases":11896,"primaryCompletion":4405,"completion":4405,"start":4136,"enrollment":130,"conditions":11897,"interventions":11898},[88],[15,18,27],[4408,876],{"trials":11900,"activeCount":99},[],{"trials":11902,"activeCount":99},[],{"trials":11904,"activeCount":99},[],{"trials":11906,"activeCount":99},[],{"intervention":3537,"totalTrials":1606,"cells":11908},{"EARLY_PHASE1":11909,"PHASE1":11911,"PHASE2":11917,"PHASE3":11919,"PHASE4":11921,"NA":11923},{"trials":11910,"activeCount":99},[],{"trials":11912,"activeCount":99},[11913],{"nctId":3531,"briefTitle":3532,"status":105,"phases":11914,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":3534,"conditions":11915,"interventions":11916},[88],[15,27],[768,557,366,3537,227],{"trials":11918,"activeCount":99},[],{"trials":11920,"activeCount":99},[],{"trials":11922,"activeCount":99},[],{"trials":11924,"activeCount":99},[],{"intervention":6353,"totalTrials":1606,"cells":11926},{"EARLY_PHASE1":11927,"PHASE1":11929,"PHASE2":11935,"PHASE3":11937,"PHASE4":11939,"NA":11941},{"trials":11928,"activeCount":99},[],{"trials":11930,"activeCount":99},[11931],{"nctId":6346,"briefTitle":6347,"status":105,"phases":11932,"primaryCompletion":6349,"completion":2869,"start":6350,"enrollment":2885,"conditions":11933,"interventions":11934},[88],[18],[842,6353,6354],{"trials":11936,"activeCount":99},[],{"trials":11938,"activeCount":99},[],{"trials":11940,"activeCount":99},[],{"trials":11942,"activeCount":99},[],{"intervention":10967,"totalTrials":1606,"cells":11944},{"EARLY_PHASE1":11945,"PHASE1":11947,"PHASE2":11953,"PHASE3":11955,"PHASE4":11957,"NA":11959},{"trials":11946,"activeCount":99},[],{"trials":11948,"activeCount":99},[11949],{"nctId":10957,"briefTitle":10958,"status":105,"phases":11950,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":11951,"interventions":11952},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":11954,"activeCount":99},[],{"trials":11956,"activeCount":99},[],{"trials":11958,"activeCount":99},[],{"trials":11960,"activeCount":99},[],{"intervention":10968,"totalTrials":1606,"cells":11962},{"EARLY_PHASE1":11963,"PHASE1":11965,"PHASE2":11971,"PHASE3":11973,"PHASE4":11975,"NA":11977},{"trials":11964,"activeCount":99},[],{"trials":11966,"activeCount":99},[11967],{"nctId":10957,"briefTitle":10958,"status":105,"phases":11968,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":11969,"interventions":11970},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":11972,"activeCount":99},[],{"trials":11974,"activeCount":99},[],{"trials":11976,"activeCount":99},[],{"trials":11978,"activeCount":99},[],{"intervention":10969,"totalTrials":1606,"cells":11980},{"EARLY_PHASE1":11981,"PHASE1":11983,"PHASE2":11989,"PHASE3":11991,"PHASE4":11993,"NA":11995},{"trials":11982,"activeCount":99},[],{"trials":11984,"activeCount":99},[11985],{"nctId":10957,"briefTitle":10958,"status":105,"phases":11986,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":11987,"interventions":11988},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":11990,"activeCount":99},[],{"trials":11992,"activeCount":99},[],{"trials":11994,"activeCount":99},[],{"trials":11996,"activeCount":99},[],{"intervention":10970,"totalTrials":1606,"cells":11998},{"EARLY_PHASE1":11999,"PHASE1":12001,"PHASE2":12007,"PHASE3":12009,"PHASE4":12011,"NA":12013},{"trials":12000,"activeCount":99},[],{"trials":12002,"activeCount":99},[12003],{"nctId":10957,"briefTitle":10958,"status":105,"phases":12004,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":12005,"interventions":12006},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":12008,"activeCount":99},[],{"trials":12010,"activeCount":99},[],{"trials":12012,"activeCount":99},[],{"trials":12014,"activeCount":99},[],{"intervention":10971,"totalTrials":1606,"cells":12016},{"EARLY_PHASE1":12017,"PHASE1":12019,"PHASE2":12025,"PHASE3":12027,"PHASE4":12029,"NA":12031},{"trials":12018,"activeCount":99},[],{"trials":12020,"activeCount":99},[12021],{"nctId":10957,"briefTitle":10958,"status":105,"phases":12022,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":12023,"interventions":12024},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":12026,"activeCount":99},[],{"trials":12028,"activeCount":99},[],{"trials":12030,"activeCount":99},[],{"trials":12032,"activeCount":99},[],{"intervention":10972,"totalTrials":1606,"cells":12034},{"EARLY_PHASE1":12035,"PHASE1":12037,"PHASE2":12043,"PHASE3":12045,"PHASE4":12047,"NA":12049},{"trials":12036,"activeCount":99},[],{"trials":12038,"activeCount":99},[12039],{"nctId":10957,"briefTitle":10958,"status":105,"phases":12040,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":12041,"interventions":12042},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":12044,"activeCount":99},[],{"trials":12046,"activeCount":99},[],{"trials":12048,"activeCount":99},[],{"trials":12050,"activeCount":99},[],{"intervention":10973,"totalTrials":1606,"cells":12052},{"EARLY_PHASE1":12053,"PHASE1":12055,"PHASE2":12061,"PHASE3":12063,"PHASE4":12065,"NA":12067},{"trials":12054,"activeCount":99},[],{"trials":12056,"activeCount":99},[12057],{"nctId":10957,"briefTitle":10958,"status":105,"phases":12058,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":10963,"conditions":12059,"interventions":12060},[88],[142,10965,862],[10967,10968,10969,10970,10950,10971,10972,10973],{"trials":12062,"activeCount":99},[],{"trials":12064,"activeCount":99},[],{"trials":12066,"activeCount":99},[],{"trials":12068,"activeCount":99},[],{"intervention":5395,"totalTrials":1606,"cells":12070},{"EARLY_PHASE1":12071,"PHASE1":12073,"PHASE2":12079,"PHASE3":12081,"PHASE4":12083,"NA":12085},{"trials":12072,"activeCount":99},[],{"trials":12074,"activeCount":99},[12075],{"nctId":5390,"briefTitle":5391,"status":105,"phases":12076,"primaryCompletion":2278,"completion":2278,"start":3872,"enrollment":2185,"conditions":12077,"interventions":12078},[88],[15,21],[5395,1978,5395,5395,5395,5395],{"trials":12080,"activeCount":99},[],{"trials":12082,"activeCount":99},[],{"trials":12084,"activeCount":99},[],{"trials":12086,"activeCount":99},[],{"intervention":12088,"totalTrials":1606,"cells":12089},"liraglutide [3H]",{"EARLY_PHASE1":12090,"PHASE1":12092,"PHASE2":12100,"PHASE3":12102,"PHASE4":12104,"NA":12106},{"trials":12091,"activeCount":99},[],{"trials":12093,"activeCount":99},[12094],{"nctId":12095,"briefTitle":12096,"status":105,"phases":12097,"primaryCompletion":5765,"completion":5765,"start":3618,"enrollment":422,"conditions":12098,"interventions":12099},"NCT01517568","Metabolism and Excretion of Liraglutide in Healthy Male Volunteers",[88],[15,27],[12088],{"trials":12101,"activeCount":99},[],{"trials":12103,"activeCount":99},[],{"trials":12105,"activeCount":99},[],{"trials":12107,"activeCount":99},[],{"intervention":12109,"totalTrials":1606,"cells":12110},"NNC0650-0013 A",{"EARLY_PHASE1":12111,"PHASE1":12113,"PHASE2":12123,"PHASE3":12125,"PHASE4":12127,"NA":12129},{"trials":12112,"activeCount":99},[],{"trials":12114,"activeCount":99},[12115],{"nctId":12116,"briefTitle":12117,"status":105,"phases":12118,"primaryCompletion":12119,"completion":12119,"start":12120,"enrollment":3578,"conditions":12121,"interventions":12122},"NCT06284798","A Research Study of a New Medicine (NNC0650-0013) in Healthy Men",[88],"2024-07-25","2024-01-29",[482],[12109],{"trials":12124,"activeCount":99},[],{"trials":12126,"activeCount":99},[],{"trials":12128,"activeCount":99},[],{"trials":12130,"activeCount":99},[],{"intervention":12132,"totalTrials":1606,"cells":12133},"NN9925",{"EARLY_PHASE1":12134,"PHASE1":12136,"PHASE2":12146,"PHASE3":12148,"PHASE4":12150,"NA":12152},{"trials":12135,"activeCount":99},[],{"trials":12137,"activeCount":99},[12138],{"nctId":12139,"briefTitle":12140,"status":105,"phases":12141,"primaryCompletion":12142,"completion":12142,"start":12143,"enrollment":3534,"conditions":12144,"interventions":12145},"NCT01087645","A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects",[88],"2010-09-16","2010-03-12",[15,18,27],[12132,12132,12132],{"trials":12147,"activeCount":99},[],{"trials":12149,"activeCount":99},[],{"trials":12151,"activeCount":99},[],{"trials":12153,"activeCount":99},[],{"intervention":328,"totalTrials":1606,"cells":12155},{"EARLY_PHASE1":12156,"PHASE1":12158,"PHASE2":12164,"PHASE3":12166,"PHASE4":12168,"NA":12170},{"trials":12157,"activeCount":99},[],{"trials":12159,"activeCount":99},[12160],{"nctId":320,"briefTitle":321,"status":105,"phases":12161,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":12162,"interventions":12163},[88],[15,27],[112,328],{"trials":12165,"activeCount":99},[],{"trials":12167,"activeCount":99},[],{"trials":12169,"activeCount":99},[],{"trials":12171,"activeCount":99},[],{"intervention":11035,"totalTrials":1606,"cells":12173},{"EARLY_PHASE1":12174,"PHASE1":12176,"PHASE2":12182,"PHASE3":12184,"PHASE4":12186,"NA":12188},{"trials":12175,"activeCount":99},[],{"trials":12177,"activeCount":99},[12178],{"nctId":11029,"briefTitle":11030,"status":105,"phases":12179,"primaryCompletion":1109,"completion":1109,"start":11032,"enrollment":372,"conditions":12180,"interventions":12181},[88],[18,482],[11022,11035],{"trials":12183,"activeCount":99},[],{"trials":12185,"activeCount":99},[],{"trials":12187,"activeCount":99},[],{"trials":12189,"activeCount":99},[],{"intervention":12191,"totalTrials":1606,"cells":12192},"FT-7051",{"EARLY_PHASE1":12193,"PHASE1":12195,"PHASE2":12206,"PHASE3":12208,"PHASE4":12210,"NA":12212},{"trials":12194,"activeCount":99},[],{"trials":12196,"activeCount":99},[12197],{"nctId":12198,"briefTitle":12199,"status":349,"phases":12200,"primaryCompletion":12201,"completion":11738,"start":12202,"enrollment":192,"conditions":12203,"interventions":12205},"NCT04575766","A Study of FT-7051 in Men With MCRPC",[88],"2022-11-08","2020-12-30",[12204],"Metastatic Castration-resistant Prostate Cancer",[12191],{"trials":12207,"activeCount":99},[],{"trials":12209,"activeCount":99},[],{"trials":12211,"activeCount":99},[],{"trials":12213,"activeCount":99},[],{"intervention":8387,"totalTrials":1606,"cells":12215},{"EARLY_PHASE1":12216,"PHASE1":12218,"PHASE2":12224,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12217,"activeCount":99},[],{"trials":12219,"activeCount":99},[12220],{"nctId":8380,"briefTitle":8381,"status":105,"phases":12221,"primaryCompletion":1051,"completion":8383,"start":8384,"enrollment":3643,"conditions":12222,"interventions":12223},[88],[21],[8387,8388,8389,5439],{"trials":12225,"activeCount":99},[],{"trials":12227,"activeCount":99},[],{"trials":12229,"activeCount":99},[],{"trials":12231,"activeCount":99},[],{"intervention":8388,"totalTrials":1606,"cells":12233},{"EARLY_PHASE1":12234,"PHASE1":12236,"PHASE2":12242,"PHASE3":12244,"PHASE4":12246,"NA":12248},{"trials":12235,"activeCount":99},[],{"trials":12237,"activeCount":99},[12238],{"nctId":8380,"briefTitle":8381,"status":105,"phases":12239,"primaryCompletion":1051,"completion":8383,"start":8384,"enrollment":3643,"conditions":12240,"interventions":12241},[88],[21],[8387,8388,8389,5439],{"trials":12243,"activeCount":99},[],{"trials":12245,"activeCount":99},[],{"trials":12247,"activeCount":99},[],{"trials":12249,"activeCount":99},[],{"intervention":8389,"totalTrials":1606,"cells":12251},{"EARLY_PHASE1":12252,"PHASE1":12254,"PHASE2":12260,"PHASE3":12262,"PHASE4":12264,"NA":12266},{"trials":12253,"activeCount":99},[],{"trials":12255,"activeCount":99},[12256],{"nctId":8380,"briefTitle":8381,"status":105,"phases":12257,"primaryCompletion":1051,"completion":8383,"start":8384,"enrollment":3643,"conditions":12258,"interventions":12259},[88],[21],[8387,8388,8389,5439],{"trials":12261,"activeCount":99},[],{"trials":12263,"activeCount":99},[],{"trials":12265,"activeCount":99},[],{"trials":12267,"activeCount":99},[],{"intervention":12269,"totalTrials":1606,"cells":12270},"NNC 0070-0002-0453",{"EARLY_PHASE1":12271,"PHASE1":12273,"PHASE2":12285,"PHASE3":12287,"PHASE4":12289,"NA":12291},{"trials":12272,"activeCount":99},[],{"trials":12274,"activeCount":99},[12275],{"nctId":12276,"briefTitle":12277,"status":349,"phases":12278,"primaryCompletion":12279,"completion":12280,"start":12281,"enrollment":12,"conditions":12282,"interventions":12283},"NCT01044108","A Two Part Trial Investigating an Anti-obesity Drug in Overweight\u002FObese Male and Female Healthy Volunteers",[88],"2010-12-13","2011-09-20","2010-01-05",[204,24],[12269,12284],"'2-0453",{"trials":12286,"activeCount":99},[],{"trials":12288,"activeCount":99},[],{"trials":12290,"activeCount":99},[],{"trials":12292,"activeCount":99},[],{"intervention":12284,"totalTrials":1606,"cells":12294},{"EARLY_PHASE1":12295,"PHASE1":12297,"PHASE2":12303,"PHASE3":12305,"PHASE4":12307,"NA":12309},{"trials":12296,"activeCount":99},[],{"trials":12298,"activeCount":99},[12299],{"nctId":12276,"briefTitle":12277,"status":349,"phases":12300,"primaryCompletion":12279,"completion":12280,"start":12281,"enrollment":12,"conditions":12301,"interventions":12302},[88],[204,24],[12269,12284],{"trials":12304,"activeCount":99},[],{"trials":12306,"activeCount":99},[],{"trials":12308,"activeCount":99},[],{"trials":12310,"activeCount":99},[],{"intervention":12312,"totalTrials":1606,"cells":12313},"Decitabine-THU",{"EARLY_PHASE1":12314,"PHASE1":12316,"PHASE2":12325,"PHASE3":12327,"PHASE4":12329,"NA":12331},{"trials":12315,"activeCount":99},[],{"trials":12317,"activeCount":99},[12318],{"nctId":12319,"briefTitle":12320,"status":105,"phases":12321,"primaryCompletion":12322,"completion":12322,"start":707,"enrollment":182,"conditions":12323,"interventions":12324},"NCT06291285","A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People",[88],"2024-06-10",[142],[12312,12312],{"trials":12326,"activeCount":99},[],{"trials":12328,"activeCount":99},[],{"trials":12330,"activeCount":99},[],{"trials":12332,"activeCount":99},[],{"intervention":12334,"totalTrials":1606,"cells":12335},"NNC0560-0004",{"EARLY_PHASE1":12336,"PHASE1":12338,"PHASE2":12348,"PHASE3":12350,"PHASE4":12352,"NA":12354},{"trials":12337,"activeCount":99},[],{"trials":12339,"activeCount":99},[12340],{"nctId":12341,"briefTitle":12342,"status":105,"phases":12343,"primaryCompletion":1631,"completion":1631,"start":12344,"enrollment":1986,"conditions":12345,"interventions":12347},"NCT06133270","A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.",[88],"2023-11-13",[12346],"Healthy Volunteers - Liver Diseases",[12334],{"trials":12349,"activeCount":99},[],{"trials":12351,"activeCount":99},[],{"trials":12353,"activeCount":99},[],{"trials":12355,"activeCount":99},[],{"intervention":11146,"totalTrials":1606,"cells":12357},{"EARLY_PHASE1":12358,"PHASE1":12360,"PHASE2":12366,"PHASE3":12368,"PHASE4":12370,"NA":12372},{"trials":12359,"activeCount":99},[],{"trials":12361,"activeCount":99},[12362],{"nctId":11135,"briefTitle":11136,"status":105,"phases":12363,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":12364,"interventions":12365},[88],[142,862],[11128,11144,11145,11146,11147,11148],{"trials":12367,"activeCount":99},[],{"trials":12369,"activeCount":99},[],{"trials":12371,"activeCount":99},[],{"trials":12373,"activeCount":99},[],{"intervention":11147,"totalTrials":1606,"cells":12375},{"EARLY_PHASE1":12376,"PHASE1":12378,"PHASE2":12384,"PHASE3":12386,"PHASE4":12388,"NA":12390},{"trials":12377,"activeCount":99},[],{"trials":12379,"activeCount":99},[12380],{"nctId":11135,"briefTitle":11136,"status":105,"phases":12381,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":12382,"interventions":12383},[88],[142,862],[11128,11144,11145,11146,11147,11148],{"trials":12385,"activeCount":99},[],{"trials":12387,"activeCount":99},[],{"trials":12389,"activeCount":99},[],{"trials":12391,"activeCount":99},[],{"intervention":11148,"totalTrials":1606,"cells":12393},{"EARLY_PHASE1":12394,"PHASE1":12396,"PHASE2":12402,"PHASE3":12404,"PHASE4":12406,"NA":12408},{"trials":12395,"activeCount":99},[],{"trials":12397,"activeCount":99},[12398],{"nctId":11135,"briefTitle":11136,"status":105,"phases":12399,"primaryCompletion":11138,"completion":11139,"start":11140,"enrollment":11141,"conditions":12400,"interventions":12401},[88],[142,862],[11128,11144,11145,11146,11147,11148],{"trials":12403,"activeCount":99},[],{"trials":12405,"activeCount":99},[],{"trials":12407,"activeCount":99},[],{"trials":12409,"activeCount":99},[],{"intervention":397,"totalTrials":1606,"cells":12411},{"EARLY_PHASE1":12412,"PHASE1":12414,"PHASE2":12420,"PHASE3":12422,"PHASE4":12424,"NA":12426},{"trials":12413,"activeCount":99},[],{"trials":12415,"activeCount":99},[12416],{"nctId":390,"briefTitle":391,"status":105,"phases":12417,"primaryCompletion":393,"completion":393,"start":394,"enrollment":306,"conditions":12418,"interventions":12419},[88],[18],[397,75],{"trials":12421,"activeCount":99},[],{"trials":12423,"activeCount":99},[],{"trials":12425,"activeCount":99},[],{"trials":12427,"activeCount":99},[],{"intervention":11043,"totalTrials":1606,"cells":12429},{"EARLY_PHASE1":12430,"PHASE1":12432,"PHASE2":12438,"PHASE3":12440,"PHASE4":12442,"NA":12444},{"trials":12431,"activeCount":99},[],{"trials":12433,"activeCount":99},[12434],{"nctId":11037,"briefTitle":11038,"status":105,"phases":12435,"primaryCompletion":11040,"completion":11040,"start":159,"enrollment":1846,"conditions":12436,"interventions":12437},[88],[6362],[11022,11043,11043,11022],{"trials":12439,"activeCount":99},[],{"trials":12441,"activeCount":99},[],{"trials":12443,"activeCount":99},[],{"trials":12445,"activeCount":99},[],{"intervention":435,"totalTrials":1606,"cells":12447},{"EARLY_PHASE1":12448,"PHASE1":12450,"PHASE2":12456,"PHASE3":12458,"PHASE4":12460,"NA":12462},{"trials":12449,"activeCount":99},[],{"trials":12451,"activeCount":99},[12452],{"nctId":426,"briefTitle":427,"status":105,"phases":12453,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":12454,"interventions":12455},[88],[433],[435,75],{"trials":12457,"activeCount":99},[],{"trials":12459,"activeCount":99},[],{"trials":12461,"activeCount":99},[],{"trials":12463,"activeCount":99},[],{"intervention":1870,"totalTrials":1606,"cells":12465},{"EARLY_PHASE1":12466,"PHASE1":12468,"PHASE2":12474,"PHASE3":12476,"PHASE4":12478,"NA":12480},{"trials":12467,"activeCount":99},[],{"trials":12469,"activeCount":99},[12470],{"nctId":1862,"briefTitle":1863,"status":105,"phases":12471,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":1867,"conditions":12472,"interventions":12473},[88],[21],[1829,1870],{"trials":12475,"activeCount":99},[],{"trials":12477,"activeCount":99},[],{"trials":12479,"activeCount":99},[],{"trials":12481,"activeCount":99},[],{"intervention":12483,"totalTrials":1606,"cells":12484},"liraglutide-depot",{"EARLY_PHASE1":12485,"PHASE1":12487,"PHASE2":12495,"PHASE3":12497,"PHASE4":12499,"NA":12501},{"trials":12486,"activeCount":99},[],{"trials":12488,"activeCount":99},[12489],{"nctId":12490,"briefTitle":12491,"status":105,"phases":12492,"primaryCompletion":9277,"completion":9277,"start":7261,"enrollment":554,"conditions":12493,"interventions":12494},"NCT01473953","Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects",[88],[15,18,27],[12483],{"trials":12496,"activeCount":99},[],{"trials":12498,"activeCount":99},[],{"trials":12500,"activeCount":99},[],{"trials":12502,"activeCount":99},[],{"intervention":11226,"totalTrials":1606,"cells":12504},{"EARLY_PHASE1":12505,"PHASE1":12507,"PHASE2":12513,"PHASE3":12515,"PHASE4":12517,"NA":12519},{"trials":12506,"activeCount":99},[],{"trials":12508,"activeCount":99},[12509],{"nctId":11220,"briefTitle":11221,"status":105,"phases":12510,"primaryCompletion":11223,"completion":11223,"start":8301,"enrollment":5006,"conditions":12511,"interventions":12512},[88],[18],[11226,11213,10730,11227],{"trials":12514,"activeCount":99},[],{"trials":12516,"activeCount":99},[],{"trials":12518,"activeCount":99},[],{"trials":12520,"activeCount":99},[],{"intervention":11227,"totalTrials":1606,"cells":12522},{"EARLY_PHASE1":12523,"PHASE1":12525,"PHASE2":12531,"PHASE3":12533,"PHASE4":12535,"NA":12537},{"trials":12524,"activeCount":99},[],{"trials":12526,"activeCount":99},[12527],{"nctId":11220,"briefTitle":11221,"status":105,"phases":12528,"primaryCompletion":11223,"completion":11223,"start":8301,"enrollment":5006,"conditions":12529,"interventions":12530},[88],[18],[11226,11213,10730,11227],{"trials":12532,"activeCount":99},[],{"trials":12534,"activeCount":99},[],{"trials":12536,"activeCount":99},[],{"trials":12538,"activeCount":99},[],{"intervention":12540,"totalTrials":1606,"cells":12541},"N9-GP",{"EARLY_PHASE1":12542,"PHASE1":12544,"PHASE2":12554,"PHASE3":12556,"PHASE4":12558,"NA":12560},{"trials":12543,"activeCount":99},[],{"trials":12545,"activeCount":99},[12546],{"nctId":12547,"briefTitle":12548,"status":105,"phases":12549,"primaryCompletion":922,"completion":922,"start":12550,"enrollment":518,"conditions":12551,"interventions":12552},"NCT03075670","A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B",[88],"2017-03-07",[30,2137],[12540,12553],"ALPROLIX®",{"trials":12555,"activeCount":99},[],{"trials":12557,"activeCount":99},[],{"trials":12559,"activeCount":99},[],{"trials":12561,"activeCount":99},[],{"intervention":12553,"totalTrials":1606,"cells":12563},{"EARLY_PHASE1":12564,"PHASE1":12566,"PHASE2":12572,"PHASE3":12574,"PHASE4":12576,"NA":12578},{"trials":12565,"activeCount":99},[],{"trials":12567,"activeCount":99},[12568],{"nctId":12547,"briefTitle":12548,"status":105,"phases":12569,"primaryCompletion":922,"completion":922,"start":12550,"enrollment":518,"conditions":12570,"interventions":12571},[88],[30,2137],[12540,12553],{"trials":12573,"activeCount":99},[],{"trials":12575,"activeCount":99},[],{"trials":12577,"activeCount":99},[],{"trials":12579,"activeCount":99},[],{"intervention":9649,"totalTrials":1606,"cells":12581},{"EARLY_PHASE1":12582,"PHASE1":12584,"PHASE2":12590,"PHASE3":12592,"PHASE4":12594,"NA":12596},{"trials":12583,"activeCount":99},[],{"trials":12585,"activeCount":99},[12586],{"nctId":9644,"briefTitle":9645,"status":105,"phases":12587,"primaryCompletion":4491,"completion":4491,"start":2270,"enrollment":691,"conditions":12588,"interventions":12589},[88],[15,18,27],[9649,9649,9650,830],{"trials":12591,"activeCount":99},[],{"trials":12593,"activeCount":99},[],{"trials":12595,"activeCount":99},[],{"trials":12597,"activeCount":99},[],{"intervention":9650,"totalTrials":1606,"cells":12599},{"EARLY_PHASE1":12600,"PHASE1":12602,"PHASE2":12608,"PHASE3":12610,"PHASE4":12612,"NA":12614},{"trials":12601,"activeCount":99},[],{"trials":12603,"activeCount":99},[12604],{"nctId":9644,"briefTitle":9645,"status":105,"phases":12605,"primaryCompletion":4491,"completion":4491,"start":2270,"enrollment":691,"conditions":12606,"interventions":12607},[88],[15,18,27],[9649,9649,9650,830],{"trials":12609,"activeCount":99},[],{"trials":12611,"activeCount":99},[],{"trials":12613,"activeCount":99},[],{"trials":12615,"activeCount":99},[],{"intervention":510,"totalTrials":1606,"cells":12617},{"EARLY_PHASE1":12618,"PHASE1":12620,"PHASE2":12626,"PHASE3":12628,"PHASE4":12630,"NA":12632},{"trials":12619,"activeCount":99},[],{"trials":12621,"activeCount":99},[12622],{"nctId":502,"briefTitle":503,"status":105,"phases":12623,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":12624,"interventions":12625},[88],[15,18],[75,510,511],{"trials":12627,"activeCount":99},[],{"trials":12629,"activeCount":99},[],{"trials":12631,"activeCount":99},[],{"trials":12633,"activeCount":99},[],{"intervention":511,"totalTrials":1606,"cells":12635},{"EARLY_PHASE1":12636,"PHASE1":12638,"PHASE2":12644,"PHASE3":12646,"PHASE4":12648,"NA":12650},{"trials":12637,"activeCount":99},[],{"trials":12639,"activeCount":99},[12640],{"nctId":502,"briefTitle":503,"status":105,"phases":12641,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":12642,"interventions":12643},[88],[15,18],[75,510,511],{"trials":12645,"activeCount":99},[],{"trials":12647,"activeCount":99},[],{"trials":12649,"activeCount":99},[],{"trials":12651,"activeCount":99},[],{"intervention":4464,"totalTrials":1606,"cells":12653},{"EARLY_PHASE1":12654,"PHASE1":12656,"PHASE2":12662,"PHASE3":12664,"PHASE4":12666,"NA":12668},{"trials":12655,"activeCount":99},[],{"trials":12657,"activeCount":99},[12658],{"nctId":4457,"briefTitle":4458,"status":105,"phases":12659,"primaryCompletion":4460,"completion":4460,"start":4461,"enrollment":130,"conditions":12660,"interventions":12661},[88],[15,18],[4464,876],{"trials":12663,"activeCount":99},[],{"trials":12665,"activeCount":99},[],{"trials":12667,"activeCount":99},[],{"trials":12669,"activeCount":99},[],{"intervention":11158,"totalTrials":1606,"cells":12671},{"EARLY_PHASE1":12672,"PHASE1":12674,"PHASE2":12680,"PHASE3":12682,"PHASE4":12684,"NA":12686},{"trials":12673,"activeCount":99},[],{"trials":12675,"activeCount":99},[12676],{"nctId":11150,"briefTitle":11151,"status":105,"phases":12677,"primaryCompletion":11153,"completion":11154,"start":11155,"enrollment":4439,"conditions":12678,"interventions":12679},[88],[24],[11128,11144,11145,11158,11159],{"trials":12681,"activeCount":99},[],{"trials":12683,"activeCount":99},[],{"trials":12685,"activeCount":99},[],{"trials":12687,"activeCount":99},[],{"intervention":11159,"totalTrials":1606,"cells":12689},{"EARLY_PHASE1":12690,"PHASE1":12692,"PHASE2":12698,"PHASE3":12700,"PHASE4":12702,"NA":12704},{"trials":12691,"activeCount":99},[],{"trials":12693,"activeCount":99},[12694],{"nctId":11150,"briefTitle":11151,"status":105,"phases":12695,"primaryCompletion":11153,"completion":11154,"start":11155,"enrollment":4439,"conditions":12696,"interventions":12697},[88],[24],[11128,11144,11145,11158,11159],{"trials":12699,"activeCount":99},[],{"trials":12701,"activeCount":99},[],{"trials":12703,"activeCount":99},[],{"trials":12705,"activeCount":99},[],{"intervention":4472,"totalTrials":1606,"cells":12707},{"EARLY_PHASE1":12708,"PHASE1":12710,"PHASE2":12716,"PHASE3":12718,"PHASE4":12720,"NA":12722},{"trials":12709,"activeCount":99},[],{"trials":12711,"activeCount":99},[12712],{"nctId":4466,"briefTitle":4467,"status":105,"phases":12713,"primaryCompletion":3961,"completion":3961,"start":3988,"enrollment":306,"conditions":12714,"interventions":12715},[88],[15,18],[4471,876,4472],{"trials":12717,"activeCount":99},[],{"trials":12719,"activeCount":99},[],{"trials":12721,"activeCount":99},[],{"trials":12723,"activeCount":99},[],{"intervention":12725,"totalTrials":1606,"cells":12726},"NNC 0070-0002-0182",{"EARLY_PHASE1":12727,"PHASE1":12729,"PHASE2":12737,"PHASE3":12739,"PHASE4":12741,"NA":12743},{"trials":12728,"activeCount":99},[],{"trials":12730,"activeCount":99},[12731],{"nctId":12732,"briefTitle":12733,"status":349,"phases":12734,"primaryCompletion":3739,"completion":3739,"start":3852,"enrollment":691,"conditions":12735,"interventions":12736},"NCT00665665","Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers",[88],[204,24],[12725,12725,12725,12725],{"trials":12738,"activeCount":99},[],{"trials":12740,"activeCount":99},[],{"trials":12742,"activeCount":99},[],{"trials":12744,"activeCount":99},[],{"intervention":5473,"totalTrials":1606,"cells":12746},{"EARLY_PHASE1":12747,"PHASE1":12749,"PHASE2":12755,"PHASE3":12757,"PHASE4":12759,"NA":12761},{"trials":12748,"activeCount":99},[],{"trials":12750,"activeCount":99},[12751],{"nctId":5467,"briefTitle":5468,"status":105,"phases":12752,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":12753,"interventions":12754},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"trials":12756,"activeCount":99},[],{"trials":12758,"activeCount":99},[],{"trials":12760,"activeCount":99},[],{"trials":12762,"activeCount":99},[],{"intervention":11277,"totalTrials":1606,"cells":12764},{"EARLY_PHASE1":12765,"PHASE1":12767,"PHASE2":12773,"PHASE3":12775,"PHASE4":12777,"NA":12779},{"trials":12766,"activeCount":99},[],{"trials":12768,"activeCount":99},[12769],{"nctId":11270,"briefTitle":11271,"status":105,"phases":12770,"primaryCompletion":11273,"completion":11273,"start":11274,"enrollment":266,"conditions":12771,"interventions":12772},[88],[142,33,24],[11263,11277],{"trials":12774,"activeCount":99},[],{"trials":12776,"activeCount":99},[],{"trials":12778,"activeCount":99},[],{"trials":12780,"activeCount":99},[],{"intervention":9588,"totalTrials":1606,"cells":12782},{"EARLY_PHASE1":12783,"PHASE1":12785,"PHASE2":12791,"PHASE3":12793,"PHASE4":12795,"NA":12797},{"trials":12784,"activeCount":99},[],{"trials":12786,"activeCount":99},[12787],{"nctId":9582,"briefTitle":9583,"status":105,"phases":12788,"primaryCompletion":4057,"completion":4057,"start":2133,"enrollment":223,"conditions":12789,"interventions":12790},[88],[9586,27],[2843,9588],{"trials":12792,"activeCount":99},[],{"trials":12794,"activeCount":99},[],{"trials":12796,"activeCount":99},[],{"trials":12798,"activeCount":99},[],{"intervention":12800,"totalTrials":1606,"cells":12801},"NNC0114-0000-0005",{"EARLY_PHASE1":12802,"PHASE1":12804,"PHASE2":12812,"PHASE3":12814,"PHASE4":12816,"NA":12818},{"trials":12803,"activeCount":99},[],{"trials":12805,"activeCount":99},[12806],{"nctId":12807,"briefTitle":12808,"status":105,"phases":12809,"primaryCompletion":3677,"completion":3677,"start":4369,"enrollment":2252,"conditions":12810,"interventions":12811},"NCT01208506","First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis",[88],[3066,9279,27],[12800,12800,12800,12800,12800],{"trials":12813,"activeCount":99},[],{"trials":12815,"activeCount":99},[],{"trials":12817,"activeCount":99},[],{"trials":12819,"activeCount":99},[],{"intervention":12821,"totalTrials":1606,"cells":12822},"NNC0247-0829",{"EARLY_PHASE1":12823,"PHASE1":12825,"PHASE2":12836,"PHASE3":12838,"PHASE4":12840,"NA":12842},{"trials":12824,"activeCount":99},[],{"trials":12826,"activeCount":99},[12827],{"nctId":12828,"briefTitle":12829,"status":105,"phases":12830,"primaryCompletion":12831,"completion":12832,"start":12833,"enrollment":776,"conditions":12834,"interventions":12835},"NCT04010786","A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity",[88],"2022-06-11","2022-06-21","2019-07-11",[33,24],[12821],{"trials":12837,"activeCount":99},[],{"trials":12839,"activeCount":99},[],{"trials":12841,"activeCount":99},[],{"trials":12843,"activeCount":99},[],{"intervention":12845,"totalTrials":1606,"cells":12846},"2 mg estradiol \u002F 1 mg norethisterone acetate",{"EARLY_PHASE1":12847,"PHASE1":12849,"PHASE2":12857,"PHASE3":12859,"PHASE4":12861,"NA":12863},{"trials":12848,"activeCount":99},[],{"trials":12850,"activeCount":99},[12851],{"nctId":12852,"briefTitle":12853,"status":105,"phases":12854,"primaryCompletion":3852,"completion":3852,"start":3961,"enrollment":182,"conditions":12855,"interventions":12856},"NCT01596010","Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women",[88],[7641,27],[12845],{"trials":12858,"activeCount":99},[],{"trials":12860,"activeCount":99},[],{"trials":12862,"activeCount":99},[],{"trials":12864,"activeCount":99},[],{"intervention":12866,"totalTrials":1606,"cells":12867},"NNC9204-1706 A",{"EARLY_PHASE1":12868,"PHASE1":12870,"PHASE2":12879,"PHASE3":12881,"PHASE4":12883,"NA":12885},{"trials":12869,"activeCount":99},[],{"trials":12871,"activeCount":99},[12872],{"nctId":12873,"briefTitle":12874,"status":105,"phases":12875,"primaryCompletion":4688,"completion":4688,"start":12876,"enrollment":708,"conditions":12877,"interventions":12878},"NCT03095807","Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity",[88],"2017-03-20",[204,24],[12866],{"trials":12880,"activeCount":99},[],{"trials":12882,"activeCount":99},[],{"trials":12884,"activeCount":99},[],{"trials":12886,"activeCount":99},[],{"intervention":10459,"totalTrials":1606,"cells":12888},{"EARLY_PHASE1":12889,"PHASE1":12891,"PHASE2":12897,"PHASE3":12899,"PHASE4":12901,"NA":12903},{"trials":12890,"activeCount":99},[],{"trials":12892,"activeCount":99},[12893],{"nctId":10451,"briefTitle":10452,"status":105,"phases":12894,"primaryCompletion":10454,"completion":10455,"start":10456,"enrollment":653,"conditions":12895,"interventions":12896},[88],[24],[10429,10459,10460,10461],{"trials":12898,"activeCount":99},[],{"trials":12900,"activeCount":99},[],{"trials":12902,"activeCount":99},[],{"trials":12904,"activeCount":99},[],{"intervention":10460,"totalTrials":1606,"cells":12906},{"EARLY_PHASE1":12907,"PHASE1":12909,"PHASE2":12915,"PHASE3":12917,"PHASE4":12919,"NA":12921},{"trials":12908,"activeCount":99},[],{"trials":12910,"activeCount":99},[12911],{"nctId":10451,"briefTitle":10452,"status":105,"phases":12912,"primaryCompletion":10454,"completion":10455,"start":10456,"enrollment":653,"conditions":12913,"interventions":12914},[88],[24],[10429,10459,10460,10461],{"trials":12916,"activeCount":99},[],{"trials":12918,"activeCount":99},[],{"trials":12920,"activeCount":99},[],{"trials":12922,"activeCount":99},[],{"intervention":10461,"totalTrials":1606,"cells":12924},{"EARLY_PHASE1":12925,"PHASE1":12927,"PHASE2":12933,"PHASE3":12935,"PHASE4":12937,"NA":12939},{"trials":12926,"activeCount":99},[],{"trials":12928,"activeCount":99},[12929],{"nctId":10451,"briefTitle":10452,"status":105,"phases":12930,"primaryCompletion":10454,"completion":10455,"start":10456,"enrollment":653,"conditions":12931,"interventions":12932},[88],[24],[10429,10459,10460,10461],{"trials":12934,"activeCount":99},[],{"trials":12936,"activeCount":99},[],{"trials":12938,"activeCount":99},[],{"trials":12940,"activeCount":99},[],{"intervention":12942,"totalTrials":1606,"cells":12943},"NNC 0070-0002-0349",{"EARLY_PHASE1":12944,"PHASE1":12946,"PHASE2":12954,"PHASE3":12956,"PHASE4":12958,"NA":12960},{"trials":12945,"activeCount":99},[],{"trials":12947,"activeCount":99},[12948],{"nctId":12949,"briefTitle":12950,"status":1135,"phases":12951,"primaryCompletion":3699,"completion":3699,"start":2162,"enrollment":99,"conditions":12952,"interventions":12953},"NCT00728455","Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight\u002FObese Volunteers",[88],[204,24],[12942,12942,12942,12942,12942],{"trials":12955,"activeCount":99},[],{"trials":12957,"activeCount":99},[],{"trials":12959,"activeCount":99},[],{"trials":12961,"activeCount":99},[],{"intervention":12963,"totalTrials":1606,"cells":12964},"NNC0705-0001",{"EARLY_PHASE1":12965,"PHASE1":12967,"PHASE2":12976,"PHASE3":12978,"PHASE4":12980,"NA":12982},{"trials":12966,"activeCount":99},[],{"trials":12968,"activeCount":99},[12969],{"nctId":12970,"briefTitle":12971,"status":105,"phases":12972,"primaryCompletion":12973,"completion":6382,"start":2061,"enrollment":8,"conditions":12974,"interventions":12975},"NCT07029568","A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People",[88],"2025-11-04",[142,840],[12963],{"trials":12977,"activeCount":99},[],{"trials":12979,"activeCount":99},[],{"trials":12981,"activeCount":99},[],{"trials":12983,"activeCount":99},[],{"intervention":8588,"totalTrials":1606,"cells":12985},{"EARLY_PHASE1":12986,"PHASE1":12988,"PHASE2":12994,"PHASE3":12996,"PHASE4":12998,"NA":13000},{"trials":12987,"activeCount":99},[],{"trials":12989,"activeCount":99},[12990],{"nctId":8579,"briefTitle":8580,"status":105,"phases":12991,"primaryCompletion":8582,"completion":8583,"start":8584,"enrollment":2195,"conditions":12992,"interventions":12993},[88],[664],[8587,8564,8588,8589,8590],{"trials":12995,"activeCount":99},[],{"trials":12997,"activeCount":99},[],{"trials":12999,"activeCount":99},[],{"trials":13001,"activeCount":99},[],{"intervention":8589,"totalTrials":1606,"cells":13003},{"EARLY_PHASE1":13004,"PHASE1":13006,"PHASE2":13012,"PHASE3":13014,"PHASE4":13016,"NA":13018},{"trials":13005,"activeCount":99},[],{"trials":13007,"activeCount":99},[13008],{"nctId":8579,"briefTitle":8580,"status":105,"phases":13009,"primaryCompletion":8582,"completion":8583,"start":8584,"enrollment":2195,"conditions":13010,"interventions":13011},[88],[664],[8587,8564,8588,8589,8590],{"trials":13013,"activeCount":99},[],{"trials":13015,"activeCount":99},[],{"trials":13017,"activeCount":99},[],{"trials":13019,"activeCount":99},[],{"intervention":8590,"totalTrials":1606,"cells":13021},{"EARLY_PHASE1":13022,"PHASE1":13024,"PHASE2":13030,"PHASE3":13032,"PHASE4":13034,"NA":13036},{"trials":13023,"activeCount":99},[],{"trials":13025,"activeCount":99},[13026],{"nctId":8579,"briefTitle":8580,"status":105,"phases":13027,"primaryCompletion":8582,"completion":8583,"start":8584,"enrollment":2195,"conditions":13028,"interventions":13029},[88],[664],[8587,8564,8588,8589,8590],{"trials":13031,"activeCount":99},[],{"trials":13033,"activeCount":99},[],{"trials":13035,"activeCount":99},[],{"trials":13037,"activeCount":99},[],{"intervention":13039,"totalTrials":1606,"cells":13040},"NNC0519-0130 B",{"EARLY_PHASE1":13041,"PHASE1":13043,"PHASE2":13054,"PHASE3":13056,"PHASE4":13058,"NA":13060},{"trials":13042,"activeCount":99},[],{"trials":13044,"activeCount":99},[13045],{"nctId":13046,"briefTitle":13047,"status":105,"phases":13048,"primaryCompletion":13049,"completion":13050,"start":8584,"enrollment":1894,"conditions":13051,"interventions":13052},"NCT06642571","A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine",[88],"2025-05-17","2025-05-31",[24],[13039,13053],"NNC0519-0130 C",{"trials":13055,"activeCount":99},[],{"trials":13057,"activeCount":99},[],{"trials":13059,"activeCount":99},[],{"trials":13061,"activeCount":99},[],{"intervention":13053,"totalTrials":1606,"cells":13063},{"EARLY_PHASE1":13064,"PHASE1":13066,"PHASE2":13072,"PHASE3":13074,"PHASE4":13076,"NA":13078},{"trials":13065,"activeCount":99},[],{"trials":13067,"activeCount":99},[13068],{"nctId":13046,"briefTitle":13047,"status":105,"phases":13069,"primaryCompletion":13049,"completion":13050,"start":8584,"enrollment":1894,"conditions":13070,"interventions":13071},[88],[24],[13039,13053],{"trials":13073,"activeCount":99},[],{"trials":13075,"activeCount":99},[],{"trials":13077,"activeCount":99},[],{"trials":13079,"activeCount":99},[],{"intervention":10983,"totalTrials":1606,"cells":13081},{"EARLY_PHASE1":13082,"PHASE1":13084,"PHASE2":13090,"PHASE3":13092,"PHASE4":13094,"NA":13096},{"trials":13083,"activeCount":99},[],{"trials":13085,"activeCount":99},[13086],{"nctId":10975,"briefTitle":10976,"status":105,"phases":13087,"primaryCompletion":8374,"completion":10978,"start":10979,"enrollment":140,"conditions":13088,"interventions":13089},[88],[10981],[10983,10984,10950],{"trials":13091,"activeCount":99},[],{"trials":13093,"activeCount":99},[],{"trials":13095,"activeCount":99},[],{"trials":13097,"activeCount":99},[],{"intervention":10984,"totalTrials":1606,"cells":13099},{"EARLY_PHASE1":13100,"PHASE1":13102,"PHASE2":13108,"PHASE3":13110,"PHASE4":13112,"NA":13114},{"trials":13101,"activeCount":99},[],{"trials":13103,"activeCount":99},[13104],{"nctId":10975,"briefTitle":10976,"status":105,"phases":13105,"primaryCompletion":8374,"completion":10978,"start":10979,"enrollment":140,"conditions":13106,"interventions":13107},[88],[10981],[10983,10984,10950],{"trials":13109,"activeCount":99},[],{"trials":13111,"activeCount":99},[],{"trials":13113,"activeCount":99},[],{"trials":13115,"activeCount":99},[],{"intervention":6571,"totalTrials":1606,"cells":13117},{"EARLY_PHASE1":13118,"PHASE1":13120,"PHASE2":13126,"PHASE3":13128,"PHASE4":13130,"NA":13132},{"trials":13119,"activeCount":99},[],{"trials":13121,"activeCount":99},[13122],{"nctId":6564,"briefTitle":6565,"status":105,"phases":13123,"primaryCompletion":6567,"completion":6567,"start":2897,"enrollment":708,"conditions":13124,"interventions":13125},[88],[6569],[257,6571],{"trials":13127,"activeCount":99},[],{"trials":13129,"activeCount":99},[],{"trials":13131,"activeCount":99},[],{"trials":13133,"activeCount":99},[],{"intervention":13135,"totalTrials":1606,"cells":13136},"Faster Aspart 200 U\u002FmL",{"EARLY_PHASE1":13137,"PHASE1":13139,"PHASE2":13150,"PHASE3":13152,"PHASE4":13154,"NA":13156},{"trials":13138,"activeCount":99},[],{"trials":13140,"activeCount":99},[13141],{"nctId":13142,"briefTitle":13143,"status":105,"phases":13144,"primaryCompletion":13145,"completion":980,"start":13146,"enrollment":673,"conditions":13147,"interventions":13148},"NCT03723759","A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus",[88],"2019-03-21","2018-10-26",[21],[13135,13149],"Faster aspart 100 U\u002FmL",{"trials":13151,"activeCount":99},[],{"trials":13153,"activeCount":99},[],{"trials":13155,"activeCount":99},[],{"trials":13157,"activeCount":99},[],{"intervention":13149,"totalTrials":1606,"cells":13159},{"EARLY_PHASE1":13160,"PHASE1":13162,"PHASE2":13168,"PHASE3":13170,"PHASE4":13172,"NA":13174},{"trials":13161,"activeCount":99},[],{"trials":13163,"activeCount":99},[13164],{"nctId":13142,"briefTitle":13143,"status":105,"phases":13165,"primaryCompletion":13145,"completion":980,"start":13146,"enrollment":673,"conditions":13166,"interventions":13167},[88],[21],[13135,13149],{"trials":13169,"activeCount":99},[],{"trials":13171,"activeCount":99},[],{"trials":13173,"activeCount":99},[],{"trials":13175,"activeCount":99},[],{"intervention":10731,"totalTrials":1606,"cells":13177},{"EARLY_PHASE1":13178,"PHASE1":13180,"PHASE2":13186,"PHASE3":13188,"PHASE4":13190,"NA":13192},{"trials":13179,"activeCount":99},[],{"trials":13181,"activeCount":99},[13182],{"nctId":10723,"briefTitle":10724,"status":105,"phases":13183,"primaryCompletion":10726,"completion":4353,"start":10727,"enrollment":335,"conditions":13184,"interventions":13185},[88],[18],[10730,10731,10732,10733,196],{"trials":13187,"activeCount":99},[],{"trials":13189,"activeCount":99},[],{"trials":13191,"activeCount":99},[],{"trials":13193,"activeCount":99},[],{"intervention":10732,"totalTrials":1606,"cells":13195},{"EARLY_PHASE1":13196,"PHASE1":13198,"PHASE2":13204,"PHASE3":13206,"PHASE4":13208,"NA":13210},{"trials":13197,"activeCount":99},[],{"trials":13199,"activeCount":99},[13200],{"nctId":10723,"briefTitle":10724,"status":105,"phases":13201,"primaryCompletion":10726,"completion":4353,"start":10727,"enrollment":335,"conditions":13202,"interventions":13203},[88],[18],[10730,10731,10732,10733,196],{"trials":13205,"activeCount":99},[],{"trials":13207,"activeCount":99},[],{"trials":13209,"activeCount":99},[],{"trials":13211,"activeCount":99},[],{"intervention":10733,"totalTrials":1606,"cells":13213},{"EARLY_PHASE1":13214,"PHASE1":13216,"PHASE2":13222,"PHASE3":13224,"PHASE4":13226,"NA":13228},{"trials":13215,"activeCount":99},[],{"trials":13217,"activeCount":99},[13218],{"nctId":10723,"briefTitle":10724,"status":105,"phases":13219,"primaryCompletion":10726,"completion":4353,"start":10727,"enrollment":335,"conditions":13220,"interventions":13221},[88],[18],[10730,10731,10732,10733,196],{"trials":13223,"activeCount":99},[],{"trials":13225,"activeCount":99},[],{"trials":13227,"activeCount":99},[],{"trials":13229,"activeCount":99},[],{"intervention":13231,"totalTrials":1606,"cells":13232},"Semaglutide, 0.25 mg",{"EARLY_PHASE1":13233,"PHASE1":13235,"PHASE2":13246,"PHASE3":13248,"PHASE4":13250,"NA":13252},{"trials":13234,"activeCount":99},[],{"trials":13236,"activeCount":99},[13237],{"nctId":13238,"briefTitle":13239,"status":105,"phases":13240,"primaryCompletion":5718,"completion":5718,"start":13241,"enrollment":325,"conditions":13242,"interventions":13243},"NCT03611322","A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)",[88],"2018-08-08",[18],[13231,13244,13245],"Semaglutide, 0.5 mg","Semaglutide, 1.0 mg",{"trials":13247,"activeCount":99},[],{"trials":13249,"activeCount":99},[],{"trials":13251,"activeCount":99},[],{"trials":13253,"activeCount":99},[],{"intervention":13244,"totalTrials":1606,"cells":13255},{"EARLY_PHASE1":13256,"PHASE1":13258,"PHASE2":13264,"PHASE3":13266,"PHASE4":13268,"NA":13270},{"trials":13257,"activeCount":99},[],{"trials":13259,"activeCount":99},[13260],{"nctId":13238,"briefTitle":13239,"status":105,"phases":13261,"primaryCompletion":5718,"completion":5718,"start":13241,"enrollment":325,"conditions":13262,"interventions":13263},[88],[18],[13231,13244,13245],{"trials":13265,"activeCount":99},[],{"trials":13267,"activeCount":99},[],{"trials":13269,"activeCount":99},[],{"trials":13271,"activeCount":99},[],{"intervention":13245,"totalTrials":1606,"cells":13273},{"EARLY_PHASE1":13274,"PHASE1":13276,"PHASE2":13282,"PHASE3":13284,"PHASE4":13286,"NA":13288},{"trials":13275,"activeCount":99},[],{"trials":13277,"activeCount":99},[13278],{"nctId":13238,"briefTitle":13239,"status":105,"phases":13279,"primaryCompletion":5718,"completion":5718,"start":13241,"enrollment":325,"conditions":13280,"interventions":13281},[88],[18],[13231,13244,13245],{"trials":13283,"activeCount":99},[],{"trials":13285,"activeCount":99},[],{"trials":13287,"activeCount":99},[],{"trials":13289,"activeCount":99},[],{"intervention":13291,"totalTrials":1606,"cells":13292},"NNC 55-0414",{"EARLY_PHASE1":13293,"PHASE1":13295,"PHASE2":13305,"PHASE3":13307,"PHASE4":13309,"NA":13311},{"trials":13294,"activeCount":99},[],{"trials":13296,"activeCount":99},[13297],{"nctId":13298,"briefTitle":13299,"status":105,"phases":13300,"primaryCompletion":13301,"completion":13301,"start":13302,"enrollment":992,"conditions":13303,"interventions":13304},"NCT00400283","A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes",[88],"2001-05-03","2001-01-19",[15,18],[13291],{"trials":13306,"activeCount":99},[],{"trials":13308,"activeCount":99},[],{"trials":13310,"activeCount":99},[],{"trials":13312,"activeCount":99},[],{"intervention":4495,"totalTrials":1606,"cells":13314},{"EARLY_PHASE1":13315,"PHASE1":13317,"PHASE2":13323,"PHASE3":13325,"PHASE4":13327,"NA":13329},{"trials":13316,"activeCount":99},[],{"trials":13318,"activeCount":99},[13319],{"nctId":4488,"briefTitle":4489,"status":105,"phases":13320,"primaryCompletion":4391,"completion":4391,"start":4491,"enrollment":4492,"conditions":13321,"interventions":13322},[88],[15,18,27],[4495,876,4495,4495,4495],{"trials":13324,"activeCount":99},[],{"trials":13326,"activeCount":99},[],{"trials":13328,"activeCount":99},[],{"trials":13330,"activeCount":99},[],{"intervention":5514,"totalTrials":1606,"cells":13332},{"EARLY_PHASE1":13333,"PHASE1":13335,"PHASE2":13341,"PHASE3":13343,"PHASE4":13345,"NA":13347},{"trials":13334,"activeCount":99},[],{"trials":13336,"activeCount":99},[13337],{"nctId":5508,"briefTitle":5509,"status":105,"phases":13338,"primaryCompletion":4336,"completion":4336,"start":5511,"enrollment":2803,"conditions":13339,"interventions":13340},[88],[15,21],[5514,4594,1919,1978],{"trials":13342,"activeCount":99},[],{"trials":13344,"activeCount":99},[],{"trials":13346,"activeCount":99},[],{"trials":13348,"activeCount":99},[],{"intervention":4503,"totalTrials":1606,"cells":13350},{"EARLY_PHASE1":13351,"PHASE1":13353,"PHASE2":13359,"PHASE3":13361,"PHASE4":13363,"NA":13365},{"trials":13352,"activeCount":99},[],{"trials":13354,"activeCount":99},[13355],{"nctId":4497,"briefTitle":4498,"status":105,"phases":13356,"primaryCompletion":4500,"completion":4500,"start":4391,"enrollment":3534,"conditions":13357,"interventions":13358},[88],[15,21,27],[4503,4503,876,4504],{"trials":13360,"activeCount":99},[],{"trials":13362,"activeCount":99},[],{"trials":13364,"activeCount":99},[],{"trials":13366,"activeCount":99},[],{"intervention":4504,"totalTrials":1606,"cells":13368},{"EARLY_PHASE1":13369,"PHASE1":13371,"PHASE2":13377,"PHASE3":13379,"PHASE4":13381,"NA":13383},{"trials":13370,"activeCount":99},[],{"trials":13372,"activeCount":99},[13373],{"nctId":4497,"briefTitle":4498,"status":105,"phases":13374,"primaryCompletion":4500,"completion":4500,"start":4391,"enrollment":3534,"conditions":13375,"interventions":13376},[88],[15,21,27],[4503,4503,876,4504],{"trials":13378,"activeCount":99},[],{"trials":13380,"activeCount":99},[],{"trials":13382,"activeCount":99},[],{"trials":13384,"activeCount":99},[],{"intervention":4513,"totalTrials":1606,"cells":13386},{"EARLY_PHASE1":13387,"PHASE1":13389,"PHASE2":13395,"PHASE3":13397,"PHASE4":13399,"NA":13401},{"trials":13388,"activeCount":99},[],{"trials":13390,"activeCount":99},[13391],{"nctId":4506,"briefTitle":4507,"status":105,"phases":13392,"primaryCompletion":4509,"completion":4509,"start":4510,"enrollment":3534,"conditions":13393,"interventions":13394},[88],[15,27],[4513,876],{"trials":13396,"activeCount":99},[],{"trials":13398,"activeCount":99},[],{"trials":13400,"activeCount":99},[],{"trials":13402,"activeCount":99},[],{"intervention":2697,"totalTrials":1606,"cells":13404},{"EARLY_PHASE1":13405,"PHASE1":13407,"PHASE2":13413,"PHASE3":13415,"PHASE4":13417,"NA":13419},{"trials":13406,"activeCount":99},[],{"trials":13408,"activeCount":99},[13409],{"nctId":2690,"briefTitle":2691,"status":105,"phases":13410,"primaryCompletion":2693,"completion":2694,"start":837,"enrollment":1846,"conditions":13411,"interventions":13412},[88],[24],[2682,2697],{"trials":13414,"activeCount":99},[],{"trials":13416,"activeCount":99},[],{"trials":13418,"activeCount":99},[],{"trials":13420,"activeCount":99},[],{"intervention":3694,"totalTrials":1606,"cells":13422},{"EARLY_PHASE1":13423,"PHASE1":13425,"PHASE2":13431,"PHASE3":13433,"PHASE4":13435,"NA":13437},{"trials":13424,"activeCount":99},[],{"trials":13426,"activeCount":99},[13427],{"nctId":3689,"briefTitle":3690,"status":105,"phases":13428,"primaryCompletion":2193,"completion":2193,"start":3618,"enrollment":507,"conditions":13429,"interventions":13430},[88],[15,18],[768,3694],{"trials":13432,"activeCount":99},[],{"trials":13434,"activeCount":99},[],{"trials":13436,"activeCount":99},[],{"trials":13438,"activeCount":99},[],{"intervention":627,"totalTrials":1606,"cells":13440},{"EARLY_PHASE1":13441,"PHASE1":13443,"PHASE2":13449,"PHASE3":13451,"PHASE4":13453,"NA":13455},{"trials":13442,"activeCount":99},[],{"trials":13444,"activeCount":99},[13445],{"nctId":618,"briefTitle":619,"status":105,"phases":13446,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":13447,"interventions":13448},[88],[15,27],[627,628,195,75],{"trials":13450,"activeCount":99},[],{"trials":13452,"activeCount":99},[],{"trials":13454,"activeCount":99},[],{"trials":13456,"activeCount":99},[],{"intervention":10676,"totalTrials":1606,"cells":13458},{"EARLY_PHASE1":13459,"PHASE1":13461,"PHASE2":13467,"PHASE3":13469,"PHASE4":13471,"NA":13473},{"trials":13460,"activeCount":99},[],{"trials":13462,"activeCount":99},[13463],{"nctId":10671,"briefTitle":10672,"status":105,"phases":13464,"primaryCompletion":652,"completion":652,"start":233,"enrollment":5047,"conditions":13465,"interventions":13466},[88],[30,36,2137],[10658,10676],{"trials":13468,"activeCount":99},[],{"trials":13470,"activeCount":99},[],{"trials":13472,"activeCount":99},[],{"trials":13474,"activeCount":99},[],{"intervention":13476,"totalTrials":1606,"cells":13477},"NNC0471-0119",{"EARLY_PHASE1":13478,"PHASE1":13480,"PHASE2":13490,"PHASE3":13492,"PHASE4":13494,"NA":13496},{"trials":13479,"activeCount":99},[],{"trials":13481,"activeCount":99},[13482],{"nctId":13483,"briefTitle":13484,"status":105,"phases":13485,"primaryCompletion":13486,"completion":13486,"start":1001,"enrollment":699,"conditions":13487,"interventions":13488},"NCT04655690","A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus",[88],"2021-11-26",[21],[13476,13489],"Fast-acting insulin aspart",{"trials":13491,"activeCount":99},[],{"trials":13493,"activeCount":99},[],{"trials":13495,"activeCount":99},[],{"trials":13497,"activeCount":99},[],{"intervention":13499,"totalTrials":1606,"cells":13500},"NNC6022-0001",{"EARLY_PHASE1":13501,"PHASE1":13503,"PHASE2":13513,"PHASE3":13515,"PHASE4":13517,"NA":13519},{"trials":13502,"activeCount":99},[],{"trials":13504,"activeCount":99},[13505],{"nctId":13506,"briefTitle":13507,"status":105,"phases":13508,"primaryCompletion":1380,"completion":3407,"start":13509,"enrollment":673,"conditions":13510,"interventions":13512},"NCT06336005","A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People",[88],"2024-03-28",[142,13511],"Cardiometabolic Diseases",[13499],{"trials":13514,"activeCount":99},[],{"trials":13516,"activeCount":99},[],{"trials":13518,"activeCount":99},[],{"trials":13520,"activeCount":99},[],{"intervention":13522,"totalTrials":1606,"cells":13523},"NNC0491-6075",{"EARLY_PHASE1":13524,"PHASE1":13526,"PHASE2":13536,"PHASE3":13538,"PHASE4":13540,"NA":13542},{"trials":13525,"activeCount":99},[],{"trials":13527,"activeCount":99},[13528],{"nctId":13529,"briefTitle":13530,"status":105,"phases":13531,"primaryCompletion":8726,"completion":8726,"start":13532,"enrollment":1271,"conditions":13533,"interventions":13535},"NCT05979428","A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood",[88],"2023-08-07",[142,13534],"Dyslipidaemia",[13522],{"trials":13537,"activeCount":99},[],{"trials":13539,"activeCount":99},[],{"trials":13541,"activeCount":99},[],{"trials":13543,"activeCount":99},[],{"intervention":5037,"totalTrials":1606,"cells":13545},{"EARLY_PHASE1":13546,"PHASE1":13548,"PHASE2":13554,"PHASE3":13556,"PHASE4":13558,"NA":13560},{"trials":13547,"activeCount":99},[],{"trials":13549,"activeCount":99},[13550],{"nctId":5030,"briefTitle":5031,"status":105,"phases":13551,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":13552,"interventions":13553},[88],[5008],[4985,5036,5037,1478,5038,628],{"trials":13555,"activeCount":99},[],{"trials":13557,"activeCount":99},[],{"trials":13559,"activeCount":99},[],{"trials":13561,"activeCount":99},[],{"intervention":5038,"totalTrials":1606,"cells":13563},{"EARLY_PHASE1":13564,"PHASE1":13566,"PHASE2":13572,"PHASE3":13574,"PHASE4":13576,"NA":13578},{"trials":13565,"activeCount":99},[],{"trials":13567,"activeCount":99},[13568],{"nctId":5030,"briefTitle":5031,"status":105,"phases":13569,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":13570,"interventions":13571},[88],[5008],[4985,5036,5037,1478,5038,628],{"trials":13573,"activeCount":99},[],{"trials":13575,"activeCount":99},[],{"trials":13577,"activeCount":99},[],{"trials":13579,"activeCount":99},[],{"intervention":13581,"totalTrials":1606,"cells":13582},"NNC9204-1177 A 1.0 mg\u002FmL",{"EARLY_PHASE1":13583,"PHASE1":13585,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13584,"activeCount":99},[],{"trials":13586,"activeCount":99},[13587],{"nctId":13588,"briefTitle":13589,"status":105,"phases":13590,"primaryCompletion":13591,"completion":13591,"start":13592,"enrollment":3269,"conditions":13593,"interventions":13594},"NCT03308721","Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity",[88],"2020-01-03","2017-10-16",[204,24],[13581],{"trials":13596,"activeCount":99},[],{"trials":13598,"activeCount":99},[],{"trials":13600,"activeCount":99},[],{"trials":13602,"activeCount":99},[],{"intervention":5146,"totalTrials":1606,"cells":13604},{"EARLY_PHASE1":13605,"PHASE1":13607,"PHASE2":13613,"PHASE3":13615,"PHASE4":13617,"NA":13619},{"trials":13606,"activeCount":99},[],{"trials":13608,"activeCount":99},[13609],{"nctId":5139,"briefTitle":5140,"status":105,"phases":13610,"primaryCompletion":5142,"completion":5142,"start":2944,"enrollment":5143,"conditions":13611,"interventions":13612},[88],[482],[5132,5146,5147],{"trials":13614,"activeCount":99},[],{"trials":13616,"activeCount":99},[],{"trials":13618,"activeCount":99},[],{"trials":13620,"activeCount":99},[],{"intervention":13622,"totalTrials":1606,"cells":13623},"Semaglutide 3 mg",{"EARLY_PHASE1":13624,"PHASE1":13626,"PHASE2":13642,"PHASE3":13644,"PHASE4":13646,"NA":13648},{"trials":13625,"activeCount":99},[],{"trials":13627,"activeCount":99},[13628],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13631,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13633,"interventions":13634},"NCT03638778","Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men",[88],"2018-08-17",[18],[13622,13635,13636,13637,13638,13639,13640,13641],"Semaglutide 7 mg","Semaglutide B 3 mg","Semaglutide B 7 mg","Semaglutide C 3 mg","Semaglutide C 7 mg","Semaglutide D 3 mg","Semaglutide D 7 mg",{"trials":13643,"activeCount":99},[],{"trials":13645,"activeCount":99},[],{"trials":13647,"activeCount":99},[],{"trials":13649,"activeCount":99},[],{"intervention":13635,"totalTrials":1606,"cells":13651},{"EARLY_PHASE1":13652,"PHASE1":13654,"PHASE2":13660,"PHASE3":13662,"PHASE4":13664,"NA":13666},{"trials":13653,"activeCount":99},[],{"trials":13655,"activeCount":99},[13656],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13657,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13658,"interventions":13659},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13661,"activeCount":99},[],{"trials":13663,"activeCount":99},[],{"trials":13665,"activeCount":99},[],{"trials":13667,"activeCount":99},[],{"intervention":13636,"totalTrials":1606,"cells":13669},{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13678,"PHASE3":13680,"PHASE4":13682,"NA":13684},{"trials":13671,"activeCount":99},[],{"trials":13673,"activeCount":99},[13674],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13675,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13676,"interventions":13677},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13679,"activeCount":99},[],{"trials":13681,"activeCount":99},[],{"trials":13683,"activeCount":99},[],{"trials":13685,"activeCount":99},[],{"intervention":13637,"totalTrials":1606,"cells":13687},{"EARLY_PHASE1":13688,"PHASE1":13690,"PHASE2":13696,"PHASE3":13698,"PHASE4":13700,"NA":13702},{"trials":13689,"activeCount":99},[],{"trials":13691,"activeCount":99},[13692],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13693,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13694,"interventions":13695},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13697,"activeCount":99},[],{"trials":13699,"activeCount":99},[],{"trials":13701,"activeCount":99},[],{"trials":13703,"activeCount":99},[],{"intervention":13638,"totalTrials":1606,"cells":13705},{"EARLY_PHASE1":13706,"PHASE1":13708,"PHASE2":13714,"PHASE3":13716,"PHASE4":13718,"NA":13720},{"trials":13707,"activeCount":99},[],{"trials":13709,"activeCount":99},[13710],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13711,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13712,"interventions":13713},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13715,"activeCount":99},[],{"trials":13717,"activeCount":99},[],{"trials":13719,"activeCount":99},[],{"trials":13721,"activeCount":99},[],{"intervention":13639,"totalTrials":1606,"cells":13723},{"EARLY_PHASE1":13724,"PHASE1":13726,"PHASE2":13732,"PHASE3":13734,"PHASE4":13736,"NA":13738},{"trials":13725,"activeCount":99},[],{"trials":13727,"activeCount":99},[13728],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13729,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13730,"interventions":13731},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13733,"activeCount":99},[],{"trials":13735,"activeCount":99},[],{"trials":13737,"activeCount":99},[],{"trials":13739,"activeCount":99},[],{"intervention":13640,"totalTrials":1606,"cells":13741},{"EARLY_PHASE1":13742,"PHASE1":13744,"PHASE2":13750,"PHASE3":13752,"PHASE4":13754,"NA":13756},{"trials":13743,"activeCount":99},[],{"trials":13745,"activeCount":99},[13746],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13747,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13748,"interventions":13749},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13751,"activeCount":99},[],{"trials":13753,"activeCount":99},[],{"trials":13755,"activeCount":99},[],{"trials":13757,"activeCount":99},[],{"intervention":13641,"totalTrials":1606,"cells":13759},{"EARLY_PHASE1":13760,"PHASE1":13762,"PHASE2":13768,"PHASE3":13770,"PHASE4":13772,"NA":13774},{"trials":13761,"activeCount":99},[],{"trials":13763,"activeCount":99},[13764],{"nctId":13629,"briefTitle":13630,"status":105,"phases":13765,"primaryCompletion":7317,"completion":7317,"start":13632,"enrollment":2820,"conditions":13766,"interventions":13767},[88],[18],[13622,13635,13636,13637,13638,13639,13640,13641],{"trials":13769,"activeCount":99},[],{"trials":13771,"activeCount":99},[],{"trials":13773,"activeCount":99},[],{"trials":13775,"activeCount":99},[],{"intervention":13777,"totalTrials":1606,"cells":13778},"Mim8 B, 10 mg\u002FmL",{"EARLY_PHASE1":13779,"PHASE1":13781,"PHASE2":13794,"PHASE3":13796,"PHASE4":13798,"NA":13800},{"trials":13780,"activeCount":99},[],{"trials":13782,"activeCount":99},[13783],{"nctId":13784,"briefTitle":13785,"status":105,"phases":13786,"primaryCompletion":13787,"completion":13787,"start":13788,"enrollment":1867,"conditions":13789,"interventions":13791},"NCT05127473","A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People",[88],"2022-05-14","2021-07-14",[13790],"Healthy Volunteers - Haemophilia A",[13777,13792,13793],"Mim8 B, 100 mg\u002FmL","Mim8 B, placebo",{"trials":13795,"activeCount":99},[],{"trials":13797,"activeCount":99},[],{"trials":13799,"activeCount":99},[],{"trials":13801,"activeCount":99},[],{"intervention":13792,"totalTrials":1606,"cells":13803},{"EARLY_PHASE1":13804,"PHASE1":13806,"PHASE2":13812,"PHASE3":13814,"PHASE4":13816,"NA":13818},{"trials":13805,"activeCount":99},[],{"trials":13807,"activeCount":99},[13808],{"nctId":13784,"briefTitle":13785,"status":105,"phases":13809,"primaryCompletion":13787,"completion":13787,"start":13788,"enrollment":1867,"conditions":13810,"interventions":13811},[88],[13790],[13777,13792,13793],{"trials":13813,"activeCount":99},[],{"trials":13815,"activeCount":99},[],{"trials":13817,"activeCount":99},[],{"trials":13819,"activeCount":99},[],{"intervention":13793,"totalTrials":1606,"cells":13821},{"EARLY_PHASE1":13822,"PHASE1":13824,"PHASE2":13830,"PHASE3":13832,"PHASE4":13834,"NA":13836},{"trials":13823,"activeCount":99},[],{"trials":13825,"activeCount":99},[13826],{"nctId":13784,"briefTitle":13785,"status":105,"phases":13827,"primaryCompletion":13787,"completion":13787,"start":13788,"enrollment":1867,"conditions":13828,"interventions":13829},[88],[13790],[13777,13792,13793],{"trials":13831,"activeCount":99},[],{"trials":13833,"activeCount":99},[],{"trials":13835,"activeCount":99},[],{"trials":13837,"activeCount":99},[],{"intervention":13839,"totalTrials":1606,"cells":13840},"NN9924",{"EARLY_PHASE1":13841,"PHASE1":13843,"PHASE2":13853,"PHASE3":13855,"PHASE4":13857,"NA":13859},{"trials":13842,"activeCount":99},[],{"trials":13844,"activeCount":99},[13845],{"nctId":13846,"briefTitle":13847,"status":105,"phases":13848,"primaryCompletion":13849,"completion":13849,"start":13850,"enrollment":3352,"conditions":13851,"interventions":13852},"NCT01037582","A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects",[88],"2010-05-07","2009-12-17",[15,18,27],[13839,13839,13839,13839],{"trials":13854,"activeCount":99},[],{"trials":13856,"activeCount":99},[],{"trials":13858,"activeCount":99},[],{"trials":13860,"activeCount":99},[],{"intervention":9366,"totalTrials":1606,"cells":13862},{"EARLY_PHASE1":13863,"PHASE1":13865,"PHASE2":13871,"PHASE3":13873,"PHASE4":13875,"NA":13877},{"trials":13864,"activeCount":99},[],{"trials":13866,"activeCount":99},[13867],{"nctId":9361,"briefTitle":9362,"status":105,"phases":13868,"primaryCompletion":3901,"completion":3901,"start":3988,"enrollment":673,"conditions":13869,"interventions":13870},[88],[2776,27],[9348,9366,9348,9366],{"trials":13872,"activeCount":99},[],{"trials":13874,"activeCount":99},[],{"trials":13876,"activeCount":99},[],{"trials":13878,"activeCount":99},[],{"intervention":4565,"totalTrials":1606,"cells":13880},{"EARLY_PHASE1":13881,"PHASE1":13883,"PHASE2":13889,"PHASE3":13891,"PHASE4":13893,"NA":13895},{"trials":13882,"activeCount":99},[],{"trials":13884,"activeCount":99},[13885],{"nctId":4558,"briefTitle":4559,"status":105,"phases":13886,"primaryCompletion":4561,"completion":4561,"start":4562,"enrollment":2549,"conditions":13887,"interventions":13888},[88],[142,18],[4565,876],{"trials":13890,"activeCount":99},[],{"trials":13892,"activeCount":99},[],{"trials":13894,"activeCount":99},[],{"trials":13896,"activeCount":99},[],{"intervention":656,"totalTrials":1606,"cells":13898},{"EARLY_PHASE1":13899,"PHASE1":13901,"PHASE2":13907,"PHASE3":13909,"PHASE4":13911,"NA":13913},{"trials":13900,"activeCount":99},[],{"trials":13902,"activeCount":99},[13903],{"nctId":648,"briefTitle":649,"status":105,"phases":13904,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":13905,"interventions":13906},[88],[15,18],[112,656],{"trials":13908,"activeCount":99},[],{"trials":13910,"activeCount":99},[],{"trials":13912,"activeCount":99},[],{"trials":13914,"activeCount":99},[],{"intervention":2415,"totalTrials":1606,"cells":13916},{"EARLY_PHASE1":13917,"PHASE1":13919,"PHASE2":13925,"PHASE3":13927,"PHASE4":13929,"NA":13931},{"trials":13918,"activeCount":99},[],{"trials":13920,"activeCount":99},[13921],{"nctId":2406,"briefTitle":2407,"status":105,"phases":13922,"primaryCompletion":570,"completion":2409,"start":2410,"enrollment":152,"conditions":13923,"interventions":13924},[88],[24],[70,2413,2414,2415],{"trials":13926,"activeCount":99},[],{"trials":13928,"activeCount":99},[],{"trials":13930,"activeCount":99},[],{"trials":13932,"activeCount":99},[],{"intervention":10815,"totalTrials":1606,"cells":13934},{"EARLY_PHASE1":13935,"PHASE1":13937,"PHASE2":13943,"PHASE3":13945,"PHASE4":13947,"NA":13949},{"trials":13936,"activeCount":99},[],{"trials":13938,"activeCount":99},[13939],{"nctId":10808,"briefTitle":10809,"status":105,"phases":13940,"primaryCompletion":10811,"completion":10811,"start":10812,"enrollment":578,"conditions":13941,"interventions":13942},[88],[21],[10815,10793],{"trials":13944,"activeCount":99},[],{"trials":13946,"activeCount":99},[],{"trials":13948,"activeCount":99},[],{"trials":13950,"activeCount":99},[],{"intervention":13952,"totalTrials":1606,"cells":13953},"Monlunabant",{"EARLY_PHASE1":13954,"PHASE1":13956,"PHASE2":13966,"PHASE3":13968,"PHASE4":13970,"NA":13972},{"trials":13955,"activeCount":99},[],{"trials":13957,"activeCount":99},[13958],{"nctId":13959,"briefTitle":13960,"status":105,"phases":13961,"primaryCompletion":13962,"completion":13962,"start":13963,"enrollment":10635,"conditions":13964,"interventions":13965},"NCT06542536","A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men",[88],"2024-10-25","2024-08-09",[24],[13952],{"trials":13967,"activeCount":99},[],{"trials":13969,"activeCount":99},[],{"trials":13971,"activeCount":99},[],{"trials":13973,"activeCount":99},[],{"intervention":13975,"totalTrials":1606,"cells":13976},"Heparin",{"EARLY_PHASE1":13977,"PHASE1":13988,"PHASE2":13990,"PHASE3":13992,"PHASE4":13994,"NA":13996},{"trials":13978,"activeCount":99},[13979],{"nctId":13980,"briefTitle":13981,"status":105,"phases":13982,"primaryCompletion":13983,"completion":13984,"start":13985,"enrollment":5047,"conditions":13986,"interventions":13987},"NCT05178550","A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.",[87],"2022-01-11","2022-01-17","2021-12-17",[142],[13975],{"trials":13989,"activeCount":99},[],{"trials":13991,"activeCount":99},[],{"trials":13993,"activeCount":99},[],{"trials":13995,"activeCount":99},[],{"trials":13997,"activeCount":99},[],{"intervention":3589,"totalTrials":2367,"cells":13999},{"EARLY_PHASE1":14000,"PHASE1":14002,"PHASE2":14094,"PHASE3":14100,"PHASE4":14287,"NA":14382},{"trials":14001,"activeCount":99},[],{"trials":14003,"activeCount":99},[14004,14010,14016,14022,14029,14035,14042,14046,14050,14057,14063,14067,14071,14077,14083,14090],{"nctId":14005,"briefTitle":14006,"status":105,"phases":14007,"primaryCompletion":3618,"completion":3618,"start":4398,"enrollment":285,"conditions":14008,"interventions":14009},"NCT01490099","Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects",[88],[15,27],[3589],{"nctId":14011,"briefTitle":14012,"status":105,"phases":14013,"primaryCompletion":4635,"completion":4635,"start":2204,"enrollment":3454,"conditions":14014,"interventions":14015},"NCT01135927","A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes",[88],[15,21],[1919,3589],{"nctId":14017,"briefTitle":14018,"status":105,"phases":14019,"primaryCompletion":2213,"completion":2213,"start":2145,"enrollment":708,"conditions":14020,"interventions":14021},"NCT01498926","Comparison of Two Insulin Detemir Formulations in Healthy Volunteers",[88],[15,27],[3589,3589],{"nctId":14023,"briefTitle":14024,"status":105,"phases":14025,"primaryCompletion":8552,"completion":8552,"start":14026,"enrollment":1624,"conditions":14027,"interventions":14028},"NCT01497600","Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes",[88],"2004-02",[15,18],[3589,4967],{"nctId":14030,"briefTitle":14031,"status":105,"phases":14032,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4542,"conditions":14033,"interventions":14034},"NCT01043510","The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and\u002For Ethnic Origin",[88],[15,18],[1919,3589],{"nctId":14036,"briefTitle":14037,"status":105,"phases":14038,"primaryCompletion":3526,"completion":3526,"start":14039,"enrollment":5316,"conditions":14040,"interventions":14041},"NCT02162407","A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin",[88],"1999-10",[15,27],[3589,5705],{"nctId":4443,"briefTitle":4444,"status":105,"phases":14043,"primaryCompletion":2225,"completion":2225,"start":2234,"enrollment":223,"conditions":14044,"interventions":14045},[88],[15,21],[3589,876],{"nctId":3582,"briefTitle":3583,"status":105,"phases":14047,"primaryCompletion":3585,"completion":3585,"start":3586,"enrollment":2803,"conditions":14048,"interventions":14049},[88],[15,18],[768,3589],{"nctId":14051,"briefTitle":14052,"status":105,"phases":14053,"primaryCompletion":14054,"completion":14054,"start":3706,"enrollment":518,"conditions":14055,"interventions":14056},"NCT01497561","Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes",[88],"2003-06",[15,18],[3589,4967],{"nctId":14058,"briefTitle":14059,"status":105,"phases":14060,"primaryCompletion":4643,"completion":4643,"start":3562,"enrollment":372,"conditions":14061,"interventions":14062},"NCT01497587","Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan",[88],[15,27],[3589],{"nctId":4515,"briefTitle":4516,"status":105,"phases":14064,"primaryCompletion":4518,"completion":4518,"start":4519,"enrollment":162,"conditions":14065,"interventions":14066},[88],[15,27],[3589,876],{"nctId":6693,"briefTitle":6694,"status":105,"phases":14068,"primaryCompletion":6696,"completion":6697,"start":6698,"enrollment":12,"conditions":14069,"interventions":14070},[88],[21],[6679,1887,5810],{"nctId":14072,"briefTitle":14073,"status":105,"phases":14074,"primaryCompletion":3594,"completion":3594,"start":3988,"enrollment":372,"conditions":14075,"interventions":14076},"NCT01498939","Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects",[88],[15,27],[3589],{"nctId":14078,"briefTitle":14079,"status":105,"phases":14080,"primaryCompletion":2225,"completion":2225,"start":3551,"enrollment":192,"conditions":14081,"interventions":14082},"NCT00760448","Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia",[88],[15,21],[3589,4967],{"nctId":14084,"briefTitle":14085,"status":105,"phases":14086,"primaryCompletion":14087,"completion":14087,"start":3764,"enrollment":992,"conditions":14088,"interventions":14089},"NCT01542450","Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes",[88],"2003-02",[15,21],[3589,4967],{"nctId":10864,"briefTitle":10865,"status":105,"phases":14091,"primaryCompletion":10867,"completion":10867,"start":10868,"enrollment":119,"conditions":14092,"interventions":14093},[88],[21],[10849,5810],{"trials":14095,"activeCount":99},[14096],{"nctId":5555,"briefTitle":5556,"status":105,"phases":14097,"primaryCompletion":4941,"completion":4941,"start":489,"enrollment":5428,"conditions":14098,"interventions":14099},[89],[15,21],[1919,3589,1978],{"trials":14101,"activeCount":99},[14102,14106,14110,14114,14121,14125,14133,14137,14143,14150,14154,14158,14164,14172,14176,14180,14184,14188,14195,14199,14203,14207,14211,14215,14222,14226,14230,14234,14238,14242,14246,14250,14254,14258,14262,14270,14279,14283],{"nctId":5567,"briefTitle":5568,"status":349,"phases":14103,"primaryCompletion":5570,"completion":5570,"start":5571,"enrollment":5572,"conditions":14104,"interventions":14105},[90],[15,21],[5575,3589,1978],{"nctId":5577,"briefTitle":5578,"status":105,"phases":14107,"primaryCompletion":2162,"completion":2162,"start":5580,"enrollment":2451,"conditions":14108,"interventions":14109},[90],[15,21],[3589,1978,3589],{"nctId":4640,"briefTitle":4641,"status":105,"phases":14111,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":1495,"conditions":14112,"interventions":14113},[90],[15,18],[3589,876,1978],{"nctId":14115,"briefTitle":14116,"status":105,"phases":14117,"primaryCompletion":3988,"completion":3988,"start":5406,"enrollment":14118,"conditions":14119,"interventions":14120},"NCT00383877","Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],263,[15,18],[3589,4967],{"nctId":3869,"briefTitle":3870,"status":105,"phases":14122,"primaryCompletion":3872,"completion":3873,"start":3586,"enrollment":3874,"conditions":14123,"interventions":14124},[90],[15,18],[768,3589,226],{"nctId":14126,"briefTitle":14127,"status":105,"phases":14128,"primaryCompletion":2213,"completion":2213,"start":14129,"enrollment":14130,"conditions":14131,"interventions":14132},"NCT00104182","Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes",[90],"2005-02",503,[15,18],[3589,4967],{"nctId":5605,"briefTitle":5606,"status":105,"phases":14134,"primaryCompletion":2305,"completion":2305,"start":4904,"enrollment":5608,"conditions":14135,"interventions":14136},[90],[15,21],[1919,3589,1978],{"nctId":14138,"briefTitle":14139,"status":105,"phases":14140,"primaryCompletion":2234,"completion":2234,"start":3634,"enrollment":5948,"conditions":14141,"interventions":14142},"NCT00604253","Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone",[90],[15,18],[3589,4967],{"nctId":14144,"briefTitle":14145,"status":105,"phases":14146,"primaryCompletion":3602,"completion":3602,"start":2225,"enrollment":14147,"conditions":14148,"interventions":14149},"NCT01709929","Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus",[90],2287,[15,21,18],[3589],{"nctId":5643,"briefTitle":5644,"status":105,"phases":14151,"primaryCompletion":5406,"completion":5406,"start":3550,"enrollment":4859,"conditions":14152,"interventions":14153},[90],[15,21],[3589,4967,1978],{"nctId":5657,"briefTitle":5658,"status":349,"phases":14155,"primaryCompletion":5660,"completion":5660,"start":5661,"enrollment":5662,"conditions":14156,"interventions":14157},[90],[15,18],[5575,3589,1978,1978],{"nctId":14159,"briefTitle":14160,"status":105,"phases":14161,"primaryCompletion":6058,"completion":6058,"start":3551,"enrollment":3222,"conditions":14162,"interventions":14163},"NCT00592527","Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes",[90],[15,18],[3589],{"nctId":14165,"briefTitle":14166,"status":105,"phases":14167,"primaryCompletion":14168,"completion":14168,"start":14169,"enrollment":4492,"conditions":14170,"interventions":14171},"NCT00605137","Safety of Insulin Detemir in Children With Type 1 Diabetes",[90],"2005-04-23","2004-05-21",[15,21],[3589,4967],{"nctId":5707,"briefTitle":5708,"status":105,"phases":14173,"primaryCompletion":5710,"completion":5710,"start":3802,"enrollment":5711,"conditions":14174,"interventions":14175},[90],[15,21],[3589,1978,4967,5705],{"nctId":8848,"briefTitle":8849,"status":105,"phases":14177,"primaryCompletion":8851,"completion":8851,"start":8852,"enrollment":8853,"conditions":14178,"interventions":14179},[90],[21],[5810,5855],{"nctId":4762,"briefTitle":4763,"status":105,"phases":14181,"primaryCompletion":4643,"completion":4643,"start":4765,"enrollment":4766,"conditions":14182,"interventions":14183},[90],[15,18],[3589,876,1978],{"nctId":5729,"briefTitle":5730,"status":105,"phases":14185,"primaryCompletion":3585,"completion":3585,"start":4015,"enrollment":5732,"conditions":14186,"interventions":14187},[90],[15,21],[3589,1978],{"nctId":14189,"briefTitle":14190,"status":105,"phases":14191,"primaryCompletion":5739,"completion":5739,"start":3706,"enrollment":14192,"conditions":14193,"interventions":14194},"NCT00604396","Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes",[90],477,[15,18],[3589,4967],{"nctId":5754,"briefTitle":5755,"status":105,"phases":14196,"primaryCompletion":5757,"completion":5757,"start":3764,"enrollment":5758,"conditions":14197,"interventions":14198},[90],[15,21],[3589,4967,1978],{"nctId":4791,"briefTitle":4792,"status":105,"phases":14200,"primaryCompletion":4794,"completion":4794,"start":3706,"enrollment":4795,"conditions":14201,"interventions":14202},[90],[15,18],[3589,876],{"nctId":5762,"briefTitle":5763,"status":105,"phases":14204,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":5767,"conditions":14205,"interventions":14206},[90],[15,18],[3589,4967,1978],{"nctId":5771,"briefTitle":5772,"status":105,"phases":14208,"primaryCompletion":4748,"completion":4748,"start":2260,"enrollment":5774,"conditions":14209,"interventions":14210},[90],[15,21],[3589,4967,1978],{"nctId":5782,"briefTitle":5783,"status":105,"phases":14212,"primaryCompletion":5785,"completion":5785,"start":2819,"enrollment":5786,"conditions":14213,"interventions":14214},[90],[15,21],[1919,3589,1978],{"nctId":14216,"briefTitle":14217,"status":105,"phases":14218,"primaryCompletion":4765,"completion":4765,"start":14219,"enrollment":1418,"conditions":14220,"interventions":14221},"NCT00604344","Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes",[90],"2003-04",[15,21],[3589,4967],{"nctId":7553,"briefTitle":7554,"status":105,"phases":14223,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":7556,"conditions":14224,"interventions":14225},[90],[15,18],[3589,984,226,4198],{"nctId":5803,"briefTitle":5804,"status":105,"phases":14227,"primaryCompletion":5806,"completion":5806,"start":5807,"enrollment":2289,"conditions":14228,"interventions":14229},[90],[15,21],[1887,5281,5810],{"nctId":5829,"briefTitle":5830,"status":105,"phases":14231,"primaryCompletion":4484,"completion":4484,"start":4794,"enrollment":5832,"conditions":14232,"interventions":14233},[90],[15,18],[4751,3589,1978],{"nctId":5840,"briefTitle":5841,"status":105,"phases":14235,"primaryCompletion":5843,"completion":5843,"start":5844,"enrollment":5845,"conditions":14236,"interventions":14237},[90],[15,18],[3589,1978],{"nctId":5849,"briefTitle":5850,"status":105,"phases":14239,"primaryCompletion":5852,"completion":5852,"start":3714,"enrollment":3303,"conditions":14240,"interventions":14241},[90],[15,21],[3589,5855,1978],{"nctId":4846,"briefTitle":4847,"status":105,"phases":14243,"primaryCompletion":3706,"completion":3706,"start":4849,"enrollment":4850,"conditions":14244,"interventions":14245},[90],[15,21],[3589,876,1978],{"nctId":5861,"briefTitle":5862,"status":105,"phases":14247,"primaryCompletion":2224,"completion":2224,"start":3731,"enrollment":5864,"conditions":14248,"interventions":14249},[90],[15,21],[3589,4967,1978],{"nctId":5892,"briefTitle":5893,"status":105,"phases":14251,"primaryCompletion":2331,"completion":2331,"start":4484,"enrollment":5895,"conditions":14252,"interventions":14253},[90],[15,21],[4594,3589,1978,1978],{"nctId":5899,"briefTitle":5900,"status":105,"phases":14255,"primaryCompletion":5902,"completion":5902,"start":5844,"enrollment":2380,"conditions":14256,"interventions":14257},[90],[15,21],[3589,4967,1978],{"nctId":4891,"briefTitle":4892,"status":105,"phases":14259,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4894,"conditions":14260,"interventions":14261},[90],[15,21],[3589,876,1978],{"nctId":14263,"briefTitle":14264,"status":105,"phases":14265,"primaryCompletion":14266,"completion":14266,"start":14267,"enrollment":498,"conditions":14268,"interventions":14269},"NCT00184639","Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes",[90],"2005-11-22","2004-08-16",[15,21],[3589],{"nctId":14271,"briefTitle":14272,"status":349,"phases":14273,"primaryCompletion":14274,"completion":14274,"start":14275,"enrollment":173,"conditions":14276,"interventions":14277},"NCT02131272","A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet\u002FExercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin",[90],"2016-06-14","2014-06-11",[15,18],[5810,14278],"Insulin NPH",{"nctId":5933,"briefTitle":5934,"status":105,"phases":14280,"primaryCompletion":5936,"completion":5937,"start":5938,"enrollment":5939,"conditions":14281,"interventions":14282},[90],[15,21],[4709,3589,1978,4709],{"nctId":5943,"briefTitle":5944,"status":105,"phases":14284,"primaryCompletion":5946,"completion":5946,"start":5947,"enrollment":5948,"conditions":14285,"interventions":14286},[90],[15,21],[4594,1978,3589,1978],{"trials":14288,"activeCount":99},[14289,14296,14300,14307,14311,14315,14321,14325,14329,14335,14339,14347,14353,14357,14361,14365,14372,14376],{"nctId":14290,"briefTitle":14291,"status":105,"phases":14292,"primaryCompletion":3739,"completion":3739,"start":4015,"enrollment":14293,"conditions":14294,"interventions":14295},"NCT00634842","Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily",[91],244,[15,18],[3589,3589],{"nctId":5969,"briefTitle":5970,"status":105,"phases":14297,"primaryCompletion":3586,"completion":3586,"start":3961,"enrollment":4737,"conditions":14298,"interventions":14299},[91],[15,18],[3589,1978,1978],{"nctId":14301,"briefTitle":14302,"status":105,"phases":14303,"primaryCompletion":3618,"completion":3618,"start":2225,"enrollment":14304,"conditions":14305,"interventions":14306},"NCT00264901","Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes",[91],5652,[15,18],[3589],{"nctId":5975,"briefTitle":5976,"status":105,"phases":14308,"primaryCompletion":3618,"completion":3618,"start":5978,"enrollment":5979,"conditions":14309,"interventions":14310},[91],[15,18],[3589,1978],{"nctId":5983,"briefTitle":5984,"status":349,"phases":14312,"primaryCompletion":334,"completion":334,"start":5366,"enrollment":109,"conditions":14313,"interventions":14314},[91],[15,18],[3589,1978,4967,5705,226],{"nctId":14316,"briefTitle":14317,"status":105,"phases":14318,"primaryCompletion":3988,"completion":3988,"start":5765,"enrollment":192,"conditions":14319,"interventions":14320},"NCT00521690","The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD",[91],[15,18],[3589],{"nctId":5993,"briefTitle":5994,"status":105,"phases":14322,"primaryCompletion":4491,"completion":4491,"start":4570,"enrollment":5996,"conditions":14323,"interventions":14324},[91],[15,18],[3589,1978,4471,226],{"nctId":6000,"briefTitle":6001,"status":105,"phases":14326,"primaryCompletion":3586,"completion":3586,"start":3594,"enrollment":192,"conditions":14327,"interventions":14328},[91],[15,21],[3589,1978,3589,1978],{"nctId":14330,"briefTitle":14331,"status":105,"phases":14332,"primaryCompletion":5852,"completion":5852,"start":488,"enrollment":4439,"conditions":14333,"interventions":14334},"NCT00795600","Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment",[91],[15,18],[3589,4967],{"nctId":6013,"briefTitle":6014,"status":105,"phases":14336,"primaryCompletion":4320,"completion":4320,"start":4635,"enrollment":1418,"conditions":14337,"interventions":14338},[91],[15,18],[1978,1978,3589],{"nctId":14340,"briefTitle":14341,"status":105,"phases":14342,"primaryCompletion":14343,"completion":4344,"start":14344,"enrollment":1245,"conditions":14345,"interventions":14346},"NCT01232491","Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes",[91],"2011-11-01","2010-10-29",[15,18],[5810],{"nctId":14348,"briefTitle":14349,"status":349,"phases":14350,"primaryCompletion":3738,"completion":3738,"start":6022,"enrollment":2298,"conditions":14351,"interventions":14352},"NCT00506662","Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes",[91],[15,18],[3589,4967],{"nctId":6019,"briefTitle":6020,"status":349,"phases":14354,"primaryCompletion":2162,"completion":2162,"start":6022,"enrollment":992,"conditions":14355,"interventions":14356},[91],[15,21],[3589,4967,1978],{"nctId":4938,"briefTitle":4939,"status":105,"phases":14358,"primaryCompletion":2204,"completion":2204,"start":4941,"enrollment":4942,"conditions":14359,"interventions":14360},[91],[15,18],[3589,876],{"nctId":6040,"briefTitle":6041,"status":105,"phases":14362,"primaryCompletion":3715,"completion":3715,"start":5496,"enrollment":6043,"conditions":14363,"interventions":14364},[91],[15,21],[3589,1978],{"nctId":14366,"briefTitle":14367,"status":105,"phases":14368,"primaryCompletion":14369,"completion":14369,"start":7687,"enrollment":1894,"conditions":14370,"interventions":14371},"NCT01868542","A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)",[91],"2015-05",[15,18],[3589],{"nctId":4962,"briefTitle":4963,"status":105,"phases":14373,"primaryCompletion":3618,"completion":3618,"start":3602,"enrollment":1986,"conditions":14374,"interventions":14375},[91],[15,21],[3589,876,4967],{"nctId":14377,"briefTitle":14378,"status":105,"phases":14379,"primaryCompletion":3739,"completion":3739,"start":3852,"enrollment":31,"conditions":14380,"interventions":14381},"NCT00455858","Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea",[91],[15,18],[3589],{"trials":14383,"activeCount":99},[14384,14388,14394,14401,14408,14415,14422,14426,14433,14440,14447,14456,14463,14470,14477,14481,14485,14492,14496,14503,14510,14517,14524,14531,14535,14542,14549,14553,14560,14567,14574,14580,14587,14593,14597,14604,14611,14618,14625,14632,14636,14640,14645,14652,14661,14668,14674],{"nctId":6102,"briefTitle":6103,"status":105,"phases":14385,"primaryCompletion":652,"completion":652,"start":3860,"enrollment":6105,"conditions":14386,"interventions":14387},[],[15,18],[1978,3589,4751],{"nctId":14389,"briefTitle":14390,"status":105,"phases":14391,"primaryCompletion":3699,"completion":3699,"start":489,"enrollment":6208,"conditions":14392,"interventions":14393},"NCT00806897","Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®",[],[15,18],[3589],{"nctId":14395,"briefTitle":14396,"status":105,"phases":14397,"primaryCompletion":233,"completion":233,"start":3860,"enrollment":14398,"conditions":14399,"interventions":14400},"NCT00793273","Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.",[],1074,[15,18],[3589],{"nctId":14402,"briefTitle":14403,"status":105,"phases":14404,"primaryCompletion":3699,"completion":3699,"start":2162,"enrollment":14405,"conditions":14406,"interventions":14407},"NCT00697450","Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics",[],206,[15,18],[3589],{"nctId":14409,"briefTitle":14410,"status":105,"phases":14411,"primaryCompletion":652,"completion":652,"start":4049,"enrollment":14412,"conditions":14413,"interventions":14414},"NCT00825643","Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes",[],18481,[15,18],[3589],{"nctId":14416,"briefTitle":14417,"status":105,"phases":14418,"primaryCompletion":2279,"completion":2279,"start":6022,"enrollment":14419,"conditions":14420,"interventions":14421},"NCT00701155","Observational Study to Evaluate the Safety While Using Levemir®",[],3593,[15,21,18],[3589],{"nctId":6109,"briefTitle":6110,"status":105,"phases":14423,"primaryCompletion":3715,"completion":3715,"start":2194,"enrollment":6112,"conditions":14424,"interventions":14425},[],[15,21,18],[3589,1978],{"nctId":14427,"briefTitle":14428,"status":105,"phases":14429,"primaryCompletion":2331,"completion":2331,"start":129,"enrollment":14430,"conditions":14431,"interventions":14432},"NCT00865397","Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment",[],1032,[15,18],[3589],{"nctId":14434,"briefTitle":14435,"status":105,"phases":14436,"primaryCompletion":4941,"completion":4941,"start":2306,"enrollment":14437,"conditions":14438,"interventions":14439},"NCT00738153","An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes",[],798,[15,21,18],[3589],{"nctId":14441,"briefTitle":14442,"status":105,"phases":14443,"primaryCompletion":3901,"completion":3901,"start":3714,"enrollment":14444,"conditions":14445,"interventions":14446},"NCT00665093","Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes",[],1569,[15,21,18],[4471,3589],{"nctId":14448,"briefTitle":14449,"status":105,"phases":14450,"primaryCompletion":14451,"completion":14451,"start":14452,"enrollment":14453,"conditions":14454,"interventions":14455},"NCT03960814","A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine",[],"2019-06-07","2019-05-21",12847,[18],[5810],{"nctId":14457,"briefTitle":14458,"status":105,"phases":14459,"primaryCompletion":652,"completion":652,"start":2224,"enrollment":14460,"conditions":14461,"interventions":14462},"NCT00740519","Observational Study on Safety of Self-titration of Once Daily Levemir®",[],882,[15,18],[3589],{"nctId":14464,"briefTitle":14465,"status":105,"phases":14466,"primaryCompletion":2306,"completion":2306,"start":3852,"enrollment":14467,"conditions":14468,"interventions":14469},"NCT00658099","Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®",[],699,[15,18],[3589,4967],{"nctId":14471,"briefTitle":14472,"status":105,"phases":14473,"primaryCompletion":5852,"completion":5852,"start":488,"enrollment":14474,"conditions":14475,"interventions":14476},"NCT00842192","An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries",[],2155,[15,18],[3589],{"nctId":6128,"briefTitle":6129,"status":105,"phases":14478,"primaryCompletion":2331,"completion":2331,"start":4015,"enrollment":6131,"conditions":14479,"interventions":14480},[],[15,18],[1978,4471,3589],{"nctId":6135,"briefTitle":6136,"status":105,"phases":14482,"primaryCompletion":4484,"completion":4484,"start":4015,"enrollment":6138,"conditions":14483,"interventions":14484},[],[15,21,18],[3589,4471,1978],{"nctId":14486,"briefTitle":14487,"status":105,"phases":14488,"primaryCompletion":128,"completion":128,"start":2171,"enrollment":14489,"conditions":14490,"interventions":14491},"NCT00709475","Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus",[],747,[15,18],[3589],{"nctId":6142,"briefTitle":6143,"status":105,"phases":14493,"primaryCompletion":2193,"completion":2193,"start":3715,"enrollment":4979,"conditions":14494,"interventions":14495},[],[15,21,18],[3589,1978,5705],{"nctId":14497,"briefTitle":14498,"status":105,"phases":14499,"primaryCompletion":5765,"completion":5765,"start":3493,"enrollment":14500,"conditions":14501,"interventions":14502},"NCT01542424","An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus",[],1889,[15,21,18],[4471,3589],{"nctId":14504,"briefTitle":14505,"status":105,"phases":14506,"primaryCompletion":2204,"completion":2204,"start":3901,"enrollment":14507,"conditions":14508,"interventions":14509},"NCT00704574","Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes",[],159,[15,18],[3589],{"nctId":14511,"briefTitle":14512,"status":105,"phases":14513,"primaryCompletion":2162,"completion":2162,"start":3594,"enrollment":14514,"conditions":14515,"interventions":14516},"NCT00706017","Observational Study to Evaluate the Safety of Levemir® in Diabetes",[],2282,[15,21,18],[3589],{"nctId":14518,"briefTitle":14519,"status":105,"phases":14520,"primaryCompletion":3860,"completion":3860,"start":2205,"enrollment":14521,"conditions":14522,"interventions":14523},"NCT00700960","Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control",[],2745,[15,18],[3589],{"nctId":14525,"briefTitle":14526,"status":105,"phases":14527,"primaryCompletion":3585,"completion":3585,"start":6022,"enrollment":14528,"conditions":14529,"interventions":14530},"NCT00670683","Observational Study of Patients With Diabetes Using Levemir® FlexPen®",[],797,[15,21,18],[3589],{"nctId":6155,"briefTitle":6156,"status":105,"phases":14532,"primaryCompletion":2278,"completion":2278,"start":3739,"enrollment":6158,"conditions":14533,"interventions":14534},[],[15,18],[3589,4471,1978],{"nctId":14536,"briefTitle":14537,"status":105,"phases":14538,"primaryCompletion":488,"completion":488,"start":2279,"enrollment":14539,"conditions":14540,"interventions":14541},"NCT00657930","Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)",[],2289,[15,18],[3589],{"nctId":14543,"briefTitle":14544,"status":105,"phases":14545,"primaryCompletion":3585,"completion":3585,"start":3901,"enrollment":14546,"conditions":14547,"interventions":14548},"NCT00700830","Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes",[],1976,[15,18],[3589],{"nctId":6168,"briefTitle":6129,"status":105,"phases":14550,"primaryCompletion":3699,"completion":3699,"start":3901,"enrollment":6170,"conditions":14551,"interventions":14552},[],[15,18],[1978,3589,4471],{"nctId":14554,"briefTitle":14555,"status":105,"phases":14556,"primaryCompletion":2204,"completion":2204,"start":4015,"enrollment":14557,"conditions":14558,"interventions":14559},"NCT00687284","Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus",[],2188,[15,18],[3589],{"nctId":14561,"briefTitle":14562,"status":105,"phases":14563,"primaryCompletion":4635,"completion":4635,"start":4941,"enrollment":14564,"conditions":14565,"interventions":14566},"NCT00842894","Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia",[],3421,[15,18],[3589,4471],{"nctId":14568,"briefTitle":14569,"status":105,"phases":14570,"primaryCompletion":4015,"completion":4015,"start":2144,"enrollment":14571,"conditions":14572,"interventions":14573},"NCT01545791","Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes",[],1037,[15,21,18],[3589],{"nctId":14575,"briefTitle":14512,"status":105,"phases":14576,"primaryCompletion":4570,"completion":4570,"start":3550,"enrollment":14577,"conditions":14578,"interventions":14579},"NCT00659295",[],51170,[15,21,18],[3589],{"nctId":14581,"briefTitle":14582,"status":105,"phases":14583,"primaryCompletion":3901,"completion":3901,"start":3714,"enrollment":14584,"conditions":14585,"interventions":14586},"NCT00655044","Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes",[],3637,[15,21,18],[3589],{"nctId":14588,"briefTitle":14589,"status":105,"phases":14590,"primaryCompletion":3961,"completion":3961,"start":4398,"enrollment":5600,"conditions":14591,"interventions":14592},"NCT01542476","The Impact of Initiating\u002FSwitching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction",[],[15,21,18],[3589],{"nctId":6188,"briefTitle":6189,"status":105,"phases":14594,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":14595,"interventions":14596},[],[15,18],[6011,6195,4967,1978,4751,3589],{"nctId":14598,"briefTitle":14599,"status":105,"phases":14600,"primaryCompletion":3738,"completion":3738,"start":3961,"enrollment":14601,"conditions":14602,"interventions":14603},"NCT00665808","Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During \"Real-life\" Usage in Germany",[],8125,[15,18],[3589,6090],{"nctId":14605,"briefTitle":14606,"status":105,"phases":14607,"primaryCompletion":2224,"completion":2224,"start":4015,"enrollment":14608,"conditions":14609,"interventions":14610},"NCT00655200","Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus",[],2286,[15,21,18],[3589],{"nctId":14612,"briefTitle":14613,"status":105,"phases":14614,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":14615,"conditions":14616,"interventions":14617},"NCT00789711","An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes",[],3131,[15,21,18],[4471,3589],{"nctId":14619,"briefTitle":14620,"status":105,"phases":14621,"primaryCompletion":6022,"completion":6022,"start":4644,"enrollment":14622,"conditions":14623,"interventions":14624},"NCT01542463","Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes",[],4464,[15,21,18],[3589],{"nctId":14626,"briefTitle":14627,"status":105,"phases":14628,"primaryCompletion":2162,"completion":2162,"start":3901,"enrollment":14629,"conditions":14630,"interventions":14631},"NCT00700765","Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes",[],1531,[15,21,18],[3589],{"nctId":6219,"briefTitle":6220,"status":105,"phases":14633,"primaryCompletion":3462,"completion":3462,"start":488,"enrollment":6222,"conditions":14634,"interventions":14635},[],[15,21],[1978,3589],{"nctId":6226,"briefTitle":6227,"status":105,"phases":14637,"primaryCompletion":3715,"completion":3715,"start":6229,"enrollment":6230,"conditions":14638,"interventions":14639},[],[15,18],[1978,3589],{"nctId":14641,"briefTitle":14442,"status":105,"phases":14642,"primaryCompletion":2224,"completion":2224,"start":6177,"enrollment":1381,"conditions":14643,"interventions":14644},"NCT00671008",[],[15,21,18],[4471,3589],{"nctId":14646,"briefTitle":14647,"status":105,"phases":14648,"primaryCompletion":129,"completion":129,"start":4049,"enrollment":14649,"conditions":14650,"interventions":14651},"NCT00687063","Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes",[],10008,[15,18],[3589],{"nctId":14653,"briefTitle":14654,"status":105,"phases":14655,"primaryCompletion":3157,"completion":3157,"start":14656,"enrollment":14657,"conditions":14658,"interventions":14659},"NCT01892319","An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry",[],"2013-09-30",2446,[2533,21,18],[3589,14660],"other injectable antidiabetic treatment regimens",{"nctId":14662,"briefTitle":14663,"status":105,"phases":14664,"primaryCompletion":2271,"completion":5511,"start":3738,"enrollment":14665,"conditions":14666,"interventions":14667},"NCT00849342","Observational Study on Levemir® in Obese Diabetic Patients",[],580,[15,21,18],[3589],{"nctId":14669,"briefTitle":14670,"status":105,"phases":14671,"primaryCompletion":2331,"completion":2331,"start":2279,"enrollment":1694,"conditions":14672,"interventions":14673},"NCT00735501","Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes",[],[15,18],[3589],{"nctId":14675,"briefTitle":14676,"status":105,"phases":14677,"primaryCompletion":2162,"completion":2162,"start":3714,"enrollment":14678,"conditions":14679,"interventions":14680},"NCT00715351","Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes",[],342,[15,18],[3589,4967],{"intervention":1919,"totalTrials":234,"cells":14682},{"EARLY_PHASE1":14683,"PHASE1":14685,"PHASE2":14884,"PHASE3":14898,"PHASE4":15089,"NA":15095},{"trials":14684,"activeCount":99},[],{"trials":14686,"activeCount":99},[14687,14693,14697,14703,14707,14711,14717,14721,14727,14733,14737,14741,14745,14753,14757,14763,14769,14773,14777,14781,14787,14791,14795,14801,14805,14809,14815,14819,14823,14827,14833,14840,14844,14848,14852,14856,14860,14866,14870,14874,14880],{"nctId":14688,"briefTitle":14689,"status":105,"phases":14690,"primaryCompletion":2163,"completion":2163,"start":5406,"enrollment":2549,"conditions":14691,"interventions":14692},"NCT01865318","Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes",[88],[15,21],[1919],{"nctId":14011,"briefTitle":14012,"status":105,"phases":14694,"primaryCompletion":4635,"completion":4635,"start":2204,"enrollment":3454,"conditions":14695,"interventions":14696},[88],[15,21],[1919,3589],{"nctId":14698,"briefTitle":14699,"status":105,"phases":14700,"primaryCompletion":4635,"completion":4635,"start":2204,"enrollment":372,"conditions":14701,"interventions":14702},"NCT01151072","A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects",[88],[15,27],[1919],{"nctId":4388,"briefTitle":4389,"status":105,"phases":14704,"primaryCompletion":4261,"completion":4261,"start":4391,"enrollment":162,"conditions":14705,"interventions":14706},[88],[15,21],[1919,876],{"nctId":3481,"briefTitle":3482,"status":105,"phases":14708,"primaryCompletion":3484,"completion":3484,"start":652,"enrollment":306,"conditions":14709,"interventions":14710},[88],[15,27],[1919,3487,768],{"nctId":14712,"briefTitle":14713,"status":105,"phases":14714,"primaryCompletion":3873,"completion":3873,"start":5852,"enrollment":2185,"conditions":14715,"interventions":14716},"NCT01193387","Comparison of Two Identical NN1250 Formulations in Healthy Volunteers",[88],[15,27],[1919,1919],{"nctId":4395,"briefTitle":4396,"status":105,"phases":14718,"primaryCompletion":3618,"completion":3618,"start":4398,"enrollment":162,"conditions":14719,"interventions":14720},[88],[15,21,18],[1919,876],{"nctId":14722,"briefTitle":14723,"status":105,"phases":14724,"primaryCompletion":128,"completion":128,"start":4484,"enrollment":335,"conditions":14725,"interventions":14726},"NCT00966368","Comparison of Two NN1250 Formulations in Healthy Volunteers",[88],[15,27],[1919,1919],{"nctId":14728,"briefTitle":14729,"status":105,"phases":14730,"primaryCompletion":3873,"completion":3873,"start":2204,"enrollment":1926,"conditions":14731,"interventions":14732},"NCT01154881","A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes",[88],[15,18],[1919],{"nctId":10831,"briefTitle":10832,"status":105,"phases":14734,"primaryCompletion":5580,"completion":5580,"start":5765,"enrollment":223,"conditions":14735,"interventions":14736},[88],[15,27],[1919,5412],{"nctId":10856,"briefTitle":10857,"status":105,"phases":14738,"primaryCompletion":10859,"completion":10859,"start":10860,"enrollment":34,"conditions":14739,"interventions":14740},[88],[142,21],[10849,1887],{"nctId":5376,"briefTitle":5377,"status":105,"phases":14742,"primaryCompletion":4636,"completion":4636,"start":128,"enrollment":335,"conditions":14743,"interventions":14744},[88],[15,21],[1919,4594,1978],{"nctId":14746,"briefTitle":14747,"status":105,"phases":14748,"primaryCompletion":14749,"completion":14749,"start":14750,"enrollment":306,"conditions":14751,"interventions":14752},"NCT01437592","Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects",[88],"2011-11-22","2011-09-06",[15,27],[1919],{"nctId":14030,"briefTitle":14031,"status":105,"phases":14754,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4542,"conditions":14755,"interventions":14756},[88],[15,18],[1919,3589],{"nctId":14758,"briefTitle":14759,"status":105,"phases":14760,"primaryCompletion":3602,"completion":3602,"start":4643,"enrollment":2252,"conditions":14761,"interventions":14762},"NCT01865279","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec",[88],[15,21,18],[1919,1919,6090],{"nctId":14764,"briefTitle":14765,"status":105,"phases":14766,"primaryCompletion":3585,"completion":3585,"start":4484,"enrollment":1846,"conditions":14767,"interventions":14768},"NCT00964964","A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics",[88],[15,21],[1919,1919],{"nctId":5403,"briefTitle":5404,"status":105,"phases":14770,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":14771,"interventions":14772},[88],[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],{"nctId":3539,"briefTitle":3540,"status":105,"phases":14774,"primaryCompletion":3542,"completion":3542,"start":3543,"enrollment":306,"conditions":14775,"interventions":14776},[88],[15,18],[3487,1919,768],{"nctId":4410,"briefTitle":4411,"status":105,"phases":14778,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":325,"conditions":14779,"interventions":14780},[88],[15,21],[1919,876],{"nctId":14782,"briefTitle":14783,"status":105,"phases":14784,"primaryCompletion":2331,"completion":2331,"start":3462,"enrollment":223,"conditions":14785,"interventions":14786},"NCT01006057","A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function",[88],[15,27],[1919,1919,1919,1919,1919],{"nctId":4427,"briefTitle":4428,"status":105,"phases":14788,"primaryCompletion":2331,"completion":2331,"start":3699,"enrollment":4430,"conditions":14789,"interventions":14790},[88],[15,21],[1919,876],{"nctId":4434,"briefTitle":4435,"status":105,"phases":14792,"primaryCompletion":4437,"completion":4437,"start":4438,"enrollment":4439,"conditions":14793,"interventions":14794},[88],[15,21],[1919,876],{"nctId":14796,"briefTitle":14797,"status":105,"phases":14798,"primaryCompletion":4603,"completion":4603,"start":2171,"enrollment":109,"conditions":14799,"interventions":14800},"NCT01868581","Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects",[88],[15,27],[1919,4594],{"nctId":5467,"briefTitle":5468,"status":105,"phases":14802,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":14803,"interventions":14804},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"nctId":1880,"briefTitle":1881,"status":105,"phases":14806,"primaryCompletion":1883,"completion":1512,"start":1884,"enrollment":119,"conditions":14807,"interventions":14808},[88],[18],[1829,1887],{"nctId":14810,"briefTitle":14811,"status":105,"phases":14812,"primaryCompletion":333,"completion":333,"start":334,"enrollment":1846,"conditions":14813,"interventions":14814},"NCT01623375","A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects",[88],[15,27],[1919,1919],{"nctId":10541,"briefTitle":10542,"status":105,"phases":14816,"primaryCompletion":4015,"completion":4015,"start":6177,"enrollment":223,"conditions":14817,"interventions":14818},[88],[15,27],[1919,5410,5472],{"nctId":4481,"briefTitle":4482,"status":105,"phases":14820,"primaryCompletion":3462,"completion":3462,"start":4484,"enrollment":335,"conditions":14821,"interventions":14822},[88],[15,21],[1919,876],{"nctId":5508,"briefTitle":5509,"status":105,"phases":14824,"primaryCompletion":4336,"completion":4336,"start":5511,"enrollment":2803,"conditions":14825,"interventions":14826},[88],[15,21],[5514,4594,1919,1978],{"nctId":14828,"briefTitle":14829,"status":105,"phases":14830,"primaryCompletion":4570,"completion":4570,"start":4484,"enrollment":5047,"conditions":14831,"interventions":14832},"NCT00976326","A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function",[88],[15,27],[1919],{"nctId":14834,"briefTitle":14835,"status":349,"phases":14836,"primaryCompletion":14837,"completion":14837,"start":7261,"enrollment":1606,"conditions":14838,"interventions":14839},"NCT01467414","A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes",[88],"2011-12",[15,18],[1919],{"nctId":4531,"briefTitle":4532,"status":105,"phases":14841,"primaryCompletion":4534,"completion":4534,"start":4535,"enrollment":1867,"conditions":14842,"interventions":14843},[88],[15,21],[1919,876],{"nctId":4539,"briefTitle":4540,"status":105,"phases":14845,"primaryCompletion":2306,"completion":2306,"start":3901,"enrollment":4542,"conditions":14846,"interventions":14847},[88],[15,21],[1919,876],{"nctId":6693,"briefTitle":6694,"status":105,"phases":14849,"primaryCompletion":6696,"completion":6697,"start":6698,"enrollment":12,"conditions":14850,"interventions":14851},[88],[21],[6679,1887,5810],{"nctId":3696,"briefTitle":3697,"status":105,"phases":14853,"primaryCompletion":3699,"completion":3699,"start":3585,"enrollment":306,"conditions":14854,"interventions":14855},[88],[15,27],[3487,1919,768],{"nctId":5531,"briefTitle":5532,"status":105,"phases":14857,"primaryCompletion":3873,"completion":3873,"start":2278,"enrollment":335,"conditions":14858,"interventions":14859},[88],[15,21],[1919,4594,1978],{"nctId":14861,"briefTitle":14862,"status":105,"phases":14863,"primaryCompletion":2278,"completion":2278,"start":4904,"enrollment":2803,"conditions":14864,"interventions":14865},"NCT01076634","Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes",[88],[15,21],[1919,1919],{"nctId":1912,"briefTitle":1913,"status":105,"phases":14867,"primaryCompletion":1915,"completion":1915,"start":1916,"enrollment":1624,"conditions":14868,"interventions":14869},[88],[15,18],[1829,1919],{"nctId":4567,"briefTitle":4568,"status":105,"phases":14871,"primaryCompletion":4570,"completion":4570,"start":128,"enrollment":413,"conditions":14872,"interventions":14873},[88],[15,21],[1919,876],{"nctId":14875,"briefTitle":14876,"status":105,"phases":14877,"primaryCompletion":334,"completion":334,"start":4320,"enrollment":3454,"conditions":14878,"interventions":14879},"NCT01590836","A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes",[88],[15,21],[1919,4594],{"nctId":1921,"briefTitle":1922,"status":105,"phases":14881,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1926,"conditions":14882,"interventions":14883},[88],[15,1467],[1829,1919],{"trials":14885,"activeCount":99},[14886,14890,14894],{"nctId":4583,"briefTitle":4584,"status":105,"phases":14887,"primaryCompletion":2306,"completion":2306,"start":3901,"enrollment":95,"conditions":14888,"interventions":14889},[89],[15,21],[1919,1919,876,1978],{"nctId":4600,"briefTitle":4601,"status":105,"phases":14891,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":734,"conditions":14892,"interventions":14893},[89],[15,18],[876,1919,1919,1919,226],{"nctId":5555,"briefTitle":5556,"status":105,"phases":14895,"primaryCompletion":4941,"completion":4941,"start":489,"enrollment":5428,"conditions":14896,"interventions":14897},[89],[15,21],[1919,3589,1978],{"trials":14899,"activeCount":99},[14900,14904,14908,14912,14916,14920,14924,14928,14932,14936,14942,14946,14950,14954,14958,14962,14971,14977,14981,14985,14991,14995,15001,15005,15009,15013,15017,15021,15025,15029,15033,15037,15041,15045,15049,15053,15057,15061,15069,15073,15081,15085],{"nctId":1969,"briefTitle":1970,"status":105,"phases":14901,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":1975,"conditions":14902,"interventions":14903},[90],[21],[376,1919,1978],{"nctId":4617,"briefTitle":4618,"status":105,"phases":14905,"primaryCompletion":3873,"completion":3873,"start":4570,"enrollment":1198,"conditions":14906,"interventions":14907},[90],[15,18],[1919,876],{"nctId":4623,"briefTitle":4624,"status":105,"phases":14909,"primaryCompletion":4626,"completion":4626,"start":4627,"enrollment":4628,"conditions":14910,"interventions":14911},[90],[15,18],[1919,876],{"nctId":5584,"briefTitle":5585,"status":105,"phases":14913,"primaryCompletion":1693,"completion":5587,"start":5588,"enrollment":1428,"conditions":14914,"interventions":14915},[90],[21,18],[5439,1311,1887],{"nctId":4648,"briefTitle":4649,"status":105,"phases":14917,"primaryCompletion":3873,"completion":3873,"start":2204,"enrollment":4651,"conditions":14918,"interventions":14919},[90],[15,18],[1919,876],{"nctId":4655,"briefTitle":4656,"status":105,"phases":14921,"primaryCompletion":4658,"completion":4658,"start":4659,"enrollment":4660,"conditions":14922,"interventions":14923},[90],[15,18],[1919,876],{"nctId":4664,"briefTitle":4618,"status":105,"phases":14925,"primaryCompletion":2305,"completion":2305,"start":4570,"enrollment":4050,"conditions":14926,"interventions":14927},[90],[15,18],[1919,876],{"nctId":5605,"briefTitle":5606,"status":105,"phases":14929,"primaryCompletion":2305,"completion":2305,"start":4904,"enrollment":5608,"conditions":14930,"interventions":14931},[90],[15,21],[1919,3589,1978],{"nctId":3906,"briefTitle":3907,"status":105,"phases":14933,"primaryCompletion":3909,"completion":3910,"start":3911,"enrollment":3912,"conditions":14934,"interventions":14935},[90],[15,18],[3487,1919,768],{"nctId":14937,"briefTitle":14938,"status":105,"phases":14939,"primaryCompletion":3873,"completion":3873,"start":4636,"enrollment":1061,"conditions":14940,"interventions":14941},"NCT01046110","Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin",[90],[15,18],[1919,984],{"nctId":1990,"briefTitle":1991,"status":105,"phases":14943,"primaryCompletion":1993,"completion":1051,"start":1994,"enrollment":1995,"conditions":14944,"interventions":14945},[90],[18],[1829,1998,1999,2000],{"nctId":3920,"briefTitle":3921,"status":105,"phases":14947,"primaryCompletion":3923,"completion":3924,"start":3925,"enrollment":3926,"conditions":14948,"interventions":14949},[90],[15,18],[3487,1919,768],{"nctId":4678,"briefTitle":4679,"status":105,"phases":14951,"primaryCompletion":4369,"completion":4369,"start":3462,"enrollment":4681,"conditions":14952,"interventions":14953},[90],[15,18],[1919,1919,876],{"nctId":4695,"briefTitle":4656,"status":105,"phases":14955,"primaryCompletion":2305,"completion":2305,"start":3585,"enrollment":4697,"conditions":14956,"interventions":14957},[90],[15,18],[1919,876],{"nctId":4711,"briefTitle":4712,"status":105,"phases":14959,"primaryCompletion":3873,"completion":3484,"start":4570,"enrollment":4714,"conditions":14960,"interventions":14961},[90],[15,21],[1919,876,1978],{"nctId":14963,"briefTitle":14964,"status":105,"phases":14965,"primaryCompletion":14966,"completion":14967,"start":4155,"enrollment":14968,"conditions":14969,"interventions":14970},"NCT03175120","A Trial Comparing Insulin Degludec\u002FLiraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)",[90],"2019-03-05","2019-04-04",453,[15,18],[4159,1887],{"nctId":14972,"briefTitle":14973,"status":105,"phases":14974,"primaryCompletion":14837,"completion":14837,"start":652,"enrollment":7556,"conditions":14975,"interventions":14976},"NCT01326026","Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus",[90],[15,18],[1919,1919],{"nctId":5666,"briefTitle":5667,"status":105,"phases":14978,"primaryCompletion":2154,"completion":2154,"start":4261,"enrollment":162,"conditions":14979,"interventions":14980},[90],[15,18],[4594,1919,1978,1978],{"nctId":5715,"briefTitle":5716,"status":105,"phases":14982,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":5721,"conditions":14983,"interventions":14984},[90],[15,18],[4709,1311,1887,1478],{"nctId":14986,"briefTitle":14987,"status":105,"phases":14988,"primaryCompletion":274,"completion":274,"start":7687,"enrollment":1061,"conditions":14989,"interventions":14990},"NCT01880736","A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes",[90],[15,18],[1919,1919,1919],{"nctId":4770,"briefTitle":4771,"status":105,"phases":14992,"primaryCompletion":4773,"completion":4774,"start":4775,"enrollment":4776,"conditions":14993,"interventions":14994},[90],[15,18],[1887,1910],{"nctId":14996,"briefTitle":14997,"status":105,"phases":14998,"primaryCompletion":651,"completion":651,"start":4958,"enrollment":5979,"conditions":14999,"interventions":15000},"NCT01364428","Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus",[90],[15,18],[1919,1919],{"nctId":5748,"briefTitle":5749,"status":105,"phases":15002,"primaryCompletion":4225,"completion":4225,"start":961,"enrollment":1178,"conditions":15003,"interventions":15004},[90],[15,18],[4594,1919,1978],{"nctId":4784,"briefTitle":4785,"status":105,"phases":15006,"primaryCompletion":4787,"completion":4787,"start":4320,"enrollment":3361,"conditions":15007,"interventions":15008},[90],[15,18],[1919,876],{"nctId":5782,"briefTitle":5783,"status":105,"phases":15010,"primaryCompletion":5785,"completion":5785,"start":2819,"enrollment":5786,"conditions":15011,"interventions":15012},[90],[15,21],[1919,3589,1978],{"nctId":4799,"briefTitle":4800,"status":105,"phases":15014,"primaryCompletion":4802,"completion":4802,"start":4320,"enrollment":306,"conditions":15015,"interventions":15016},[90],[15,21],[1919,876],{"nctId":2039,"briefTitle":2040,"status":105,"phases":15018,"primaryCompletion":2042,"completion":2043,"start":932,"enrollment":2044,"conditions":15019,"interventions":15020},[90],[18],[1887,1518],{"nctId":4820,"briefTitle":4821,"status":105,"phases":15022,"primaryCompletion":4823,"completion":4823,"start":4824,"enrollment":4825,"conditions":15023,"interventions":15024},[90],[15,18],[1919,876],{"nctId":5803,"briefTitle":5804,"status":105,"phases":15026,"primaryCompletion":5806,"completion":5806,"start":5807,"enrollment":2289,"conditions":15027,"interventions":15028},[90],[15,21],[1887,5281,5810],{"nctId":5812,"briefTitle":5813,"status":105,"phases":15030,"primaryCompletion":5815,"completion":2811,"start":5816,"enrollment":5817,"conditions":15031,"interventions":15032},[90],[15,21],[4709,1978,1919],{"nctId":4107,"briefTitle":4108,"status":105,"phases":15034,"primaryCompletion":4110,"completion":4110,"start":4111,"enrollment":4112,"conditions":15035,"interventions":15036},[90],[15,18],[1919,768],{"nctId":4829,"briefTitle":4830,"status":105,"phases":15038,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":4834,"conditions":15039,"interventions":15040},[90],[15,21],[1919,876,1978],{"nctId":4125,"briefTitle":4126,"status":105,"phases":15042,"primaryCompletion":4128,"completion":4128,"start":3461,"enrollment":4129,"conditions":15043,"interventions":15044},[90],[15,18],[1919,1978,768],{"nctId":4838,"briefTitle":4839,"status":105,"phases":15046,"primaryCompletion":4841,"completion":4841,"start":4833,"enrollment":4842,"conditions":15047,"interventions":15048},[90],[15,18],[1919,876,1978],{"nctId":2048,"briefTitle":2049,"status":105,"phases":15050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":2053,"conditions":15051,"interventions":15052},[90],[18],[1829,1887],{"nctId":4854,"briefTitle":4855,"status":105,"phases":15054,"primaryCompletion":4857,"completion":4857,"start":4858,"enrollment":4859,"conditions":15055,"interventions":15056},[90],[15,21],[1919,876,1978],{"nctId":4872,"briefTitle":4873,"status":105,"phases":15058,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":15059,"interventions":15060},[90],[15,18],[1999,1957],{"nctId":15062,"briefTitle":15063,"status":105,"phases":15064,"primaryCompletion":15065,"completion":5807,"start":15066,"enrollment":1252,"conditions":15067,"interventions":15068},"NCT02911948","A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec\u002FLiraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix\u002FCombination Insulin Therapy and Oral Anti-diabetic Drugs",[90],"2017-11-17","2016-09-21",[15,18],[4159,1887],{"nctId":4150,"briefTitle":4151,"status":105,"phases":15070,"primaryCompletion":4153,"completion":4154,"start":4155,"enrollment":4156,"conditions":15071,"interventions":15072},[90],[15,18],[4159,1887,57],{"nctId":15074,"briefTitle":15075,"status":105,"phases":15076,"primaryCompletion":4111,"completion":15077,"start":15078,"enrollment":4129,"conditions":15079,"interventions":15080},"NCT01392573","A Trial Comparing the Efficacy and Safety of Insulin Degludec\u002FLiraglutide and Insulin Degludec in Subjects With Type 2 Diabetes",[90],"2012-10-04","2011-11-28",[15,18],[3487,1919],{"nctId":5916,"briefTitle":5917,"status":105,"phases":15082,"primaryCompletion":5919,"completion":5920,"start":5816,"enrollment":5921,"conditions":15083,"interventions":15084},[90],[15,21],[4709,1978,1919],{"nctId":4902,"briefTitle":4618,"status":105,"phases":15086,"primaryCompletion":3873,"completion":3873,"start":4904,"enrollment":1198,"conditions":15087,"interventions":15088},[90],[15,18],[1919,876],{"trials":15090,"activeCount":99},[15091],{"nctId":4921,"briefTitle":4922,"status":105,"phases":15092,"primaryCompletion":4924,"completion":4925,"start":4926,"enrollment":4927,"conditions":15093,"interventions":15094},[91],[18],[1887,1910],{"trials":15096,"activeCount":99},[15097,15107,15116,15123,15131,15139,15148,15156,15165],{"nctId":15098,"briefTitle":15099,"status":105,"phases":15100,"primaryCompletion":15101,"completion":15102,"start":15103,"enrollment":15104,"conditions":15105,"interventions":15106},"NCT03674866","A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus",[],"2019-04-25","2019-04-26","2018-10-29",662,[21,18],[1887],{"nctId":15108,"briefTitle":15109,"status":105,"phases":15110,"primaryCompletion":15111,"completion":15111,"start":15112,"enrollment":15113,"conditions":15114,"interventions":15115},"NCT02392117","Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus",[],"2018-03-19","2015-03-16",1262,[15,21,18],[1919],{"nctId":15117,"briefTitle":15118,"status":105,"phases":15119,"primaryCompletion":8271,"completion":8271,"start":931,"enrollment":15120,"conditions":15121,"interventions":15122},"NCT04315688","A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia",[],494,[18],[1919],{"nctId":15124,"briefTitle":15125,"status":105,"phases":15126,"primaryCompletion":15127,"completion":15127,"start":517,"enrollment":15128,"conditions":15129,"interventions":15130},"NCT02779413","A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea",[],"2019-06-24",3303,[15],[1919],{"nctId":15132,"briefTitle":15133,"status":105,"phases":15134,"primaryCompletion":15135,"completion":15135,"start":15136,"enrollment":4362,"conditions":15137,"interventions":15138},"NCT02117622","A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India",[],"2017-04-05","2015-07-24",[15,21,18],[1919],{"nctId":15140,"briefTitle":15141,"status":105,"phases":15142,"primaryCompletion":15143,"completion":15143,"start":15144,"enrollment":15145,"conditions":15146,"interventions":15147},"NCT01984372","Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®",[],"2019-04-30","2013-11-06",6163,[21,18],[1919],{"nctId":15149,"briefTitle":15150,"status":105,"phases":15151,"primaryCompletion":10812,"completion":10812,"start":15152,"enrollment":15153,"conditions":15154,"interventions":15155},"NCT05069545","A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice",[],"2021-10-11",411,[21],[1887,13489],{"nctId":15157,"briefTitle":15158,"status":105,"phases":15159,"primaryCompletion":15160,"completion":15160,"start":15161,"enrollment":15162,"conditions":15163,"interventions":15164},"NCT03785522","A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia",[],"2020-11-30","2018-12-23",597,[18],[1887],{"nctId":15166,"briefTitle":15167,"status":105,"phases":15168,"primaryCompletion":15169,"completion":15169,"start":15170,"enrollment":15171,"conditions":15172,"interventions":15173},"NCT06153537","A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level",[],"2025-03-24","2023-11-29",179,[18],[1887],{"intervention":4471,"totalTrials":7364,"cells":15175},{"EARLY_PHASE1":15176,"PHASE1":15178,"PHASE2":15273,"PHASE3":15296,"PHASE4":15337,"NA":15437},{"trials":15177,"activeCount":99},[],{"trials":15179,"activeCount":99},[15180,15186,15192,15199,15205,15211,15215,15219,15225,15229,15233,15240,15246,15255,15263,15269],{"nctId":15181,"briefTitle":15182,"status":105,"phases":15183,"primaryCompletion":3699,"completion":3699,"start":3585,"enrollment":2803,"conditions":15184,"interventions":15185},"NCT00993096","Investigation of the Response Relationship of NN5401 in Type 1 Diabetics",[88],[15,21],[4594,4594,4594,4471,4471,4471],{"nctId":15187,"briefTitle":15188,"status":105,"phases":15189,"primaryCompletion":2145,"completion":2145,"start":2234,"enrollment":1624,"conditions":15190,"interventions":15191},"NCT01487811","Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers",[88],[15,27],[4471],{"nctId":15193,"briefTitle":15194,"status":105,"phases":15195,"primaryCompletion":3803,"completion":3803,"start":15196,"enrollment":2185,"conditions":15197,"interventions":15198},"NCT01524809","Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes",[88],"2001-01",[15,21],[4471,5457],{"nctId":15200,"briefTitle":15201,"status":105,"phases":15202,"primaryCompletion":3873,"completion":3873,"start":2331,"enrollment":4430,"conditions":15203,"interventions":15204},"NCT01134224","A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes",[88],[15,18],[4594,4594,4594,4471,4471,4471],{"nctId":15206,"briefTitle":15207,"status":105,"phases":15208,"primaryCompletion":3872,"completion":3872,"start":4636,"enrollment":507,"conditions":15209,"interventions":15210},"NCT01051102","Effect of NN5401 in Japanese Subjects With Type 1 Diabetes",[88],[15,21],[4594,4471],{"nctId":5403,"briefTitle":5404,"status":105,"phases":15212,"primaryCompletion":3731,"completion":3731,"start":5406,"enrollment":5407,"conditions":15213,"interventions":15214},[88],[15,21,18],[5410,5411,5412,1919,1978,4471,5411,5412,4471],{"nctId":5449,"briefTitle":5450,"status":105,"phases":15216,"primaryCompletion":5452,"completion":5452,"start":5453,"enrollment":2558,"conditions":15217,"interventions":15218},[88],[15,27],[4471,5456,5457,1978],{"nctId":15220,"briefTitle":15221,"status":105,"phases":15222,"primaryCompletion":3873,"completion":3873,"start":5852,"enrollment":413,"conditions":15223,"interventions":15224},"NCT01174303","A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes",[88],[15,21],[4594,4471],{"nctId":4466,"briefTitle":4467,"status":105,"phases":15226,"primaryCompletion":3961,"completion":3961,"start":3988,"enrollment":306,"conditions":15227,"interventions":15228},[88],[15,18],[4471,876,4472],{"nctId":5467,"briefTitle":5468,"status":105,"phases":15230,"primaryCompletion":4603,"completion":4603,"start":4049,"enrollment":614,"conditions":15231,"interventions":15232},[88],[15,21],[1919,5410,5411,5472,5473,1978,4471],{"nctId":15234,"briefTitle":15235,"status":105,"phases":15236,"primaryCompletion":15237,"completion":15237,"start":3757,"enrollment":335,"conditions":15238,"interventions":15239},"NCT01526941","Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes",[88],"2001-07",[15,21],[4471,5457],{"nctId":15241,"briefTitle":15242,"status":105,"phases":15243,"primaryCompletion":3642,"completion":3642,"start":3650,"enrollment":1546,"conditions":15244,"interventions":15245},"NCT01620424","Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes",[88],[15,18],[4471,5456],{"nctId":15247,"briefTitle":15248,"status":105,"phases":15249,"primaryCompletion":15250,"completion":15250,"start":15251,"enrollment":306,"conditions":15252,"interventions":15253},"NCT01707160","Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers",[88],"1995-12","1995-11",[15,27],[4471,15254],"biphasic human insulin 30",{"nctId":15256,"briefTitle":15257,"status":105,"phases":15258,"primaryCompletion":15259,"completion":15259,"start":15260,"enrollment":5407,"conditions":15261,"interventions":15262},"NCT01538511","Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers",[88],"2007-03-13","2006-06-05",[15,18],[5457,4471],{"nctId":15264,"briefTitle":15265,"status":105,"phases":15266,"primaryCompletion":3714,"completion":3714,"start":5580,"enrollment":306,"conditions":15267,"interventions":15268},"NCT00825253","Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes",[88],[15,18],[4471,15254],{"nctId":5537,"briefTitle":5538,"status":105,"phases":15270,"primaryCompletion":3619,"completion":3619,"start":3602,"enrollment":223,"conditions":15271,"interventions":15272},[88],[15,21],[4471,5456,5457,1978],{"trials":15274,"activeCount":99},[15275,15283,15289],{"nctId":15276,"briefTitle":15277,"status":105,"phases":15278,"primaryCompletion":15279,"completion":15279,"start":15280,"enrollment":5316,"conditions":15281,"interventions":15282},"NCT01697618","Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes",[89],"1998-11","1997-04",[15,18],[4471,15254],{"nctId":15284,"briefTitle":15285,"status":105,"phases":15286,"primaryCompletion":3933,"completion":3933,"start":489,"enrollment":1867,"conditions":15287,"interventions":15288},"NCT00842361","Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus",[89],[15,18],[4594,4471],{"nctId":15290,"briefTitle":15291,"status":105,"phases":15292,"primaryCompletion":4748,"completion":4748,"start":15293,"enrollment":554,"conditions":15294,"interventions":15295},"NCT01526980","Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes",[89],"2002-05",[15,18],[4471,5457,15254],{"trials":15297,"activeCount":99},[15298,15305,15313,15321,15329],{"nctId":15299,"briefTitle":15300,"status":105,"phases":15301,"primaryCompletion":489,"completion":489,"start":4015,"enrollment":15302,"conditions":15303,"interventions":15304},"NCT00627445","Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],441,[15,18],[4471,226,5456],{"nctId":15306,"briefTitle":15307,"status":105,"phases":15308,"primaryCompletion":15309,"completion":15309,"start":15310,"enrollment":3454,"conditions":15311,"interventions":15312},"NCT01486381","Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes",[90],"2003-05-30","2002-03-20",[15,21],[4471],{"nctId":15314,"briefTitle":15315,"status":105,"phases":15316,"primaryCompletion":15317,"completion":15317,"start":15318,"enrollment":192,"conditions":15319,"interventions":15320},"NCT01527539","Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes",[90],"2004-10-12","2001-11-23",[15,18],[4471],{"nctId":15322,"briefTitle":15323,"status":105,"phases":15324,"primaryCompletion":15325,"completion":15325,"start":4659,"enrollment":15326,"conditions":15327,"interventions":15328},"NCT01059812","A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes",[90],"2010-12-23",424,[15,18],[4594,4471],{"nctId":15330,"briefTitle":15331,"status":105,"phases":15332,"primaryCompletion":15333,"completion":15333,"start":15334,"enrollment":4894,"conditions":15335,"interventions":15336},"NCT01009580","Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes",[90],"2010-08-23","2009-11-05",[15,18],[4594,4471],{"trials":15338,"activeCount":99},[15339,15346,15354,15360,15364,15372,15376,15386,15392,15398,15404,15410,15414,15421,15427,15433],{"nctId":15340,"briefTitle":15341,"status":105,"phases":15342,"primaryCompletion":15343,"completion":15343,"start":5928,"enrollment":276,"conditions":15344,"interventions":15345},"NCT01487798","Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes",[91],"2003-11",[15,18],[15254,4471],{"nctId":15347,"briefTitle":15348,"status":105,"phases":15349,"primaryCompletion":15350,"completion":15350,"start":15351,"enrollment":3352,"conditions":15352,"interventions":15353},"NCT01589653","Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients",[91],"2015-07-09","2012-05-26",[15,18],[4471,4471],{"nctId":15355,"briefTitle":15356,"status":105,"phases":15357,"primaryCompletion":3619,"completion":3619,"start":2225,"enrollment":2185,"conditions":15358,"interventions":15359},"NCT01486862","Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs",[91],[15,18],[4471],{"nctId":4931,"briefTitle":4932,"status":105,"phases":15361,"primaryCompletion":923,"completion":923,"start":4438,"enrollment":4934,"conditions":15362,"interventions":15363},[91],[15,18],[4471,876,1978],{"nctId":15365,"briefTitle":15366,"status":105,"phases":15367,"primaryCompletion":4518,"completion":15368,"start":15369,"enrollment":2280,"conditions":15370,"interventions":15371},"NCT00791895","Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs",[91],"2004-11-29","2003-06-26",[15,18],[4471],{"nctId":5993,"briefTitle":5994,"status":105,"phases":15373,"primaryCompletion":4491,"completion":4491,"start":4570,"enrollment":5996,"conditions":15374,"interventions":15375},[91],[15,18],[3589,1978,4471,226],{"nctId":15377,"briefTitle":15378,"status":105,"phases":15379,"primaryCompletion":15380,"completion":15381,"start":15382,"enrollment":15383,"conditions":15384,"interventions":15385},"NCT02582242","Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin",[91],"2017-03-18","2017-04-18","2015-10-19",437,[15,1467],[4471],{"nctId":15387,"briefTitle":15388,"status":105,"phases":15389,"primaryCompletion":128,"completion":128,"start":3738,"enrollment":3361,"conditions":15390,"interventions":15391},"NCT00807092","Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes",[91],[15,18],[4471,15254,226],{"nctId":15393,"briefTitle":15394,"status":105,"phases":15395,"primaryCompletion":4057,"completion":4057,"start":334,"enrollment":1975,"conditions":15396,"interventions":15397},"NCT01519674","Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin",[91],[15,18],[4471,4471,984,226],{"nctId":15399,"briefTitle":15400,"status":105,"phases":15401,"primaryCompletion":3461,"completion":3461,"start":233,"enrollment":15171,"conditions":15402,"interventions":15403},"NCT01278160","Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756",[91],[15,18],[4471,4471,226],{"nctId":15405,"briefTitle":15406,"status":105,"phases":15407,"primaryCompletion":488,"completion":488,"start":3852,"enrollment":4911,"conditions":15408,"interventions":15409},"NCT00669864","Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin",[91],[15,18],[4471,226],{"nctId":4955,"briefTitle":4956,"status":105,"phases":15411,"primaryCompletion":4958,"completion":4958,"start":2331,"enrollment":1815,"conditions":15412,"interventions":15413},[91],[15,18],[4471,226,3597,876],{"nctId":15415,"briefTitle":15416,"status":105,"phases":15417,"primaryCompletion":5511,"completion":5511,"start":334,"enrollment":15418,"conditions":15419,"interventions":15420},"NCT01618214","Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes",[91],344,[15,18],[4471],{"nctId":15422,"briefTitle":15423,"status":105,"phases":15424,"primaryCompletion":4128,"completion":4128,"start":3461,"enrollment":5864,"conditions":15425,"interventions":15426},"NCT01427920","Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes",[91],[15,18],[4471],{"nctId":15428,"briefTitle":15429,"status":105,"phases":15430,"primaryCompletion":4058,"completion":4058,"start":652,"enrollment":734,"conditions":15431,"interventions":15432},"NCT01215435","Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone",[91],[15,18],[4471,4471],{"nctId":6092,"briefTitle":6093,"status":105,"phases":15434,"primaryCompletion":6095,"completion":6095,"start":6096,"enrollment":5774,"conditions":15435,"interventions":15436},[91],[15,18],[4471,1978],{"trials":15438,"activeCount":99},[15439,15446,15455,15462,15469,15476,15483,15490,15497,15504,15511,15515,15522,15528,15535,15542,15549,15553,15557,15561,15565,15569,15575,15579,15583,15590,15594,15601,15608],{"nctId":15440,"briefTitle":15441,"status":105,"phases":15442,"primaryCompletion":6177,"completion":6177,"start":3731,"enrollment":15443,"conditions":15444,"interventions":15445},"NCT00715663","Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes",[],1584,[15,18,4478],[4471],{"nctId":15447,"briefTitle":15448,"status":105,"phases":15449,"primaryCompletion":15450,"completion":15450,"start":15451,"enrollment":15452,"conditions":15453,"interventions":15454},"NCT01536626","Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands",[],"2007-04-10","2006-06-09",211,[15,18],[4471],{"nctId":15456,"briefTitle":15457,"status":105,"phases":15458,"primaryCompletion":5765,"completion":5765,"start":4644,"enrollment":15459,"conditions":15460,"interventions":15461},"NCT01536600","Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes",[],33010,[15,18],[4471],{"nctId":15463,"briefTitle":15464,"status":105,"phases":15465,"primaryCompletion":3901,"completion":3901,"start":2194,"enrollment":15466,"conditions":15467,"interventions":15468},"NCT01486875","Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes",[],1155,[15,18],[4471],{"nctId":15470,"briefTitle":15471,"status":105,"phases":15472,"primaryCompletion":3618,"completion":3618,"start":2194,"enrollment":15473,"conditions":15474,"interventions":15475},"NCT01536652","Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes",[],4994,[15,18],[4471],{"nctId":15477,"briefTitle":15478,"status":105,"phases":15479,"primaryCompletion":2224,"completion":2224,"start":2163,"enrollment":15480,"conditions":15481,"interventions":15482},"NCT00696995","An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment",[],509,[15,18],[4471],{"nctId":15484,"briefTitle":15485,"status":105,"phases":15486,"primaryCompletion":4904,"completion":4904,"start":488,"enrollment":15487,"conditions":15488,"interventions":15489},"NCT00834262","Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients",[],339,[15,18],[4471,5456,5457],{"nctId":15491,"briefTitle":15492,"status":105,"phases":15493,"primaryCompletion":489,"completion":489,"start":2171,"enrollment":15494,"conditions":15495,"interventions":15496},"NCT00675493","Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30",[],942,[15,21,18],[4471],{"nctId":15498,"briefTitle":15499,"status":105,"phases":15500,"primaryCompletion":4941,"completion":4941,"start":2171,"enrollment":15501,"conditions":15502,"interventions":15503},"NCT00709683","Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®",[],216,[15,18],[4471],{"nctId":15505,"briefTitle":15506,"status":105,"phases":15507,"primaryCompletion":2279,"completion":4049,"start":3961,"enrollment":15508,"conditions":15509,"interventions":15510},"NCT00657319","Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins",[],3495,[15,18],[4471],{"nctId":14441,"briefTitle":14442,"status":105,"phases":15512,"primaryCompletion":3901,"completion":3901,"start":3714,"enrollment":14444,"conditions":15513,"interventions":15514},[],[15,21,18],[4471,3589],{"nctId":15516,"briefTitle":15517,"status":105,"phases":15518,"primaryCompletion":2193,"completion":2193,"start":2213,"enrollment":15519,"conditions":15520,"interventions":15521},"NCT01548235","Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment",[],423,[15,18],[4471],{"nctId":15523,"briefTitle":15524,"status":105,"phases":15525,"primaryCompletion":6058,"completion":6058,"start":5739,"enrollment":9566,"conditions":15526,"interventions":15527},"NCT01542060","Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus",[],[15,18],[4471],{"nctId":15529,"briefTitle":15530,"status":105,"phases":15531,"primaryCompletion":4636,"completion":4636,"start":2171,"enrollment":15532,"conditions":15533,"interventions":15534},"NCT00737776","Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes",[],1068,[15,21,18],[4471],{"nctId":15536,"briefTitle":15537,"status":105,"phases":15538,"primaryCompletion":3586,"completion":3586,"start":4049,"enrollment":15539,"conditions":15540,"interventions":15541},"NCT00696163","Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes",[],24975,[15,18],[4471],{"nctId":15543,"briefTitle":15544,"status":105,"phases":15545,"primaryCompletion":5765,"completion":5765,"start":2194,"enrollment":15546,"conditions":15547,"interventions":15548},"NCT01536639","Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes",[],454,[15,18],[4471],{"nctId":6128,"briefTitle":6129,"status":105,"phases":15550,"primaryCompletion":2331,"completion":2331,"start":4015,"enrollment":6131,"conditions":15551,"interventions":15552},[],[15,18],[1978,4471,3589],{"nctId":6135,"briefTitle":6136,"status":105,"phases":15554,"primaryCompletion":4484,"completion":4484,"start":4015,"enrollment":6138,"conditions":15555,"interventions":15556},[],[15,21,18],[3589,4471,1978],{"nctId":14497,"briefTitle":14498,"status":105,"phases":15558,"primaryCompletion":5765,"completion":5765,"start":3493,"enrollment":14500,"conditions":15559,"interventions":15560},[],[15,21,18],[4471,3589],{"nctId":6155,"briefTitle":6156,"status":105,"phases":15562,"primaryCompletion":2278,"completion":2278,"start":3739,"enrollment":6158,"conditions":15563,"interventions":15564},[],[15,18],[3589,4471,1978],{"nctId":6168,"briefTitle":6129,"status":105,"phases":15566,"primaryCompletion":3699,"completion":3699,"start":3901,"enrollment":6170,"conditions":15567,"interventions":15568},[],[15,18],[1978,3589,4471],{"nctId":15570,"briefTitle":15571,"status":105,"phases":15572,"primaryCompletion":4369,"completion":4369,"start":2279,"enrollment":953,"conditions":15573,"interventions":15574},"NCT00729898","Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes",[],[15,18],[4471],{"nctId":14561,"briefTitle":14562,"status":105,"phases":15576,"primaryCompletion":4635,"completion":4635,"start":4941,"enrollment":14564,"conditions":15577,"interventions":15578},[],[15,18],[3589,4471],{"nctId":14612,"briefTitle":14613,"status":105,"phases":15580,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":14615,"conditions":15581,"interventions":15582},[],[15,21,18],[4471,3589],{"nctId":15584,"briefTitle":15585,"status":105,"phases":15586,"primaryCompletion":3585,"completion":3585,"start":2306,"enrollment":15587,"conditions":15588,"interventions":15589},"NCT00699179","Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes",[],2308,[15,21,18],[4471],{"nctId":14641,"briefTitle":14442,"status":105,"phases":15591,"primaryCompletion":2224,"completion":2224,"start":6177,"enrollment":1381,"conditions":15592,"interventions":15593},[],[15,21,18],[4471,3589],{"nctId":15595,"briefTitle":15596,"status":105,"phases":15597,"primaryCompletion":3731,"completion":3731,"start":4644,"enrollment":15598,"conditions":15599,"interventions":15600},"NCT01536613","Post Marketing Surveillance Study of Biphasic Insulin Aspart 30",[],5346,[15,21,18],[4471],{"nctId":15602,"briefTitle":15603,"status":105,"phases":15604,"primaryCompletion":6022,"completion":6022,"start":2163,"enrollment":15605,"conditions":15606,"interventions":15607},"NCT01565733","Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes",[],2223,[15,18],[4471],{"nctId":15609,"briefTitle":15610,"status":105,"phases":15611,"primaryCompletion":233,"completion":233,"start":3739,"enrollment":1245,"conditions":15612,"interventions":15613},"NCT00775736","Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin",[],[15,18],[4471,5456,5457],{"intervention":2831,"totalTrials":363,"cells":15615},{"EARLY_PHASE1":15616,"PHASE1":15618,"PHASE2":15655,"PHASE3":15678,"PHASE4":15824,"NA":15894},{"trials":15617,"activeCount":99},[],{"trials":15619,"activeCount":99},[15620,15627,15635,15645,15649],{"nctId":15621,"briefTitle":15622,"status":105,"phases":15623,"primaryCompletion":2145,"completion":2145,"start":5496,"enrollment":507,"conditions":15624,"interventions":15626},"NCT01502137","Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis",[88],[840,15625,27],"End-Stage Renal Disease",[2831,2831],{"nctId":15628,"briefTitle":15629,"status":105,"phases":15630,"primaryCompletion":15631,"completion":15631,"start":15632,"enrollment":2298,"conditions":15633,"interventions":15634},"NCT00931476","A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin",[88],"2000-06-08","2000-04-06",[2776,2777,27],[2831],{"nctId":15636,"briefTitle":15637,"status":105,"phases":15638,"primaryCompletion":15639,"completion":15639,"start":15640,"enrollment":119,"conditions":15641,"interventions":15644},"NCT01401244","Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers",[88],"2011-09-27","2011-07-14",[7968,15642,9586,15643,27],"Prader-Willi Syndrome","Idiopathic Short Stature",[2831,2831],{"nctId":2824,"briefTitle":2825,"status":105,"phases":15646,"primaryCompletion":2827,"completion":2827,"start":2828,"enrollment":223,"conditions":15647,"interventions":15648},[88],[2776,2778],[2788,2831],{"nctId":15650,"briefTitle":15651,"status":1135,"phases":15652,"primaryCompletion":2132,"completion":2132,"start":4336,"enrollment":99,"conditions":15653,"interventions":15654},"NCT01512095","Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers",[88],[9586,27],[2831,2831],{"trials":15656,"activeCount":99},[15657,15667,15671],{"nctId":15658,"briefTitle":15659,"status":105,"phases":15660,"primaryCompletion":15661,"completion":15661,"start":15662,"enrollment":4217,"conditions":15663,"interventions":15666},"NCT00254514","Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures",[89],"2003-10","2001-08",[15664,15665],"Bone Fracture","Tibia Fractures",[2831],{"nctId":9376,"briefTitle":9377,"status":105,"phases":15668,"primaryCompletion":2278,"completion":2278,"start":4484,"enrollment":554,"conditions":15669,"interventions":15670},[89],[2776,2778],[9348,2831],{"nctId":15672,"briefTitle":15673,"status":105,"phases":15674,"primaryCompletion":5978,"completion":5978,"start":14219,"enrollment":15675,"conditions":15676,"interventions":15677},"NCT00184652","Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease",[89],140,[840,15625],[2831],{"trials":15679,"activeCount":99},[15680,15692,15700,15706,15710,15717,15725,15732,15740,15749,15753,15759,15766,15772,15778,15786,15792,15800,15808,15816],{"nctId":15681,"briefTitle":15682,"status":105,"phases":15683,"primaryCompletion":15684,"completion":15685,"start":15686,"enrollment":15687,"conditions":15688,"interventions":15691},"NCT00184717","Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)",[90],"2006-03-29","2009-12-28","2004-08-18",98,[15689,15690],"Foetal Growth Problem","Small for Gestational Age",[2831,2831],{"nctId":15693,"briefTitle":15694,"status":105,"phases":15695,"primaryCompletion":15696,"completion":15696,"start":15697,"enrollment":7110,"conditions":15698,"interventions":15699},"NCT00557336","Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age",[90],"2005-06-29","2003-07-28",[15689,15690],[2831],{"nctId":15701,"briefTitle":15702,"status":105,"phases":15703,"primaryCompletion":1060,"completion":1060,"start":4383,"enrollment":1986,"conditions":15704,"interventions":15705},"NCT01927861","Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome",[90],[7968,2889],[2831],{"nctId":2855,"briefTitle":2856,"status":105,"phases":15707,"primaryCompletion":2858,"completion":2859,"start":2860,"enrollment":2861,"conditions":15708,"interventions":15709},[90],[2776,2777],[2788,2831],{"nctId":15711,"briefTitle":15712,"status":105,"phases":15713,"primaryCompletion":3619,"completion":3619,"start":4748,"enrollment":15714,"conditions":15715,"interventions":15716},"NCT00184756","Efficacy on Height in SGA Children Treated With Growth Hormone",[90],151,[15689,15690],[2831],{"nctId":15718,"briefTitle":15719,"status":105,"phases":15720,"primaryCompletion":15721,"completion":15721,"start":15722,"enrollment":325,"conditions":15723,"interventions":15724},"NCT01778023","Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature",[90],"2014-12-17","2013-01-17",[9586,15643],[2831],{"nctId":15726,"briefTitle":15727,"status":105,"phases":15728,"primaryCompletion":5978,"completion":5978,"start":15729,"enrollment":306,"conditions":15730,"interventions":15731},"NCT01529840","Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome",[90],"1990-06",[7968,2889],[2831,2831],{"nctId":15733,"briefTitle":15734,"status":105,"phases":15735,"primaryCompletion":15736,"completion":15736,"start":15737,"enrollment":11,"conditions":15738,"interventions":15739},"NCT01518036","Use of Somatropin in Turner Syndrome",[90],"2004-04-11","1987-09-14",[7968,2888],[2831,2831],{"nctId":15741,"briefTitle":15742,"status":105,"phases":15743,"primaryCompletion":5765,"completion":5765,"start":15744,"enrollment":15745,"conditions":15746,"interventions":15748},"NCT00102817","Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children",[90],"2003-05",149,[2776,15747],"Pituitary Dwarfism",[2831],{"nctId":2874,"briefTitle":2875,"status":105,"phases":15750,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":2879,"conditions":15751,"interventions":15752},[90],[2777,2776],[2788,2831],{"nctId":15754,"briefTitle":15755,"status":105,"phases":15756,"primaryCompletion":3619,"completion":3619,"start":3756,"enrollment":442,"conditions":15757,"interventions":15758},"NCT00184678","Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency",[90],[2776,2777],[2831],{"nctId":15760,"briefTitle":15761,"status":349,"phases":15762,"primaryCompletion":3738,"completion":3738,"start":6022,"enrollment":15763,"conditions":15764,"interventions":15765},"NCT00503698","The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis",[90],712,[840,15625],[2831],{"nctId":15767,"briefTitle":15768,"status":105,"phases":15769,"primaryCompletion":5496,"completion":5496,"start":5453,"enrollment":404,"conditions":15770,"interventions":15771},"NCT00184691","Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years",[90],[15689,15690],[2831],{"nctId":15773,"briefTitle":15774,"status":105,"phases":15775,"primaryCompletion":3739,"completion":3739,"start":2224,"enrollment":3454,"conditions":15776,"interventions":15777},"NCT01529944","Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658",[90],[7968,2889],[2831,2831],{"nctId":15779,"briefTitle":15780,"status":105,"phases":15781,"primaryCompletion":15782,"completion":15782,"start":15783,"enrollment":404,"conditions":15784,"interventions":15785},"NCT01502124","Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency",[90],"2003-03-05","2001-05-08",[2776,2778],[2831,2831],{"nctId":15787,"briefTitle":15788,"status":105,"phases":15789,"primaryCompletion":5406,"completion":5406,"start":4794,"enrollment":2298,"conditions":15790,"interventions":15791},"NCT00184730","Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)",[90],[2776,2777],[2831],{"nctId":15793,"briefTitle":15794,"status":105,"phases":15795,"primaryCompletion":15796,"completion":15796,"start":15797,"enrollment":604,"conditions":15798,"interventions":15799},"NCT01563926","Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency",[90],"2002-10-10","2000-10-23",[2776,2778,7968,2888],[2831],{"nctId":15801,"briefTitle":15802,"status":105,"phases":15803,"primaryCompletion":15804,"completion":15804,"start":15805,"enrollment":480,"conditions":15806,"interventions":15807},"NCT00519558","Growth Hormone Deficiency in Adults (GHDA)",[90],"2005-01-24","2003-05-31",[2776,2777],[2831],{"nctId":15809,"briefTitle":15788,"status":105,"phases":15810,"primaryCompletion":15811,"completion":15811,"start":15812,"enrollment":15813,"conditions":15814,"interventions":15815},"NCT00184743",[90],"2005-12-28","2003-12-06",112,[2776,2777],[2831],{"nctId":15817,"briefTitle":15818,"status":105,"phases":15819,"primaryCompletion":7775,"completion":7775,"start":15820,"enrollment":15821,"conditions":15822,"interventions":15823},"NCT00262249","Effect of Growth Hormone in Children With Growth Hormone Deficiency",[90],"2000-08",173,[2776,2778,9586,15643],[2831],{"trials":15825,"activeCount":99},[15826,15834,15841,15849,15856,15864,15868,15876,15885],{"nctId":15827,"briefTitle":15828,"status":105,"phases":15829,"primaryCompletion":15830,"completion":15830,"start":15831,"enrollment":554,"conditions":15832,"interventions":15833},"NCT01734486","Growth Response in Girls With Turner Syndrome",[91],"2003-05-21","1996-09-23",[7968,2888],[2831,2831],{"nctId":15835,"briefTitle":15836,"status":105,"phases":15837,"primaryCompletion":2234,"completion":2234,"start":15838,"enrollment":385,"conditions":15839,"interventions":15840},"NCT01697644","Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation",[91],"1990-10",[15689,15690],[2831,2831],{"nctId":15842,"briefTitle":15843,"status":349,"phases":15844,"primaryCompletion":15845,"completion":15845,"start":15846,"enrollment":422,"conditions":15847,"interventions":15848},"NCT01698944","Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency",[91],"2002-11-18","2001-05-16",[2776,2777],[2831],{"nctId":15850,"briefTitle":15851,"status":105,"phases":15852,"primaryCompletion":2194,"completion":2194,"start":15853,"enrollment":1827,"conditions":15854,"interventions":15855},"NCT00519844","Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction",[91],"2005-07",[15689,15690],[2831],{"nctId":15857,"briefTitle":15858,"status":105,"phases":15859,"primaryCompletion":15860,"completion":15860,"start":15861,"enrollment":11,"conditions":15862,"interventions":15863},"NCT01734447","Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation",[91],"2003-04-30","2000-04-30",[15689,15690],[2831,2831,2831],{"nctId":7963,"briefTitle":7964,"status":105,"phases":15865,"primaryCompletion":3501,"completion":3501,"start":7966,"enrollment":5428,"conditions":15866,"interventions":15867},[91],[7968,2888],[2831,2831,2831,7950],{"nctId":15869,"briefTitle":15870,"status":105,"phases":15871,"primaryCompletion":15872,"completion":15872,"start":15873,"enrollment":3454,"conditions":15874,"interventions":15875},"NCT01562834","Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients",[91],"2002-12-01","1998-10-21",[2776,2777],[2831],{"nctId":15877,"briefTitle":15878,"status":105,"phases":15879,"primaryCompletion":15880,"completion":15880,"start":15881,"enrollment":5006,"conditions":15882,"interventions":15884},"NCT00184769","Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.",[91],"2005-12-21","1998-01-29",[840,15883],"Chronic Renal Insufficiency",[2831],{"nctId":15886,"briefTitle":15887,"status":105,"phases":15888,"primaryCompletion":15889,"completion":15889,"start":15890,"enrollment":15891,"conditions":15892,"interventions":15893},"NCT00567385","Liquid Somatropin Formulation in Children With Growth Hormone Deficiency",[91],"2004-03-22","2003-03-10",176,[2776,2778],[2831],{"trials":15895,"activeCount":99},[15896,15903,15913,15920,15928,15936,15943,15949,15958,15967,15974,15982,15988,15997,16004],{"nctId":15897,"briefTitle":15898,"status":105,"phases":15899,"primaryCompletion":15078,"completion":15078,"start":15900,"enrollment":1428,"conditions":15901,"interventions":15902},"NCT01580605","French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin",[],"2003-07-17",[2776,2777],[2831],{"nctId":15904,"briefTitle":15905,"status":105,"phases":15906,"primaryCompletion":15907,"completion":15907,"start":15908,"enrollment":15909,"conditions":15910,"interventions":15912},"NCT01009905","An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)",[],"2016-09-30","2002-06-24",22960,[2776,15747,15911],"Hypopituitarism",[2831],{"nctId":15914,"briefTitle":15915,"status":105,"phases":15916,"primaryCompletion":233,"completion":233,"start":129,"enrollment":3006,"conditions":15917,"interventions":15918},"NCT00787878","Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects",[],[15689,15690],[2831,15919,15919],"No treatment given",{"nctId":15921,"briefTitle":15922,"status":105,"phases":15923,"primaryCompletion":4823,"completion":4823,"start":3910,"enrollment":15924,"conditions":15925,"interventions":15927},"NCT01435629","A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin",[],81,[7968,15926],"Achondroplasia",[2831],{"nctId":15929,"briefTitle":15930,"status":105,"phases":15931,"primaryCompletion":15932,"completion":15932,"start":15933,"enrollment":1677,"conditions":15934,"interventions":15935},"NCT01578135","French National Registry of Children Born Small for Gestational Age Treated With Somatropin",[],"2018-10-09","2007-03-18",[9586,15690],[2831,2831],{"nctId":15937,"briefTitle":15938,"status":105,"phases":15939,"primaryCompletion":14837,"completion":14837,"start":15196,"enrollment":15940,"conditions":15941,"interventions":15942},"NCT01543867","Safety and Efficacy of Long-term Somatropin Treatment in Children",[],5442,[2776,2778,15689,15690,7968,2888,9586,15643],[2831],{"nctId":15944,"briefTitle":15945,"status":105,"phases":15946,"primaryCompletion":4204,"completion":403,"start":6229,"enrollment":8853,"conditions":15947,"interventions":15948},"NCT01543880","Safety and Efficacy of Long-term Somatropin Treatment in Adults",[],[2776,2777],[2831],{"nctId":15950,"briefTitle":15951,"status":105,"phases":15952,"primaryCompletion":15953,"completion":15953,"start":15954,"enrollment":15955,"conditions":15956,"interventions":15957},"NCT01516229","Special Survey for Long Term Application",[],"2007-03-31","1997-05-01",395,[7968,15926],[2831],{"nctId":15959,"briefTitle":15960,"status":105,"phases":15961,"primaryCompletion":15962,"completion":15962,"start":15963,"enrollment":498,"conditions":15964,"interventions":15965},"NCT03435627","Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)",[],"2022-01-18","2018-02-26",[7968,2889],[15966],"Somatropin",{"nctId":15968,"briefTitle":15969,"status":105,"phases":15970,"primaryCompletion":9293,"completion":9293,"start":128,"enrollment":15971,"conditions":15972,"interventions":15973},"NCT01109017","Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency",[],387,[2776,2777],[2831],{"nctId":15975,"briefTitle":15976,"status":105,"phases":15977,"primaryCompletion":15978,"completion":15978,"start":15979,"enrollment":7494,"conditions":15980,"interventions":15981},"NCT01110928","Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing",[],"2018-11-12","2009-11-26",[15689,15690],[2831],{"nctId":15983,"briefTitle":15984,"status":105,"phases":15985,"primaryCompletion":3860,"completion":3860,"start":3860,"enrollment":624,"conditions":15986,"interventions":15987},"NCT00705172","Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome",[],[7968,15642],[2831],{"nctId":15989,"briefTitle":15990,"status":105,"phases":15991,"primaryCompletion":15992,"completion":15992,"start":15993,"enrollment":15994,"conditions":15995,"interventions":15996},"NCT00960128","Observational Prospective Study on Patients Treated With Norditropin®",[],"2016-12-31","2006-04-01",21249,[2776,2778,2777,7968,2888,15689,15690,840,15883,2889],[2831,2831],{"nctId":15998,"briefTitle":15999,"status":105,"phases":16000,"primaryCompletion":4136,"completion":4136,"start":2234,"enrollment":16001,"conditions":16002,"interventions":16003},"NCT01604161","Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome",[],2016,[2776,2778,7968,2888],[2831],{"nctId":16005,"briefTitle":16006,"status":105,"phases":16007,"primaryCompletion":4204,"completion":403,"start":6191,"enrollment":480,"conditions":16008,"interventions":16009},"NCT00934063","An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®",[],[2776,2777],[2831],{"intervention":226,"totalTrials":1926,"cells":16011},{"EARLY_PHASE1":16012,"PHASE1":16014,"PHASE2":16040,"PHASE3":16073,"PHASE4":16146,"NA":16239},{"trials":16013,"activeCount":99},[],{"trials":16015,"activeCount":99},[16016,16020,16024,16028,16032,16036],{"nctId":218,"briefTitle":219,"status":105,"phases":16017,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":16018,"interventions":16019},[88],[15,27],[112,226,227],{"nctId":301,"briefTitle":302,"status":105,"phases":16021,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":16022,"interventions":16023},[88],[15,18,27],[112,226,309],{"nctId":8414,"briefTitle":8415,"status":105,"phases":16025,"primaryCompletion":4398,"completion":4398,"start":3492,"enrollment":8417,"conditions":16026,"interventions":16027},[88],[15,18],[7618,226,8407],{"nctId":8421,"briefTitle":8422,"status":105,"phases":16029,"primaryCompletion":3619,"completion":3619,"start":3492,"enrollment":37,"conditions":16030,"interventions":16031},[88],[15,18],[7618,226,8407],{"nctId":8427,"briefTitle":8428,"status":105,"phases":16033,"primaryCompletion":128,"completion":128,"start":4484,"enrollment":173,"conditions":16034,"interventions":16035},[88],[15,27],[8407,8407,7618,226],{"nctId":5030,"briefTitle":5031,"status":105,"phases":16037,"primaryCompletion":4809,"completion":4809,"start":5033,"enrollment":285,"conditions":16038,"interventions":16039},[88],[5008],[4985,5036,5037,1478,5038,628],{"trials":16041,"activeCount":99},[16042,16046,16050,16054,16061,16065,16069],{"nctId":3761,"briefTitle":3762,"status":105,"phases":16043,"primaryCompletion":3707,"completion":3707,"start":3764,"enrollment":3361,"conditions":16044,"interventions":16045},[89],[15,18],[768,226,3597],{"nctId":4589,"briefTitle":4590,"status":105,"phases":16047,"primaryCompletion":2162,"completion":2162,"start":3901,"enrollment":95,"conditions":16048,"interventions":16049},[89],[15,18],[4594,4594,876,226],{"nctId":4600,"briefTitle":4601,"status":105,"phases":16051,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":734,"conditions":16052,"interventions":16053},[89],[15,18],[876,1919,1919,1919,226],{"nctId":16055,"briefTitle":16056,"status":105,"phases":16057,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":16058,"conditions":16059,"interventions":16060},"NCT00613951","Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes",[89],182,[15,18],[4594,4594,4751,226],{"nctId":1959,"briefTitle":1960,"status":105,"phases":16062,"primaryCompletion":595,"completion":1953,"start":1866,"enrollment":1962,"conditions":16063,"interventions":16064},[89],[18],[1829,1478,1965,1910],{"nctId":3822,"briefTitle":3823,"status":105,"phases":16066,"primaryCompletion":3610,"completion":3610,"start":3650,"enrollment":22,"conditions":16067,"interventions":16068},[89],[15,18],[768,226],{"nctId":3838,"briefTitle":3839,"status":105,"phases":16070,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":3843,"conditions":16071,"interventions":16072},[89],[15,2937],[57,1478,3846],{"trials":16074,"activeCount":99},[16075,16079,16083,16087,16091,16095,16102,16106,16110,16114,16118,16122,16126,16130,16134,16138,16142],{"nctId":3857,"briefTitle":3858,"status":105,"phases":16076,"primaryCompletion":3714,"completion":3860,"start":2144,"enrollment":3861,"conditions":16077,"interventions":16078},[90],[15,18],[768,226,3597,768,768],{"nctId":3869,"briefTitle":3870,"status":105,"phases":16080,"primaryCompletion":3872,"completion":3873,"start":3586,"enrollment":3874,"conditions":16081,"interventions":16082},[90],[15,18],[768,3589,226],{"nctId":3898,"briefTitle":3899,"status":105,"phases":16084,"primaryCompletion":129,"completion":129,"start":3901,"enrollment":3902,"conditions":16085,"interventions":16086},[90],[15,18],[768,768,768,3597,226],{"nctId":15299,"briefTitle":15300,"status":105,"phases":16088,"primaryCompletion":489,"completion":489,"start":4015,"enrollment":15302,"conditions":16089,"interventions":16090},[90],[15,18],[4471,226,5456],{"nctId":7490,"briefTitle":7491,"status":349,"phases":16092,"primaryCompletion":7493,"completion":7493,"start":3812,"enrollment":7494,"conditions":16093,"interventions":16094},[90],[15,18],[3896,5575,226,3597],{"nctId":16096,"briefTitle":16097,"status":105,"phases":16098,"primaryCompletion":3493,"completion":3493,"start":5766,"enrollment":16099,"conditions":16100,"interventions":16101},"NCT00184574","Comparison of Biphasic Insulin Aspart 70\u002F30, 50\u002F50, and 30\u002F70 in Subjects With Type 2 Diabetes",[90],603,[15,18],[4751,226],{"nctId":3930,"briefTitle":3931,"status":105,"phases":16103,"primaryCompletion":3933,"completion":2204,"start":2306,"enrollment":3934,"conditions":16104,"interventions":16105},[90],[15,18],[768,984,226,768],{"nctId":8549,"briefTitle":8550,"status":105,"phases":16107,"primaryCompletion":3562,"completion":3562,"start":8552,"enrollment":1790,"conditions":16108,"interventions":16109},[90],[15,18],[4751,4752,226],{"nctId":4745,"briefTitle":4746,"status":105,"phases":16111,"primaryCompletion":3500,"completion":3500,"start":4748,"enrollment":1188,"conditions":16112,"interventions":16113},[90],[15,18],[4751,876,226,4752],{"nctId":3986,"briefTitle":3789,"status":105,"phases":16115,"primaryCompletion":3988,"completion":3988,"start":2144,"enrollment":3989,"conditions":16116,"interventions":16117},[90],[15,18],[768,3896,226],{"nctId":5715,"briefTitle":5716,"status":105,"phases":16119,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":5721,"conditions":16120,"interventions":16121},[90],[15,18],[4709,1311,1887,1478],{"nctId":7553,"briefTitle":7554,"status":105,"phases":16123,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":7556,"conditions":16124,"interventions":16125},[90],[15,18],[3589,984,226,4198],{"nctId":8170,"briefTitle":8171,"status":349,"phases":16127,"primaryCompletion":5615,"completion":5615,"start":8173,"enrollment":2861,"conditions":16128,"interventions":16129},[90],[15,18],[3896,5575,226],{"nctId":7514,"briefTitle":7515,"status":349,"phases":16131,"primaryCompletion":7517,"completion":7517,"start":7518,"enrollment":7519,"conditions":16132,"interventions":16133},[90],[15,18],[5575,226,3597,5575],{"nctId":1470,"briefTitle":1471,"status":1135,"phases":16135,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":99,"conditions":16136,"interventions":16137},[90],[18],[75,1218,1478],{"nctId":4161,"briefTitle":4162,"status":105,"phases":16139,"primaryCompletion":4164,"completion":4165,"start":4166,"enrollment":4167,"conditions":16140,"interventions":16141},[90],[15,18],[768,226],{"nctId":4171,"briefTitle":3789,"status":105,"phases":16143,"primaryCompletion":2193,"completion":2193,"start":2144,"enrollment":4173,"conditions":16144,"interventions":16145},[90],[15,18],[768,876,226,3597],{"trials":16147,"activeCount":99},[16148,16152,16156,16162,16166,16170,16178,16186,16190,16194,16198,16202,16206,16212,16216,16224,16231,16235],{"nctId":5983,"briefTitle":5984,"status":349,"phases":16149,"primaryCompletion":334,"completion":334,"start":5366,"enrollment":109,"conditions":16150,"interventions":16151},[91],[15,18],[3589,1978,4967,5705,226],{"nctId":5993,"briefTitle":5994,"status":105,"phases":16153,"primaryCompletion":4491,"completion":4491,"start":4570,"enrollment":5996,"conditions":16154,"interventions":16155},[91],[15,18],[3589,1978,4471,226],{"nctId":16157,"briefTitle":16158,"status":105,"phases":16159,"primaryCompletion":3492,"completion":3492,"start":5978,"enrollment":1668,"conditions":16160,"interventions":16161},"NCT00491725","Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs",[91],[15,18],[7618,226],{"nctId":15387,"briefTitle":15388,"status":105,"phases":16163,"primaryCompletion":128,"completion":128,"start":3738,"enrollment":3361,"conditions":16164,"interventions":16165},[91],[15,18],[4471,15254,226],{"nctId":7986,"briefTitle":7987,"status":105,"phases":16167,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":1495,"conditions":16168,"interventions":16169},[91],[15,18],[7618,226,7973],{"nctId":16171,"briefTitle":16172,"status":105,"phases":16173,"primaryCompletion":16174,"completion":16174,"start":16175,"enrollment":16058,"conditions":16176,"interventions":16177},"NCT01465152","Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes",[91],"2004-10-21","2002-03-06",[15,18],[226,7618],{"nctId":16179,"briefTitle":16180,"status":105,"phases":16181,"primaryCompletion":16182,"completion":16182,"start":16183,"enrollment":7303,"conditions":16184,"interventions":16185},"NCT01720290","Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes",[91],"2003-02-25","2002-07-25",[15,18],[7618,226,226],{"nctId":15393,"briefTitle":15394,"status":105,"phases":16187,"primaryCompletion":4057,"completion":4057,"start":334,"enrollment":1975,"conditions":16188,"interventions":16189},[91],[15,18],[4471,4471,984,226],{"nctId":15399,"briefTitle":15400,"status":105,"phases":16191,"primaryCompletion":3461,"completion":3461,"start":233,"enrollment":15171,"conditions":16192,"interventions":16193},[91],[15,18],[4471,4471,226],{"nctId":4946,"briefTitle":4947,"status":105,"phases":16195,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":4951,"conditions":16196,"interventions":16197},[91],[15,18],[4751,876,226],{"nctId":15405,"briefTitle":15406,"status":105,"phases":16199,"primaryCompletion":488,"completion":488,"start":3852,"enrollment":4911,"conditions":16200,"interventions":16201},[91],[15,18],[4471,226],{"nctId":4955,"briefTitle":4956,"status":105,"phases":16203,"primaryCompletion":4958,"completion":4958,"start":2331,"enrollment":1815,"conditions":16204,"interventions":16205},[91],[15,18],[4471,226,3597,876],{"nctId":16207,"briefTitle":16208,"status":105,"phases":16209,"primaryCompletion":2234,"completion":2234,"start":7775,"enrollment":15675,"conditions":16210,"interventions":16211},"NCT00624364","Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes",[91],[15,18],[4751,226],{"nctId":4969,"briefTitle":4970,"status":105,"phases":16213,"primaryCompletion":4765,"completion":4765,"start":3634,"enrollment":4972,"conditions":16214,"interventions":16215},[91],[15,18],[4751,876,226,3597],{"nctId":16217,"briefTitle":16218,"status":105,"phases":16219,"primaryCompletion":16220,"completion":16220,"start":16221,"enrollment":10700,"conditions":16222,"interventions":16223},"NCT00592969","Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes",[91],"2004-11-02","2003-12-03",[15,18],[226,4751],{"nctId":16225,"briefTitle":16226,"status":105,"phases":16227,"primaryCompletion":3462,"completion":3462,"start":129,"enrollment":16228,"conditions":16229,"interventions":16230},"NCT00819741","Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs",[91],433,[15,18],[7618,226,7618],{"nctId":4976,"briefTitle":4977,"status":105,"phases":16232,"primaryCompletion":4049,"completion":4049,"start":3714,"enrollment":4979,"conditions":16233,"interventions":16234},[91],[15,18],[4751,876,226,3597],{"nctId":4221,"briefTitle":4222,"status":105,"phases":16236,"primaryCompletion":4224,"completion":3517,"start":4225,"enrollment":4226,"conditions":16237,"interventions":16238},[91],[15,18],[768,226,4198],{"trials":16240,"activeCount":99},[16241],{"nctId":16242,"briefTitle":16243,"status":105,"phases":16244,"primaryCompletion":3586,"completion":3586,"start":3901,"enrollment":16245,"conditions":16246,"interventions":16247},"NCT00745433","Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide",[],906,[15,18],[7618,226],{"intervention":4967,"totalTrials":285,"cells":16249},{"EARLY_PHASE1":16250,"PHASE1":16252,"PHASE2":16270,"PHASE3":16276,"PHASE4":16363,"NA":16405},{"trials":16251,"activeCount":99},[],{"trials":16253,"activeCount":99},[16254,16258,16262,16266],{"nctId":14023,"briefTitle":14024,"status":105,"phases":16255,"primaryCompletion":8552,"completion":8552,"start":14026,"enrollment":1624,"conditions":16256,"interventions":16257},[88],[15,18],[3589,4967],{"nctId":14051,"briefTitle":14052,"status":105,"phases":16259,"primaryCompletion":14054,"completion":14054,"start":3706,"enrollment":518,"conditions":16260,"interventions":16261},[88],[15,18],[3589,4967],{"nctId":14078,"briefTitle":14079,"status":105,"phases":16263,"primaryCompletion":2225,"completion":2225,"start":3551,"enrollment":192,"conditions":16264,"interventions":16265},[88],[15,21],[3589,4967],{"nctId":14084,"briefTitle":14085,"status":105,"phases":16267,"primaryCompletion":14087,"completion":14087,"start":3764,"enrollment":992,"conditions":16268,"interventions":16269},[88],[15,21],[3589,4967],{"trials":16271,"activeCount":99},[16272],{"nctId":9673,"briefTitle":9674,"status":105,"phases":16273,"primaryCompletion":3586,"completion":3586,"start":4015,"enrollment":9676,"conditions":16274,"interventions":16275},[89],[15,18],[4967,9664],{"trials":16277,"activeCount":99},[16278,16282,16286,16295,16299,16303,16307,16311,16315,16319,16323,16327,16331,16335,16339,16343,16347,16351,16355,16359],{"nctId":14115,"briefTitle":14116,"status":105,"phases":16279,"primaryCompletion":3988,"completion":3988,"start":5406,"enrollment":14118,"conditions":16280,"interventions":16281},[90],[15,18],[3589,4967],{"nctId":14126,"briefTitle":14127,"status":105,"phases":16283,"primaryCompletion":2213,"completion":2213,"start":14129,"enrollment":14130,"conditions":16284,"interventions":16285},[90],[15,18],[3589,4967],{"nctId":16287,"briefTitle":16288,"status":105,"phases":16289,"primaryCompletion":16290,"completion":16290,"start":16291,"enrollment":16292,"conditions":16293,"interventions":16294},"NCT01562561","Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes",[90],"2002-12-20","2001-06-01",213,[15,18],[7618,4967],{"nctId":14138,"briefTitle":14139,"status":105,"phases":16296,"primaryCompletion":2234,"completion":2234,"start":3634,"enrollment":5948,"conditions":16297,"interventions":16298},[90],[15,18],[3589,4967],{"nctId":5631,"briefTitle":5632,"status":105,"phases":16300,"primaryCompletion":5634,"completion":5634,"start":5418,"enrollment":5635,"conditions":16301,"interventions":16302},[90],[15,21],[5575,1978,4967],{"nctId":5643,"briefTitle":5644,"status":105,"phases":16304,"primaryCompletion":5406,"completion":5406,"start":3550,"enrollment":4859,"conditions":16305,"interventions":16306},[90],[15,21],[3589,4967,1978],{"nctId":14165,"briefTitle":14166,"status":105,"phases":16308,"primaryCompletion":14168,"completion":14168,"start":14169,"enrollment":4492,"conditions":16309,"interventions":16310},[90],[15,21],[3589,4967],{"nctId":5698,"briefTitle":5699,"status":105,"phases":16312,"primaryCompletion":5452,"completion":5452,"start":5701,"enrollment":5702,"conditions":16313,"interventions":16314},[90],[15,21],[1978,5705,4967],{"nctId":5707,"briefTitle":5708,"status":105,"phases":16316,"primaryCompletion":5710,"completion":5710,"start":3802,"enrollment":5711,"conditions":16317,"interventions":16318},[90],[15,21],[3589,1978,4967,5705],{"nctId":5736,"briefTitle":5737,"status":105,"phases":16320,"primaryCompletion":2214,"completion":2214,"start":5739,"enrollment":5740,"conditions":16321,"interventions":16322},[90],[15,18],[4751,4967,1978],{"nctId":14189,"briefTitle":14190,"status":105,"phases":16324,"primaryCompletion":5739,"completion":5739,"start":3706,"enrollment":14192,"conditions":16325,"interventions":16326},[90],[15,18],[3589,4967],{"nctId":5754,"briefTitle":5755,"status":105,"phases":16328,"primaryCompletion":5757,"completion":5757,"start":3764,"enrollment":5758,"conditions":16329,"interventions":16330},[90],[15,21],[3589,4967,1978],{"nctId":5762,"briefTitle":5763,"status":105,"phases":16332,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":5767,"conditions":16333,"interventions":16334},[90],[15,18],[3589,4967,1978],{"nctId":5771,"briefTitle":5772,"status":105,"phases":16336,"primaryCompletion":4748,"completion":4748,"start":2260,"enrollment":5774,"conditions":16337,"interventions":16338},[90],[15,21],[3589,4967,1978],{"nctId":5790,"briefTitle":5791,"status":105,"phases":16340,"primaryCompletion":3634,"completion":3634,"start":5793,"enrollment":335,"conditions":16341,"interventions":16342},[90],[15,5795],[5797,4967,1978],{"nctId":14216,"briefTitle":14217,"status":105,"phases":16344,"primaryCompletion":4765,"completion":4765,"start":14219,"enrollment":1418,"conditions":16345,"interventions":16346},[90],[15,21],[3589,4967],{"nctId":5861,"briefTitle":5862,"status":105,"phases":16348,"primaryCompletion":2224,"completion":2224,"start":3731,"enrollment":5864,"conditions":16349,"interventions":16350},[90],[15,21],[3589,4967,1978],{"nctId":5876,"briefTitle":5877,"status":105,"phases":16352,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":385,"conditions":16353,"interventions":16354},[90],[15,21],[1978,4967],{"nctId":5899,"briefTitle":5900,"status":105,"phases":16356,"primaryCompletion":5902,"completion":5902,"start":5844,"enrollment":2380,"conditions":16357,"interventions":16358},[90],[15,21],[3589,4967,1978],{"nctId":14271,"briefTitle":14272,"status":349,"phases":16360,"primaryCompletion":14274,"completion":14274,"start":14275,"enrollment":173,"conditions":16361,"interventions":16362},[90],[15,18],[5810,14278],{"trials":16364,"activeCount":99},[16365,16369,16373,16381,16385,16389,16393,16397,16401],{"nctId":5983,"briefTitle":5984,"status":349,"phases":16366,"primaryCompletion":334,"completion":334,"start":5366,"enrollment":109,"conditions":16367,"interventions":16368},[91],[15,18],[3589,1978,4967,5705,226],{"nctId":14330,"briefTitle":14331,"status":105,"phases":16370,"primaryCompletion":5852,"completion":5852,"start":488,"enrollment":4439,"conditions":16371,"interventions":16372},[91],[15,18],[3589,4967],{"nctId":16374,"briefTitle":16375,"status":349,"phases":16376,"primaryCompletion":16377,"completion":16377,"start":16378,"enrollment":162,"conditions":16379,"interventions":16380},"NCT00799448","Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes",[91],"2004-09-20","2003-09-16",[15,18],[7618,15254,4967],{"nctId":14348,"briefTitle":14349,"status":349,"phases":16382,"primaryCompletion":3738,"completion":3738,"start":6022,"enrollment":2298,"conditions":16383,"interventions":16384},[91],[15,18],[3589,4967],{"nctId":6019,"briefTitle":6020,"status":349,"phases":16386,"primaryCompletion":2162,"completion":2162,"start":6022,"enrollment":992,"conditions":16387,"interventions":16388},[91],[15,21],[3589,4967,1978],{"nctId":4962,"briefTitle":4963,"status":105,"phases":16390,"primaryCompletion":3618,"completion":3618,"start":3602,"enrollment":1986,"conditions":16391,"interventions":16392},[91],[15,21],[3589,876,4967],{"nctId":6055,"briefTitle":6056,"status":105,"phases":16394,"primaryCompletion":3602,"completion":3602,"start":6058,"enrollment":2803,"conditions":16395,"interventions":16396},[91],[15,18],[1978,4967],{"nctId":6062,"briefTitle":6063,"status":105,"phases":16398,"primaryCompletion":5766,"completion":5766,"start":2214,"enrollment":6065,"conditions":16399,"interventions":16400},[91],[15,21,18],[6011,1978,4967],{"nctId":6069,"briefTitle":6070,"status":105,"phases":16402,"primaryCompletion":3707,"completion":3707,"start":5710,"enrollment":2172,"conditions":16403,"interventions":16404},[91],[15,21],[1978,6011,4967],{"trials":16406,"activeCount":99},[16407,16411,16415],{"nctId":14464,"briefTitle":14465,"status":105,"phases":16408,"primaryCompletion":2306,"completion":2306,"start":3852,"enrollment":14467,"conditions":16409,"interventions":16410},[],[15,18],[3589,4967],{"nctId":6188,"briefTitle":6189,"status":105,"phases":16412,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":16413,"interventions":16414},[],[15,18],[6011,6195,4967,1978,4751,3589],{"nctId":14675,"briefTitle":14676,"status":105,"phases":16416,"primaryCompletion":2162,"completion":2162,"start":3714,"enrollment":14678,"conditions":16417,"interventions":16418},[],[15,18],[3589,4967],{"intervention":4751,"totalTrials":2549,"cells":16420},{"EARLY_PHASE1":16421,"PHASE1":16423,"PHASE2":16425,"PHASE3":16431,"PHASE4":16537,"NA":16612},{"trials":16422,"activeCount":99},[],{"trials":16424,"activeCount":99},[],{"trials":16426,"activeCount":99},[16427],{"nctId":16055,"briefTitle":16056,"status":105,"phases":16428,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":16058,"conditions":16429,"interventions":16430},[89],[15,18],[4594,4594,4751,226],{"trials":16432,"activeCount":99},[16433,16442,16448,16452,16461,16468,16472,16476,16480,16488,16492,16501,16507,16516,16522,16526,16533],{"nctId":16434,"briefTitle":16435,"status":105,"phases":16436,"primaryCompletion":16437,"completion":16437,"start":16438,"enrollment":16439,"conditions":16440,"interventions":16441},"NCT00617565","Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes",[90],"2003-11-26","2003-07-08",219,[15,21,18],[4751,6195],{"nctId":16443,"briefTitle":16444,"status":105,"phases":16445,"primaryCompletion":2214,"completion":2214,"start":15343,"enrollment":1235,"conditions":16446,"interventions":16447},"NCT00280046","Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes",[90],[15,18],[4751],{"nctId":16096,"briefTitle":16097,"status":105,"phases":16449,"primaryCompletion":3493,"completion":3493,"start":5766,"enrollment":16099,"conditions":16450,"interventions":16451},[90],[15,18],[4751,226],{"nctId":16453,"briefTitle":16454,"status":105,"phases":16455,"primaryCompletion":16456,"completion":16456,"start":16457,"enrollment":16458,"conditions":16459,"interventions":16460},"NCT01467375","Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes",[90],"2004-10-22","2001-01-08",89,[15,18],[4751],{"nctId":16462,"briefTitle":16463,"status":105,"phases":16464,"primaryCompletion":2205,"completion":2205,"start":3602,"enrollment":16465,"conditions":16466,"interventions":16467},"NCT00318786","Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes",[90],289,[15,18],[4751],{"nctId":8549,"briefTitle":8550,"status":105,"phases":16469,"primaryCompletion":3562,"completion":3562,"start":8552,"enrollment":1790,"conditions":16470,"interventions":16471},[90],[15,18],[4751,4752,226],{"nctId":4745,"briefTitle":4746,"status":105,"phases":16473,"primaryCompletion":3500,"completion":3500,"start":4748,"enrollment":1188,"conditions":16474,"interventions":16475},[90],[15,18],[4751,876,226,4752],{"nctId":5736,"briefTitle":5737,"status":105,"phases":16477,"primaryCompletion":2214,"completion":2214,"start":5739,"enrollment":5740,"conditions":16478,"interventions":16479},[90],[15,18],[4751,4967,1978],{"nctId":16481,"briefTitle":16482,"status":105,"phases":16483,"primaryCompletion":16484,"completion":16485,"start":2877,"enrollment":14118,"conditions":16486,"interventions":16487},"NCT02648217","Comparing Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan",[90],"2016-09-04","2016-09-05",[15,18],[4594,4751],{"nctId":8467,"briefTitle":8468,"status":105,"phases":16489,"primaryCompletion":6022,"completion":6022,"start":3602,"enrollment":5979,"conditions":16490,"interventions":16491},[90],[15,18],[4751,1131],{"nctId":16493,"briefTitle":16494,"status":105,"phases":16495,"primaryCompletion":16496,"completion":16496,"start":16497,"enrollment":16498,"conditions":16499,"interventions":16500},"NCT00564668","Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes",[90],"2005-04-12","2004-06-19",126,[15,18],[4751],{"nctId":16502,"briefTitle":16503,"status":105,"phases":16504,"primaryCompletion":3550,"completion":3550,"start":3501,"enrollment":385,"conditions":16505,"interventions":16506},"NCT00612599","Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes",[90],[15,18],[4751],{"nctId":16508,"briefTitle":16509,"status":105,"phases":16510,"primaryCompletion":1318,"completion":16511,"start":16512,"enrollment":16513,"conditions":16514,"interventions":16515},"NCT02762578","Comparing Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes",[90],"2017-06-19","2016-05-03",543,[15,18],[4594,4751],{"nctId":16517,"briefTitle":16518,"status":105,"phases":16519,"primaryCompletion":3852,"completion":3852,"start":2193,"enrollment":15924,"conditions":16520,"interventions":16521},"NCT00476437","Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.",[90],[15,18],[4751,6195],{"nctId":5829,"briefTitle":5830,"status":105,"phases":16523,"primaryCompletion":4484,"completion":4484,"start":4794,"enrollment":5832,"conditions":16524,"interventions":16525},[90],[15,18],[4751,3589,1978],{"nctId":16527,"briefTitle":16528,"status":105,"phases":16529,"primaryCompletion":16530,"completion":16530,"start":7776,"enrollment":4103,"conditions":16531,"interventions":16532},"NCT01467323","Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes",[90],"1998-09",[15,21,18],[4751,6195],{"nctId":4908,"briefTitle":4909,"status":105,"phases":16534,"primaryCompletion":3618,"completion":3618,"start":3748,"enrollment":4911,"conditions":16535,"interventions":16536},[90],[15,18],[4751,876],{"trials":16538,"activeCount":99},[16539,16545,16554,16558,16566,16573,16579,16583,16587,16594,16598,16604,16608],{"nctId":16540,"briefTitle":16541,"status":105,"phases":16542,"primaryCompletion":489,"completion":489,"start":3961,"enrollment":442,"conditions":16543,"interventions":16544},"NCT00537277","Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs",[91],[15,18],[4751],{"nctId":16546,"briefTitle":16547,"status":105,"phases":16548,"primaryCompletion":16549,"completion":16549,"start":16550,"enrollment":16551,"conditions":16552,"interventions":16553},"NCT01467401","Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes",[91],"2003-05-15","2002-08-19",292,[15,18],[4751,6195],{"nctId":6026,"briefTitle":6027,"status":105,"phases":16555,"primaryCompletion":4398,"completion":4398,"start":2213,"enrollment":6029,"conditions":16556,"interventions":16557},[91],[15,18],[4751,1978],{"nctId":16559,"briefTitle":16560,"status":105,"phases":16561,"primaryCompletion":16562,"completion":16562,"start":16563,"enrollment":16458,"conditions":16564,"interventions":16565},"NCT01704378","Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes",[91],"2003-03-14","2001-04-18",[15,18],[4751],{"nctId":16567,"briefTitle":16568,"status":105,"phases":16569,"primaryCompletion":5599,"completion":5599,"start":3634,"enrollment":16570,"conditions":16571,"interventions":16572},"NCT00605111","Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes",[91],193,[15,18],[4751],{"nctId":16574,"briefTitle":16575,"status":105,"phases":16576,"primaryCompletion":3619,"completion":3619,"start":15853,"enrollment":2316,"conditions":16577,"interventions":16578},"NCT00184561","Effectiveness and Safety of Biphasic Insulin Aspart 70\u002F30 in Subjects With Type 2 Diabetes",[91],[15,18],[4751],{"nctId":4946,"briefTitle":4947,"status":105,"phases":16580,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":4951,"conditions":16581,"interventions":16582},[91],[15,18],[4751,876,226],{"nctId":16207,"briefTitle":16208,"status":105,"phases":16584,"primaryCompletion":2234,"completion":2234,"start":7775,"enrollment":15675,"conditions":16585,"interventions":16586},[91],[15,18],[4751,226],{"nctId":16588,"briefTitle":16589,"status":105,"phases":16590,"primaryCompletion":3492,"completion":3492,"start":5599,"enrollment":16591,"conditions":16592,"interventions":16593},"NCT00101751","INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study",[91],4877,[15,18],[4751],{"nctId":4969,"briefTitle":4970,"status":105,"phases":16595,"primaryCompletion":4765,"completion":4765,"start":3634,"enrollment":4972,"conditions":16596,"interventions":16597},[91],[15,18],[4751,876,226,3597],{"nctId":16599,"briefTitle":16600,"status":105,"phases":16601,"primaryCompletion":3748,"completion":3748,"start":3500,"enrollment":498,"conditions":16602,"interventions":16603},"NCT00600366","Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes",[91],[15,18],[4751],{"nctId":16217,"briefTitle":16218,"status":105,"phases":16605,"primaryCompletion":16220,"completion":16220,"start":16221,"enrollment":10700,"conditions":16606,"interventions":16607},[91],[15,18],[226,4751],{"nctId":4976,"briefTitle":4977,"status":105,"phases":16609,"primaryCompletion":4049,"completion":4049,"start":3714,"enrollment":4979,"conditions":16610,"interventions":16611},[91],[15,18],[4751,876,226,3597],{"trials":16613,"activeCount":99},[16614,16618,16627,16634,16641],{"nctId":6102,"briefTitle":6103,"status":105,"phases":16615,"primaryCompletion":652,"completion":652,"start":3860,"enrollment":6105,"conditions":16616,"interventions":16617},[],[15,18],[1978,3589,4751],{"nctId":16619,"briefTitle":16620,"status":105,"phases":16621,"primaryCompletion":16622,"completion":16622,"start":16623,"enrollment":16624,"conditions":16625,"interventions":16626},"NCT00659282","Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes",[],"2008-11-15","2006-09-11",57610,[15,18],[4751],{"nctId":16628,"briefTitle":16629,"status":105,"phases":16630,"primaryCompletion":4941,"completion":4941,"start":3961,"enrollment":16631,"conditions":16632,"interventions":16633},"NCT00698126","Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes",[],4099,[15,18],[6011,4751],{"nctId":16635,"briefTitle":16636,"status":105,"phases":16637,"primaryCompletion":3860,"completion":3860,"start":2171,"enrollment":16638,"conditions":16639,"interventions":16640},"NCT00704223","Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes",[],619,[15,18],[4751],{"nctId":6188,"briefTitle":6189,"status":105,"phases":16642,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":16643,"interventions":16644},[],[15,18],[6011,6195,4967,1978,4751,3589],{"intervention":4594,"totalTrials":2549,"cells":16646},{"EARLY_PHASE1":16647,"PHASE1":16649,"PHASE2":16713,"PHASE3":16727,"PHASE4":16800,"NA":16802},{"trials":16648,"activeCount":99},[],{"trials":16650,"activeCount":99},[16651,16655,16661,16667,16671,16675,16679,16683,16687,16693,16701,16705,16709],{"nctId":15181,"briefTitle":15182,"status":105,"phases":16652,"primaryCompletion":3699,"completion":3699,"start":3585,"enrollment":2803,"conditions":16653,"interventions":16654},[88],[15,21],[4594,4594,4594,4471,4471,4471],{"nctId":16656,"briefTitle":16657,"status":105,"phases":16658,"primaryCompletion":3873,"completion":3873,"start":2204,"enrollment":578,"conditions":16659,"interventions":16660},"NCT01138488","A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec\u002FInsulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes",[88],[15,21],[4594],{"nctId":16662,"briefTitle":16663,"status":105,"phases":16664,"primaryCompletion":651,"completion":651,"start":7261,"enrollment":223,"conditions":16665,"interventions":16666},"NCT01455142","A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes",[88],[15,21],[4594],{"nctId":5376,"briefTitle":5377,"status":105,"phases":16668,"primaryCompletion":4636,"completion":4636,"start":128,"enrollment":335,"conditions":16669,"interventions":16670},[88],[15,21],[1919,4594,1978],{"nctId":15200,"briefTitle":15201,"status":105,"phases":16672,"primaryCompletion":3873,"completion":3873,"start":2331,"enrollment":4430,"conditions":16673,"interventions":16674},[88],[15,18],[4594,4594,4594,4471,4471,4471],{"nctId":15206,"briefTitle":15207,"status":105,"phases":16676,"primaryCompletion":3872,"completion":3872,"start":4636,"enrollment":507,"conditions":16677,"interventions":16678},[88],[15,21],[4594,4471],{"nctId":15220,"briefTitle":15221,"status":105,"phases":16680,"primaryCompletion":3873,"completion":3873,"start":5852,"enrollment":413,"conditions":16681,"interventions":16682},[88],[15,21],[4594,4471],{"nctId":14796,"briefTitle":14797,"status":105,"phases":16684,"primaryCompletion":4603,"completion":4603,"start":2171,"enrollment":109,"conditions":16685,"interventions":16686},[88],[15,27],[1919,4594],{"nctId":16688,"briefTitle":16689,"status":105,"phases":16690,"primaryCompletion":5852,"completion":5852,"start":2331,"enrollment":2185,"conditions":16691,"interventions":16692},"NCT01125553","A Comparison Between Two Formulations of NN5401 in Healthy Subjects",[88],[15,27],[4594],{"nctId":16694,"briefTitle":16695,"status":105,"phases":16696,"primaryCompletion":16697,"completion":16698,"start":10481,"enrollment":306,"conditions":16699,"interventions":16700},"NCT02844790","A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec\u002FInsulin Aspart in Healthy Chinese Subjects",[88],"2016-09-26","2016-09-27",[27],[4594],{"nctId":5508,"briefTitle":5509,"status":105,"phases":16702,"primaryCompletion":4336,"completion":4336,"start":5511,"enrollment":2803,"conditions":16703,"interventions":16704},[88],[15,21],[5514,4594,1919,1978],{"nctId":5531,"briefTitle":5532,"status":105,"phases":16706,"primaryCompletion":3873,"completion":3873,"start":2278,"enrollment":335,"conditions":16707,"interventions":16708},[88],[15,21],[1919,4594,1978],{"nctId":14875,"briefTitle":14876,"status":105,"phases":16710,"primaryCompletion":334,"completion":334,"start":4320,"enrollment":3454,"conditions":16711,"interventions":16712},[88],[15,21],[1919,4594],{"trials":16714,"activeCount":99},[16715,16719,16723],{"nctId":4589,"briefTitle":4590,"status":105,"phases":16716,"primaryCompletion":2162,"completion":2162,"start":3901,"enrollment":95,"conditions":16717,"interventions":16718},[89],[15,18],[4594,4594,876,226],{"nctId":16055,"briefTitle":16056,"status":105,"phases":16720,"primaryCompletion":4603,"completion":4603,"start":3901,"enrollment":16058,"conditions":16721,"interventions":16722},[89],[15,18],[4594,4594,4751,226],{"nctId":15284,"briefTitle":15285,"status":105,"phases":16724,"primaryCompletion":3933,"completion":3933,"start":489,"enrollment":1867,"conditions":16725,"interventions":16726},[89],[15,18],[4594,4471],{"trials":16728,"activeCount":99},[16729,16733,16737,16741,16745,16752,16756,16760,16764,16768,16777,16784,16788,16792,16796],{"nctId":4632,"briefTitle":4633,"status":105,"phases":16730,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":838,"conditions":16731,"interventions":16732},[90],[15,18],[4594,876],{"nctId":4685,"briefTitle":4686,"status":105,"phases":16734,"primaryCompletion":4688,"completion":4689,"start":923,"enrollment":4690,"conditions":16735,"interventions":16736},[90],[15,18],[4693,1910,1311],{"nctId":4718,"briefTitle":4719,"status":105,"phases":16738,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4721,"conditions":16739,"interventions":16740},[90],[15,18],[4594,876],{"nctId":5666,"briefTitle":5667,"status":105,"phases":16742,"primaryCompletion":2154,"completion":2154,"start":4261,"enrollment":162,"conditions":16743,"interventions":16744},[90],[15,18],[4594,1919,1978,1978],{"nctId":16746,"briefTitle":16747,"status":105,"phases":16748,"primaryCompletion":16749,"completion":16749,"start":2819,"enrollment":5740,"conditions":16750,"interventions":16751},"NCT01513590","A Trial Comparing Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes",[90],"2012-11-19",[15,18],[4594],{"nctId":4734,"briefTitle":4735,"status":105,"phases":16753,"primaryCompletion":3461,"completion":3461,"start":233,"enrollment":4737,"conditions":16754,"interventions":16755},[90],[15,18],[4594,876],{"nctId":5748,"briefTitle":5749,"status":105,"phases":16757,"primaryCompletion":4225,"completion":4225,"start":961,"enrollment":1178,"conditions":16758,"interventions":16759},[90],[15,18],[4594,1919,1978],{"nctId":15322,"briefTitle":15323,"status":105,"phases":16761,"primaryCompletion":15325,"completion":15325,"start":4659,"enrollment":15326,"conditions":16762,"interventions":16763},[90],[15,18],[4594,4471],{"nctId":16481,"briefTitle":16482,"status":105,"phases":16765,"primaryCompletion":16484,"completion":16485,"start":2877,"enrollment":14118,"conditions":16766,"interventions":16767},[90],[15,18],[4594,4751],{"nctId":16769,"briefTitle":16770,"status":105,"phases":16771,"primaryCompletion":16772,"completion":16772,"start":16773,"enrollment":16774,"conditions":16775,"interventions":16776},"NCT01680341","Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec\u002FInsulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine",[90],"2013-08-22","2012-08-31",272,[15,18],[4594,4594],{"nctId":16778,"briefTitle":16779,"status":105,"phases":16780,"primaryCompletion":4320,"completion":4320,"start":4958,"enrollment":16781,"conditions":16782,"interventions":16783},"NCT01365507","Efficacy and Safety of Insulin Degludec\u002FInsulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens",[90],276,[15,18],[4594],{"nctId":16508,"briefTitle":16509,"status":105,"phases":16785,"primaryCompletion":1318,"completion":16511,"start":16512,"enrollment":16513,"conditions":16786,"interventions":16787},[90],[15,18],[4594,4751],{"nctId":15330,"briefTitle":15331,"status":105,"phases":16789,"primaryCompletion":15333,"completion":15333,"start":15334,"enrollment":4894,"conditions":16790,"interventions":16791},[90],[15,18],[4594,4471],{"nctId":5892,"briefTitle":5893,"status":105,"phases":16793,"primaryCompletion":2331,"completion":2331,"start":4484,"enrollment":5895,"conditions":16794,"interventions":16795},[90],[15,21],[4594,3589,1978,1978],{"nctId":5943,"briefTitle":5944,"status":105,"phases":16797,"primaryCompletion":5946,"completion":5946,"start":5947,"enrollment":5948,"conditions":16798,"interventions":16799},[90],[15,21],[4594,1978,3589,1978],{"trials":16801,"activeCount":99},[],{"trials":16803,"activeCount":99},[16804,16812,16821,16830,16838],{"nctId":16805,"briefTitle":16806,"status":105,"phases":16807,"primaryCompletion":2323,"completion":2323,"start":16808,"enrollment":16809,"conditions":16810,"interventions":16811},"NCT02230618","Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec\u002FInsulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India",[],"2015-11-24",1029,[15,21,18],[4594],{"nctId":16813,"briefTitle":16814,"status":105,"phases":16815,"primaryCompletion":16816,"completion":16816,"start":16817,"enrollment":16818,"conditions":16819,"interventions":16820},"NCT02821052","Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®",[],"2018-11-24","2016-07-01",1355,[15],[4594],{"nctId":16822,"briefTitle":16823,"status":105,"phases":16824,"primaryCompletion":16825,"completion":16825,"start":16826,"enrollment":4439,"conditions":16827,"interventions":16828},"NCT04892069","Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon",[],"2021-11-18","2021-05-27",[18],[16829],"Insulin Degludec\u002FInsulin Aspart",{"nctId":16831,"briefTitle":16832,"status":105,"phases":16833,"primaryCompletion":4422,"completion":4422,"start":16834,"enrollment":16835,"conditions":16836,"interventions":16837},"NCT03745157","RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan",[],"2018-11-21",246,[18],[16829],{"nctId":16839,"briefTitle":16840,"status":105,"phases":16841,"primaryCompletion":16842,"completion":16842,"start":3200,"enrollment":16843,"conditions":16844,"interventions":16845},"NCT04042441","A Research Study, Looking at How Ryzodeg® (Insulin Degludec\u002FInsulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice",[],"2020-12-11",1122,[18],[16829],{"intervention":2157,"totalTrials":708,"cells":16847},{"EARLY_PHASE1":16848,"PHASE1":16850,"PHASE2":16887,"PHASE3":16986,"PHASE4":17001,"NA":17013},{"trials":16849,"activeCount":99},[],{"trials":16851,"activeCount":99},[16852,16859,16865,16871,16875,16881],{"nctId":16853,"briefTitle":16854,"status":105,"phases":16855,"primaryCompletion":16856,"completion":16856,"start":3610,"enrollment":4430,"conditions":16857,"interventions":16858},"NCT01563471","Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers",[88],"2002-07",[30,2136,2138,27],[2157],{"nctId":16860,"briefTitle":16861,"status":105,"phases":16862,"primaryCompletion":5406,"completion":5406,"start":3602,"enrollment":413,"conditions":16863,"interventions":16864},"NCT01561417","Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects",[88],[2197,2310,30,2308,2309,2136,2138,27],[2157,2157],{"nctId":16866,"briefTitle":16867,"status":105,"phases":16868,"primaryCompletion":3602,"completion":3602,"start":2145,"enrollment":119,"conditions":16869,"interventions":16870},"NCT01562457","Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State",[88],[30,36,2137],[2157],{"nctId":2150,"briefTitle":2151,"status":1135,"phases":16872,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":99,"conditions":16873,"interventions":16874},[88],[30,36,2136,2137,2138,27],[2157,2122],{"nctId":16876,"briefTitle":16877,"status":105,"phases":16878,"primaryCompletion":15744,"completion":15744,"start":5964,"enrollment":1846,"conditions":16879,"interventions":16880},"NCT01562587","Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State",[88],[30,36,2137],[2157,2157],{"nctId":16882,"briefTitle":16883,"status":105,"phases":16884,"primaryCompletion":4794,"completion":4794,"start":3550,"enrollment":2252,"conditions":16885,"interventions":16886},"NCT00104455","Dose Response to Recombinant Factor VIIa When Administered for Bleed",[88],[30,27],[2157],{"trials":16888,"activeCount":99},[16889,16895,16903,16910,16918,16924,16932,16936,16942,16949,16954,16960,16967,16974,16980],{"nctId":16890,"briefTitle":16891,"status":105,"phases":16892,"primaryCompletion":3706,"completion":3706,"start":3641,"enrollment":162,"conditions":16893,"interventions":16894},"NCT01563445","Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage",[89],[2197,2198],[2157],{"nctId":16896,"briefTitle":16897,"status":349,"phases":16898,"primaryCompletion":3852,"completion":3852,"start":8552,"enrollment":16899,"conditions":16900,"interventions":16902},"NCT00154427","Use of Activated Recombinant Human Factor VII in Cardiac Surgery",[89],172,[2197,16901],"Cardiac Surgery Requiring Cardiopulmonary Bypass",[2157],{"nctId":16904,"briefTitle":16905,"status":105,"phases":16906,"primaryCompletion":4748,"completion":4748,"start":15237,"enrollment":413,"conditions":16907,"interventions":16909},"NCT01601613","Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever",[89],[2197,16908],"Dengue Haemorrhagic Fever",[2157],{"nctId":16911,"briefTitle":16912,"status":105,"phases":16913,"primaryCompletion":3707,"completion":3707,"start":15237,"enrollment":16914,"conditions":16915,"interventions":16917},"NCT01562821","Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy",[89],235,[2197,16916],"Cirrhosis",[2157,2157],{"nctId":16919,"briefTitle":16920,"status":105,"phases":16921,"primaryCompletion":15661,"completion":15661,"start":3642,"enrollment":528,"conditions":16922,"interventions":16923},"NCT01562158","Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation",[89],[2197,9949],[2157,2157,2157],{"nctId":16925,"briefTitle":16926,"status":105,"phases":16927,"primaryCompletion":15343,"completion":15343,"start":2260,"enrollment":422,"conditions":16928,"interventions":16931},"NCT01561352","Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis",[89],[16929,16930],"Other Haemostasis Disorder","Haemorrhagic Cystitis",[2157],{"nctId":9943,"briefTitle":9944,"status":349,"phases":16933,"primaryCompletion":9946,"completion":9946,"start":9947,"enrollment":3578,"conditions":16934,"interventions":16935},[89],[2197,9949],[9934,2157,2157],{"nctId":16937,"briefTitle":16938,"status":105,"phases":16939,"primaryCompletion":2144,"completion":2144,"start":3748,"enrollment":234,"conditions":16940,"interventions":16941},"NCT00123591","Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury",[89],[2197,2228],[2157],{"nctId":16943,"briefTitle":16944,"status":105,"phases":16945,"primaryCompletion":15661,"completion":15661,"start":3802,"enrollment":16946,"conditions":16947,"interventions":16948},"NCT01563523","Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients",[89],283,[2197,2228],[2157],{"nctId":16950,"briefTitle":2232,"status":105,"phases":16951,"primaryCompletion":3550,"completion":3550,"start":3764,"enrollment":1381,"conditions":16952,"interventions":16953},"NCT00426803",[89],[2197,2198],[2157],{"nctId":16955,"briefTitle":16956,"status":105,"phases":16957,"primaryCompletion":3551,"completion":3551,"start":5964,"enrollment":699,"conditions":16958,"interventions":16959},"NCT01601457","Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction",[89],[2197,2228],[2157],{"nctId":16961,"briefTitle":16962,"status":105,"phases":16963,"primaryCompletion":4398,"completion":4398,"start":3551,"enrollment":16964,"conditions":16965,"interventions":16966},"NCT00154492","Use of NovoSeven® in Active Variceal Bleeding",[89],265,[2197,16916],[2157],{"nctId":16968,"briefTitle":16969,"status":105,"phases":16970,"primaryCompletion":5757,"completion":5757,"start":15662,"enrollment":16971,"conditions":16972,"interventions":16973},"NCT01563458","Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation",[89],208,[2197,9949],[2157,2157],{"nctId":16975,"briefTitle":16976,"status":105,"phases":16977,"primaryCompletion":5710,"completion":5710,"start":15662,"enrollment":699,"conditions":16978,"interventions":16979},"NCT01566786","Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage",[89],[2197,2198],[2157],{"nctId":16981,"briefTitle":16982,"status":105,"phases":16983,"primaryCompletion":2145,"completion":2145,"start":3500,"enrollment":992,"conditions":16984,"interventions":16985},"NCT00108758","Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia",[89],[30,2136,2138],[2157],{"trials":16987,"activeCount":99},[16988,16994],{"nctId":16989,"briefTitle":16990,"status":1135,"phases":16991,"primaryCompletion":2205,"completion":2205,"start":2144,"enrollment":99,"conditions":16992,"interventions":16993},"NCT00323570","Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma",[90],[2197,2228],[2157],{"nctId":16995,"briefTitle":16996,"status":105,"phases":16997,"primaryCompletion":8552,"completion":8552,"start":16998,"enrollment":5519,"conditions":16999,"interventions":17000},"NCT01562574","Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease",[90],"2002-01",[2197,16901],[2157],{"trials":17002,"activeCount":99},[17003,17007],{"nctId":7772,"briefTitle":7773,"status":105,"phases":17004,"primaryCompletion":7775,"completion":7775,"start":7776,"enrollment":2549,"conditions":17005,"interventions":17006},[91],[30,2136,2138],[2157,2157,7759],{"nctId":17008,"briefTitle":17009,"status":105,"phases":17010,"primaryCompletion":3500,"completion":3500,"start":4748,"enrollment":306,"conditions":17011,"interventions":17012},"NCT00571584","High Dose of Activated Recombinant Human Factor VII for Treatment of Mild\u002FModerate Joint Bleeds in Haemophilia Patients With Inhibitors",[91],[30,2136,2138],[2157],{"trials":17014,"activeCount":99},[17015,17025,17032,17040,17046,17052,17058,17065,17071],{"nctId":17016,"briefTitle":17017,"status":105,"phases":17018,"primaryCompletion":651,"completion":651,"start":2225,"enrollment":3518,"conditions":17019,"interventions":17020},"NCT01779921","Treatment of Congenital Factor VII Deficiency",[],[30,2308],[2157,17021,17022,17023,17024,17024],"Fresh frozen plasma","Plasma-derived FVII","Prothrombin Complex conc.","Plasma-derived FVII conc.",{"nctId":17026,"briefTitle":17027,"status":105,"phases":17028,"primaryCompletion":4958,"completion":4958,"start":3901,"enrollment":17029,"conditions":17030,"interventions":17031},"NCT00853086","Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database",[],139,[30,36,2137],[2157],{"nctId":17033,"briefTitle":17034,"status":105,"phases":17035,"primaryCompletion":17036,"completion":17036,"start":17037,"enrollment":4542,"conditions":17038,"interventions":17039},"NCT00124293","Incidence\u002FMagnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury",[],"2005-11-23","2004-10-06",[2197,2228],[2157],{"nctId":17041,"briefTitle":17042,"status":105,"phases":17043,"primaryCompletion":4057,"completion":4057,"start":2305,"enrollment":507,"conditions":17044,"interventions":17045},"NCT01285089","Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia",[],[2197,2310],[2157],{"nctId":17047,"briefTitle":17048,"status":105,"phases":17049,"primaryCompletion":4320,"completion":4320,"start":4635,"enrollment":2558,"conditions":17050,"interventions":17051},"NCT01234545","Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors",[],[30,36,2137],[2157],{"nctId":17053,"briefTitle":17054,"status":105,"phases":17055,"primaryCompletion":172,"completion":172,"start":652,"enrollment":2549,"conditions":17056,"interventions":17057},"NCT01312636","Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency",[],[30,2308],[2157],{"nctId":17059,"briefTitle":17060,"status":105,"phases":17061,"primaryCompletion":17062,"completion":17062,"start":3873,"enrollment":1986,"conditions":17063,"interventions":17064},"NCT01220141","Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B",[],"2015-03",[30,36,2137],[2157],{"nctId":17066,"briefTitle":17067,"status":105,"phases":17068,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":363,"conditions":17069,"interventions":17070},"NCT00710619","Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX",[],[30,2136,2138],[2157,2263],{"nctId":17072,"briefTitle":17073,"status":105,"phases":17074,"primaryCompletion":7261,"completion":7261,"start":5739,"enrollment":1738,"conditions":17075,"interventions":17076},"NCT01476423","Observational Registry of the Treatment of Glanzmann's Thrombasthenia",[],[30,2309],[2157],{"intervention":4709,"totalTrials":192,"cells":17078},{"EARLY_PHASE1":17079,"PHASE1":17081,"PHASE2":17151,"PHASE3":17153,"PHASE4":17193,"NA":17195},{"trials":17080,"activeCount":99},[],{"trials":17082,"activeCount":99},[17083,17087,17091,17095,17099,17103,17107,17111,17115,17119,17123,17127,17135,17139,17143,17147],{"nctId":5274,"briefTitle":5275,"status":105,"phases":17084,"primaryCompletion":5277,"completion":5277,"start":2965,"enrollment":5278,"conditions":17085,"interventions":17086},[88],[15,18],[4709,5281],{"nctId":5283,"briefTitle":5284,"status":105,"phases":17088,"primaryCompletion":5286,"completion":5286,"start":5287,"enrollment":1624,"conditions":17089,"interventions":17090},[88],[15,21],[4709,1978],{"nctId":5291,"briefTitle":5292,"status":105,"phases":17092,"primaryCompletion":5294,"completion":5294,"start":5295,"enrollment":212,"conditions":17093,"interventions":17094},[88],[15,21],[4709,1978],{"nctId":5299,"briefTitle":5300,"status":105,"phases":17096,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":109,"conditions":17097,"interventions":17098},[88],[15,21],[4709,1311],{"nctId":5320,"briefTitle":5321,"status":105,"phases":17100,"primaryCompletion":403,"completion":403,"start":4787,"enrollment":1894,"conditions":17101,"interventions":17102},[88],[15,21],[4709,1978],{"nctId":5336,"briefTitle":5337,"status":105,"phases":17104,"primaryCompletion":4261,"completion":4261,"start":4058,"enrollment":653,"conditions":17105,"interventions":17106},[88],[15,21],[4709,4709,1978],{"nctId":5357,"briefTitle":5358,"status":105,"phases":17108,"primaryCompletion":2132,"completion":2132,"start":4336,"enrollment":2549,"conditions":17109,"interventions":17110},[88],[15,21],[4709,1978],{"nctId":5363,"briefTitle":5364,"status":105,"phases":17112,"primaryCompletion":651,"completion":651,"start":5366,"enrollment":162,"conditions":17113,"interventions":17114},[88],[15,21],[4709,1978],{"nctId":5370,"briefTitle":5371,"status":105,"phases":17116,"primaryCompletion":2153,"completion":2153,"start":3446,"enrollment":2803,"conditions":17117,"interventions":17118},[88],[15,21],[4709,1978],{"nctId":5382,"briefTitle":5383,"status":105,"phases":17120,"primaryCompletion":5385,"completion":5385,"start":5386,"enrollment":363,"conditions":17121,"interventions":17122},[88],[15,21],[4709,1978],{"nctId":5441,"briefTitle":5442,"status":105,"phases":17124,"primaryCompletion":5444,"completion":5444,"start":5445,"enrollment":624,"conditions":17125,"interventions":17126},[88],[15,21],[4709,1978],{"nctId":17128,"briefTitle":17129,"status":105,"phases":17130,"primaryCompletion":17131,"completion":17131,"start":17132,"enrollment":507,"conditions":17133,"interventions":17134},"NCT02089451","A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects",[88],"2014-06-06","2014-03-17",[15,27],[4709],{"nctId":5459,"briefTitle":5460,"status":105,"phases":17136,"primaryCompletion":5462,"completion":5462,"start":5463,"enrollment":173,"conditions":17137,"interventions":17138},[88],[15,21],[4709,1978],{"nctId":5479,"briefTitle":5480,"status":105,"phases":17140,"primaryCompletion":652,"completion":652,"start":4262,"enrollment":162,"conditions":17141,"interventions":17142},[88],[15,21],[4709,1978],{"nctId":5516,"briefTitle":5517,"status":105,"phases":17144,"primaryCompletion":4369,"completion":4369,"start":3872,"enrollment":5519,"conditions":17145,"interventions":17146},[88],[15,21,18],[4709,1978,4709,4709,4709],{"nctId":5543,"briefTitle":5544,"status":105,"phases":17148,"primaryCompletion":2154,"completion":2154,"start":2132,"enrollment":699,"conditions":17149,"interventions":17150},[88],[15,21],[4709,1978],{"trials":17152,"activeCount":99},[],{"trials":17154,"activeCount":99},[17155,17159,17163,17167,17177,17181,17185,17189],{"nctId":4701,"briefTitle":4702,"status":105,"phases":17156,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":4706,"conditions":17157,"interventions":17158},[90],[15,18],[4709,1311,1910],{"nctId":5681,"briefTitle":5682,"status":105,"phases":17160,"primaryCompletion":2774,"completion":5684,"start":3516,"enrollment":5685,"conditions":17161,"interventions":17162},[90],[15,21],[4709,1978],{"nctId":5715,"briefTitle":5716,"status":105,"phases":17164,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":5721,"conditions":17165,"interventions":17166},[90],[15,18],[4709,1311,1887,1478],{"nctId":17168,"briefTitle":17169,"status":105,"phases":17170,"primaryCompletion":17171,"completion":17171,"start":17172,"enrollment":17173,"conditions":17174,"interventions":17175},"NCT01850615","Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",[90],"2014-11-17","2013-09-23",323,[15,18],[4709,17176],"basal insulin",{"nctId":5812,"briefTitle":5813,"status":105,"phases":17178,"primaryCompletion":5815,"completion":2811,"start":5816,"enrollment":5817,"conditions":17179,"interventions":17180},[90],[15,21],[4709,1978,1919],{"nctId":5868,"briefTitle":5869,"status":105,"phases":17182,"primaryCompletion":5871,"completion":5871,"start":5872,"enrollment":285,"conditions":17183,"interventions":17184},[90],[15,21],[4709,1978],{"nctId":5916,"briefTitle":5917,"status":105,"phases":17186,"primaryCompletion":5919,"completion":5920,"start":5816,"enrollment":5921,"conditions":17187,"interventions":17188},[90],[15,21],[4709,1978,1919],{"nctId":5933,"briefTitle":5934,"status":105,"phases":17190,"primaryCompletion":5936,"completion":5937,"start":5938,"enrollment":5939,"conditions":17191,"interventions":17192},[90],[15,21],[4709,3589,1978,4709],{"trials":17194,"activeCount":99},[],{"trials":17196,"activeCount":99},[17197],{"nctId":17198,"briefTitle":17199,"status":105,"phases":17200,"primaryCompletion":17201,"completion":17201,"start":3156,"enrollment":173,"conditions":17202,"interventions":17203},"NCT03987802","An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice",[],"2022-06-28",[21,18],[4709],{"intervention":7618,"totalTrials":507,"cells":17205},{"EARLY_PHASE1":17206,"PHASE1":17208,"PHASE2":17222,"PHASE3":17224,"PHASE4":17230,"NA":17280},{"trials":17207,"activeCount":99},[],{"trials":17209,"activeCount":99},[17210,17214,17218],{"nctId":8414,"briefTitle":8415,"status":105,"phases":17211,"primaryCompletion":4398,"completion":4398,"start":3492,"enrollment":8417,"conditions":17212,"interventions":17213},[88],[15,18],[7618,226,8407],{"nctId":8421,"briefTitle":8422,"status":105,"phases":17215,"primaryCompletion":3619,"completion":3619,"start":3492,"enrollment":37,"conditions":17216,"interventions":17217},[88],[15,18],[7618,226,8407],{"nctId":8427,"briefTitle":8428,"status":105,"phases":17219,"primaryCompletion":128,"completion":128,"start":4484,"enrollment":173,"conditions":17220,"interventions":17221},[88],[15,27],[8407,8407,7618,226],{"trials":17223,"activeCount":99},[],{"trials":17225,"activeCount":99},[17226],{"nctId":16287,"briefTitle":16288,"status":105,"phases":17227,"primaryCompletion":16290,"completion":16290,"start":16291,"enrollment":16292,"conditions":17228,"interventions":17229},[90],[15,18],[7618,4967],{"trials":17231,"activeCount":99},[17232,17236,17240,17244,17248,17256,17260,17264,17268,17272,17276],{"nctId":7728,"briefTitle":7729,"status":105,"phases":17233,"primaryCompletion":3873,"completion":3873,"start":3462,"enrollment":7731,"conditions":17234,"interventions":17235},[91],[15,18],[7618,7715],{"nctId":7611,"briefTitle":7612,"status":105,"phases":17237,"primaryCompletion":7614,"completion":7614,"start":7615,"enrollment":2338,"conditions":17238,"interventions":17239},[91],[15,18],[7618,7598],{"nctId":16157,"briefTitle":16158,"status":105,"phases":17241,"primaryCompletion":3492,"completion":3492,"start":5978,"enrollment":1668,"conditions":17242,"interventions":17243},[91],[15,18],[7618,226],{"nctId":16374,"briefTitle":16375,"status":349,"phases":17245,"primaryCompletion":16377,"completion":16377,"start":16378,"enrollment":162,"conditions":17246,"interventions":17247},[91],[15,18],[7618,15254,4967],{"nctId":17249,"briefTitle":17250,"status":105,"phases":17251,"primaryCompletion":17252,"completion":17252,"start":17253,"enrollment":14507,"conditions":17254,"interventions":17255},"NCT01720303","Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes",[91],"2003-04-10","2002-09-19",[15,18],[7618,6090,3947],{"nctId":7986,"briefTitle":7987,"status":105,"phases":17257,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":1495,"conditions":17258,"interventions":17259},[91],[15,18],[7618,226,7973],{"nctId":16171,"briefTitle":16172,"status":105,"phases":17261,"primaryCompletion":16174,"completion":16174,"start":16175,"enrollment":16058,"conditions":17262,"interventions":17263},[91],[15,18],[226,7618],{"nctId":16179,"briefTitle":16180,"status":105,"phases":17265,"primaryCompletion":16182,"completion":16182,"start":16183,"enrollment":7303,"conditions":17266,"interventions":17267},[91],[15,18],[7618,226,226],{"nctId":7620,"briefTitle":7621,"status":105,"phases":17269,"primaryCompletion":7623,"completion":7623,"start":7624,"enrollment":1986,"conditions":17270,"interventions":17271},[91],[15,18],[7618,7598],{"nctId":8009,"briefTitle":8010,"status":105,"phases":17273,"primaryCompletion":8012,"completion":8012,"start":8013,"enrollment":5774,"conditions":17274,"interventions":17275},[91],[15,18],[7618,7996,8016],{"nctId":16225,"briefTitle":16226,"status":105,"phases":17277,"primaryCompletion":3462,"completion":3462,"start":129,"enrollment":16228,"conditions":17278,"interventions":17279},[91],[15,18],[7618,226,7618],{"trials":17281,"activeCount":99},[17282,17286,17292,17299,17306,17315],{"nctId":16242,"briefTitle":16243,"status":105,"phases":17283,"primaryCompletion":3586,"completion":3586,"start":3901,"enrollment":16245,"conditions":17284,"interventions":17285},[],[15,18],[7618,226],{"nctId":17287,"briefTitle":17288,"status":105,"phases":17289,"primaryCompletion":4261,"completion":4261,"start":2270,"enrollment":2367,"conditions":17290,"interventions":17291},"NCT01355718","Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea",[],[15,18],[7618],{"nctId":17293,"briefTitle":17294,"status":105,"phases":17295,"primaryCompletion":4262,"completion":4262,"start":4570,"enrollment":17296,"conditions":17297,"interventions":17298},"NCT01077570","An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients",[],2033,[15,18],[7618],{"nctId":17300,"briefTitle":17301,"status":105,"phases":17302,"primaryCompletion":3901,"completion":3901,"start":5580,"enrollment":17303,"conditions":17304,"interventions":17305},"NCT00709917","Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes",[],2171,[15,18],[7618],{"nctId":17307,"briefTitle":17308,"status":105,"phases":17309,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":17312,"conditions":17313,"interventions":17314},"NCT01498913","Observational Study of NovoNorm® in Subjects With Diabetes",[],"2005-03-25","2001-08-30",5841,[15,18],[7618],{"nctId":17316,"briefTitle":17317,"status":105,"phases":17318,"primaryCompletion":3619,"completion":3619,"start":8552,"enrollment":17319,"conditions":17320,"interventions":17321},"NCT01498900","An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice",[],30554,[15,18],[7618],{"intervention":3487,"totalTrials":507,"cells":17323},{"EARLY_PHASE1":17324,"PHASE1":17326,"PHASE2":17346,"PHASE3":17348,"PHASE4":17413,"NA":17415},{"trials":17325,"activeCount":99},[],{"trials":17327,"activeCount":99},[17328,17332,17336,17342],{"nctId":3481,"briefTitle":3482,"status":105,"phases":17329,"primaryCompletion":3484,"completion":3484,"start":652,"enrollment":306,"conditions":17330,"interventions":17331},[88],[15,27],[1919,3487,768],{"nctId":3539,"briefTitle":3540,"status":105,"phases":17333,"primaryCompletion":3542,"completion":3542,"start":3543,"enrollment":306,"conditions":17334,"interventions":17335},[88],[15,18],[3487,1919,768],{"nctId":17337,"briefTitle":17338,"status":105,"phases":17339,"primaryCompletion":2132,"completion":2132,"start":4336,"enrollment":1624,"conditions":17340,"interventions":17341},"NCT01916174","A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec\u002FLiraglutide Formulations, B5 and V2 in Healthy Subjects",[88],[15,18,27],[3487,3487],{"nctId":3696,"briefTitle":3697,"status":105,"phases":17343,"primaryCompletion":3699,"completion":3699,"start":3585,"enrollment":306,"conditions":17344,"interventions":17345},[88],[15,27],[3487,1919,768],{"trials":17347,"activeCount":99},[],{"trials":17349,"activeCount":99},[17350,17354,17358,17362,17366,17370,17378,17385,17389,17393,17397,17401,17405,17409],{"nctId":3906,"briefTitle":3907,"status":105,"phases":17351,"primaryCompletion":3909,"completion":3910,"start":3911,"enrollment":3912,"conditions":17352,"interventions":17353},[90],[15,18],[3487,1919,768],{"nctId":3920,"briefTitle":3921,"status":105,"phases":17355,"primaryCompletion":3923,"completion":3924,"start":3925,"enrollment":3926,"conditions":17356,"interventions":17357},[90],[15,18],[3487,1919,768],{"nctId":5621,"briefTitle":5622,"status":105,"phases":17359,"primaryCompletion":4084,"completion":4084,"start":274,"enrollment":554,"conditions":17360,"interventions":17361},[90],[15,18],[3487,1978],{"nctId":14963,"briefTitle":14964,"status":105,"phases":17363,"primaryCompletion":14966,"completion":14967,"start":4155,"enrollment":14968,"conditions":17364,"interventions":17365},[90],[15,18],[4159,1887],{"nctId":4725,"briefTitle":4726,"status":105,"phases":17367,"primaryCompletion":4728,"completion":4728,"start":4729,"enrollment":4730,"conditions":17368,"interventions":17369},[90],[15,18],[3487,876],{"nctId":17371,"briefTitle":17372,"status":105,"phases":17373,"primaryCompletion":17374,"completion":17374,"start":17375,"enrollment":4887,"conditions":17376,"interventions":17377},"NCT02298192","A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec\u002FLiraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms",[90],"2015-12-23","2014-11-21",[15,18],[3487],{"nctId":17379,"briefTitle":17380,"status":105,"phases":17381,"primaryCompletion":17382,"completion":17382,"start":4067,"enrollment":4660,"conditions":17383,"interventions":17384},"NCT01618162","The Efficacy of Insulin Degludec\u002FLiraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy",[90],"2013-10-23",[15,18],[3487],{"nctId":4754,"briefTitle":4755,"status":105,"phases":17386,"primaryCompletion":2827,"completion":2827,"start":4757,"enrollment":4758,"conditions":17387,"interventions":17388},[90],[15,18],[3487,876],{"nctId":4063,"briefTitle":4064,"status":105,"phases":17390,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":4068,"conditions":17391,"interventions":17392},[90],[15,18],[3487,768,1131],{"nctId":4863,"briefTitle":4864,"status":105,"phases":17394,"primaryCompletion":4866,"completion":4866,"start":4867,"enrollment":4868,"conditions":17395,"interventions":17396},[90],[15,18],[3487,876,1978],{"nctId":15062,"briefTitle":15063,"status":105,"phases":17398,"primaryCompletion":15065,"completion":5807,"start":15066,"enrollment":1252,"conditions":17399,"interventions":17400},[90],[15,18],[4159,1887],{"nctId":4881,"briefTitle":4882,"status":105,"phases":17402,"primaryCompletion":4884,"completion":4885,"start":4886,"enrollment":4887,"conditions":17403,"interventions":17404},[90],[15,18],[3487,876],{"nctId":4150,"briefTitle":4151,"status":105,"phases":17406,"primaryCompletion":4153,"completion":4154,"start":4155,"enrollment":4156,"conditions":17407,"interventions":17408},[90],[15,18],[4159,1887,57],{"nctId":15074,"briefTitle":15075,"status":105,"phases":17410,"primaryCompletion":4111,"completion":15077,"start":15078,"enrollment":4129,"conditions":17411,"interventions":17412},[90],[15,18],[3487,1919],{"trials":17414,"activeCount":99},[],{"trials":17416,"activeCount":99},[17417,17425,17432],{"nctId":17418,"briefTitle":17419,"status":105,"phases":17420,"primaryCompletion":17421,"completion":17421,"start":17422,"enrollment":1245,"conditions":17423,"interventions":17424},"NCT02754817","A Study of the Effectiveness of Xultophy® (Insulin Degludec\u002FLiraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus",[],"2016-10-20","2016-04-26",[15,18],[3487],{"nctId":17426,"briefTitle":17427,"status":105,"phases":17428,"primaryCompletion":17429,"completion":17429,"start":5719,"enrollment":943,"conditions":17430,"interventions":17431},"NCT03823339","A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates",[],"2020-12-14",[18],[4159],{"nctId":17433,"briefTitle":17434,"status":1135,"phases":17435,"primaryCompletion":9249,"completion":17436,"start":2811,"enrollment":99,"conditions":17437,"interventions":17438},"NCT03070704","Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec\u002FLiraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India",[],"2019-08-16",[15,18],[3487],{"intervention":5456,"totalTrials":1846,"cells":17440},{"EARLY_PHASE1":17441,"PHASE1":17443,"PHASE2":17510,"PHASE3":17512,"PHASE4":17537,"NA":17543},{"trials":17442,"activeCount":99},[],{"trials":17444,"activeCount":99},[17445,17453,17457,17463,17467,17475,17483,17491,17499,17506],{"nctId":17446,"briefTitle":17447,"status":105,"phases":17448,"primaryCompletion":17449,"completion":17449,"start":17450,"enrollment":119,"conditions":17451,"interventions":17452},"NCT01527630","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects",[88],"2003-01-08","2002-11-16",[15,18],[5456],{"nctId":5449,"briefTitle":5450,"status":105,"phases":17454,"primaryCompletion":5452,"completion":5452,"start":5453,"enrollment":2558,"conditions":17455,"interventions":17456},[88],[15,27],[4471,5456,5457,1978],{"nctId":17458,"briefTitle":17459,"status":105,"phases":17460,"primaryCompletion":652,"completion":652,"start":4262,"enrollment":306,"conditions":17461,"interventions":17462},"NCT01242826","Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects",[88],[15,27],[5456],{"nctId":15241,"briefTitle":15242,"status":105,"phases":17464,"primaryCompletion":3642,"completion":3642,"start":3650,"enrollment":1546,"conditions":17465,"interventions":17466},[88],[15,18],[4471,5456],{"nctId":17468,"briefTitle":17469,"status":105,"phases":17470,"primaryCompletion":17471,"completion":17471,"start":17472,"enrollment":119,"conditions":17473,"interventions":17474},"NCT01527643","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects",[88],"2003-12-17","2003-11-11",[15,27],[5456],{"nctId":17476,"briefTitle":17477,"status":105,"phases":17478,"primaryCompletion":17479,"completion":17479,"start":17480,"enrollment":306,"conditions":17481,"interventions":17482},"NCT01523041","Comparison of Two Formulations of Biphasic Insulin Aspart 70",[88],"1999-11-30","1999-11-03",[15,27],[5457,5457,5456],{"nctId":17484,"briefTitle":17485,"status":105,"phases":17486,"primaryCompletion":17487,"completion":17487,"start":17488,"enrollment":119,"conditions":17489,"interventions":17490},"NCT01527552","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects",[88],"2002-12-18","2002-11-05",[15,27],[5456],{"nctId":17492,"briefTitle":17493,"status":105,"phases":17494,"primaryCompletion":17495,"completion":17495,"start":17496,"enrollment":119,"conditions":17497,"interventions":17498},"NCT01620437","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects",[88],"2003-12-30","2003-11-29",[15,27],[5456],{"nctId":17500,"briefTitle":17501,"status":105,"phases":17502,"primaryCompletion":5793,"completion":5793,"start":17503,"enrollment":306,"conditions":17504,"interventions":17505},"NCT01620333","Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers",[88],"2000-02",[15,27],[5456,5457],{"nctId":5537,"briefTitle":5538,"status":105,"phases":17507,"primaryCompletion":3619,"completion":3619,"start":3602,"enrollment":223,"conditions":17508,"interventions":17509},[88],[15,21],[4471,5456,5457,1978],{"trials":17511,"activeCount":99},[],{"trials":17513,"activeCount":99},[17514,17518,17522,17530],{"nctId":15299,"briefTitle":15300,"status":105,"phases":17515,"primaryCompletion":489,"completion":489,"start":4015,"enrollment":15302,"conditions":17516,"interventions":17517},[90],[15,18],[4471,226,5456],{"nctId":7674,"briefTitle":7675,"status":105,"phases":17519,"primaryCompletion":7677,"completion":7677,"start":7678,"enrollment":4492,"conditions":17520,"interventions":17521},[90],[15,18],[5456,7663],{"nctId":17523,"briefTitle":17524,"status":105,"phases":17525,"primaryCompletion":3642,"completion":3642,"start":17526,"enrollment":17527,"conditions":17528,"interventions":17529},"NCT01520818","Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes",[90],"2000-03",666,[15,21,18],[5456,5457,15254],{"nctId":17531,"briefTitle":17532,"status":105,"phases":17533,"primaryCompletion":17534,"completion":17534,"start":3527,"enrollment":5006,"conditions":17535,"interventions":17536},"NCT01520753","Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes",[90],"1999-06",[15,18],[5457,5457,5456],{"trials":17538,"activeCount":99},[17539],{"nctId":7684,"briefTitle":7685,"status":105,"phases":17540,"primaryCompletion":3446,"completion":3446,"start":7687,"enrollment":442,"conditions":17541,"interventions":17542},[91],[15,18],[5456,7663],{"trials":17544,"activeCount":99},[17545,17549,17555],{"nctId":15484,"briefTitle":15485,"status":105,"phases":17546,"primaryCompletion":4904,"completion":4904,"start":488,"enrollment":15487,"conditions":17547,"interventions":17548},[],[15,18],[4471,5456,5457],{"nctId":17550,"briefTitle":17551,"status":105,"phases":17552,"primaryCompletion":3872,"completion":3872,"start":2224,"enrollment":723,"conditions":17553,"interventions":17554},"NCT00755833","Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months",[],[15,18],[5456],{"nctId":15609,"briefTitle":15610,"status":105,"phases":17556,"primaryCompletion":233,"completion":233,"start":3739,"enrollment":1245,"conditions":17557,"interventions":17558},[],[15,18],[4471,5456,5457],{"intervention":5457,"totalTrials":3148,"cells":17560},{"EARLY_PHASE1":17561,"PHASE1":17563,"PHASE2":17607,"PHASE3":17613,"PHASE4":17623,"NA":17625},{"trials":17562,"activeCount":99},[],{"trials":17564,"activeCount":99},[17565,17573,17577,17583,17587,17591,17595,17599,17603],{"nctId":17566,"briefTitle":17567,"status":105,"phases":17568,"primaryCompletion":17569,"completion":17569,"start":17570,"enrollment":119,"conditions":17571,"interventions":17572},"NCT01527565","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects",[88],"2003-02-26","2003-01-20",[15,27],[5457],{"nctId":15193,"briefTitle":15194,"status":105,"phases":17574,"primaryCompletion":3803,"completion":3803,"start":15196,"enrollment":2185,"conditions":17575,"interventions":17576},[88],[15,21],[4471,5457],{"nctId":17578,"briefTitle":17579,"status":105,"phases":17580,"primaryCompletion":14026,"completion":14026,"start":3634,"enrollment":162,"conditions":17581,"interventions":17582},"NCT01527656","Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects",[88],[15,27],[5457],{"nctId":5449,"briefTitle":5450,"status":105,"phases":17584,"primaryCompletion":5452,"completion":5452,"start":5453,"enrollment":2558,"conditions":17585,"interventions":17586},[88],[15,27],[4471,5456,5457,1978],{"nctId":15234,"briefTitle":15235,"status":105,"phases":17588,"primaryCompletion":15237,"completion":15237,"start":3757,"enrollment":335,"conditions":17589,"interventions":17590},[88],[15,21],[4471,5457],{"nctId":17476,"briefTitle":17477,"status":105,"phases":17592,"primaryCompletion":17479,"completion":17479,"start":17480,"enrollment":306,"conditions":17593,"interventions":17594},[88],[15,27],[5457,5457,5456],{"nctId":15256,"briefTitle":15257,"status":105,"phases":17596,"primaryCompletion":15259,"completion":15259,"start":15260,"enrollment":5407,"conditions":17597,"interventions":17598},[88],[15,18],[5457,4471],{"nctId":17500,"briefTitle":17501,"status":105,"phases":17600,"primaryCompletion":5793,"completion":5793,"start":17503,"enrollment":306,"conditions":17601,"interventions":17602},[88],[15,27],[5456,5457],{"nctId":5537,"briefTitle":5538,"status":105,"phases":17604,"primaryCompletion":3619,"completion":3619,"start":3602,"enrollment":223,"conditions":17605,"interventions":17606},[88],[15,21],[4471,5456,5457,1978],{"trials":17608,"activeCount":99},[17609],{"nctId":15290,"briefTitle":15291,"status":105,"phases":17610,"primaryCompletion":4748,"completion":4748,"start":15293,"enrollment":554,"conditions":17611,"interventions":17612},[89],[15,18],[4471,5457,15254],{"trials":17614,"activeCount":99},[17615,17619],{"nctId":17523,"briefTitle":17524,"status":105,"phases":17616,"primaryCompletion":3642,"completion":3642,"start":17526,"enrollment":17527,"conditions":17617,"interventions":17618},[90],[15,21,18],[5456,5457,15254],{"nctId":17531,"briefTitle":17532,"status":105,"phases":17620,"primaryCompletion":17534,"completion":17534,"start":3527,"enrollment":5006,"conditions":17621,"interventions":17622},[90],[15,18],[5457,5457,5456],{"trials":17624,"activeCount":99},[],{"trials":17626,"activeCount":99},[17627,17631],{"nctId":15484,"briefTitle":15485,"status":105,"phases":17628,"primaryCompletion":4904,"completion":4904,"start":488,"enrollment":15487,"conditions":17629,"interventions":17630},[],[15,18],[4471,5456,5457],{"nctId":15609,"briefTitle":15610,"status":105,"phases":17632,"primaryCompletion":233,"completion":233,"start":3739,"enrollment":1245,"conditions":17633,"interventions":17634},[],[15,18],[4471,5456,5457],{"intervention":984,"totalTrials":5316,"cells":17636},{"EARLY_PHASE1":17637,"PHASE1":17639,"PHASE2":17641,"PHASE3":17643,"PHASE4":17681,"NA":17695},{"trials":17638,"activeCount":99},[],{"trials":17640,"activeCount":99},[],{"trials":17642,"activeCount":99},[],{"trials":17644,"activeCount":99},[17645,17649,17653,17657,17661,17665,17669,17673,17677],{"nctId":3196,"briefTitle":3197,"status":105,"phases":17646,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":3201,"conditions":17647,"interventions":17648},[90],[18],[3125,3204],{"nctId":976,"briefTitle":977,"status":105,"phases":17650,"primaryCompletion":979,"completion":980,"start":923,"enrollment":981,"conditions":17651,"interventions":17652},[90],[15,18],[112,984],{"nctId":14937,"briefTitle":14938,"status":105,"phases":17654,"primaryCompletion":3873,"completion":3873,"start":4636,"enrollment":1061,"conditions":17655,"interventions":17656},[90],[15,18],[1919,984],{"nctId":8627,"briefTitle":8628,"status":105,"phases":17658,"primaryCompletion":8630,"completion":8631,"start":8632,"enrollment":8633,"conditions":17659,"interventions":17660},[90],[15,18],[8621,8294,8636,3204,8637,8638],{"nctId":1066,"briefTitle":1067,"status":105,"phases":17662,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":17663,"interventions":17664},[90],[15,18],[112,112,984],{"nctId":3930,"briefTitle":3931,"status":105,"phases":17666,"primaryCompletion":3933,"completion":2204,"start":2306,"enrollment":3934,"conditions":17667,"interventions":17668},[90],[15,18],[768,984,226,768],{"nctId":7553,"briefTitle":7554,"status":105,"phases":17670,"primaryCompletion":4484,"completion":4484,"start":3860,"enrollment":7556,"conditions":17671,"interventions":17672},[90],[15,18],[3589,984,226,4198],{"nctId":1356,"briefTitle":1357,"status":105,"phases":17674,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":17675,"interventions":17676},[90],[15,18],[112,984],{"nctId":1451,"briefTitle":1452,"status":105,"phases":17678,"primaryCompletion":1454,"completion":1454,"start":826,"enrollment":1455,"conditions":17679,"interventions":17680},[90],[15,18],[112,984],{"trials":17682,"activeCount":99},[17683,17687,17691],{"nctId":4201,"briefTitle":4202,"status":105,"phases":17684,"primaryCompletion":698,"completion":698,"start":4204,"enrollment":4205,"conditions":17685,"interventions":17686},[91],[15,18],[768,984],{"nctId":15393,"briefTitle":15394,"status":105,"phases":17688,"primaryCompletion":4057,"completion":4057,"start":334,"enrollment":1975,"conditions":17689,"interventions":17690},[91],[15,18],[4471,4471,984,226],{"nctId":4213,"briefTitle":4214,"status":105,"phases":17692,"primaryCompletion":4216,"completion":4216,"start":826,"enrollment":4217,"conditions":17693,"interventions":17694},[91],[15,18],[768,984],{"trials":17696,"activeCount":99},[17697],{"nctId":4240,"briefTitle":4241,"status":105,"phases":17698,"primaryCompletion":4243,"completion":4243,"start":4244,"enrollment":4245,"conditions":17699,"interventions":17700},[],[15,18],[768,984],{"intervention":17702,"totalTrials":5316,"cells":17703},"catridecacog",{"EARLY_PHASE1":17704,"PHASE1":17706,"PHASE2":17747,"PHASE3":17763,"PHASE4":17791,"NA":17793},{"trials":17705,"activeCount":99},[],{"trials":17707,"activeCount":99},[17708,17714,17722,17728,17734,17740],{"nctId":17709,"briefTitle":17710,"status":105,"phases":17711,"primaryCompletion":3901,"completion":3901,"start":2225,"enrollment":653,"conditions":17712,"interventions":17713},"NCT02239146","Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass",[88],[2197,16901],[17702],{"nctId":17715,"briefTitle":17716,"status":105,"phases":17717,"primaryCompletion":2278,"completion":2278,"start":4570,"enrollment":1986,"conditions":17718,"interventions":17720},"NCT01082406","Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects",[88],[30,17719,27],"Congenital FXIII Deficiency",[17702,17721],"recombinant factor XIII",{"nctId":17723,"briefTitle":17724,"status":105,"phases":17725,"primaryCompletion":15661,"completion":15661,"start":3706,"enrollment":3578,"conditions":17726,"interventions":17727},"NCT00056589","Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency",[88],[30,17719],[17702],{"nctId":17729,"briefTitle":17730,"status":105,"phases":17731,"primaryCompletion":5757,"completion":5757,"start":15744,"enrollment":306,"conditions":17732,"interventions":17733},"NCT01848002","Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers",[88],[30,17719,27],[17702],{"nctId":17735,"briefTitle":17736,"status":105,"phases":17737,"primaryCompletion":5852,"completion":5852,"start":2204,"enrollment":306,"conditions":17738,"interventions":17739},"NCT01153997","Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers",[88],[2197,16901,27],[17702,17702],{"nctId":17741,"briefTitle":17742,"status":105,"phases":17743,"primaryCompletion":15744,"completion":15744,"start":17744,"enrollment":1624,"conditions":17745,"interventions":17746},"NCT01847989","Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers",[88],"2003-01",[30,17719,27],[17702],{"trials":17748,"activeCount":99},[17749,17756],{"nctId":17750,"briefTitle":17751,"status":105,"phases":17752,"primaryCompletion":4262,"completion":4262,"start":6191,"enrollment":17753,"conditions":17754,"interventions":17755},"NCT00914589","Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery",[89],479,[2197,16901],[17702,17702],{"nctId":17757,"briefTitle":17758,"status":349,"phases":17759,"primaryCompletion":4500,"completion":4500,"start":4391,"enrollment":372,"conditions":17760,"interventions":17762},"NCT01706159","A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis",[89],[3066,17761],"Ulcerative Colitis",[17702],{"trials":17764,"activeCount":99},[17765,17771,17779,17785],{"nctId":17766,"briefTitle":17767,"status":105,"phases":17768,"primaryCompletion":651,"completion":651,"start":3873,"enrollment":2134,"conditions":17769,"interventions":17770},"NCT01230021","Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency",[90],[30,17719],[17702],{"nctId":17772,"briefTitle":17773,"status":105,"phases":17774,"primaryCompletion":17775,"completion":17775,"start":17776,"enrollment":4542,"conditions":17777,"interventions":17778},"NCT00978380","Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725",[90],"2015-10-20","2009-09-21",[30,17719],[17702],{"nctId":17780,"briefTitle":17781,"status":105,"phases":17782,"primaryCompletion":17062,"completion":17062,"start":233,"enrollment":2134,"conditions":17783,"interventions":17784},"NCT01253811","Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency",[90],[30,17719],[17702],{"nctId":17786,"briefTitle":17787,"status":105,"phases":17788,"primaryCompletion":3872,"completion":3872,"start":4603,"enrollment":624,"conditions":17789,"interventions":17790},"NCT00713648","Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency",[90],[30,17719],[17702],{"trials":17792,"activeCount":99},[],{"trials":17794,"activeCount":99},[17795],{"nctId":17796,"briefTitle":17797,"status":105,"phases":17798,"primaryCompletion":17799,"completion":17799,"start":17800,"enrollment":119,"conditions":17801,"interventions":17802},"NCT01862367","Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study",[],"2019-06-26","2013-05-17",[30,17719],[17702],{"intervention":15254,"totalTrials":5047,"cells":17804},{"EARLY_PHASE1":17805,"PHASE1":17807,"PHASE2":17831,"PHASE3":17841,"PHASE4":17847,"NA":17861},{"trials":17806,"activeCount":99},[],{"trials":17808,"activeCount":99},[17809,17817,17823,17827],{"nctId":17810,"briefTitle":17811,"status":105,"phases":17812,"primaryCompletion":17813,"completion":17813,"start":17814,"enrollment":708,"conditions":17815,"interventions":17816},"NCT01620450","Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese",[88],"2005-02-26","2004-11-20",[15,27],[15254],{"nctId":17818,"briefTitle":17819,"status":105,"phases":17820,"primaryCompletion":3619,"completion":3619,"start":2144,"enrollment":266,"conditions":17821,"interventions":17822},"NCT01486888","Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects",[88],[15,27],[15254],{"nctId":15247,"briefTitle":15248,"status":105,"phases":17824,"primaryCompletion":15250,"completion":15250,"start":15251,"enrollment":306,"conditions":17825,"interventions":17826},[88],[15,27],[4471,15254],{"nctId":15264,"briefTitle":15265,"status":105,"phases":17828,"primaryCompletion":3714,"completion":3714,"start":5580,"enrollment":306,"conditions":17829,"interventions":17830},[88],[15,18],[4471,15254],{"trials":17832,"activeCount":99},[17833,17837],{"nctId":15276,"briefTitle":15277,"status":105,"phases":17834,"primaryCompletion":15279,"completion":15279,"start":15280,"enrollment":5316,"conditions":17835,"interventions":17836},[89],[15,18],[4471,15254],{"nctId":15290,"briefTitle":15291,"status":105,"phases":17838,"primaryCompletion":4748,"completion":4748,"start":15293,"enrollment":554,"conditions":17839,"interventions":17840},[89],[15,18],[4471,5457,15254],{"trials":17842,"activeCount":99},[17843],{"nctId":17523,"briefTitle":17524,"status":105,"phases":17844,"primaryCompletion":3642,"completion":3642,"start":17526,"enrollment":17527,"conditions":17845,"interventions":17846},[90],[15,21,18],[5456,5457,15254],{"trials":17848,"activeCount":99},[17849,17853,17857],{"nctId":15340,"briefTitle":15341,"status":105,"phases":17850,"primaryCompletion":15343,"completion":15343,"start":5928,"enrollment":276,"conditions":17851,"interventions":17852},[91],[15,18],[15254,4471],{"nctId":16374,"briefTitle":16375,"status":349,"phases":17854,"primaryCompletion":16377,"completion":16377,"start":16378,"enrollment":162,"conditions":17855,"interventions":17856},[91],[15,18],[7618,15254,4967],{"nctId":15387,"briefTitle":15388,"status":105,"phases":17858,"primaryCompletion":128,"completion":128,"start":3738,"enrollment":3361,"conditions":17859,"interventions":17860},[91],[15,18],[4471,15254,226],{"trials":17862,"activeCount":99},[17863,17872],{"nctId":17864,"briefTitle":17865,"status":105,"phases":17866,"primaryCompletion":17867,"completion":17867,"start":17868,"enrollment":17869,"conditions":17870,"interventions":17871},"NCT01492218","Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction",[],"2004-08-30","2004-03-15",1330,[15,21,18],[15254],{"nctId":17873,"briefTitle":17874,"status":105,"phases":17875,"primaryCompletion":2205,"completion":2205,"start":3618,"enrollment":17876,"conditions":17877,"interventions":17878},"NCT01492166","Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice",[],1935,[15,18],[15254],{"intervention":5797,"totalTrials":2683,"cells":17880},{"EARLY_PHASE1":17881,"PHASE1":17883,"PHASE2":17892,"PHASE3":17898,"PHASE4":17912,"NA":17926},{"trials":17882,"activeCount":99},[],{"trials":17884,"activeCount":99},[17885],{"nctId":17886,"briefTitle":17887,"status":105,"phases":17888,"primaryCompletion":16290,"completion":16290,"start":17889,"enrollment":413,"conditions":17890,"interventions":17891},"NCT01448070","Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers",[88],"2002-10-15",[15,27],[5797],{"trials":17893,"activeCount":99},[17894],{"nctId":8124,"briefTitle":8125,"status":105,"phases":17895,"primaryCompletion":8127,"completion":8127,"start":8128,"enrollment":335,"conditions":17896,"interventions":17897},[89],[15,21],[5797,5575],{"trials":17899,"activeCount":99},[17900,17908],{"nctId":17901,"briefTitle":17902,"status":105,"phases":17903,"primaryCompletion":17904,"completion":17904,"start":17905,"enrollment":5677,"conditions":17906,"interventions":17907},"NCT00569400","Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes",[90],"2004-01-19","2003-05-01",[15,21],[5797],{"nctId":5790,"briefTitle":5791,"status":105,"phases":17909,"primaryCompletion":3634,"completion":3634,"start":5793,"enrollment":335,"conditions":17910,"interventions":17911},[90],[15,5795],[5797,4967,1978],{"trials":17913,"activeCount":99},[17914,17918,17922],{"nctId":5961,"briefTitle":5962,"status":105,"phases":17915,"primaryCompletion":5766,"completion":5766,"start":5964,"enrollment":5965,"conditions":17916,"interventions":17917},[91],[15,21],[5797,1978],{"nctId":6047,"briefTitle":6048,"status":105,"phases":17919,"primaryCompletion":6050,"completion":6050,"start":6051,"enrollment":3643,"conditions":17920,"interventions":17921},[91],[15,18],[1978,5797],{"nctId":6083,"briefTitle":6084,"status":105,"phases":17923,"primaryCompletion":6086,"completion":6086,"start":6087,"enrollment":2185,"conditions":17924,"interventions":17925},[91],[15,21],[1978,5797,6090],{"trials":17927,"activeCount":99},[17928],{"nctId":17929,"briefTitle":17930,"status":105,"phases":17931,"primaryCompletion":3699,"completion":3699,"start":3738,"enrollment":17932,"conditions":17933,"interventions":17934},"NCT00806936","Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects",[],4847,[15,18],[5797,17935],"insulin analogue",{"intervention":6195,"totalTrials":422,"cells":17937},{"EARLY_PHASE1":17938,"PHASE1":17940,"PHASE2":17942,"PHASE3":17948,"PHASE4":17962,"NA":17968},{"trials":17939,"activeCount":99},[],{"trials":17941,"activeCount":99},[],{"trials":17943,"activeCount":99},[17944],{"nctId":9680,"briefTitle":9681,"status":105,"phases":17945,"primaryCompletion":3586,"completion":3586,"start":2306,"enrollment":1400,"conditions":17946,"interventions":17947},[89],[15,18],[9664,6195],{"trials":17949,"activeCount":99},[17950,17954,17958],{"nctId":16434,"briefTitle":16435,"status":105,"phases":17951,"primaryCompletion":16437,"completion":16437,"start":16438,"enrollment":16439,"conditions":17952,"interventions":17953},[90],[15,21,18],[4751,6195],{"nctId":16517,"briefTitle":16518,"status":105,"phases":17955,"primaryCompletion":3852,"completion":3852,"start":2193,"enrollment":15924,"conditions":17956,"interventions":17957},[90],[15,18],[4751,6195],{"nctId":16527,"briefTitle":16528,"status":105,"phases":17959,"primaryCompletion":16530,"completion":16530,"start":7776,"enrollment":4103,"conditions":17960,"interventions":17961},[90],[15,21,18],[4751,6195],{"trials":17963,"activeCount":99},[17964],{"nctId":16546,"briefTitle":16547,"status":105,"phases":17965,"primaryCompletion":16549,"completion":16549,"start":16550,"enrollment":16551,"conditions":17966,"interventions":17967},[91],[15,18],[4751,6195],{"trials":17969,"activeCount":99},[17970,17979],{"nctId":17971,"briefTitle":17972,"status":105,"phases":17973,"primaryCompletion":17974,"completion":17974,"start":17975,"enrollment":17976,"conditions":17977,"interventions":17978},"NCT01492153","NovoLet® Surveillance Study on Using Human Insulin System in Indonesia",[],"2006-09-05","2003-02-11",1981,[15,21,18],[6195,6090,5705],{"nctId":6188,"briefTitle":6189,"status":105,"phases":17980,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":17981,"interventions":17982},[],[15,18],[6011,6195,4967,1978,4751,3589],{"intervention":6090,"totalTrials":422,"cells":17984},{"EARLY_PHASE1":17985,"PHASE1":17987,"PHASE2":17999,"PHASE3":18001,"PHASE4":18003,"NA":18013},{"trials":17986,"activeCount":99},[],{"trials":17988,"activeCount":99},[17989,17993],{"nctId":14758,"briefTitle":14759,"status":105,"phases":17990,"primaryCompletion":3602,"completion":3602,"start":4643,"enrollment":2252,"conditions":17991,"interventions":17992},[88],[15,21,18],[1919,1919,6090],{"nctId":17994,"briefTitle":17995,"status":105,"phases":17996,"primaryCompletion":3619,"completion":3619,"start":2144,"enrollment":182,"conditions":17997,"interventions":17998},"NCT01486901","Bioequivalence of Two Insulatard® Formulations in Healthy Subjects",[88],[15,27],[6090],{"trials":18000,"activeCount":99},[],{"trials":18002,"activeCount":99},[],{"trials":18004,"activeCount":99},[18005,18009],{"nctId":17249,"briefTitle":17250,"status":105,"phases":18006,"primaryCompletion":17252,"completion":17252,"start":17253,"enrollment":14507,"conditions":18007,"interventions":18008},[91],[15,18],[7618,6090,3947],{"nctId":6083,"briefTitle":6084,"status":105,"phases":18010,"primaryCompletion":6086,"completion":6086,"start":6087,"enrollment":2185,"conditions":18011,"interventions":18012},[91],[15,21],[1978,5797,6090],{"trials":18014,"activeCount":99},[18015,18019,18023],{"nctId":17971,"briefTitle":17972,"status":105,"phases":18016,"primaryCompletion":17974,"completion":17974,"start":17975,"enrollment":17976,"conditions":18017,"interventions":18018},[],[15,21,18],[6195,6090,5705],{"nctId":14598,"briefTitle":14599,"status":105,"phases":18020,"primaryCompletion":3738,"completion":3738,"start":3961,"enrollment":14601,"conditions":18021,"interventions":18022},[],[15,18],[3589,6090],{"nctId":6204,"briefTitle":6205,"status":105,"phases":18024,"primaryCompletion":2144,"completion":2144,"start":6207,"enrollment":6208,"conditions":18025,"interventions":18026},[92],[15,21],[6011,6090,1978],{"intervention":3947,"totalTrials":2134,"cells":18028},{"EARLY_PHASE1":18029,"PHASE1":18031,"PHASE2":18033,"PHASE3":18035,"PHASE4":18041,"NA":18047},{"trials":18030,"activeCount":99},[],{"trials":18032,"activeCount":99},[],{"trials":18034,"activeCount":99},[],{"trials":18036,"activeCount":99},[18037],{"nctId":3938,"briefTitle":3939,"status":105,"phases":18038,"primaryCompletion":3941,"completion":3942,"start":3943,"enrollment":3944,"conditions":18039,"interventions":18040},[90],[15,18],[768,3947],{"trials":18042,"activeCount":99},[18043],{"nctId":17249,"briefTitle":17250,"status":105,"phases":18044,"primaryCompletion":17252,"completion":17252,"start":17253,"enrollment":14507,"conditions":18045,"interventions":18046},[91],[15,18],[7618,6090,3947],{"trials":18048,"activeCount":99},[18049,18055,18062,18066],{"nctId":18050,"briefTitle":18051,"status":105,"phases":18052,"primaryCompletion":3586,"completion":3586,"start":3594,"enrollment":2380,"conditions":18053,"interventions":18054},"NCT00712478","Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes",[],[15,18],[3947],{"nctId":18056,"briefTitle":18057,"status":105,"phases":18058,"primaryCompletion":4058,"completion":4058,"start":4491,"enrollment":18059,"conditions":18060,"interventions":18061},"NCT01628341","French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients",[],4424,[15,21,18],[3947],{"nctId":4341,"briefTitle":4342,"status":105,"phases":18063,"primaryCompletion":2860,"completion":2860,"start":4344,"enrollment":4345,"conditions":18064,"interventions":18065},[],[15,18],[768,3947],{"nctId":18067,"briefTitle":18068,"status":105,"phases":18069,"primaryCompletion":4128,"completion":4128,"start":9277,"enrollment":9676,"conditions":18070,"interventions":18071},"NCT01493388","To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1",[],[15,21],[3947],{"intervention":8333,"totalTrials":2134,"cells":18073},{"EARLY_PHASE1":18074,"PHASE1":18076,"PHASE2":18088,"PHASE3":18090,"PHASE4":18113,"NA":18115},{"trials":18075,"activeCount":99},[],{"trials":18077,"activeCount":99},[18078,18082],{"nctId":8327,"briefTitle":8328,"status":105,"phases":18079,"primaryCompletion":3714,"completion":3714,"start":2163,"enrollment":109,"conditions":18080,"interventions":18081},[88],[7641,8331],[8320,8333],{"nctId":18083,"briefTitle":18084,"status":105,"phases":18085,"primaryCompletion":2331,"completion":2331,"start":4570,"enrollment":3534,"conditions":18086,"interventions":18087},"NCT01085877","Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis",[88],[7641,8331],[8333,8333],{"trials":18089,"activeCount":99},[],{"trials":18091,"activeCount":99},[18092,18096,18104],{"nctId":8339,"briefTitle":8340,"status":105,"phases":18093,"primaryCompletion":8342,"completion":8342,"start":8343,"enrollment":1790,"conditions":18094,"interventions":18095},[90],[7641,8331],[8320,8333],{"nctId":18097,"briefTitle":18098,"status":105,"phases":18099,"primaryCompletion":18100,"completion":18100,"start":18101,"enrollment":2280,"conditions":18102,"interventions":18103},"NCT00464971","Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial",[90],"1996-11-30","1995-01-31",[7641,8331],[8333],{"nctId":18105,"briefTitle":18106,"status":349,"phases":18107,"primaryCompletion":18108,"completion":18108,"start":18109,"enrollment":2134,"conditions":18110,"interventions":18112},"NCT00560924","Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women",[90],"2004-03-17","2003-03-21",[7641,18111],"Urinary Infections",[8333],{"trials":18114,"activeCount":99},[],{"trials":18116,"activeCount":99},[18117],{"nctId":18118,"briefTitle":18119,"status":105,"phases":18120,"primaryCompletion":3618,"completion":3618,"start":3602,"enrollment":18121,"conditions":18122,"interventions":18123},"NCT01507454","Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency",[],1613,[7641,8331],[8333],{"intervention":3613,"totalTrials":2134,"cells":18125},{"EARLY_PHASE1":18126,"PHASE1":18128,"PHASE2":18138,"PHASE3":18140,"PHASE4":18146,"NA":18148},{"trials":18127,"activeCount":99},[],{"trials":18129,"activeCount":99},[18130,18134],{"nctId":5313,"briefTitle":5314,"status":105,"phases":18131,"primaryCompletion":652,"completion":652,"start":233,"enrollment":5316,"conditions":18132,"interventions":18133},[88],[15,21],[1978,3613,1978,3613],{"nctId":3606,"briefTitle":3607,"status":105,"phases":18135,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":223,"conditions":18136,"interventions":18137},[88],[15,27],[768,768,768,3613,3613,768],{"trials":18139,"activeCount":99},[],{"trials":18141,"activeCount":99},[18142],{"nctId":5925,"briefTitle":5926,"status":105,"phases":18143,"primaryCompletion":3550,"completion":3550,"start":5928,"enrollment":5929,"conditions":18144,"interventions":18145},[90],[15,21],[3613,5603,1978],{"trials":18147,"activeCount":99},[],{"trials":18149,"activeCount":99},[18150,18158,18165],{"nctId":18151,"briefTitle":18152,"status":105,"phases":18153,"primaryCompletion":18154,"completion":18154,"start":18155,"enrollment":4697,"conditions":18156,"interventions":18157},"NCT01492959","Observational Study With InnoLet® in Daily Clinical Practice",[],"2005-03-23","2004-03-23",[15,21,18],[3613],{"nctId":18159,"briefTitle":18160,"status":349,"phases":18161,"primaryCompletion":4802,"completion":4802,"start":3461,"enrollment":18162,"conditions":18163,"interventions":18164},"NCT02382757","Changing Diabetes in Children",[],3089,[15,21],[3613],{"nctId":18166,"briefTitle":18167,"status":105,"phases":18168,"primaryCompletion":3492,"completion":3492,"start":5978,"enrollment":18169,"conditions":18170,"interventions":18171},"NCT01492205","NovoLet® Acceptance Study Within the Hospital Practise in Indonesia",[],203,[15,21,18],[3613],{"intervention":6011,"totalTrials":2134,"cells":18173},{"EARLY_PHASE1":18174,"PHASE1":18176,"PHASE2":18178,"PHASE3":18180,"PHASE4":18182,"NA":18196},{"trials":18175,"activeCount":99},[],{"trials":18177,"activeCount":99},[],{"trials":18179,"activeCount":99},[],{"trials":18181,"activeCount":99},[],{"trials":18183,"activeCount":99},[18184,18188,18192],{"nctId":6006,"briefTitle":6007,"status":105,"phases":18185,"primaryCompletion":5599,"completion":5599,"start":5757,"enrollment":5278,"conditions":18186,"interventions":18187},[91],[15,21],[1978,6011],{"nctId":6062,"briefTitle":6063,"status":105,"phases":18189,"primaryCompletion":5766,"completion":5766,"start":2214,"enrollment":6065,"conditions":18190,"interventions":18191},[91],[15,21,18],[6011,1978,4967],{"nctId":6069,"briefTitle":6070,"status":105,"phases":18193,"primaryCompletion":3707,"completion":3707,"start":5710,"enrollment":2172,"conditions":18194,"interventions":18195},[91],[15,21],[1978,6011,4967],{"trials":18197,"activeCount":99},[18198,18202,18206],{"nctId":16628,"briefTitle":16629,"status":105,"phases":18199,"primaryCompletion":4941,"completion":4941,"start":3961,"enrollment":16631,"conditions":18200,"interventions":18201},[],[15,18],[6011,4751],{"nctId":6188,"briefTitle":6189,"status":105,"phases":18203,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":6192,"conditions":18204,"interventions":18205},[],[15,18],[6011,6195,4967,1978,4751,3589],{"nctId":6204,"briefTitle":6205,"status":105,"phases":18207,"primaryCompletion":2144,"completion":2144,"start":6207,"enrollment":6208,"conditions":18208,"interventions":18209},[92],[15,21],[6011,6090,1978],{"intervention":5705,"totalTrials":2134,"cells":18211},{"EARLY_PHASE1":18212,"PHASE1":18214,"PHASE2":18220,"PHASE3":18222,"PHASE4":18232,"NA":18238},{"trials":18213,"activeCount":99},[],{"trials":18215,"activeCount":99},[18216],{"nctId":14036,"briefTitle":14037,"status":105,"phases":18217,"primaryCompletion":3526,"completion":3526,"start":14039,"enrollment":5316,"conditions":18218,"interventions":18219},[88],[15,27],[3589,5705],{"trials":18221,"activeCount":99},[],{"trials":18223,"activeCount":99},[18224,18228],{"nctId":5698,"briefTitle":5699,"status":105,"phases":18225,"primaryCompletion":5452,"completion":5452,"start":5701,"enrollment":5702,"conditions":18226,"interventions":18227},[90],[15,21],[1978,5705,4967],{"nctId":5707,"briefTitle":5708,"status":105,"phases":18229,"primaryCompletion":5710,"completion":5710,"start":3802,"enrollment":5711,"conditions":18230,"interventions":18231},[90],[15,21],[3589,1978,4967,5705],{"trials":18233,"activeCount":99},[18234],{"nctId":5983,"briefTitle":5984,"status":349,"phases":18235,"primaryCompletion":334,"completion":334,"start":5366,"enrollment":109,"conditions":18236,"interventions":18237},[91],[15,18],[3589,1978,4967,5705,226],{"trials":18239,"activeCount":99},[18240,18244],{"nctId":17971,"briefTitle":17972,"status":105,"phases":18241,"primaryCompletion":17974,"completion":17974,"start":17975,"enrollment":17976,"conditions":18242,"interventions":18243},[],[15,21,18],[6195,6090,5705],{"nctId":6142,"briefTitle":6143,"status":105,"phases":18245,"primaryCompletion":2193,"completion":2193,"start":3715,"enrollment":4979,"conditions":18246,"interventions":18247},[],[15,21,18],[3589,1978,5705],{"intervention":18249,"totalTrials":713,"cells":18250},"IDegLira",{"EARLY_PHASE1":18251,"PHASE1":18253,"PHASE2":18255,"PHASE3":18257,"PHASE4":18259,"NA":18261},{"trials":18252,"activeCount":99},[],{"trials":18254,"activeCount":99},[],{"trials":18256,"activeCount":99},[],{"trials":18258,"activeCount":99},[],{"trials":18260,"activeCount":99},[],{"trials":18262,"activeCount":99},[18263,18271,18279,18287],{"nctId":18264,"briefTitle":18265,"status":1135,"phases":18266,"primaryCompletion":18267,"completion":6905,"start":18268,"enrollment":99,"conditions":18269,"interventions":18270},"NCT06113341","A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes",[],"2025-02-23","2024-11-07",[18],[18249],{"nctId":18272,"briefTitle":18273,"status":105,"phases":18274,"primaryCompletion":18275,"completion":18275,"start":18276,"enrollment":14293,"conditions":18277,"interventions":18278},"NCT04838743","GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.",[],"2022-10-26","2021-04-23",[18],[18249],{"nctId":18280,"briefTitle":18281,"status":105,"phases":18282,"primaryCompletion":9612,"completion":9612,"start":18283,"enrollment":18284,"conditions":18285,"interventions":18286},"NCT05324462","Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia",[],"2022-03-22",175,[18],[18249],{"nctId":18288,"briefTitle":18289,"status":1135,"phases":18290,"primaryCompletion":18291,"completion":18291,"start":18292,"enrollment":99,"conditions":18293,"interventions":18294},"NCT05479591","A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec\u002FLiraglutide (IDegLira) in Local Clinical Practice in Croatia",[],"2023-04-30","2022-07-30",[18],[18249],{"intervention":13489,"totalTrials":713,"cells":18296},{"EARLY_PHASE1":18297,"PHASE1":18299,"PHASE2":18305,"PHASE3":18316,"PHASE4":18318,"NA":18320},{"trials":18298,"activeCount":99},[],{"trials":18300,"activeCount":99},[18301],{"nctId":13483,"briefTitle":13484,"status":105,"phases":18302,"primaryCompletion":13486,"completion":13486,"start":1001,"enrollment":699,"conditions":18303,"interventions":18304},[88],[21],[13476,13489],{"trials":18306,"activeCount":99},[18307],{"nctId":18308,"briefTitle":18309,"status":105,"phases":18310,"primaryCompletion":18311,"completion":18312,"start":18313,"enrollment":306,"conditions":18314,"interventions":18315},"NCT03816761","Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes",[89],"2019-05-31","2019-06-10","2019-02-25",[21],[13489],{"trials":18317,"activeCount":99},[],{"trials":18319,"activeCount":99},[],{"trials":18321,"activeCount":99},[18322,18330],{"nctId":18323,"briefTitle":18324,"status":105,"phases":18325,"primaryCompletion":774,"completion":774,"start":18326,"enrollment":744,"conditions":18327,"interventions":18329},"NCT03450863","Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device",[],"2018-03-22",[15,18328],"Diabetes Mellitus, Type 1 Diabetes",[13489],{"nctId":15149,"briefTitle":15150,"status":105,"phases":18331,"primaryCompletion":10812,"completion":10812,"start":15152,"enrollment":15153,"conditions":18332,"interventions":18333},[],[21],[1887,13489],{"intervention":7643,"totalTrials":2578,"cells":18335},{"EARLY_PHASE1":18336,"PHASE1":18338,"PHASE2":18344,"PHASE3":18346,"PHASE4":18352,"NA":18354},{"trials":18337,"activeCount":99},[],{"trials":18339,"activeCount":99},[18340],{"nctId":7637,"briefTitle":7638,"status":105,"phases":18341,"primaryCompletion":5496,"completion":5496,"start":4765,"enrollment":306,"conditions":18342,"interventions":18343},[88],[7641,27],[7643,7644,7630],{"trials":18345,"activeCount":99},[],{"trials":18347,"activeCount":99},[18348],{"nctId":8879,"briefTitle":8880,"status":105,"phases":18349,"primaryCompletion":8882,"completion":8882,"start":3664,"enrollment":3989,"conditions":18350,"interventions":18351},[90],[7641,8884],[7643,7644],{"trials":18353,"activeCount":99},[],{"trials":18355,"activeCount":99},[18356],{"nctId":18357,"briefTitle":18358,"status":105,"phases":18359,"primaryCompletion":7687,"completion":7687,"start":2331,"enrollment":15891,"conditions":18360,"interventions":18362},"NCT01076621","Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol\u002FNETA for 12 Months",[],[7641,18361],"Postmenopausal Bleeding",[7643],{"intervention":9252,"totalTrials":2578,"cells":18364},{"EARLY_PHASE1":18365,"PHASE1":18367,"PHASE2":18369,"PHASE3":18375,"PHASE4":18385,"NA":18387},{"trials":18366,"activeCount":99},[],{"trials":18368,"activeCount":99},[],{"trials":18370,"activeCount":99},[18371],{"nctId":9245,"briefTitle":9246,"status":105,"phases":18372,"primaryCompletion":4562,"completion":9248,"start":9249,"enrollment":765,"conditions":18373,"interventions":18374},[89],[33,24],[539,9252],{"trials":18376,"activeCount":99},[18377],{"nctId":18378,"briefTitle":18379,"status":105,"phases":18380,"primaryCompletion":18381,"completion":1369,"start":3981,"enrollment":18382,"conditions":18383,"interventions":18384},"NCT02963922","Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin",[90],"2018-09-10",396,[204,24],[9252],{"trials":18386,"activeCount":99},[],{"trials":18388,"activeCount":99},[18389],{"nctId":18390,"briefTitle":18391,"status":105,"phases":18392,"primaryCompletion":4673,"completion":18393,"start":18394,"enrollment":335,"conditions":18395,"interventions":18396},"NCT02773355","Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients",[],"2022-02-28","2016-05-16",[24],[18397],"liraglutide 3.0 mg",{"intervention":2789,"totalTrials":864,"cells":18399},{"EARLY_PHASE1":18400,"PHASE1":18402,"PHASE2":18408,"PHASE3":18410,"PHASE4":18412,"NA":18414},{"trials":18401,"activeCount":99},[],{"trials":18403,"activeCount":99},[18404],{"nctId":2781,"briefTitle":2782,"status":105,"phases":18405,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":2558,"conditions":18406,"interventions":18407},[88],[2776,2777],[2788,2789],{"trials":18409,"activeCount":99},[],{"trials":18411,"activeCount":99},[],{"trials":18413,"activeCount":99},[],{"trials":18415,"activeCount":99},[18416],{"nctId":18417,"briefTitle":18418,"status":105,"phases":18419,"primaryCompletion":334,"completion":334,"start":2271,"enrollment":18420,"conditions":18421,"interventions":18422},"NCT01327924","Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone",[],77,[2776,2778,7968,2888,15689,15690,840,15883,4478],[2789],{"intervention":17721,"totalTrials":864,"cells":18424},{"EARLY_PHASE1":18425,"PHASE1":18427,"PHASE2":18433,"PHASE3":18435,"PHASE4":18437,"NA":18439},{"trials":18426,"activeCount":99},[],{"trials":18428,"activeCount":99},[18429],{"nctId":17715,"briefTitle":17716,"status":105,"phases":18430,"primaryCompletion":2278,"completion":2278,"start":4570,"enrollment":1986,"conditions":18431,"interventions":18432},[88],[30,17719,27],[17702,17721],{"trials":18434,"activeCount":99},[],{"trials":18436,"activeCount":99},[],{"trials":18438,"activeCount":99},[],{"trials":18440,"activeCount":99},[18441],{"nctId":18442,"briefTitle":18443,"status":105,"phases":18444,"primaryCompletion":3302,"completion":3302,"start":3477,"enrollment":2683,"conditions":18445,"interventions":18446},"NCT02670213","A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan",[],[30,17719],[17721],{"intervention":18448,"totalTrials":864,"cells":18449},"BIAsp 30",{"EARLY_PHASE1":18450,"PHASE1":18452,"PHASE2":18454,"PHASE3":18456,"PHASE4":18458,"NA":18460},{"trials":18451,"activeCount":99},[],{"trials":18453,"activeCount":99},[],{"trials":18455,"activeCount":99},[],{"trials":18457,"activeCount":99},[],{"trials":18459,"activeCount":99},[],{"trials":18461,"activeCount":99},[18462,18470],{"nctId":18463,"briefTitle":18464,"status":1135,"phases":18465,"primaryCompletion":18466,"completion":18466,"start":18467,"enrollment":99,"conditions":18468,"interventions":18469},"NCT03862690","A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria",[],"2021-06-28","2020-05-28",[18],[18448],{"nctId":18471,"briefTitle":18472,"status":105,"phases":18473,"primaryCompletion":1444,"completion":1444,"start":18474,"enrollment":18475,"conditions":18476,"interventions":18477},"NCT03374774","A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)",[],"2017-11-13",516,[15,18],[18448],{"intervention":2263,"totalTrials":864,"cells":18479},{"EARLY_PHASE1":18480,"PHASE1":18482,"PHASE2":18484,"PHASE3":18486,"PHASE4":18488,"NA":18494},{"trials":18481,"activeCount":99},[],{"trials":18483,"activeCount":99},[],{"trials":18485,"activeCount":99},[],{"trials":18487,"activeCount":99},[],{"trials":18489,"activeCount":99},[18490],{"nctId":2257,"briefTitle":2258,"status":105,"phases":18491,"primaryCompletion":2213,"completion":2213,"start":2260,"enrollment":173,"conditions":18492,"interventions":18493},[91],[30,2136,2138],[2122,2263],{"trials":18495,"activeCount":99},[18496],{"nctId":17066,"briefTitle":17067,"status":105,"phases":18497,"primaryCompletion":6191,"completion":6191,"start":2306,"enrollment":363,"conditions":18498,"interventions":18499},[],[30,2136,2138],[2157,2263],{"intervention":18501,"totalTrials":864,"cells":18502},"Basal insulin",{"EARLY_PHASE1":18503,"PHASE1":18505,"PHASE2":18507,"PHASE3":18509,"PHASE4":18515,"NA":18517},{"trials":18504,"activeCount":99},[],{"trials":18506,"activeCount":99},[],{"trials":18508,"activeCount":99},[],{"trials":18510,"activeCount":99},[18511],{"nctId":17168,"briefTitle":17169,"status":105,"phases":18512,"primaryCompletion":17171,"completion":17171,"start":17172,"enrollment":17173,"conditions":18513,"interventions":18514},[90],[15,18],[4709,17176],{"trials":18516,"activeCount":99},[],{"trials":18518,"activeCount":99},[18519],{"nctId":18520,"briefTitle":18521,"status":105,"phases":18522,"primaryCompletion":18523,"completion":18523,"start":18524,"enrollment":2996,"conditions":18525,"interventions":18526},"NCT04809311","Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments",[],"2025-01-07","2024-04-30",[18],[18527,18501,18528],"Oral antidiabetetic drugs","Glucagon-like peptide-1",{"intervention":18530,"totalTrials":864,"cells":18531},"Ryzodeg®",{"EARLY_PHASE1":18532,"PHASE1":18534,"PHASE2":18536,"PHASE3":18538,"PHASE4":18540,"NA":18542},{"trials":18533,"activeCount":99},[],{"trials":18535,"activeCount":99},[],{"trials":18537,"activeCount":99},[],{"trials":18539,"activeCount":99},[],{"trials":18541,"activeCount":99},[],{"trials":18543,"activeCount":99},[18544,18551],{"nctId":18545,"briefTitle":18546,"status":105,"phases":18547,"primaryCompletion":18548,"completion":18548,"start":6584,"enrollment":1110,"conditions":18549,"interventions":18550},"NCT04656106","A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec\u002FInsulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea",[],"2021-07-01",[18],[18530],{"nctId":18552,"briefTitle":18553,"status":105,"phases":18554,"primaryCompletion":18555,"completion":18555,"start":18556,"enrollment":18557,"conditions":18558,"interventions":18559},"NCT05221580","China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)",[],"2023-03-31","2022-03-18",887,[18],[18530],{"intervention":18561,"totalTrials":1606,"cells":18562},"Xultophy®",{"EARLY_PHASE1":18563,"PHASE1":18565,"PHASE2":18567,"PHASE3":18569,"PHASE4":18571,"NA":18573},{"trials":18564,"activeCount":99},[],{"trials":18566,"activeCount":99},[],{"trials":18568,"activeCount":99},[],{"trials":18570,"activeCount":99},[],{"trials":18572,"activeCount":99},[],{"trials":18574,"activeCount":99},[18575],{"nctId":18576,"briefTitle":18577,"status":105,"phases":18578,"primaryCompletion":18579,"completion":18579,"start":18580,"enrollment":7451,"conditions":18581,"interventions":18582},"NCT04952779","Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec\u002FLiraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",[],"2024-12-15","2021-06-02",[18],[18561],{"intervention":17021,"totalTrials":1606,"cells":18584},{"EARLY_PHASE1":18585,"PHASE1":18587,"PHASE2":18589,"PHASE3":18591,"PHASE4":18593,"NA":18595},{"trials":18586,"activeCount":99},[],{"trials":18588,"activeCount":99},[],{"trials":18590,"activeCount":99},[],{"trials":18592,"activeCount":99},[],{"trials":18594,"activeCount":99},[],{"trials":18596,"activeCount":99},[18597],{"nctId":17016,"briefTitle":17017,"status":105,"phases":18598,"primaryCompletion":651,"completion":651,"start":2225,"enrollment":3518,"conditions":18599,"interventions":18600},[],[30,2308],[2157,17021,17022,17023,17024,17024],{"intervention":17022,"totalTrials":1606,"cells":18602},{"EARLY_PHASE1":18603,"PHASE1":18605,"PHASE2":18607,"PHASE3":18609,"PHASE4":18611,"NA":18613},{"trials":18604,"activeCount":99},[],{"trials":18606,"activeCount":99},[],{"trials":18608,"activeCount":99},[],{"trials":18610,"activeCount":99},[],{"trials":18612,"activeCount":99},[],{"trials":18614,"activeCount":99},[18615],{"nctId":17016,"briefTitle":17017,"status":105,"phases":18616,"primaryCompletion":651,"completion":651,"start":2225,"enrollment":3518,"conditions":18617,"interventions":18618},[],[30,2308],[2157,17021,17022,17023,17024,17024],{"intervention":17023,"totalTrials":1606,"cells":18620},{"EARLY_PHASE1":18621,"PHASE1":18623,"PHASE2":18625,"PHASE3":18627,"PHASE4":18629,"NA":18631},{"trials":18622,"activeCount":99},[],{"trials":18624,"activeCount":99},[],{"trials":18626,"activeCount":99},[],{"trials":18628,"activeCount":99},[],{"trials":18630,"activeCount":99},[],{"trials":18632,"activeCount":99},[18633],{"nctId":17016,"briefTitle":17017,"status":105,"phases":18634,"primaryCompletion":651,"completion":651,"start":2225,"enrollment":3518,"conditions":18635,"interventions":18636},[],[30,2308],[2157,17021,17022,17023,17024,17024],{"intervention":17024,"totalTrials":1606,"cells":18638},{"EARLY_PHASE1":18639,"PHASE1":18641,"PHASE2":18643,"PHASE3":18645,"PHASE4":18647,"NA":18649},{"trials":18640,"activeCount":99},[],{"trials":18642,"activeCount":99},[],{"trials":18644,"activeCount":99},[],{"trials":18646,"activeCount":99},[],{"trials":18648,"activeCount":99},[],{"trials":18650,"activeCount":99},[18651],{"nctId":17016,"briefTitle":17017,"status":105,"phases":18652,"primaryCompletion":651,"completion":651,"start":2225,"enrollment":3518,"conditions":18653,"interventions":18654},[],[30,2308],[2157,17021,17022,17023,17024,17024],{"intervention":15919,"totalTrials":1606,"cells":18656},{"EARLY_PHASE1":18657,"PHASE1":18659,"PHASE2":18661,"PHASE3":18663,"PHASE4":18665,"NA":18667},{"trials":18658,"activeCount":99},[],{"trials":18660,"activeCount":99},[],{"trials":18662,"activeCount":99},[],{"trials":18664,"activeCount":99},[],{"trials":18666,"activeCount":99},[],{"trials":18668,"activeCount":99},[18669],{"nctId":15914,"briefTitle":15915,"status":105,"phases":18670,"primaryCompletion":233,"completion":233,"start":129,"enrollment":3006,"conditions":18671,"interventions":18672},[],[15689,15690],[2831,15919,15919],{"intervention":18674,"totalTrials":1606,"cells":18675},"Fiasp®",{"EARLY_PHASE1":18676,"PHASE1":18678,"PHASE2":18680,"PHASE3":18682,"PHASE4":18684,"NA":18686},{"trials":18677,"activeCount":99},[],{"trials":18679,"activeCount":99},[],{"trials":18681,"activeCount":99},[],{"trials":18683,"activeCount":99},[],{"trials":18685,"activeCount":99},[],{"trials":18687,"activeCount":99},[18688],{"nctId":18689,"briefTitle":18690,"status":105,"phases":18691,"primaryCompletion":18692,"completion":18692,"start":13591,"enrollment":95,"conditions":18693,"interventions":18694},"NCT03895515","Effect of Fiasp® in Type 1 Diabetes Treatment",[],"2020-12-21",[21],[18674],{"intervention":18696,"totalTrials":1606,"cells":18697},"Saxenda®",{"EARLY_PHASE1":18698,"PHASE1":18700,"PHASE2":18702,"PHASE3":18704,"PHASE4":18706,"NA":18708},{"trials":18699,"activeCount":99},[],{"trials":18701,"activeCount":99},[],{"trials":18703,"activeCount":99},[],{"trials":18705,"activeCount":99},[],{"trials":18707,"activeCount":99},[],{"trials":18709,"activeCount":99},[18710],{"nctId":18711,"briefTitle":18712,"status":105,"phases":18713,"primaryCompletion":18714,"completion":18714,"start":18715,"enrollment":18716,"conditions":18717,"interventions":18718},"NCT05153590","A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland",[],"2022-04-15","2021-12-03",269,[1291],[18696],{"intervention":18720,"totalTrials":1606,"cells":18721},"Vagifem®",{"EARLY_PHASE1":18722,"PHASE1":18724,"PHASE2":18726,"PHASE3":18728,"PHASE4":18730,"NA":18732},{"trials":18723,"activeCount":99},[],{"trials":18725,"activeCount":99},[],{"trials":18727,"activeCount":99},[],{"trials":18729,"activeCount":99},[],{"trials":18731,"activeCount":99},[],{"trials":18733,"activeCount":99},[18734],{"nctId":18735,"briefTitle":18736,"status":105,"phases":18737,"primaryCompletion":1692,"completion":1692,"start":18738,"enrollment":18739,"conditions":18740,"interventions":18741},"NCT05243823","Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy",[],"2022-01-15",500000,[8331],[18720,18742],"Non-Vagifem® LDVE, Estradiol",{"intervention":18742,"totalTrials":1606,"cells":18744},{"EARLY_PHASE1":18745,"PHASE1":18747,"PHASE2":18749,"PHASE3":18751,"PHASE4":18753,"NA":18755},{"trials":18746,"activeCount":99},[],{"trials":18748,"activeCount":99},[],{"trials":18750,"activeCount":99},[],{"trials":18752,"activeCount":99},[],{"trials":18754,"activeCount":99},[],{"trials":18756,"activeCount":99},[18757],{"nctId":18735,"briefTitle":18736,"status":105,"phases":18758,"primaryCompletion":1692,"completion":1692,"start":18738,"enrollment":18739,"conditions":18759,"interventions":18760},[],[8331],[18720,18742],{"intervention":18527,"totalTrials":1606,"cells":18762},{"EARLY_PHASE1":18763,"PHASE1":18765,"PHASE2":18767,"PHASE3":18769,"PHASE4":18771,"NA":18773},{"trials":18764,"activeCount":99},[],{"trials":18766,"activeCount":99},[],{"trials":18768,"activeCount":99},[],{"trials":18770,"activeCount":99},[],{"trials":18772,"activeCount":99},[],{"trials":18774,"activeCount":99},[18775],{"nctId":18520,"briefTitle":18521,"status":105,"phases":18776,"primaryCompletion":18523,"completion":18523,"start":18524,"enrollment":2996,"conditions":18777,"interventions":18778},[],[18],[18527,18501,18528],{"intervention":18528,"totalTrials":1606,"cells":18780},{"EARLY_PHASE1":18781,"PHASE1":18783,"PHASE2":18785,"PHASE3":18787,"PHASE4":18789,"NA":18791},{"trials":18782,"activeCount":99},[],{"trials":18784,"activeCount":99},[],{"trials":18786,"activeCount":99},[],{"trials":18788,"activeCount":99},[],{"trials":18790,"activeCount":99},[],{"trials":18792,"activeCount":99},[18793],{"nctId":18520,"briefTitle":18521,"status":105,"phases":18794,"primaryCompletion":18523,"completion":18523,"start":18524,"enrollment":2996,"conditions":18795,"interventions":18796},[],[18],[18527,18501,18528],{"intervention":17935,"totalTrials":1606,"cells":18798},{"EARLY_PHASE1":18799,"PHASE1":18801,"PHASE2":18803,"PHASE3":18805,"PHASE4":18807,"NA":18809},{"trials":18800,"activeCount":99},[],{"trials":18802,"activeCount":99},[],{"trials":18804,"activeCount":99},[],{"trials":18806,"activeCount":99},[],{"trials":18808,"activeCount":99},[],{"trials":18810,"activeCount":99},[18811],{"nctId":17929,"briefTitle":17930,"status":105,"phases":18812,"primaryCompletion":3699,"completion":3699,"start":3738,"enrollment":17932,"conditions":18813,"interventions":18814},[],[15,18],[5797,17935],{"intervention":18816,"totalTrials":1606,"cells":18817},"Refixia®",{"EARLY_PHASE1":18818,"PHASE1":18820,"PHASE2":18822,"PHASE3":18824,"PHASE4":18826,"NA":18828},{"trials":18819,"activeCount":99},[],{"trials":18821,"activeCount":99},[],{"trials":18823,"activeCount":99},[],{"trials":18825,"activeCount":99},[],{"trials":18827,"activeCount":99},[],{"trials":18829,"activeCount":99},[18830],{"nctId":18831,"briefTitle":18832,"status":105,"phases":18833,"primaryCompletion":2869,"completion":2869,"start":18834,"enrollment":413,"conditions":18835,"interventions":18836},"NCT03875547","Post-marketing Surveillance (Use Result Surveillance) With Refixia®",[],"2019-08-23",[2137],[18816],{"intervention":18838,"totalTrials":1606,"cells":18839},"Marketed low dose hormone replacement therapy",{"EARLY_PHASE1":18840,"PHASE1":18842,"PHASE2":18844,"PHASE3":18846,"PHASE4":18848,"NA":18850},{"trials":18841,"activeCount":99},[],{"trials":18843,"activeCount":99},[],{"trials":18845,"activeCount":99},[],{"trials":18847,"activeCount":99},[],{"trials":18849,"activeCount":99},[],{"trials":18851,"activeCount":99},[18852],{"nctId":18853,"briefTitle":18854,"status":105,"phases":18855,"primaryCompletion":3492,"completion":3492,"start":5766,"enrollment":18856,"conditions":18857,"interventions":18859},"NCT01487304","Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy",[],3760,[7641,18858],"Hormone Replacement Therapy, Post-Menopausal",[18838],{"intervention":18861,"totalTrials":1606,"cells":18862},"Ozempic®",{"EARLY_PHASE1":18863,"PHASE1":18865,"PHASE2":18867,"PHASE3":18869,"PHASE4":18871,"NA":18873},{"trials":18864,"activeCount":99},[],{"trials":18866,"activeCount":99},[],{"trials":18868,"activeCount":99},[],{"trials":18870,"activeCount":99},[],{"trials":18872,"activeCount":99},[],{"trials":18874,"activeCount":99},[18875],{"nctId":18876,"briefTitle":18877,"status":18878,"phases":18879,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":18882,"conditions":18883,"interventions":18884},"NCT04572165","Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","UNKNOWN",[],"2024-12-31","2021-01-26",600000,[18],[18861,18885,18886],"Active Comparator","Rybelsus®",{"intervention":18885,"totalTrials":1606,"cells":18888},{"EARLY_PHASE1":18889,"PHASE1":18891,"PHASE2":18893,"PHASE3":18895,"PHASE4":18897,"NA":18899},{"trials":18890,"activeCount":99},[],{"trials":18892,"activeCount":99},[],{"trials":18894,"activeCount":99},[],{"trials":18896,"activeCount":99},[],{"trials":18898,"activeCount":99},[],{"trials":18900,"activeCount":99},[18901],{"nctId":18876,"briefTitle":18877,"status":18878,"phases":18902,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":18882,"conditions":18903,"interventions":18904},[],[18],[18861,18885,18886],{"intervention":18886,"totalTrials":1606,"cells":18906},{"EARLY_PHASE1":18907,"PHASE1":18909,"PHASE2":18911,"PHASE3":18913,"PHASE4":18915,"NA":18917},{"trials":18908,"activeCount":99},[],{"trials":18910,"activeCount":99},[],{"trials":18912,"activeCount":99},[],{"trials":18914,"activeCount":99},[],{"trials":18916,"activeCount":99},[],{"trials":18918,"activeCount":99},[18919],{"nctId":18876,"briefTitle":18877,"status":18878,"phases":18920,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":18882,"conditions":18921,"interventions":18922},[],[18],[18861,18885,18886],{"intervention":18924,"totalTrials":1606,"cells":18925},"Insulin degludec \u002Finsulin aspart",{"EARLY_PHASE1":18926,"PHASE1":18928,"PHASE2":18930,"PHASE3":18932,"PHASE4":18934,"NA":18936},{"trials":18927,"activeCount":99},[],{"trials":18929,"activeCount":99},[],{"trials":18931,"activeCount":99},[],{"trials":18933,"activeCount":99},[],{"trials":18935,"activeCount":99},[],{"trials":18937,"activeCount":99},[18938],{"nctId":18939,"briefTitle":18940,"status":105,"phases":18941,"primaryCompletion":18942,"completion":18942,"start":18943,"enrollment":18944,"conditions":18945,"interventions":18946},"NCT03416855","A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec \u002FInsulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea",[],"2020-05-19","2018-01-31",768,[15,21,18],[18924],{"intervention":14660,"totalTrials":1606,"cells":18948},{"EARLY_PHASE1":18949,"PHASE1":18951,"PHASE2":18953,"PHASE3":18955,"PHASE4":18957,"NA":18959},{"trials":18950,"activeCount":99},[],{"trials":18952,"activeCount":99},[],{"trials":18954,"activeCount":99},[],{"trials":18956,"activeCount":99},[],{"trials":18958,"activeCount":99},[],{"trials":18960,"activeCount":99},[18961],{"nctId":14653,"briefTitle":14654,"status":105,"phases":18962,"primaryCompletion":3157,"completion":3157,"start":14656,"enrollment":14657,"conditions":18963,"interventions":18964},[],[2533,21,18],[3589,14660],{"intervention":18966,"totalTrials":1606,"cells":18967},"Insulin degludec and liraglutide",{"EARLY_PHASE1":18968,"PHASE1":18970,"PHASE2":18972,"PHASE3":18974,"PHASE4":18976,"NA":18978},{"trials":18969,"activeCount":99},[],{"trials":18971,"activeCount":99},[],{"trials":18973,"activeCount":99},[],{"trials":18975,"activeCount":99},[],{"trials":18977,"activeCount":99},[],{"trials":18979,"activeCount":99},[18980],{"nctId":18981,"briefTitle":18982,"status":105,"phases":18983,"primaryCompletion":18984,"completion":18985,"start":3320,"enrollment":3972,"conditions":18986,"interventions":18987},"NCT04666987","A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy",[],"2022-12-30","2023-02-10",[18],[18966]]